References

1.

Mechanism of action, safety and efficacy of intrauterine devices. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser. 1987;753:1–91. X-1, X-3, X-5, X-9, X-10. [PubMed: 3118580]

2.

Phase III clinical trial with Norplant II (two covered rods): report on five years of use. Contraception. 1993 Aug;48(2):120–32. X-3, X-9. [PubMed: 8403909]

3.

Hysteroscopic surgery for dysfunctional uterine bleeding. Professional Nurse. 1994;10(3):142–3. X-8.

4.

Menstrual regulation by mifepristone plus prostaglandin: results from a multicentre trial. World Health Organization Task Force on Post-Ovulatory Methods of Fertility Regulation. Hum Reprod. 1995 Feb;10(2):308–14. X-3, X-5, X-6. [PubMed: 7769054]

5.

Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception. 1997 Dec;56(6):341–52. X-9. [PubMed: 9494767]

6.

A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Collaborative Study Group on the Desogestrel-containing Progestogen-only Pill. Eur J Contracept Reprod Health Care. 1998 Dec;3(4):169–78. X-9. [PubMed: 10036599]

7.

Thermal ablation as a treatment for dysfunctional uterine bleeding. Point of View. 1998;36(1):14–20. X-8.

8.

The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 microg and ethinylestradiol 15 microg. Eur J Contracept Reprod Health Care. 1999 Nov;4 Suppl 2:9–15. X-4, X-5. [PubMed: 14677620]

9.

Levonorgestrel intrauterine device: new preparation. An alternative. Prescrire Int. 1999 Dec;8(44):175–7. X-1, X-4, X-5. [PubMed: 11503815]

10.

Raloxifene: new preparation. Not better than oestrogen. Prescrire Int. 1999 Dec;8(44):165–7. X-1, X-4, X-5, X-7, X-9. [PubMed: 11503811]

11.

Which operation for menorrhagia? Drug and Therapeutics Bulletin. 2000;38(10):77–80. X-1, X-3, X-5, X-8. [PubMed: 11127163]

12.

Levonorgestrel. New preparation. Emergency contraceptive. Prescrire International. 2000;9(45):202–4. X-1, X-3, X-5, X-9. [PubMed: 11503796]

13.

Post-marketing surveillance of Norplant contraceptive implants: I. Contraceptive efficacy and reproductive health. Contraception. 2001 Apr;63(4):167–86. X-4, X-5. [PubMed: 11376646]

14.

Levonorgestrel intra-uterine system for menorrhagia. Drug and Therapeutics Bulletin. 2001;39(11):85–7. X-1, X-3, X-10. [PubMed: 11760591]

15.

Information from your family doctor. Birth control pills and bleeding. Am Fam Physician. 2002 May 15;65(10):2083. X-1, X-3, X-5, X-10. [PubMed: 12046777]

16.

Hysterectomy improves quality-of-life in women with prolonged abnormal uterine bleeding. Evidence Based Healthcare and Public Health. 2004;8(5):306–7. X-8.

17.

Anastrozole: new indication. Adjuvant treatment of non metastatic breast cancer: useful for some patients. Prescrire Int. 2005 Apr;14(76):43–4. X-1, X-4, X-5, X-9. [PubMed: 15875334]

18.

Estrogen and progestogen therapy in postmenopausal women. Fertility and Sterility. 2008;90(5 SUPPL):S88–S102. X-1, X-3, X-7. [PubMed: 19007655]

19.

ACOG Committee Opinion No. 451: Von Willebrand disease in women. Obstet Gynecol. 2009 Dec;114(6):1439–43. X-1, X-4, X-5, X-9. [PubMed: 20134302]

20.

Urinary problems after hysterectomy. Journal of the National Medical Association. 2010;102(7) X-8.

21.

Abbott JA, Hawe J, Garry R. Quality of life should be considered the primary outcome for measuring success of endometrial ablation. J Am Assoc Gynecol Laparosc. 2003 Nov;10(4):491–5. discussion 5. X-4, X-5, X-8, X-9. [PubMed: 14738636]

22.

Abdel Malak K, Shawki O. Management of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. Gynecological Surgery. 2006;3(4):275–80. X-8.

23.

Abdel-Aleem H, Shaaban OM, Amin AF, et al. Tamoxifen treatment of bleeding irregularities associated with Norplant use. Contraception. 2005 Dec;72(6):432–7. X-5, X-6. [PubMed: 16307966]

24.

Abdelrazik N, Ghanem H. Failure of puberty in Egyptian beta thalassemic patients: experience in north east region - Dakahlia province. Hematology. 2007 Oct;12(5):449–56. X-4, X-5, X-9. [PubMed: 17852439]

25.

Abdulwahid NA, Adams J, van der Spuy ZM, et al. Gonadotrophin control of follicular development. Clin Endocrinol (Oxf). 1985 Dec;23(6):613–26. X-3, X-4, X-5. [PubMed: 3938350]

26.

Aberg LE, Tiitinen A, Autti TH, et al. Hyperandrogenism in girls with juvenile neuronal ceroid lipofuscinosis. Eur J Paediatr Neurol. 2002;6(4):199–205. X-4, X-5, X-6, X-9. [PubMed: 12374586]

27.

Aboulghar MA, Mansour RT, Serour GI, et al. Improvement of spontaneous pregnancy rate after stopping gonadotropin therapy for anovulatory infertility. Fertil Steril. 1991 Apr;55(4):722–5. X-3, X-5. [PubMed: 1901280]

28.

Abou-Salem N, Elmazny A, El-Sherbiny W. Value of 3-dimensional sonohysterography for detection of intrauterine lesions in women with abnormal uterine bleeding. J Minim Invasive Gynecol. 2010 Mar-Apr;17(2):200–4. X-4, X-5, X-9. [PubMed: 20226408]

29.

Adam J. Contraception and therapy with Tri Regol tablet. Ther Hung. 1991;39(2):75–7. X-3, X-9. [PubMed: 1948781]

30.

Adeyemi AS, Adekanle DA. Progestogen-only injectable contraceptive: experience of women in Osogbo, southwestern Nigeria. Ann Afr Med. 2012 Jan-Mar;11(1):27–31. X-3, X-9. [PubMed: 22199044]

31.

Affinito P, Monterubbianesi M, Primizia M, et al. Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: Gestodene/ethinylestradiol and norgestimate/ethinylestradiol. Gynecological Endocrinology. 1993;7(4):259–66. X-9. [PubMed: 8147235]

32.

Agarwal K, Sharma U, Acharya V. Microbial and cytopathological study of intrauterine contraceptive device users. Indian J Med Sci. 2004 Sep;58(9):394–9. X-4, X-5. [PubMed: 15470281]

33.

Agnusdei D, Gennari C, Bufalino L. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone. Osteoporosis International. 1995;5(6):462–6. X-7. [PubMed: 8695969]

34.

Agosta C, Atlante M, Benvenuti C. Randomized controlled study on clinical efficacy of isoflavones plus Lactobacillus sporogenes, associated or not with a natural anxiolytic agent in menopause. Minerva Ginecol. 2011 Feb;63(1):11–7. X-5, X-7, X-9. [PubMed: 21311416]

35.

Ahmed WU, Kirmani SR, Qureshi H, et al. Misoprostol in the treatment of NSAID-induced gastroduodenal lesions. Indian J Gastroenterol. 1991 Oct;10(4):135–6. X-5. [PubMed: 1748495]

36.

Ahrendt HJ, Makalova D, Parke S, et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009 Nov;80(5):436–44. X-5. [PubMed: 19835717]

37.

AinMelk Y. Comparison of two continuous combined estrogen progestogen regimens in postmenopausal women: a randomized trial. Fertil Steril. 1996 Dec;66(6):962–8. X-5, X-7. [PubMed: 8941062]

38.

Aisien AO, Enosolease ME. Safety, efficacy and acceptability of implanon a single rod implantable contraceptive (etonogestrel) in University of Benin Teaching Hospital. Niger J Clin Pract. 2010 Sep;13(3):331–5. X-4, X-5. [PubMed: 20857796]

39.

Akase T, Onodera S, Jobo T, et al. A comparative study of the usefulness of toki-shakuyaku-san and an oral iron preparation in the treatment of hypochromic anemia in cases of uterine myoma. Yakugaku Zasshi. 2003 Sep;123(9):817–24. X-4, X-5, X-6, X-7, X-9. [PubMed: 14513774]

40.

Akerlund M, Rode A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 mug desogestrel and either 30 mug or 20 mug ethinyl oestradiol. British Journal of Obstetrics and Gynaecology. 1993;100(9):832–8. X-9. [PubMed: 8218004]

41.

Akhter H, Dunson TR, Amatya RN, et al. A five-year clinical evaluation of Norplant contraceptive subdermal implants in Bangladeshi acceptors. Contraception. 1993 Jun;47(6):569–82. X-3, X-6, X-9. [PubMed: 8334891]

42.

Akkad AA, Habiba MA, Ismail N, et al. Abnormal uterine bleeding on hormone replacement: the importance of intrauterine structural abnormalities. Obstet Gynecol. 1995 Sep;86(3):330–4. X-3, X-5, X-6, X-8. [PubMed: 7651636]

43.

Al Inizi SA, Ezimokhai M. Vaginal misoprostol versus dinoprostone for the management of missed abortion. Int J Gynaecol Obstet. 2003 Oct;83(1):73–4. X-5, X-9. [PubMed: 14511878]

44.

Al-Azzawi F, Buckler HM. Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms. Climacteric. 2003;6(2):118–27. X-7. [PubMed: 12841882]

45.

Al-Azzawi F, Wahab M, Habiba M, et al. Continuous combined hormone replacement therapy compared with tibolone. Obstetrics and Gynecology. 1999;93(2):258–64. X-7. [PubMed: 9932566]

46.

al-Azzawi F, Wahab M, Thompson J, et al. Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate. Climacteric. 2001 Dec;4(4):343–54. X-5, X-7, X-10. [PubMed: 11770191]

47.

Al-Azzawi F, Wahab M, Thompson J, et al. Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone replacement therapy: a dose-ranging study. Hum Reprod. 1999 Mar;14(3):636–41. X-5, X-9. [PubMed: 10221688]

48.

Albert A, Altabre C, Baro F, et al. Efficacy and safety of a phytoestrogen preparation derived from Glycine max (L.) Merr in climacteric symptomatology: a multicentric, open, prospective and non-randomized trial. Phytomedicine. 2002 Mar;9(2):85–92. X-4, X-5, X-7. [PubMed: 11995954]

49.

Alborzi S, Parsanezhad ME, Dehbashi S. A comparison of hysteroscopic endometrial ablation for abnormal uterine bleeding in two groups of patients with or without endometrial preparation. Middle East Fertility Society Journal. 2002;7(2):135–9. X-8.

50.

Alexandersen P, Byrjalsen I, Christiansen C. Piperazine oestrone sulphate and interrupted norethisterone in postmenopausal women: Effects on bone mass, lipoprotein metabolism, climacteric symptoms, and adverse effects. British Journal of Obstetrics and Gynaecology. 2000;107(3):356–64. X-7. [PubMed: 10740332]

51.

Alford WS, Hopkins MP. Endometrial rollerball ablation. J Reprod Med. 1996 Apr;41(4):251–4. X-4, X-5, X-8, X-9. [PubMed: 8728077]

52.

Al-Khawajah MM. Finasteride for hirsutism: A dose finding study. Saudi Medical Journal. 1998;19(1):19–21. X-5. [PubMed: 27701508]

53.

Allais G, Bussone G, Airola G, et al. Oral contraceptive-induced menstrual migraine. Clinical aspects and response to frovatriptan. Neurol Sci. 2008 May;29 Suppl 1:S186–90. X-4, X-5, X-9. [PubMed: 18545931]

54.

Allais G, Bussone G, D'Andrea G, et al. Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2011 Jan;31(2):144–51. X-4, X-5, X-9. [PMC free article: PMC3057443] [PubMed: 20660540]

55.

Allais G, Sanchez del Rio M, Diener HC, et al. Perimenstrual migraines and their response to preventive therapy with topiramate. Cephalalgia. 2011 Jan;31(2):152–60. X-4, X-5, X-9. [PubMed: 20650999]

56.

Al-Quaiz JM. Iron deficiency anemia. A study of risk factors. Saudi Med J. 2001 Jun;22(6):490–6. X-4, X-5, X-9. [PubMed: 11426238]

57.

Althaus F. Sterilization is unlikely to alter most women's menstrual symptoms. Family Planning Perspectives. 1990 Jan-Feb;22(1):44–5. 1990. X-8.

58.

Alvarez-Sanchez F, Brache V, Thevenin F, et al. Hormonal treatment for bleeding irregularities in Norplant implant users. Am J Obstet Gynecol. 1996 Mar;174(3):919–22. X-5, X-6. [PubMed: 8633669]

59.

Ambriz R, Pizzuto J, Morales M, et al. Therapeutic effect of danazol on metrorrhagia in patients with idiopathic thrombocytopenic purpura (ITP). Nouv Rev Fr Hematol. 1986;28(5):275–9. X-3, X-6. [PubMed: 3808937]

60.

Amesse LS, Boyce C, Pfaff-Amesse T. Menstrual control in the developmentally delayed adolescent: new treatment options. J Pediatr Adolesc Gynecol. 2006 Jun;19(3):237–41. X-1, X-3, X-5, X-10. [PubMed: 16731421]

61.

Amesse LS, Pfaff-Amesse T, Leonardi R, et al. Oral contraceptives and DDAVP nasal spray: patterns of use in managing vWD-associated menorrhagia: a single-institution study. J Pediatr Hematol Oncol. 2005 Jul;27(7):357–63. X-4, X-5, X-6. [PubMed: 16012324]

62.

Amso NN, Fernandez H, Vilos G, et al. Uterine endometrial thermal balloon therapy for the treatment of menorrhagia: long-term multicentre follow-up study. Hum Reprod. 2003 May;18(5):1082–7. X-4, X-5, X-8. [PubMed: 12721188]

63.

Amso NN, Stabinsky SA, McFaul P, et al. Uterine thermal balloon therapy for the treatment of menorrhagia: the first 300 patients from a multi-centre study. International Collaborative Uterine Thermal Balloon Working Group. Br J Obstet Gynaecol. 1998 May;105(5):517–23. X-4, X-5, X-8. [PubMed: 9637121]

64.

Anderer P, Saletu B, Gruber D, et al. Age-related cognitive decline in the menopause: Effects of hormone replacement therapy on cognitive event-related potentials. Maturitas. 2005;51(3):254–69. X-7. [PubMed: 15978969]

65.

Andersch B. The effect of various oral contraceptive combinations on premenstrual symptoms. Int J Gynaecol Obstet. 1982 Dec;20(6):463–9. X-3, X-5. [PubMed: 6130993]

66.

Andersen LF, Meinert L, Rygaard C, et al. Thermal balloon endometrial ablation: safety aspects evaluated by serosal temperature, light microscopy and electron microscopy. Eur J Obstet Gynecol Reprod Biol. 1998 Jul;79(1):63–8. X-4, X-5, X-8. [PubMed: 9643406]

67.

Andersen PE, Lund N, Justesen P, et al. Uterine artery embolization of symptomatic uterine fibroida . Initial success and short-term results. Acta Radiol. 2001 Mar;42(2):234–8. X-4, X-5, X-6, X-8. [PubMed: 11259954]

68.

Andersen T, Astrup A, Quaade F. Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: A randomized clinical trial. International Journal of Obesity. 1992;16(1):35–40. X-5. [PubMed: 1314242]

69.

Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol. 1990 Aug;97(8):690–4. X-3. [PubMed: 2119218]

70.

Andersson K. Intrauterine release of levonorgestrel. A contraceptive and therapeutical system. Acta Obstetricia et Gynecologica Scandinavica. 1995;74(3):236–7. X-1, X-3, X-9, X-10.

71.

Andersson K, Mattsson LA, Rybo G, et al. Intrauterine release of levonorgestrel--a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol. 1992 Jun;79(6):963–7. X-5, X-10. [PubMed: 1579323]

72.

Andersson K, Ryde-Blomqvist E, Lindell K, et al. Perforations with intrauterine devices. Report from a Swedish survey. Contraception. 1998 Apr;57(4):251–5. X-4, X-5, X-9. [PubMed: 9649917]

73.

Andolsek L, Kozuh-novak M, Waszak C. A comparative study of the nylon T and copper T 200. Contracept Deliv Syst. 1983 Sep;4(4):297–300. X-9. [PubMed: 12265805]

74.

Annos T, Thompson IE, Taymor ML. Luteal phase deficiency and infertility: difficulties encountered in diagnosis and treatment. Obstet Gynecol. 1980 Jun;55(6):705–10. X-5. [PubMed: 7383457]

75.

Anstee P, Kovacs GT. A prospective randomized study comparing the clinical effects of a norethisterone and a levonorgestrel containing low dose oestrogen oral contraceptive pills. Aust N Z J Obstet Gynaecol. 1993 Feb;33(1):81–3. X-9. [PubMed: 8498949]

76.

Anthuber S, Schramm GA, Heskamp ML. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study. Clin Drug Investig. 2010;30(4):211–20. X-4, X-5, X-6. [PubMed: 20225905]

77.

Anttila L, Koskinen P, Erkkola R, et al. Serum testosterone, androstenedione and luteinizing hormone levels after short-term medroxyprogesterone acetate treatment in women with polycystic ovarian disease. Acta Obstet Gynecol Scand. 1994 Sep;73(8):634–6. X-3, X-4. [PubMed: 7941988]

78.

Anttila L, Kunz M, Marr J. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive. Contraception. 2009 Nov;80(5):445–51. X-5. [PubMed: 19835718]

79.

Apgar BS, DeWitt D. Diagnostic hysteroscopy. Am Fam Physician. 1992 Nov;46(5 Suppl):19S–24S. 9S–32S, 5S–6S. X-1, X-3, X-4, X-5. [PubMed: 1442472]

80.

Api O, Unal O, Ugurel V, et al. Analgesic efficacy of intravenous paracetamol for outpatient fractional curettage: a randomised, controlled trial. Int J Clin Pract. 2009 Jan;63(1):105–11. X-5, X-9. [PubMed: 18422592]

81.

Apostol G, Cady RK, Laforet GA, et al. Divalproex extended-release in adolescent migraine prophylaxis: Results of a randomized, double-blind, placebo-controlled study. Headache. 2008;48(7):1012–25. X-5. [PubMed: 18705027]

82.

Appel TB, Kambi AA, Birdsall C, et al. A comparison of a new graduated estrogen formulation with three constant-dosed oral contraceptives. Contraception. 1987 Jun;35(6):523–32. X-9. [PubMed: 3311619]

83.

Archer DF, Dorin M, Lewis V, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril. 2001 Jun;75(6):1080–7. X-5, X-7. [PubMed: 11384630]

84.

Archer DF, Dorin MH, Heine W, et al. Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Endometrium Study Group. Obstet Gynecol. 1999 Sep;94(3):323–9. X-5, X-6, X-7. [PubMed: 10472853]

85.

Archer DF, Dorin MH, Heine W, et al. Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Obstetrics and Gynecology. 1999;94(3):323–9. X-7. [PubMed: 10472853]

86.

Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab. 2007 Mar;92(3):911–8. X-5, X-7, X-9. [PubMed: 17192288]

87.

Archer DF, Lewis V, Carr BR, et al. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril. 2009 Sep;92(3):1039–44. X-5, X-7. [PubMed: 19635614]

88.

Archer DF, Lobo RA, Land HF, et al. A comparative study of transvaginal uterine ultrasound and endometrial biopsy for evaluating the endometrium of postmenopausal women taking hormone replacement therapy. Menopause. 1999 Fall;6(3):201–8. X-4, X-5, X-7. [PubMed: 10486789]

89.

Archer DF, Maheux R, DelConte A, et al. A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG). Contraception. 1997 Mar;55(3):139–44. X-4, X-5. [PubMed: 9115001]

90.

Archer DF, Maheux R, DelConte A, et al. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North american Levonorgestrel Study Group (NALSG). Am J Obstet Gynecol. 1999 Nov;181(5 Pt 2):39–44. X-4, X-5. [PubMed: 10561674]

91.

Archer DF, Philput CA, Weber ME. Management of irregular uterine bleeding and spotting associated with Norplant. Hum Reprod. 1996 Oct;11 Suppl 2:24–30. X-4, X-5, X-6. [PubMed: 8982742]

92.

Archer DF, Philput CB, Levine AS, et al. Effects of ethinyl estradiol and ibuprofen compared to placebo on endometrial bleeding, cervical mucus and the postcoital test in levonorgestrel subcutaneous implant users. Contraception. 2008 Aug;78(2):106–12. X-3, X-5, X-6. [PubMed: 18672110]

93.

Archer DF, Pickar JH. Hormone replacement therapy: effect of progestin dose and time since menopause on endometrial bleeding. Obstet Gynecol. 2000 Dec;96(6):899–905. X-5, X-7. [PubMed: 11084175]

94.

Archer DF, Pickar JH. The assessment of bleeding patterns in postmenopausal women during continuous combined hormone replacement therapy: A review of methodology and recommendations for reporting of the data. Climacteric. 2002;5(1):45–59. X-1, X-3, X-7. [PubMed: 11974559]

95.

Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol. 1994 May;83(5 Pt 1):686–92. X-7. [PubMed: 8164926]

96.

Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause. 2005 Nov-Dec;12(6):716–27. X-5, X-7. [PubMed: 16278615]

97.

Arias F. Cervical cerclage for the temporary treatment of patients with placenta previa. Obstet Gynecol. 1988 Apr;71(4):545–8. X-5. [PubMed: 3353045]

98.

Arias RD, Jain JK, Brucker C, et al. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. Contraception. 2006 Sep;74(3):234–8. X-4, X-5, X-6. [PubMed: 16904417]

99.

Armanini D, Castello R, Scaroni C, et al. Treatment of polycystic ovary syndrome with spironolactone plus licorice. Eur J Obstet Gynecol Reprod Biol. 2007 Mar;131(1):61–7. X-4, X-5, X-9. [PubMed: 17113210]

100.

Arowojolu AO. Treatment of endometriosis with depot medroxyprogesterone acetate: a preliminary experience. Afr J Med Med Sci. 2000 Mar;29(1):55–8. X-4, X-5, X-6, X-9. [PubMed: 11379470]

101.

Arowojolu AO, Okewole IA, Adekunle AO. Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in Nigerians. Contraception. 2002 Oct;66(4):269–73. X-4, X-5, X-9. [PubMed: 12413624]

102.

Arowojolu AO, Otolorin EO, Ladipo OA. Performances of copper T 380A and multiload copper 375/250 intrauterine contraceptive devices in a comparative clinical trial. African journal of medicine and medical sciences. 1995;24(1):59–65. X-9. [PubMed: 7495202]

103.

Arrenbrecht S, Caubel P, Garnero P, et al. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women. Maturitas. 2004;48(3):197–207. X-7. [PubMed: 15207885]

104.

Arvidsson C, Hellborg M, Gemzell-Danielsson K. Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. Eur J Obstet Gynecol Reprod Biol. 2005 Nov 1;123(1):87–91. X-5, X-9. [PubMed: 16260342]

105.

Aslan DL, Crapanzano JP, Harshan M, et al. The Bethesda System 2001 recommendation for reporting of benign appearing endometrial cells in Pap tests of women age 40 years and older leads to unwarranted surveillance when followed without clinical qualifiers. Gynecol Oncol. 2007 Oct;107(1):86–93. X-4, X-5, X-9. [PubMed: 17604086]

106.

Asuncion M, Calvo RM, San Millan JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000 Jul;85(7):2434–8. X-4, X-5, X-9. [PubMed: 10902790]

107.

Ataya K, Mercado A, Kartaginer J, et al. Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil Steril. 1988 Dec;50(6):876–81. X-3, X-4, X-5. [PubMed: 2904890]

108.

Au CL, Affandi B, Rogers PA. Immunohistochemical staining of von Willebrand factor in endometrium of women during the first year of Norplant implants use. Contraception. 1994 Nov;50(5):477–89. X-3, X-4. [PubMed: 7859456]

109.

Aubeny E. RU486 combined with PG analogs in voluntary termination of pregnancy. Adv Contracept. 1991 Dec;7(4):339–43. X-3, X-5. [PubMed: 1776558]

110.

Aubeny E, Peyron R, Turpin CL, et al. Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol [corrected] Int J Fertil Menopausal Stud. 1995;40 Suppl 2:85–91. X-3, X-5. [PubMed: 8574255]

111.

Aufricht C, Marik JL, Ettenger RB. Subcutaneous recombinant human erythropoietin in chronic renal allograft dysfunction. Pediatr Nephrol. 1998 Jan;12(1):10–3. X-5, X-9. [PubMed: 9502558]

112.

Ayers JW, Birenbaum DL, Menon KM. Luteal phase dysfunction in endometriosis: elevated progesterone levels in peripheral and ovarian veins during the follicular phase. Fertil Steril. 1987 Jun;47(6):925–9. X-3, X-4. [PubMed: 3595900]

113.

Ayton RA, Darling GM, Murkies AL, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol. 1996 Apr;103(4):351–8. X-5, X-7. [PubMed: 8605133]

114.

Azlin MIN, Maryasalwati I, Norzilawati MN, et al. The efficacy of etoricoxib vs mefenamic acid in the treatment of primary dysmenorrhoea: A randomised comparative trial. Journal of Obstetrics and Gynaecology. 2008;28(4):424–6. X-5, X-10. [PubMed: 18604680]

115.

Azziz R, Black VY, Knochenhauer ES, et al. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level. J Clin Endocrinol Metab. 1999 Mar;84(3):946–50. X-3, X-5. [PubMed: 10084576]

116.

Azziz R, Rittmaster RS, Fox LM, et al. Role of the ovary in the adrenal androgen excess of hyperandrogenic women. Fertil Steril. 1998 May;69(5):851–9. X-4, X-5, X-9. [PubMed: 9591492]

117.

Azziz R, Zacur HA. 21-Hydroxylase deficiency in female hyperandrogenism: screening and diagnosis. J Clin Endocrinol Metab. 1989 Sep;69(3):577–84. X-3, X-4. [PubMed: 2547827]

118.

Ba MG, Moreau JC, Sokal D, et al. A 5-year clinical evaluation of Norplant implants in Senegal. Contraception. 1999 Jun;59(6):377–81. X-4, X-5, X-6. [PubMed: 10518232]

119.

Bachmann G, Sulak PJ, Sampson-Landers C, et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception. 2004 Sep;70(3):191–8. X-4, X-5. [PubMed: 15325887]

120.

Bachmann GA, Timmons MC, Abernethy WD. Breakthrough bleeding patterns in two continuous combined estrogen/progestogen hormone replacement therapies, one of which d androgens. Journal of Women's Health. 1996;5(3):205–12. X-7.

121.

Backman C, Sandstrom B, Solheim F. Changes in central circulation in premenopausal women during application of an estradiol valerate-norgestrel combination (Cyclabil). Acta Obstet Gynecol Scand Suppl. 1981;106:47–50. X-3, X-4, X-5. [PubMed: 6951875]

122.

Baerug U, Winge T, Nordland G, et al. Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms? Climacteric. 1998 Sep;1(3):219–28. X-4, X-5, X-7, X-9. [PubMed: 11907946]

123.

Bagaria M, Suneja A, Vaid NB, et al. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust N Z J Obstet Gynaecol. 2009 Feb;49(1):77–83. X-5, X-6, X-9. [PubMed: 19281585]

124.

Bahamondes L, Diaz J, Petta C, et al. Comparison of the performances of TCu380A and TCu380S IUDs up to five years. Advances in Contraception. 1999;15(4):275–81. X-9. [PubMed: 11145369]

125.

Bai W, Henneicke-von Zepelin HH, Wang S, et al. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone. Maturitas. 2007 Sep 20;58(1):31–41. X-4, X-5, X-7, X-9. [PubMed: 17587516]

126.

Bailie GR. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications. Arzneimittelforschung. 2010;60(6a):386–98. X-1, X-4, X-5, X-9. [PubMed: 20648930]

127.

Bain C, Parkin DE, Cooper KG. Is outpatient diagnostic hysteroscopy more useful than endometrial biopsy alone for the investigation of abnormal uterine bleeding in unselected premenopausal women? A randomised comparison. BJOG. 2002 Jul;109(7):805–11. X-4, X-5, X-8. [PubMed: 12135218]

128.

Balasch J, Creus M, Fabregues F, et al. Midluteal immunoreactive alpha-inhibin serum concentrations as markers of luteal phase deficiency. Hum Reprod. 1996 Dec;11(12):2591–4. X-4, X-5, X-9. [PubMed: 9021356]

129.

Balasch J, Creus M, Marquez M, et al. The significance of luteal phase deficiency on fertility: a diagnostic and therapeutic approach. Hum Reprod. 1986 Apr;1(3):145–7. X-3, X-4, X-5. [PubMed: 3114310]

130.

Balen AH, Mulders AG, Fauser BC, et al. Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility. Journal of Clinical Endocrinology and Metabolism. 2004;89(12):6297–304. X-4, X-5. [PubMed: 15579793]

131.

Bannemerschult R, Hanker JP, Wunsch C, et al. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 micrograms ethinyl estradiol and 100 micrograms levonorgestrel over six treatment cycles. Contraception. 1997 Nov;56(5):285–90. X-3, X-9. [PubMed: 9437556]

132.

Bapst JL, Ermer JC, Ferron GM, et al. Pharmacokinetics and safety of tanaproget, a nonsteroidal progesterone receptor agonist, in healthy women. Contraception. 2006;74(5):414–8. X-4, X-5. [PubMed: 17046384]

133.

Baracat EC, Barbosa IC, Giordano MG, et al. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability. Climacteric. 2002 Mar;5(1):60–9. X-5, X-7. [PubMed: 11974560]

134.

Barbosa IC, Filho CI, Faggion D Jr., et al. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse). Contraception. 2006 Jan;73(1):30–3. X-4, X-5, X-9. [PubMed: 16371291]

135.

Barbosa IC, Maia H Jr., Coutinho E, et al. Effects of a single Silastic contraceptive implant containing nomegestrol acetate (Uniplant) on endometrial morphology and ovarian function for 1 year. Contraception. 2006 Dec;74(6):492–7. X-4, X-5, X-9. [PubMed: 17157108]

136.

Barnabei VM, Grady D, Stovall DW, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstetrics and Gynecology. 2002;100(6):1209–18. X-6, X-7. [PubMed: 12468165]

137.

Barr F, Brabin L, Agbaje S, et al. Reducing iron deficiency anaemia due to heavy menstrual blood loss in Nigerian rural adolescents. Public Health Nutr. 1998 Dec;1(4):249–57. X-4, X-5, X-9. [PubMed: 10933425]

138.

Barrington JW, Arunkalaivanan AS, Abdel-Fattah M. Comparison between the levonorgestrel intrauterine system (LNG-IUS) and thermal balloon ablation in the treatment of menorrhagia. Eur J Obstet Gynecol Reprod Biol. 2003 May 1;108(1):72–4. X-8. [PubMed: 12694974]

139.

Baskett TF, Farrell SA, Zilbert AW. Uterine fluid irrigation and absorption in hysteroscopic endometrial ablation. Obstet Gynecol. 1998 Dec;92(6):976–8. X-5, X-8, X-9. [PubMed: 9840561]

140.

Bassol S, Cravioto MC, Durand M, et al. Mesigyna once-a-month combined injectable contraceptive: experience in Latin America. Contraception. 2000 May;61(5):309–16. X-4, X-5. [PubMed: 10906501]

141.

Batar I, Kuukankorpi A, Rauramo I, et al. Two-year clinical experience with Nova-T 380, a novel copper-silver IUD. Adv Contracept. 1999;15(1):37–48. X-4, X-5. [PubMed: 10794045]

142.

Bates GW, Bates SR, Whitworth NS. Reproductive failure in women who practice weight control. Fertil Steril. 1982 Mar;37(3):373–8. X-3, X-5. [PubMed: 6800847]

143.

Bath LE, Critchley HO, Chambers SE, et al. Ovarian and uterine characteristics after total body irradiation in childhood and adolescence: response to sex steroid replacement. Br J Obstet Gynaecol. 1999 Dec;106(12):1265–72. X-4, X-5, X-6, X-9. [PubMed: 10609720]

144.

Battino S, Ben-Ami M, Geslevich Y, et al. Factors associated with withdrawal bleeding after administration of oral dydrogesterone or medroxyprogesterone acetate in women with secondary amenorrhea. Gynecol Obstet Invest. 1996;42(2):113–6. X-5. [PubMed: 8878716]

145.

Batukan C, Muderris II, Ozcelik B, et al. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecological Endocrinology. 2007;23(1):38–44. X-5. [PubMed: 17484511]

146.

Batzer FR. Formulation and noncontraceptive uses of the new, low-dose oral contraceptive. J Reprod Med. 1984 Jul;29(7 Suppl):503–12. X-1, X-3, X-5. [PubMed: 6237195]

147.

Baveja R, Bichille LK, Coyaji KJ, et al. Randomized clinical trial with intrauterine devices (levonorgestrel intrauterine device (LNG), CuT 380Ag, CuT 220C and CuT 200B). A 36-month study. Indian Council of Medical Research Task Force on IUD. Contraception. 1989 Jan;39(1):37–52. X-9. [PubMed: 2491981]

148.

Baveja R, Bichille LK, Coyaji KJ, et al. Randomized clinical trial with intrauterine devices (levonorgestrel intrauterine device (LNG), CuT 380Ag, CuT 220C and CuT 200B). A 36-month study. Contraception. 1989;39(1):37–52. X-9. [PubMed: 2491981]

149.

Baweja R, Bhattacharya SK, Choudhury SD, et al. Indian Council of Medical Research. Task Force on Hormonal Contraception: Phase II randomized clinical trial with norethisterone oenanthate 50 mg alone and in combination with 5 mg or 2.5 mg of either estradiol valerate or cypionate as a monthly injectable contraceptive. Contraception. 1985 Oct;32(4):383–94. X-9. [PubMed: 3907967]

150.

Bayhan G, Bahceci M, Demirkol T, et al. A comparative study of a gonadotropin-releasing hormone agonist and finasteride on idiopathic hirsutism. Clinical and Experimental Obstetrics and Gynecology. 2000;27(3-4):203–6. X-5, X-10. [PubMed: 11214952]

151.

Beals KA. Eating disorder and menstrual dysfunction screening, education, and treatment programs: survey results from NCAA Division 1 schools. Physician & Sportsmedicine. 2003;31(7):33–8. X-3, X-5. [PubMed: 20086473]

152.

Beeby D, Morgan Hughes JO. Oxytocic drugs and anaesthesia. A controlled clinical trial of ergometrine, syntocinon and normal saline during evacuation of the uterus after spontaneous abortion. Anaesthesia. 1984 Aug;39(8):764–7. X-5. [PubMed: 6383111]

153.

Beitins IZ, McArthur JW, Turnbull BA, et al. Exercise induces two types of human luteal dysfunction: confirmation by urinary free progesterone. J Clin Endocrinol Metab. 1991 Jun;72(6):1350–8. X-3, X-4, X-5. [PubMed: 1902847]

154.

Belsey EM. The association between vaginal bleeding patterns and reasons for discontinuation of contraceptive use. Contraception. 1988 Aug;38(2):207–25. X-3, X-5, X-6. [PubMed: 2971506]

155.

Belsey EM, Machin D, d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception. 1986 Sep;34(3):253–60. X-1, X-3, X-5. [PubMed: 3539509]

156.

Benagiano G, Kivinen ST, Fadini R, et al. Zoladex (goserelin acetate) and the anemic patient: results of a multicenter fibroid study. Fertil Steril. 1996 Aug;66(2):223–9. X-5, X-6. [PubMed: 8690106]

157.

Ben-Chetrit A, Hochner-Celnikier D, Lindenberg T, et al. Vaginal ring delivering estradiol and progesterone: a possible alternative to relieve climacteric symptoms. Isr Med Assoc J. 2005 May;7(5):302–6. X-5, X-7. [PubMed: 15909462]

158.

Ben-Haroush A, Yogev Y, Mashiach R, et al. Pregnancy outcome of threatened abortion with subchorionic hematoma: possible benefit of bed-rest? Isr Med Assoc J. 2003 Jun;5(6):422–4. X-4, X-5, X-9. [PubMed: 12841015]

159.

Bennett KL, Ohrmundt C, Maloni JA. Preventing intravasation in women undergoing hysteroscopic procedures. AORN J. 1996 Nov;64(5):792–9. X-4, X-5, X-8, X-9. [PubMed: 8922218]

160.

Benster B, Carey A, Wadsworth F, et al. A double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women. Menopause International. 2009;15(2):63–9. X-7. [PubMed: 19465671]

161.

Berenson AB, Wiemann CM. Patient satisfaction and side effects with levonorgestrel implant (Norplant) use in adolescents 18 years of age or younger. Pediatrics. 1993 Aug;92(2):257–60. X-3, X-5, X-9. [PubMed: 8337026]

162.

Berenson AB, Wiemann CM, Rickerr VI, et al. Contraceptive outcomes among adolescents prescribed Norplant implants versus oral contraceptives after one year of use. Am J Obstet Gynecol. 1997 Mar;176(3):586–92. X-4, X-5. [PubMed: 9077611]

163.

Berga SL, Marcus MD, Loucks TL, et al. Recovery of ovarian activity in women with functional hypothalamic amenorrhea who were treated with cognitive behavior therapy. Fertility and Sterility. 2003 Oct 01;80(4):976–81. X-5. [PubMed: 14556820]

164.

Bergman A, Ebel D, Liu F, et al. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharmaceutics and Drug Disposition. 2007;28(6):315–22. X-4, X-5. [PubMed: 17575559]

165.

Berkowitz RS, Bernstein MR, Harlow BL, et al. Case-control study of risk factors for partial molar pregnancy. Am J Obstet Gynecol. 1995 Sep;173(3 Pt 1):788–94. X-3, X-5. [PubMed: 7573245]

166.

Bertoli A, Fusco A, Magnani A, et al. Efficacy of low-dose GnRH analogue (Buserelin) in the treatment of hirsutism. Exp Clin Endocrinol Diabetes. 1995;103(1):15–20. X-3, X-5. [PubMed: 7621099]

167.

Bewtra C, Kable WT, Gallagher JC. Endometrial histology and bleeding patterns in menopausal women treated with estrogen and continuous or cyclic progestin. J Reprod Med. 1988 Feb;33(2):205–8. X-7. [PubMed: 2832598]

168.

Bhattacharya S, Mollison J, Pinion S, et al. A comparison of bladder and ovarian function two years following hysterectomy or endometrial ablation. Br J Obstet Gynaecol. 1996 Sep;103(9):898–903. X-5, X-8. [PubMed: 8813310]

169.

Bhattacharya S, Parkin DE, Reid TM, et al. A prospective randomised study of the effects of prophylactic antibiotics on the incidence of bacteraemia following hysteroscopic surgery. Eur J Obstet Gynecol Reprod Biol. 1995 Nov;63(1):37–40. X-5, X-8. [PubMed: 8674563]

170.

Bij de Vaate AJ, van Doorninck CE, Visser M, et al. Endometrial aspiration before or after saline infusion sonography and the effect on specimen quality: a randomized study. J Minim Invasive Gynecol. 2008 Sep-Oct;15(5):580–3. X-4, X-5, X-9. [PubMed: 18675597]

171.

Biller BM, Baum HB, Rosenthal DI, et al. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab. 1992 Sep;75(3):692–7. X-3, X-5. [PubMed: 1517356]

172.

Billiet K, Dhont M, Vervaet C, et al. A multi-center prospective, randomized, double-blind trial studying the effect of misoprostol on the outcome of intrauterine insemination. Gynecol Obstet Invest. 2008;66(3):145–51. X-5, X-9. [PubMed: 18493141]

173.

Bingol B, Gunenc MZ, Gedikbasi A, et al. Comparison of diagnostic accuracy of saline infusion sonohysterography, transvaginal sonography and hysteroscopy in postmenopausal bleeding. Arch Gynecol Obstet. 2011 Jul;284(1):111–7. X-3, X-4, X-5, X-7. [PubMed: 20665218]

174.

Birbara C, Ruoff G, Sheldon E, et al. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. Current Medical Research and Opinion. 2006;22(1):199–210. X-5. [PubMed: 16393445]

175.

Bitto A, Granese R, Triolo O, et al. Genistein aglycone: a new therapeutic approach to reduce endometrial hyperplasia. Phytomedicine. 2010 Sep;17(11):844–50. X-6. [PubMed: 20570122]

176.

Bjarnadottir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol. 2002 Mar;186(3):389–95. X-4, X-5. [PubMed: 11904596]

177.

Blankstein J, Rabinovici J, Goldenberg M, et al. Changing pituitary reactivity to follicle-stimulating hormone and luteinizing hormone-releasing hormone after induced ovulatory cycles and after anovulation in patients with polycystic ovarian disease. J Clin Endocrinol Metab. 1987 Dec;65(6):1164–7. X-4, X-5, X-10. [PubMed: 3119650]

178.

Bloch-Thomsen A, Silvestri S, Christiansen C, et al. Associated response in bone mineral density and atherogenic lipid profile during treatment with two different selective estrogen receptor modulators: Levormeloxifene and raloxifene. Climacteric. 2003;6(2):159–67. X-5, X-7. [PubMed: 12841887]

179.

Blode H, Klipping C, Richard F, et al. Bioequivalence study of an oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium relative to ethinylestradiol/drospirenone and to levomefolate calcium alone. Contraception. 2012 February;85(2):177–84. X-3, X-4, X-9, X-10. [PubMed: 22067789]

180.

Blum M, Blum G. The possible relationship between menorrhagia and occult hypothyroidism in IUD-wearing women. Adv Contracept. 1992 Dec;8(4):313–7. X-3, X-4, X-5. [PubMed: 1290333]

181.

Blumenfeld Z, Von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Human Reproduction Update. 2008;14(6):543–52. X-1, X-3, X-5. [PubMed: 18824495]

182.

Boateng J, Chi IC, Jones DB. An evaluation of six new intrauterine devices. Adv Contracept. 1994 Mar;10(1):57–70. X-1, X-3, X-5, X-9. [PubMed: 8030456]

183.

Boerrigter PJ, van de Weijer PH, Baak JP, et al. Endometrial response in estrogen replacement therapy quarterly combined with a progestogen. Maturitas. 1996 May;24(1-2):63–71. X-5, X-7. [PubMed: 8794436]

184.

Bolaji II, Mortimer G, Grimes H, et al. Clinical evaluation of near-continuous oral micronized progesterone therapy in estrogenized postmenopausal women. Gynecol Endocrinol. 1996 Feb;10(1):41–7. X-3, X-7. [PubMed: 8737191]

185.

Bonduelle M, Walker JJ, Calder AA. A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgrad Med J. 1991 Sep;67(791):833–6. X-5. [PMC free article: PMC2399106] [PubMed: 1835005]

186.

Bongers MY, Bourdrez P, Heintz AP, et al. Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health-related quality of life. Fertil Steril. 2005 Mar;83(3):724–34. X-5, X-8. [PubMed: 15749505]

187.

Bongers MY, Bourdrez P, Mol BW, et al. Randomised controlled trial of bipolar radio-frequency endometrial ablation and balloon endometrial ablation. BJOG. 2004 Oct;111(10):1095–102. X-5, X-8. [PubMed: 15383112]

188.

Bonn M, Eydeler U, Barkworth M, et al. Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers. Arzneimittel Forschung/Drug Research. 2009;59(12):651–8. X-4. [PubMed: 20108652]

189.

Bonnar J. Acquired bleeding disorders: bleeding in obstetrics and surgery. Southeast Asian J Trop Med Public Health. 1993;24 Suppl 1:10–2. X-3, X-5. [PubMed: 7886547]

190.

Bonnema RA, McNamara MC, Spencer AL. Contraception choices in women with underlying medical conditions. Am Fam Physician. 2010 Sep 15;82(6):621–8. X-1, X-4, X-5, X-9. [PubMed: 20842989]

191.

Boonkasemsanti W, Reinprayoon D, Pruksananonda K, et al. The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users. Hum Reprod. 1996 Oct;11 Suppl 2:115–23. X-4, X-5, X-6. [PubMed: 8982753]

192.

Boonyarangkul A, Taneepanichskul S. Comparison of cycle control and side effects between transdermal contraceptive patch and an oral contraceptive in women older than 35 years. Journal of the Medical Association of Thailand. 2007;90(9):1715–9. X-9. [PubMed: 17957909]

193.

Bouchard P, De Cicco-Nardone F, Spielmann D, et al. Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17beta-estradiol/trimegestone versus 1 or 2 mg 17beta-estradiol/norethisterone acetate in postmenopausal women. Gynecol Endocrinol. 2005 Sep;21(3):142–8. X-5, X-7. [PubMed: 16353319]

194.

Boucher M, Horbay GL, Griffin P, et al. Double-blind, randomized comparison of the effect of carbetocin and oxytocin on intraoperative blood loss and uterine tone of patients undergoing cesarean section. J Perinatol. 1998 May-Jun;18(3):202–7. X-5, X-9. [PubMed: 9659650]

195.

Bourdy G, Walter A. Maternity and medicinal plants in Vanuatu. I. The cycle of reproduction. J Ethnopharmacol. 1992 Oct;37(3):179–96. X-3, X-5. [PubMed: 1453707]

196.

Braam LAJLM, Knapen MHJ, Geusens P, et al. Factors Affecting Bone Loss in Female Endurance Athletes. A Two-Year Follow-Up Study. American Journal of Sports Medicine. 2003;31(6):889–95. X-3, X-5. [PubMed: 14623654]

197.

Bratby MJ, Walker WJ. Uterine artery embolisation for symptomatic adenomyosis--mid-term results. Eur J Radiol. 2009 Apr;70(1):128–32. X-4, X-5, X-8, X-9. [PubMed: 18280686]

198.

Brenner B, Wiis J. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency. Hematology. 2007 Feb;12(1):55–62. X-4, X-5, X-9. [PubMed: 17364994]

199.

Breum L, Bjerre U, Bak JF, et al. Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: Influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism: Clinical and Experimental. 1996;44(12):1570–6. X-4, X-5. [PubMed: 8786726]

200.

Brill K, Schnitker J, Albring M. Clinical experience with a modern low-dose gestodene-containing oral contraceptive in adolescents. Adv Contracept. 1994 Dec;10(4):237–47. X-3, X-9. [PubMed: 7740990]

201.

Broocks A, Pirke KM, Schweiger U, et al. Cyclic ovarian function in recreational athletes. J Appl Physiol. 1990 May;68(5):2083–6. X-3, X-4, X-5. [PubMed: 2361910]

202.

Brooks PG, Serden SP. Preparation of the endometrium for ablation with a single dose of leuprolide acetate depot. J Reprod Med. 1991 Jul;36(7):477–8. X-3, X-5, X-8. [PubMed: 1941784]

203.

Brown LM, Pottern LM, Hoover RN. Prenatal and perinatal risk factors for testicular cancer. Cancer Res. 1986 Sep;46(9):4812–6. X-3, X-5. [PubMed: 3731127]

204.

Brown PM, Farquhar CM, Lethaby A, et al. Cost-effectiveness analysis of levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding. BJOG. 2006 Jul;113(7):797–803. X-8. [PubMed: 16827763]

205.

Browne DS. Endometrial resection--a comparison of techniques. Aust N Z J Obstet Gynaecol. 1996 Nov;36(4):448–52. X-4, X-5, X-8. [PubMed: 9006832]

206.

Bruce D, Robinson J, Rymer J. Long-term effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy. Climacteric. 2004 Sep;7(3):261–6. X-4, X-5, X-7. [PubMed: 15669550]

207.

Bruhat M, Rudolf K, Vaheri R, et al. Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy: a randomized comparative dose-ranging study. Maturitas. 2001 Dec 14;40(3):259–71. X-5, X-7. [PubMed: 11731187]

208.

Bruni V, Croxatto H, De La Cruz J, et al. A comparison of cycle control and effect on well-being of monophasic gestodene-, triphasic gestodene- and monophasic desogestrel-containing oral contraceptives. Gestodene Study Group. Gynecol Endocrinol. 2000 Apr;14(2):90–8. X-4, X-5. [PubMed: 10836195]

209.

Bruni V, Croxatto H, De La Cruz J, et al. A comparison of cycle control and effect on well-being of monophasic gestodene-, triphasic gestodene- and monophasic desogestrel-containing oral contraceptives. Gynecological Endocrinology. 2000;14(2):90–8. X-6, X-9. [PubMed: 10836195]

210.

Bruni V, Pontello V, Luisi S, et al. An open-label, multicentre trial to evaluate the vaginal bleeding pattern of the combined contraceptive vaginal ring NuvaRing. Eur J Obstet Gynecol Reprod Biol. 2008 Jul;139(1):65–71. X-4, X-5. [PubMed: 18358586]

211.

Brynhildsen J, Hammar M. Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women. Menopause. 2002 Mar-Apr;9(2):137–44. X-5, X-7. [PubMed: 11875333]

212.

Buasang K, Taneepanichskul S. Efficacy of celecoxib on controlling irregular uterine bleeding secondary to Jadelle use. J Med Assoc Thai. 2009 Mar;92(3):301–7. X-4, X-5, X-6, X-9. [PubMed: 19301720]

213.

Buchanan RB, Blamey RW, Durrant KR, et al. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol. 1986 Sep;4(9):1326–30. X-5. [PubMed: 3528402]

214.

Buckley RG, King KJ, Disney JD, et al. Serum progesterone testing to predict ectopic pregnancy in symptomatic first-trimester patients. Ann Emerg Med. 2000 Aug;36(2):95–100. X-4, X-5, X-6, X-9. [PubMed: 10918099]

215.

Buckshee K, Banerjee K, Bhatla H. Uterine balloon therapy to treat menorrhagia. Int J Gynaecol Obstet. 1998 Nov;63(2):139–43. X-4, X-5, X-8. [PubMed: 9856319]

216.

Buehler JW, Schulz KF, Grimes DA, et al. The risk of serious complications from induced abortion: do personal characteristics make a difference? Am J Obstet Gynecol. 1985 Sep 1;153(1):14–20. X-3, X-5. [PubMed: 4036997]

217.

Bulletti C, Flamigni C, Prefetto RA, et al. Dysfunctional uterine bleeding (DUB). Ann N Y Acad Sci. 1994 Sep 30;734:80–90. X-5. [PubMed: 7978956]

218.

Buppasiri P, Tangmanowutikul S, Yoosuk W. Randomized controlled trial of mefenamic acid vs paracervical block for relief of pain for outpatient uterine curettage. J Med Assoc Thai. 2005 Jul;88(7):881–5. X-5, X-9. [PubMed: 16241013]

219.

Burch D, Bieshuevel E, Smith S, et al. Can endometrial protection be inferred from the bleeding pattern on combined cyclical hormone replacement therapy. Maturitas. 2000 Feb 15;34(2):155–60. X-5, X-7. [PubMed: 10714910]

220.

Burch DJ, Spowart KJ, Jesinger DK, et al. A dose-ranging study of the use of cyclical dydrogesterone with continuous 17 beta oestradiol. Br J Obstet Gynaecol. 1995 Mar;102(3):243–8. X-7. [PubMed: 7794851]

221.

Busacca M, Luchini S, Molinari MA, et al. Hysteroscopic pictures following danazol therapy in endometrial hyperplasia. Acta Eur Fertil. 1987 May-Jun;18(3):197–201. X-3. [PubMed: 3439406]

222.

Busfield RA, Farquhar CM, Sowter MC, et al. A randomised trial comparing the levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding. BJOG. 2006 Mar;113(3):257–63. X-8. [PubMed: 16487195]

223.

Bushnell DM, Martin ML, Moore KA, et al. Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life. Curr Med Res Opin. 2010 Dec;26(12):2745–55. X-4, X-5, X-9. [PubMed: 21043553]

224.

Buyuk E, Durmusoglu F, Dokmeci C. Effect of initial gestagen treatment on bleeding patterns in postmenopausal women receiving continuous combined hormone replacement therapy. Menopause. 1999 Summer;6(2):156–60. X-4, X-5, X-7. [PubMed: 10374223]

225.

Byrjalsen I, Alexandersen P, Christiansen C. Piperazine oestrone sulphate and interrupted norethisterone: effects on the postmenopausal endometrium. BJOG. 2000 Mar;107(3):347–55. X-4, X-5, X-7. [PubMed: 10740331]

226.

Byrjalsen I, Bjarnason NH, Christiansen C. Progestational effects of combinations of gestodene on the postmenopausal endometrium during hormone replacement therapy. Am J Obstet Gynecol. 1999 Mar;180(3 Pt 1):539–49. X-5, X-7. [PubMed: 10076125]

227.

Byrjalsen I, Thormann L, Meinecke B, et al. Sequential estrogen and progestogen therapy: assessment of progestational effects on the postmenopausal endometrium. Obstet Gynecol. 1992 Apr;79(4):523–8. X-4, X-7. [PubMed: 1532445]

228.

Byrjalsen I, Thormann L, Riis BJ, et al. Secretory endometrial protein PP14 in serum from post-menopausal women receiving continuous combined oestradiol-cyproterone acetate: correlation with serum hormone concentrations and bleeding patterns. Maturitas. 1992 Aug;15(1):39–46. X-3, X-4, X-7. [PubMed: 1388220]

229.

Cachrimanidou AC, Hellberg D, Nilsson S, et al. Long-interval treatment regimen with a desogestrel-containing oral contraceptive. Contraception. 1993 Sep;48(3):205–16. X-5, X-6, X-9. [PubMed: 8222651]

230.

Cai XM, Wu J. The mind-tranquilizing and menstruation-regulating method for acupuncture treatment of delayed menstrual cycle - A clinical controlled study. Journal of Traditional Chinese Medicine. 2009;29(1):35–8. X-12. [PubMed: 19514186]

231.

Calguneri M, Ozbalkan Z, Ozturk MA, et al. Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome). Clin Rheumatol. 2006 Nov;25(6):782–8. X-4, X-5, X-9. [PubMed: 16547692]

232.

Caliskan E, Filiz T, Yucesoy G, et al. Sublingual versus vaginal misoprostol for cervical ripening PRIOR to manual vacuum aspiration under local anaesthesia: A randomized study. European Journal of Contraception and Reproductive Health Care. 2007;12(4):372–7. X-5. [PubMed: 17853158]

233.

Cameron IT, Baird DT. A controlled release form of 16,16-dimethyl-trans-delta 2-PGE, methyl ester for early abortion. Contraception. 1986 Feb;33(2):121–5. X-3, X-5. [PubMed: 3698593]

234.

Cameron ST, Glasier AF, Gebbie A, et al. Comparison of a transdermal continuous combined and an interrupted progestogen HRT. Maturitas. 2006 Jan 10;53(1):19–26. X-5, X-7. [PubMed: 16325020]

235.

Cameron ST, Walker J, Chambers S, et al. Comparison of transvaginal ultrasound, saline infusion sonography and hysteroscopy to investigate postmenopausal bleeding and unscheduled bleeding on HRT. Aust N Z J Obstet Gynaecol. 2001 Aug;41(3):291–4. X-4, X-5, X-7. [PubMed: 11592543]

236.

Candiani GB, Vercellini P, Fedele L, et al. Use of goserelin depot, a gonadotropin-releasing hormone agonist, for the treatment of menorrhagia and severe anemia in women with leiomyomata uteri. Acta Obstet Gynecol Scand. 1990;69(5):413–5. X-3, X-6. [PubMed: 2148663]

237.

Canning S, Waterman M, Orsi N, et al. The efficacy of hypericum perforatum (st john's wort) for the treatment of premenstrual syndrome: A randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010;24(3):207–25. X-5. [PubMed: 20155996]

238.

Cano A, Tarin JJ, Duenas JL. Two-year prospective, randomized trial comparing an innovative twice-a- week progestin regimen with a continuous combined regimen as postmenopausal hormone therapy. Fertility and Sterility. 1999;71(1):129–36. X-7. [PubMed: 9935129]

239.

Canto De, Cetina TE, Canto P, Ordonez Luna M. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. Contraception. 2001 Mar;63(3):143–6. X-4, X-5, X-6, X-9. [PubMed: 11368986]

240.

Canto de Cetina TE, Luna MO, Cetina Canto JA, et al. Menstrual pattern and lipid profiles during use of medroxyprogesterone acetate and estradiol cypionate and NET-EN (200 mg) as contraceptive injections. Contraception. 2004 Feb;69(2):115–9. X-4, X-5. [PubMed: 14759615]

241.

Carbonell JL, Rodriguez J, Aragon S, et al. Vaginal misoprostol 1000 microg for early abortion. Contraception. 2001 Mar;63(3):131–6. X-4, X-5, X-9. [PubMed: 11368984]

242.

Carbonell JL, Rodriguez J, Delgado E, et al. Vaginal misoprostol 800 microg every 12 h for second-trimester abortion. Contraception. 2004 Jul;70(1):55–60. X-4, X-5, X-9. [PubMed: 15208053]

243.

Carbonell JL, Varela L, Velazco A, et al. The use of misoprostol for abortion at < or = 9 weeks' gestation. Eur J Contracept Reprod Health Care. 1997 Sep;2(3):181–5. X-4, X-5, X-6, X-9. [PubMed: 9678090]

244.

Cardamakis E, Georgopoulos A, Fotopoulos A, et al. Clinical experience with Norplant subdermal implant system as long-term contraception during adolescence. Eur J Contracept Reprod Health Care. 2002 Mar;7(1):36–40. X-4, X-5, X-6. [PubMed: 12041863]

245.

Carlborg L. Comparison of contraceptive acceptability of levonorgestrel and ethinyl oestradiol administered in one three-phasic (Trionetta) and one monophasic (Neovletta) version. Contraception. 1983;27(5):439–52. X-9. [PubMed: 6349925]

246.

Carr BR. Cycle control with desogestrel-containing oral contraceptives--comparison of a monophasic and triphasic regimen. Int J Fertil Menopausal Stud. 1993 Sep-Oct;38(5):274–9. X-3, X-5, X-9. [PubMed: 8298666]

247.

Carr BR, DelConte A. Using a low-dose contraceptive in women 35 years of age and over: 20 microg estradiol/100 microg levonorgestrel. Contraception. 2002 Jun;65(6):397–402. X-4, X-5. [PubMed: 12127636]

248.

Carranza-Lira S, Martinez-Chequer JC, Santa Rita MT, et al. Endometrial changes according to hormone replacement therapy schedule. Menopause. 1998 Summer;5(2):86–9. X-3, X-4, X-7, X-8. [PubMed: 9689201]

249.

Castaman G, Tosetto A, Federici AB, et al. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. Thromb Haemost. 2011 Apr;105(4):647–54. X-4, X-5, X-6, X-9. [PubMed: 21264446]

250.

Castelo-Branco C, Vicente JJ, Pons F, et al. Bone mineral density in young, hypothalamic oligoamenorrheic women treated with oral contraceptives. J Reprod Med. 2001 Oct;46(10):875–9. X-5, X-6, X-9. [PubMed: 11725730]

251.

Cayan F, Dilek U, Pata O, et al. Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women. Journal of Sexual Medicine. 2008;5(1):132–8. X-7. [PubMed: 17961145]

252.

Cetin A, Cetin M. Diagnostic and therapeutic decision-making with transvaginal sonography for first trimester spontaneous abortion, clinically thought to be incomplete or complete. Contraception. 1998 Jun;57(6):393–7. X-4, X-5, X-9. [PubMed: 9693399]

253.

Cetin NN, Karabacak O, Korucuoglu U, et al. Gonadotropin-releasing hormone analog combined with a low-dose oral contraceptive to treat heavy menstrual bleeding. Int J Gynaecol Obstet. 2009 Mar;104(3):236–9. X-5. [PubMed: 19062012]

254.

Cetinkalp S, Karadeniz M, Erdogan M, et al. The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist. 2009;19(3):94–7. X-4, X-5, X-10.

255.

Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2007 Sep;92(9):3582–9. X-4, X-5, X-9. [PubMed: 17579200]

256.

Chadha Y, Mollison J, Howie F, et al. Guidelines in gynaecology: evaluation in menorrhagia and in urinary incontinence. BJOG. 2000 Apr;107(4):535–43. X-4, X-5, X-9. [PubMed: 10759275]

257.

Chakraborti AS, Chatterjee P, Dutta S, et al. Rate of formation of hydrogen peroxide (H2O2) in IUD-fitted human endometrium--a preliminary report. Int J Fertil. 1982;27(3):132–3. X-3, X-4, X-5. [PubMed: 6128316]

258.

Chamberlain G. Comparing treatments for menorrhagia. Nurs Times. 1992 Mar 11-17;88(11):46. X-1, X-3, X-5, X-10. [PubMed: 1297082]

259.

Chamberlain G, Freeman R, Price F, et al. A comparative study of ethamsylate and mefenamic acid in dysfunctional uterine bleeding. Br J Obstet Gynaecol. 1991 Jul;98(7):707–11. X-3. [PubMed: 1883797]

260.

Chamberlain JA, Jamieson WM. Patient response to endometrial ablation with the Nd:YAG laser. Laser Nursing. 1989;3(3):5–11. X-3, X-8.

261.

Chan CC, To WW. Antepartum hemorrhage of unknown origin--what is its clinical significance? Acta Obstet Gynecol Scand. 1999 Mar;78(3):186–90. X-4, X-5, X-9. [PubMed: 10078578]

262.

Chan KK, Tam KF, Tse KY, et al. The use of vaginal antimicrobial after large loop excision of transformation zone: a prospective randomised trial. BJOG. 2007 Aug;114(8):970–6. X-5, X-9. [PubMed: 17635487]

263.

Chan YF, Ho PC, Ma HK. Blood loss in termination of early pregnancy by vacuum aspiration and by combination of mifepristone and gemeprost. Contraception. 1993 Jan;47(1):85–95. X-3, X-5. [PubMed: 8436004]

264.

Chang BH, Edelman A, Godder K. Management of menstrual bleeding and cycle control after hematopoietic stem cell transplant. Int J Gynaecol Obstet. 2008 Jan;100(1):76–7. X-5, X-9. [PubMed: 17612542]

265.

Chatterjee R, Banerjee S, Ghosh KK, et al. A study of postpill amenorrhea. Int J Gynaecol Obstet. 1980 Sep-Oct;18(2):113–4. X-3, X-5, X-6. [PubMed: 6108247]

266.

Chattopdhyay B, Nigam A, Goswami S, et al. Clinical outcome of levonorgestrel intra-uterine system in idiopathic menorrhagia. Eur Rev Med Pharmacol Sci. 2011 Jul;15(7):764–8. X-4. [PubMed: 21780544]

267.

Chaudhuri SK, Das A, De KC, et al. Some hitherto unreported findings on the extragenital effects of progesterone in human females--a clinical study. Indian J Physiol Pharmacol. 1994 Jul;38(3):174–80. X-3. [PubMed: 7814077]

268.

Chaudhury N, Gupta AN, Hazra MN, et al. Phase III-clinical trial with Norplant-2 (covered rods). Report of a 24-month study. National Programme of Research in Human Reproduction. Division of Human Resource Development Research Indian Council of Medical Research Ansari Nagar, New Delhi, India. Contraception. 1988 Dec;38(6):659–73. X-3, X-5, X-9. [PubMed: 3146464]

269.

Chavez A, DelConte A. A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 micrograms/20 micrograms versus triphasic norethindrone/ethinylestradiol 500-750-1000 micrograms/35 micrograms: a multicenter, randomized, open-label study. Eur J Contracept Reprod Health Care. 1999 Jun;4(2):75–83. X-5. [PubMed: 10427482]

270.

Chavez A, DelConte A. A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 mug/20 mug versus triphasic norethindrone/ethinylestradiol 500-750-1000 mug/35 mug: A multicenter, randomized, open-label study. European Journal of Contraception and Reproductive Health Care. 1999;4(2):75–83. X-9. [PubMed: 10427482]

271.

Cheewadhanaraks S, Peeyananjarassri K, Choksuchat C, et al. Interval of injections of intramuscular depot medroxyprogesterone acetate in the long-term treatment of endometriosis-associated pain: A randomized comparative trial. Gynecologic and Obstetric Investigation. 2009;68(2):116–21. X-5, X-10. [PubMed: 19556801]

272.

Chen AY, Mottl-Santiago J, Vragovic O, et al. Bleeding after medication-induced termination of pregnancy with two dosing schedules of mifepristone and misoprostol. Contraception. 2006 Apr;73(4):415–9. X-4, X-5, X-9. [PubMed: 16531178]

273.

Chen H, Li J, Cui T, et al. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database of Systematic Reviews. 2011;(11) X-1, X-3, X-5. [PubMed: 22071842]

274.

Chen JH, Wu SC, Shao WQ, et al. The comparative trial of TCu 380A IUD and progesterone-releasing vaginal ring used by lactating women. Contraception. 1998 Jun;57(6):371–9. X-3, X-9. [PubMed: 9693396]

275.

Cheng L, Zhu H, Wang A, et al. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel. Hum Reprod. 2000 Sep;15(9):1969–72. X-5, X-6. [PubMed: 10966997]

276.

Cheng WC, Yen ML, Hsu SHJ, et al. Effects of raloxifene, one of the selective estrogen receptor modulators, on pituitary-ovary axis and prolactin in postmenopausal women. Endocrine. 2004;23(2-3):215–8. X-7. [PubMed: 15146102]

277.

Cheng WF, Lin HH, Torng PL, et al. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol. 1997 Aug;66(2):233–7. X-4, X-5, X-6, X-7, X-9. [PubMed: 9264568]

278.

Chetri M, Bhatta A, Amatya RN, et al. Five-year evaluation of safety, efficacy and acceptability of Norplant implants in Nepal. Adv Contracept. 1996 Sep;12(3):187–99. X-4, X-5. [PubMed: 8910661]

279.

Cheung TH, Lo KW, Yim SF, et al. Dose effects of progesterone in add-back therapy during GnRHa treatment. J Reprod Med. 2005 Jan;50(1):35–40. X-5, X-9. [PubMed: 15730171]

280.

Chick P. Prescribing an oral contraceptive for the individual woman. Aust Fam Physician. 1980 Feb;(Suppl):8–12. X-5, X-9. [PubMed: 6444808]

281.

Chimbira TH, Anderson AB, Naish C, et al. Reduction of menstrual blood loss by danazol in unexplained menorrhagia: lack of effect of placebo. Br J Obstet Gynaecol. 1980 Dec;87(12):1152–8. X-3, X-5. [PubMed: 7002206]

282.

Chiwuzie J, Braimoh S, Unuigbe J, et al. Causes of maternal mortality in a semi-urban Nigerian setting. World Health Forum. 1995;16(4):405–8. X-3, X-5. [PubMed: 8534349]

283.

Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004 Mar 4;350(10):991–1004. X-5, X-7. [PubMed: 14999111]

284.

Chompootaweep S, Kochagarn E, Tang-Usaha J, et al. Experience of Thai women in Bangkok with Norplant-2 implants. Contraception. 1998 Oct;58(4):221–5. X-3, X-9. [PubMed: 9866003]

285.

Christodoulacos G, Panoulis C, Botsis D, et al. Transvaginal sonographic monitoring of the uterine effects of raloxifene and a continuous combined replacement therapy in postmenopausal women. Maturitas. 2002;42(1):77–84. X-4, X-7. [PubMed: 12020983]

286.

Christodoulakos GE, Botsis DS, Lambrinoudaki IV, et al. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness. Maturitas. 2006 Mar 20;53(4):413–23. X-4, X-5, X-7. [PubMed: 16140483]

287.

Chuansumrit A, Wangruangsatid S, Lektrakul Y, et al. Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study. Blood Coagul Fibrinolysis. 2005 Nov;16(8):549–55. X-5, X-9. [PubMed: 16269927]

288.

Chung JW, Jeong HJ, Joh JH, et al. Percutaneous transcatheter angiographic embolization in the management of obstetric hemorrhage. J Reprod Med. 2003 Apr;48(4):268–76. X-4, X-5, X-6, X-8. [PubMed: 12746991]

289.

Chuni N, Chandrashekhar TS. Early pregnancy termination with a simplified mifepristone: Medical abortion outpatient regimen. Kathmandu Univ Med J (KUMJ). 2009 Jul-Sep;7(27):209–12. X-4, X-5, X-9. [PubMed: 20071864]

290.

Churchyard GJ, Morgan C, Adams E, et al. A phase iia randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade RAD5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One. 2011;6(8) X-5. [PMC free article: PMC3152265] [PubMed: 21857901]

291.

Chwalisz K, Elger W, Stickler T, et al. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Human Reproduction. 2005;20(4):1090–9. X-5. [PubMed: 15665012]

292.

Chwalisz K, Larsen L, Mattia-Goldberg C, et al. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril. 2007 Jun;87(6):1399–412. X-5, X-6. [PubMed: 17307170]

293.

Cicardi M, Castelli R, Zingale LC, et al. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol. 1997 Feb;99(2):194–6. X-4, X-5, X-9. [PubMed: 9042044]

294.

Cicinelli E, de Ziegler D, Alfonso R, et al. Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study. Fertil Steril. 2005 Jun;83(6):1859–63. X-4, X-5, X-7. [PubMed: 15950667]

295.

Cicinelli E, Pinto V, Tinelli R, et al. Rapid endometrial preparation for hysteroscopic surgery with oral desogestrel plus vaginal raloxifene: a prospective, randomized pilot study. Fertility and Sterility. 2007;88(3):698–701. X-5, X-6. [PubMed: 17678902]

296.

Cirkel U, Ochs H, Schneider HP. A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. Eur J Obstet Gynecol Reprod Biol. 1995 Mar;59(1):61–9. X-5, X-6, X-10. [PubMed: 7781864]

297.

Claessens EA, Cowell CA. Acute adolescent menorrhagia. Am J Obstet Gynecol. 1981 Feb 1;139(3):277–80. X-3, X-5. [PubMed: 6970521]

298.

Clark LR, Barnes-Harper KT, Ginsburg KR, et al. Menstrual irregularity from hormonal contraception: a cause of reproductive health concerns in minority adolescent young women. Contraception. 2006 Sep;74(3):214–9. X-4, X-5, X-6, X-9. [PubMed: 16904414]

299.

Clark TJ, Gupta JK. Outpatient thermal balloon ablation of the endometrium. Fertil Steril. 2004 Nov;82(5):1395–401. X-4, X-5, X-8. [PubMed: 15533366]

300.

Clark TJ, Samuel N, Malick S, et al. Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office: A randomized controlled trial. Obstetrics and Gynecology. 2011;117(1):109–18. X-8. [PubMed: 21173651]

301.

Clegg JP, Guest JF, Hurskainen R. Cost-utility of levonorgestrel intrauterine system compared with hysterectomy and second generation endometrial ablative techniques in managing patients with menorrhagia in the UK. Curr Med Res Opin. 2007 Jul;23(7):1637–48. X-5, X-8, X-9. [PubMed: 17559758]

302.

Clisham PR, Cedars MI, Greendale G, et al. Long-term transdermal estradiol therapy: effects on endometrial histology and bleeding patterns. Obstet Gynecol. 1992 Feb;79(2):196–201. X-7. [PubMed: 1731285]

303.

Clisham PR, de Ziegler D, Lozano K, et al. Comparison of continuous versus sequential estrogen and progestin therapy in postmenopausal women. Obstet Gynecol. 1991 Feb;77(2):241–6. X-7. [PubMed: 1846438]

304.

Cobb KL, Bachrach LK, Greendale G, et al. Disordered eating, menstrual irregularity, and bone mineral density in female runners. Medicine and Science in Sports and Exercise. 2003;35(5):711–9. X-3, X-4, X-5. [PubMed: 12750578]

305.

Cobb KL, Bachrach LK, Sowers M, et al. The effect of oral contraceptives on bone mass and stress fractures in female runners. Med Sci Sports Exerc. 2007 Sep;39(9):1464–73. X-5, X-9. [PubMed: 17805075]

306.

Cochrane R, Regan L. Undetected gynaecological disorders in women with renal disease. Hum Reprod. 1997 Apr;12(4):667–70. X-4, X-5, X-9. [PubMed: 9159421]

307.

Coelingh Bennink HJ, van der Steeg HJ. Failure of bromocriptine to restore the menstrual cycle in normoprolactinemic post-pill amenorrhea. Fertil Steril. 1983 Feb;39(2):238–40. X-5, X-6, X-10. [PubMed: 6822306]

308.

Coenen CMH, Thomas CMG, Borm GF, et al. Changes in androgens during treatment with four low-dose contraceptives. Contraception. 1996;53(3):171–6. X-4, X-5. [PubMed: 8689882]

309.

Cohen CR, Brown J, Moscicki AB, et al. A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel(R)) in healthy young women administered twice daily for 14 days. PLoS One. 2011;6(1):e16258. X-5. [PMC free article: PMC3024437] [PubMed: 21311578]

310.

Cohen I, Azaria R, Fishman A, et al. Endometrial cancers in postmenopausal breast cancer patients with tamoxifen treatment. Int J Gynecol Pathol. 1999 Oct;18(4):304–9. X-4, X-5, X-6, X-7. [PubMed: 10542937]

311.

Cohen I, Figer A, Tepper R, et al. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients. Gynecol Oncol. 1999 Feb;72(2):202–7. X-4, X-5, X-6, X-9. [PubMed: 10021302]

312.

Colacurci N, De Placido G, Mollo A, et al. Short-term use of Goserelin depot in the treatment of dysfunctional uterine bleeding. Clin Exp Obstet Gynecol. 1995;22(3):212–9. X-3. [PubMed: 7554259]

313.

Colao A, Pivonello R, Di Somma C, et al. Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome. Clin Endocrinol (Oxf). 2007 May;66(5):714–22. X-4, X-5, X-9. [PubMed: 17388794]

314.

Cole LP, Potts DM, Aranda C, et al. An evaluation of the TCu 380Ag and the Multiload Cu375. Fertil Steril. 1985 Feb;43(2):214–7. X-9. [PubMed: 3881295]

315.

Colgan TJ, Pendergast S, LeBlanc M. The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues. Hum Pathol. 1993 Oct;24(10):1073–7. X-3, X-6, X-8. [PubMed: 8406417]

316.

Collett D, Weerasooriya N. A modelling approach to the analysis of menstrual diary data. Stat Med. 1993 May 30;12(10):955–65. X-3, X-4, X-5. [PubMed: 8337552]

317.

Comparato MR, Yabur JA, Bajares M. Contraceptive efficacy and acceptability of a monophasic oral contraceptive containing 30 microg ethinyl estradiol and 150 microg desogestrel in Latin-American women. Adv Contracept. 1998 Mar;14(1):15–26. X-3, X-9. [PubMed: 9587005]

318.

Confino E, Ismajovich B, Rudick A, et al. Comparison between OM-GA Cu and Copper-T IUCDs. Contraception. 1983 Dec;28(6):521–5. X-9. [PubMed: 6370586]

319.

Connor PD, Tavernier LA, Thomas SM, et al. Determining risk between Depo-Provera use and increased uterine bleeding in obese and overweight women. J Am Board Fam Pract. 2002 Jan-Feb;15(1):7–10. X-4, X-5, X-9. [PubMed: 11841143]

320.

Contreras CM, Azamar-Arizmendi G, Saavedra M, et al. A Five-Day Gradual Reduction Regimen of Chlormadinone Reduces Premenstrual Anxiety and Depression: A Pilot Study. Archives of Medical Research. 2006;37(7):907–13. X-5. [PubMed: 16971235]

321.

Cooper KG, Grant AM, Garratt AM. The impact of using a partially randomised patient preference design when evaluating alternative managements for heavy menstrual bleeding. Br J Obstet Gynaecol. 1997 Dec;104(12):1367–73. X-5, X-8. [PubMed: 9422014]

322.

Cooper KG, Jack SA, Parkin DE, et al. Five-year follow up of women randomised to medical management or transcervical resection of the endometrium for heavy menstrual loss: clinical and quality of life outcomes. BJOG. 2001 Dec;108(12):1222–8. X-5, X-8. [PubMed: 11843383]

323.

Cooper KG, Parkin DE, Garratt AM, et al. A randomised comparison of medical and hysteroscopic management in women consulting a gynaecologist for treatment of heavy menstrual loss. Br J Obstet Gynaecol. 1997 Dec;104(12):1360–6. X-4, X-8. [PubMed: 9422013]

324.

Cooper KG, Parkin DE, Garratt AM, et al. Two-year follow up of women randomised to medical management or transcervical resection of the endometrium for heavy menstrual loss: clinical and quality of life outcomes. Br J Obstet Gynaecol. 1999 Mar;106(3):258–65. X-5, X-8. [PubMed: 10426646]

325.

Corson SL. A multicenter evaluation of endometrial ablation by Hydro ThermAblator and rollerball for treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 2001 Aug;8(3):359–67. X-5, X-8. [PubMed: 11509774]

326.

Corson SL, Brill AI, Brooks PG, et al. One-year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists. 2000;7(4):489–97. X-8. [PubMed: 11044499]

327.

Coskun E, Cakiroglu Y, Aygun BK, et al. Effect of copper intrauterine device on the cyclooxygenase and inducible nitric oxide synthase expression in the luteal phase endometrium. Contraception. 2011 Dec;84(6):637–41. X-3, X-4, X-5. [PubMed: 22078195]

328.

Cosman F, Baz-Hecht M, Cushman M, et al. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: A randomized-controlled study and review of the literature. Thrombosis Research. 2005;116(1):1–3. X-7. [PubMed: 15850603]

329.

Costa SH, Vessey MP. Misoprostol and illegal abortion in Rio de Janeiro, Brazil. Lancet. 1993 May 15;341(8855):1258–61. X-3, X-5. [PubMed: 8098402]

330.

Coulter A, Peto V, Doll H. Patients' preferences and general practitioners' decisions in the treatment of menstrual disorders. Fam Pract. 1994 Mar;11(1):67–74. X-3. [PubMed: 8034155]

331.

Coulter A, Peto V, Jenkinson C. Quality of life and patient satisfaction following treatment for menorrhagia. Fam Pract. 1994 Dec;11(4):394–401. X-3. [PubMed: 7895967]

332.

Coutinho EM. One year contraception with a single subdermal implant containing nomegestrol acetate (Uniplant). Contraception. 1993 Jan;47(1):97–105. X-3, X-9. [PubMed: 8436005]

333.

Coutinho EM, Boulanger GA, Goncalves MT. Regression of uterine leiomyomas after treament with gestrinone, an antiestrogen, antiprogesterone. American Journal of Obstetrics and Gynecology. 1986;155(4):761–7. X-3, X-6. [PubMed: 3532799]

334.

Coutinho EM, de Souza JC, Athayde C, et al. Multicenter clinical trial on the efficacy and acceptability of a single contraceptive implant of nomegestrol acetate, Uniplant. Contraception. 1996 Feb;53(2):121–5. X-3, X-9. [PubMed: 8838490]

335.

Coutinho EM, Spinola P, Barbosa I, et al. Multicenter, double-blind, comparative clinical study on the efficacy and acceptability of a monthly injectable contraceptive combination of 150 mg dihydroxyprogesterone acetophenide and 10 mg estradiol enanthate compared to a monthly injectable contraceptive combination of 90 mg dihydroxyprogesterone acetophenide and 6 mg estradiol enanthate. Contraception. 1997 Mar;55(3):175–81. X-5. [PubMed: 9115007]

336.

Coutinho EM, Spinola P, Tomaz G, et al. Efficacy, acceptability, and clinical effects of a low-dose injectable contraceptive combination of dihydroxyprogesterone acetophenide and estradiol enanthate. Contraception. 2000 Apr;61(4):277–80. X-4, X-5, X-6. [PubMed: 10899484]

337.

Cox M, Tripp J, Blacksell S. Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. J Fam Plann Reprod Health Care. 2002 Apr;28(2):73–7. X-4, X-5. [PubMed: 12396776]

338.

Cox M, Tripp J, Blacksell S. Clinical performance of the Nova T380 intrauterine device in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. J Fam Plann Reprod Health Care. 2002 Apr;28(2):69–72. X-4, X-5. [PubMed: 12396775]

339.

Cramer DW, Liberman RF, Hornstein MD, et al. Basal hormone levels in women who use acetaminophen for menstrual pain. Fertil Steril. 1998 Aug;70(2):371–3. X-4, X-5, X-9. [PubMed: 9696240]

340.

Cramer EH, Jones P, Keenan NL, et al. Is naturopathy as effective as conventional therapy for treatment of menopausal symptoms? Journal of Alternative and Complementary Medicine. 2003;9(4):529–38. X-3, X-5. [PubMed: 14499029]

341.

Creasy GW, Fisher AC, Hall N, et al. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol: Effects on the lipid profile. Journal of Reproductive Medicine for the Obstetrician and Gynecologist. 2003;48(3):179–86. X-4, X-5. [PubMed: 12698776]

342.

Creatsas G, Cardamakis E, Deligeoroglou E, et al. Tenoxicam versus lynestrenol-ethinyl estradiol treatment of dysfunctional uterine bleeding cases during adolescence. J Pediatr Adolesc Gynecol. 1998 Nov;11(4):177–80. X-5. [PubMed: 9806127]

343.

Creinin MD, Harwood B, Guido RS, et al. Endometrial thickness after misoprostol use for early pregnancy failure. Int J Gynaecol Obstet. 2004 Jul;86(1):22–6. X-4, X-5, X-9. [PMC free article: PMC1360146] [PubMed: 15207665]

344.

Creinin MD, Meyn LA, Borgatta L, et al. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstet Gynecol. 2008 Feb;111(2 Pt 1):267–77. X-5. [PubMed: 18238962]

345.

Creinin MD, Schlaff W, Archer DF, et al. Progesterone receptor modulator for emergency contraception: A randomized controlled trial. Obstetrics and Gynecology. 2006;108(5):1089–97. X-5. [PMC free article: PMC2853373] [PubMed: 17077229]

346.

Creinin MD, Schreiber CA, Bednarek P, et al. Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: A randomized controlled trial. Obstetrics and Gynecology. 2007;109(4):885–94. X-5. [PubMed: 17400850]

347.

Crosignani PG, Luciano A, Ray A, et al. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Human Reproduction. 2006;21(1):248–56. X-5, X-6, X-10. [PubMed: 16176939]

348.

Crosignani PG, Vercellini P, Mosconi P, et al. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol. 1997 Aug;90(2):257–63. X-8. [PubMed: 9241305]

349.

Croxatto HB. Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care. 2000 Sep;5 Suppl 2:21–8. X-4, X-5. [PubMed: 11246604]

350.

Croxatto HB, Brache V, Massai R, et al. Feasibility study of Nestorone-ethinylestradiol vaginal contraceptive ring for emergency contraception. Contraception. 2006 Jan;73(1):46–52. X-4, X-5, X-9. [PubMed: 16371294]

351.

Croxatto HB, Massai MR, Salvatierra AM, et al. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters. Contraception. 1996 Aug;54(2):79–86. X-4, X-5. [PubMed: 8842583]

352.

Croxatto HB, Urbancsek J, Massai R, et al. A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group. Hum Reprod. 1999 Apr;14(4):976–81. X-3, X-9. [PubMed: 10221230]

353.

Csemiczky G, Dieben T, Coeling Bennink HJ, et al. The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17 beta-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days. Contraception. 1996 Dec;54(6):333–8. X-4, X-9. [PubMed: 8968661]

354.

Csermely T, Halvax L, Schmidt E, et al. Occurrence of osteopenia among adolescent girls with oligo/amenorrhea. Gynecol Endocrinol. 2002 Apr;16(2):99–105. X-4, X-5, X-9. [PubMed: 12012630]

355.

Cuong DT, My Huong NT. Comparative phase III clinical trial of two injectable contraceptive preparations, depot-medroxyprogesterone acetate and Cyclofem, in Vietnamese women. Contraception. 1996 Sep;54(3):169–79. X-9. [PubMed: 8899259]

356.

Cusan L, Dupont A, Gomez JL, et al. Comparison of flutamide and spironolactone in the treatment of hirsutism: A randomized controlled trial. Fertility and Sterility. 1994;61(2):281–7. X-5. [PubMed: 8299783]

357.

Czeizel A, Keller S, Bod M. An aetiological evaluation of increased occurrence of congenital limb reduction abnormalities in Hungary, 1975-1978. Int J Epidemiol. 1983 Dec;12(4):445–9. X-3, X-5. [PubMed: 6654566]

358.

da Silva MO, Costa MM. Reason, myths and fantasies: preliminary data and reflections about the Portuguese experience with LNG-IUS-induced hypomenorrhea. Eur J Contracept Reprod Health Care. 1999 Mar;4(1):21–5. X-4, X-5. [PubMed: 10367192]

359.

Dada OA, Godfrey EM, Piaggio G, et al. A randomized, double-blind, noninferiority study to compare two regimens of levonorgestrel for emergency contraception in Nigeria. Contraception. 2010;82(4):373–8. X-5, X-9. [PubMed: 20851232]

360.

Dahlgren E, Johansson S, Lindstedt G, et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril. 1992 Mar;57(3):505–13. X-3, X-4, X-5. [PubMed: 1740195]

361.

Dahmoun M, Odmark IS, Risberg B, et al. Apoptosis, proliferation, and sex steroid receptors in postmenopausal endometrium before and during HRT. Maturitas. 2004 Oct 15;49(2):114–23. X-4, X-5, X-7. [PubMed: 15474755]

362.

Danli S, Qingxiang S, Guowei S. A multicentered clinical trial of the long-acting injectable contraceptive Depo Provera in Chinese women. Contraception. 2000 Jul;62(1):15–8. X-4, X-5, X-6. [PubMed: 11024223]

363.

D'Anna R, Cannata ML, Atteritano M, et al. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: A 1-year randomized, double-blind, placebo-controlled study. Menopause. 2007;14(4):648–55. X-7. [PubMed: 17251874]

364.

d'Arcangues C, Piaggio G, Brache V, et al. Effectiveness and acceptability of vitamin E and low-dose aspirin, alone or in combination, on Norplant-induced prolonged bleeding. Contraception. 2004 Dec;70(6):451–62. X-5, X-6. [PubMed: 15541406]

365.

Darney P, Patel A, Rosen K, et al. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril. 2009 May;91(5):1646–53. X-4, X-5. [PubMed: 18423453]

366.

Dasgupta PR, Dutta S, Banerjee P, et al. Vitamin E (alpha tocopherol) in the management of menorrhagia associated with the use of intrauterine contraceptive devices (IUCD). Int J Fertil. 1983;28(1):55–6. X-5, X-6. [PubMed: 6134690]

367.

Datey S, Gaur LN, Saxena BN. Vaginal bleeding patterns of women using different contraceptive methods (implants, injectables, IUDs, oral pills)--an Indian experience. An ICMR Task Force Study. Indian Council of Medical Research. Contraception. 1995 Mar;51(3):155–65. X-3, X-6, X-9. [PubMed: 7621684]

368.

David M, Chen FC, Lichtenegger W. NO-donor nitroglycerin versus the prostaglandin gemeprost for cervical ripening in first trimester missed abortion. Int J Gynaecol Obstet. 2003 Oct;83(1):71–2. X-4, X-5, X-9. [PubMed: 14511877]

369.

Davies AJ, Anderson AB, Turnbull AC. Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstet Gynecol. 1981 Jan;57(1):74–8. X-5, X-6. [PubMed: 7005780]

370.

Davies GC, Feng LX, Newton JR, et al. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel. Contraception. 1993 Mar;47(3):251–61. X-3, X-4, X-5, X-9. [PubMed: 8462316]

371.

Davies GC, Huster WJ, Lu Y, et al. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol. 1999 Apr;93(4):558–65. X-4, X-5, X-7. [PubMed: 10214833]

372.

Davies KE, Halkes M, Swart M, et al. Paracervical local anaesthetic block as a useful adjunct for analgesia following endometrial balloon thermoablation. Journal of One-Day Surgery. 2007;17(3):76–8. X-3, X-5, X-8, X-10.

373.

Davis A, Westhoff C, De Nonno L. Bleeding patterns after early abortion with mifepristone and misoprostol or manual vacuum aspiration. J Am Med Womens Assoc. 2000;55(3 Suppl):141–4. X-4, X-5, X-6, X-9. [PubMed: 10846324]

374.

Davis AR, Hendlish SK, Westhoff C, et al. Bleeding patterns after misoprostol vs surgical treatment of early pregnancy failure: results from a randomized trial. Am J Obstet Gynecol. 2007 Jan;196(1):31 e1–7. X-5, X-9. [PubMed: 17240222]

375.

Davis AR, Robilotto CM, Westhoff CL, et al. Bleeding patterns after vaginal misoprostol for treatment of early pregnancy failure. Hum Reprod. 2004 Jul;19(7):1655–8. X-4, X-5, X-9. [PubMed: 15178656]

376.

De Aloysio D, Altieri P, Penacchioni P, et al. Bleeding patterns in recent postmenopausal outpatients with uterine myomas: Comparison between two regimens of HRT. Maturitas. 1998;29(3):261–4. X-6, X-7. [PubMed: 9699198]

377.

de Castro A, Perez-Iglesias R, Vicandi F, et al. Comparison of two copper IUDs: the MLCu375 and the Nova-T. Adv Contracept. 1987 Dec;3(4):319–22. X-9. [PubMed: 3445799]

378.

de Cetina TC, Reyes LP, Gamboa LV, et al. A comparative clinical trial of Norinyl 1 + 35 versus Norinyl 1 + 50 in Merida, Yucatan, Mexico. Adv Contracept. 1990 Jun;6(2):125–39. X-9. [PubMed: 2206018]

379.

De Falco M, Staibano S, D'Armiento FP, et al. Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor. J Soc Gynecol Investig. 2006 May;13(4):297–303. X-4, X-5, X-6, X-8, X-9. [PubMed: 16697947]

380.

De Franciscis P, Cobellis L, Fornaro F, et al. Low-dose hormone therapy in the perimenopause. Int J Gynaecol Obstet. 2007 Aug;98(2):138–42. X-10. [PubMed: 17572422]

381.

De Lena M, Tommasi S, Schittulli F, et al. Sequential alternate administration of tamoxifen and medroxyprogesterone acetate in advanced breast cancer: clinical-biological randomized study. Tumori. 1990 Apr 30;76(2):190–5. X-5, X-7. [PubMed: 2139523]

382.

De Leo V, la Marca A, Morgante G, et al. Comparison of two HRT regimens with bimonthly and monthly progestin administration in postmenopause. Maturitas. 1999 Jan 4;31(2):171–7. X-4, X-5, X-7. [PubMed: 10227012]

383.

De Luis DA, Becerra A, Lahera M, et al. A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients. J Endocrinol Invest. 2000 Jul-Aug;23(7):428–34. X-4, X-5, X-6, X-9. [PubMed: 11005266]

384.

De Nonno LJ, Westhoff C, Fielding S, et al. Timing of pain and bleeding after mifepristone-induced abortion. Contraception. 2000 Dec;62(6):305–9. X-4, X-5, X-6, X-9. [PubMed: 11239617]

385.

de Souza SS, Camargos AF, de Rezende CP, et al. A randomized prospective trial comparing the levonorgestrel-releasing intrauterine system with thermal balloon ablation for the treatment of heavy menstrual bleeding. Contraception. 2010 Mar;81(3):226–31. X-5, X-8. [PubMed: 20159179]

386.

de Ziegler D, Ferriani R, Moraes LA, et al. Vaginal progesterone in menopause: Crinone 4% in cyclical and constant combined regimens. Hum Reprod. 2000 Jun;15 Suppl 1:149–58. X-4, X-5, X-7. [PubMed: 10928426]

387.

Delconte A, Loffer F, Grubb GS. Cycle control with oral contraceptives containing 20 mug of ethinyl estradiol: A multicenter, randomized comparison of levonorgestrel/ethinyl estradiol (100 mug/20 mug) and norethindrone/ethinyl estradiol (1000 mug/20 mug). Contraception. 1999;59(3):187–93. X-9. [PubMed: 10382082]

388.

Demarquay G, Caclin A, Brudon F, et al. Exacerbated attention orienting to auditory stimulation in migraine patients. Clin Neurophysiol. 2011 Sep;122(9):1755–63. X-4, X-5, X-9. [PubMed: 21396888]

389.

Dempsey A, Roca C, Westhoff C. Vaginal estrogen supplementation during Depo-Provera initiation: A randomized controlled trial. Contraception. 2010;82(3):250–5. X-6. [PubMed: 20705153]

390.

Dennehy CE. The Use of Herbs and Dietary Supplements in Gynecology:An Evidence-Based Review. Journal of Midwifery and Women's Health. 2006;51(6):402–9. X-1, X-3, X-5. [PubMed: 17081929]

391.

Dennis AR, Leeson-Payne CG, Hobbs GJ. Analgesia after Caesarean section - The use of rectal diclofenac as an adjunct to spinal morphine. Anaesthesia. 1995;50(4):297–9. X-5. [PubMed: 7747843]

392.

Descargues G, Douvrin F, Degre S, et al. Abnormal placentation and selective embolization of the uterine arteries. Eur J Obstet Gynecol Reprod Biol. 2001 Nov;99(1):47–52. X-4, X-5, X-6, X-8. [PubMed: 11604185]

393.

Dessole S, Coccollone E, Ambrosini G, et al. Oligomenorrhea treatment by purified FSH using a fixed protocol. Gynecol Obstet Invest. 1996;42(3):187–90. X-3, X-5. [PubMed: 8938472]

394.

DeVore GR, Owens O, Kase N. Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding--a double-blind randomized control study. Obstet Gynecol. 1982 Mar;59(3):285–91. X-5, X-10. [PubMed: 6281704]

395.

Dhingra N, Punia RS, Radotra A, et al. Arias-Stella reaction in upper genital tract in pregnant and non-pregnant women: a study of 120 randomly selected cases. Arch Gynecol Obstet. 2007 Jul;276(1):47–52. X-4, X-5, X-9. [PubMed: 17219163]

396.

Di Carlo C, Sammartino A, Di Spiezio Sardo A, et al. Bleeding patterns during continuous estradiol with different sequential progestogens therapy. Menopause. 2005 Sep-Oct;12(5):520–5. X-5, X-7. [PubMed: 16145305]

397.

Di Carlo C, Tommaselli GA, Gargano V, et al. Transdermal estradiol and oral or vaginal natural progesterone: bleeding patterns. Climacteric. 2010 Oct;13(5):442–6. X-5, X-7. [PubMed: 20575654]

398.

Di Caro S, Hamad GG, Fernstrom MH, et al. Medical strategies for weight loss in the overweight and obese patient. Minerva Gastroenterologica e Dietologica. 2006;52(4):415–30. X-1, X-3, X-5. [PubMed: 17108871]

399.

Di Lieto A, Catalano D, Miranda L, et al. Action of a prostaglandin synthetase inhibitor on IUD associated uterine bleeding. Clin Exp Obstet Gynecol. 1987;14(1):41–4. X-3, X-5, X-6. [PubMed: 3102127]

400.

Diamond MP, Greene JW, Thompson JM, et al. Interaction of anticonvulsants and oral contraceptives in epileptic adolescents. Contraception. 1985 Jun;31(6):623–32. X-3, X-5, X-6. [PubMed: 4042660]

401.

Diaz J, Bahamondes L, Monteiro I, et al. Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinas, Brazil. Contraception. 2000 Aug;62(2):59–61. X-4. [PubMed: 11102588]

402.

Diaz S, Herreros C, Juez G, et al. Fertility regulation in nursing women: VII. Influence of NORPLANT levonorgestrel implants upon lactation and infant growth. Contraception. 1985 Jul;32(1):53–74. X-6, X-9. [PubMed: 3931973]

403.

Dickason LA, Dinsmoor MJ. Red blood cell transfusion and cesarean section. Am J Obstet Gynecol. 1992 Aug;167(2):327–30. discussion 30-2. X-3, X-5. [PubMed: 1497033]

404.

Dickerson J, Bressler R, Christian CD. Liver function tests and low-dose estrogen oral contraceptives. Contraception. 1980 Dec;22(6):597–603. X-3, X-4. [PubMed: 7214908]

405.

Dickey RP, Nichols JE, Steinkampf MP, et al. Highly purified human-derived follicle-stimulating hormone (Bravelle has equivalent efficacy to follitropin-beta (Follistim ) in infertile women undergoing in vitro fertilization. Reproductive Biology and Endocrinology. 2003;1(03) X-5. [PMC free article: PMC270000] [PubMed: 14609434]

406.

Dieben TO, op ten Berg MT, Coelingh Bennink HJ. Cycle control and side effects of a new combiphasic oral contraceptive regimen. Arzneimittelforschung. 1994 Jul;44(7):877–9. X-3, X-9. [PubMed: 7945527]

407.

Dildy GA, Scott JR, Saffer CS, et al. An effective pressure pack for severe pelvic hemorrhage. Obstet Gynecol. 2006 Nov;108(5):1222–6. X-4, X-5, X-8, X-9. [PubMed: 17077246]

408.

Dittrich R, Parker L, Rosen JB, et al. Transdermal contraception: Evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study. American Journal of Obstetrics and Gynecology. 2002;186(1):15–20. X-9. [PubMed: 11810078]

409.

Dockeray CJ, Sheppard BL, Bonnar J. Comparison between mefenamic acid and danazol in the treatment of established menorrhagia. Br J Obstet Gynaecol. 1989 Jul;96(7):840–4. X-5. [PubMed: 2765430]

410.

Dockeray CJ, Sheppard BL, Daly L, et al. The fibrinolytic enzyme system in normal menstruation and excessive uterine bleeding and the effect of tranexamic acid. Eur J Obstet Gynecol Reprod Biol. 1987 Apr;24(4):309–18. X-3, X-4. [PubMed: 2953634]

411.

Dodick DW, Freitag F, Banks J, et al. Topiramate versus amitriptyline in migraine prevention: A 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clinical Therapeutics. 2009;31(3):542–59. X-5. [PubMed: 19393844]

412.

Doherty L, Harper A, Russell M. Menorrhagia management options. Ulster Med J. 1995 Apr;64(1):64–71. X-3, X-5. [PMC free article: PMC2449066] [PubMed: 7502405]

413.

Doll H, Brown S, Thurston A, et al. Pyridoxine (vitamin B6) and the premenstrual syndrome: a randomized crossover trial. The Journal of the Royal College of General Practitioners. 1989;39(326):364–8. X-5. [PMC free article: PMC1711872] [PubMed: 2558186]

414.

Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012 Feb 2;366(5):409–20. X-6. [PubMed: 22296075]

415.

Donnez J, Tomaszewski J, Vazquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012 Feb 2;366(5):421–32. X-6. [PubMed: 22296076]

416.

Donnez J, Vilos G, Gannon MJ, et al. Goserelin acetate (Zoladex) plus endometrial ablation for dysfunctional uterine bleeding: a 3-year follow-up evaluation. Fertil Steril. 2001 Mar;75(3):620–2. X-8. [PubMed: 11239552]

417.

Donnez J, Vilos G, Gannon MJ, et al. Goserelin acetate (Zoladex) plus endometrial ablation for dysfunctional uterine bleeding: a large randomized, double-blind study. Fertil Steril. 1997 Jul;68(1):29–36. X-5, X-8, X-9. [PubMed: 9207580]

418.

Doren M, Rubig A, Coelingh Bennink HJ, et al. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause. 1999 Winter;6(4):299–306. X-5, X-7. [PubMed: 10614676]

419.

Dorenberg EJ, Novakovic Z, Smith HJ, et al. Uterine fibroid embolization can still be improved: observations on post-procedure magnetic resonance imaging. Acta Radiol. 2005 Aug;46(5):547–53. X-4, X-5, X-6, X-8, X-9. [PubMed: 16224935]

420.

Doyle M, Warwick A, Redman C, et al. Does application of Monsel's solution after loop diathermy excision of the transformation zone reduce post operative discharge? Results of a prospective randomised controlled trial. Br J Obstet Gynaecol. 1992 Dec;99(12):1023–4. X-5, X-8. [PubMed: 1341890]

421.

Dreher E, von Fischer B. Treatment of primary dysmenorrhea and dysmenorrhea because of IUP with PG-synthetase inhibitors. Adv Prostaglandin Thromboxane Res. 1980;8:1487–93. X-3, X-5, X-10. [PubMed: 6769316]

422.

Droegemueller W, Katta LR, Bright TG, et al. Triphasic Randomized Clinical Trial: comparative frequency of intermenstrual bleeding. Am J Obstet Gynecol. 1989 Nov;161(5):1407–11. X-6, X-9. [PubMed: 2686457]

423.

D'Souza RE, Masters T, Bounds W, et al. Randomised controlled trial assessing the acceptability of GyneFix versus Gyne-T380S for emergency contraception. J Fam Plann Reprod Health Care. 2003 Apr;29(2):23–9. X-5, X-9. [PubMed: 12681033]

424.

Du MK, Zheng HM, Chen HC, et al. Study of Norplant implants in Shanghai: three-year experience. Int J Gynaecol Obstet. 1990 Dec;33(4):345–57. X-3, X-9. [PubMed: 1979289]

425.

Duclos M. A critical assessment of hormonal methods used in monitoring training status in athletes. International SportMed Journal. 2008;9(2):56–66. X-1, X-3, X-5.

426.

Duflos-Cohade C, Amandruz M, Thibaud E. Pubertal metrorrhagia. J Pediatr Adolesc Gynecol. 1996 Feb;9(1):16–20. X-4, X-5, X-9. [PubMed: 9551371]

427.

Duijkers IJM, Klipping C, Grob P, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol. European Journal of Contraception and Reproductive Health Care. 2010;15(5):314–25. X-4, X-9. [PubMed: 20695770]

428.

Dunphy BC, Goerzen J, Greene CA, et al. A double-blind randomised study comparing danazol and medroxyprogesterone acetate in the management of menorrhagia. Journal of Obstetrics and Gynaecology. 1998;18(6):553–5. X-5. [PubMed: 15512177]

429.

Dunson TR, McLaurin VL, Israngkura B, et al. A comparative study of two low-dose combined oral contraceptives: results from a multicenter trial. Contraception. 1993 Aug;48(2):109–19. X-9. [PubMed: 8403908]

430.

Durning P, Sellwood RA. Bromocriptine in severe cyclical breast pain. Br J Surg. 1982 May;69(5):248–9. X-5. [PubMed: 7042033]

431.

Dushay J, Gao C, Gopalakrishnan GS, et al. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care. 2012 January;35(1):4–11. X-5. [PMC free article: PMC3241299] [PubMed: 22040840]

432.

Dusterberg B, Ellman H, Muller U, et al. A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene. Gynecol Endocrinol. 1996 Feb;10(1):33–9. X-3, X-9. [PubMed: 8737190]

433.

Edelman AB, Koontz SL, Nichols MD, et al. Continuous oral contraceptives: are bleeding patterns dependent on the hormones given? Obstet Gynecol. 2006 Mar;107(3):657–65. X-6, X-9, X-10. [PubMed: 16507938]

434.

Edelman DA, Kothenbeutel R, Levinski MJ, et al. Comparative trials of low-dose combined oral contraceptives. Journal of Reproductive Medicine for the Obstetrician and Gynecologist. 1983;28(3):195–200. X-9. [PubMed: 6854550]

435.

Edlund M, Andersson K, Rybo G, et al. Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi 2161). Br J Obstet Gynaecol. 1995 Nov;102(11):913–7. X-5. [PubMed: 8534629]

436.

Edlund M, Blomback M, Fried G. Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time. Blood Coagul Fibrinolysis. 2002 Apr;13(3):225–31. X-5. [PubMed: 11943936]

437.

Egarter C, Geurts P, Boschitsch E, et al. The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women. Acta Obstetricia et Gynecologica Scandinavica. 1996;75(4):386–93. X-5, X-10. [PubMed: 8638462]

438.

Egarter C, Huber J, Leikermoser R, et al. Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas. 1996 Feb;23(1):55–62. X-5, X-7. [PubMed: 8861087]

439.

Eisinger SH, Fiscella J, Bonfiglio T, et al. Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata. Eur J Obstet Gynecol Reprod Biol. 2009 Oct;146(2):215–8. X-4, X-5, X-6, X-9. [PubMed: 19586708]

440.

El Beltagy NS, Darwish EA, Kasem MS, et al. Comparison between Cupper T380 IUD and Multiload 375 IUD in early post partum insertion. Middle East Fertility Society Journal. 2011;16(2):143–8. X-9.

441.

El Sahwi S, Kamel M, Haiba N, et al. Hysteroscopic and hysterosalpingographic study after intrauterine insertion of quinacrine pellets for non-surgical sterilization. Advances in Contraceptive Delivery Systems. 1992;8(1-2):151–9. X-5, X-9. [PubMed: 12285561]

442.

Elbehery MM, Nouh AA, Mohamed ML, et al. Insulin-like growth factor binding protein-1 and glycodelin levels in uterine flushing before and after hysteroscopic polypectomy. Clin Lab. 2011;57(11-12):953–7. X-3, X-4, X-8. [PubMed: 22239027]

443.

Elder MG. Injectable contraception. Clin Obstet Gynaecol. 1984 Dec;11(3):723–41. X-1, X-3, X-5, X-9, X-10. [PubMed: 6239732]

444.

Elder MG, Lawson JP, Elstein M, et al. The efficacy and acceptability of a low-dose levonorgestrel intravaginal ring for contraception in a UK cohort. Contraception. 1991 Feb;43(2):129–37. X-3, X-9. [PubMed: 1904020]

445.

Eldred JM, Haynes PJ, Thomas EJ. A randomized double blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone. Clin Endocrinol (Oxf). 1992 Oct;37(4):354–9. X-4, X-5, X-6, X-9, X-10. [PubMed: 1483292]

446.

Elechi EN, Elechi GN. Surgical management of patients with severe anaemia due to acute blood loss: a case for withholding perioperative blood transfusion. East Afr Med J. 1995 Jun;72(6):343–4. X-3, X-5. [PubMed: 7497999]

447.

Elkind-Hirsch KE, Darensbourg C, Ogden B, et al. Contraceptive vaginal ring use for women has less adverse metabolic effects than an oral contraceptive. Contraception. 2007;76(5):348–56. X-4. [PubMed: 17963858]

448.

Elkind-Hirsch KE, Phillips K, Bello SM, et al. Sequential hormonal supplementation with vaginal estradiol and progesterone gel corrects the effect of clomiphene on the endometrium in oligo-ovulatory women. Human Reproduction. 2002;17(2):295–8. X-5, X-6, X-10. [PubMed: 11821266]

449.

Ellison PT, Lager C, Calfee J. Low profiles of salivary progesterone among college undergraduate women. J Adolesc Health Care. 1987 Mar;8(2):204–7. X-3, X-4. [PubMed: 3818407]

450.

El-Mahgoub S. The norgestrel-T-IUD. Contraception. 1980 Sep;22(3):271–86. X-4, X-9. [PubMed: 7438754]

451.

El-Mazny A, Abou-Salem N. A double-blind randomized controlled trial of vaginal misoprostol for cervical priming before outpatient hysteroscopy. Fertil Steril. 2011 Oct;96(4):962–5. X-4, X-5. [PubMed: 21575939]

452.

Elnashar A, Abdelmageed E, Fayed M, et al. Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective placebo-controlled study. Hum Reprod. 2006 Jul;21(7):1805–8. X-5, X-10. [PubMed: 16543255]

453.

Elomaa K, Ranta S, Tuominen J, et al. Charcoal treatment and risk of escape ovulation in oral contraceptive users. Human Reproduction. 2001;16(1):76–81. X-9. [PubMed: 11139541]

454.

Elovainio M, Teperi J, Aalto AM, et al. Depressive symptoms as predictors of discontinuation of treatment of menorrhagia by levonorgestrel-releasing intrauterine system. Int J Behav Med. 2007;14(2):70–5. X-5, X-8. [PubMed: 17926434]

455.

Elsedeek MS. Puerperal and menstrual bleeding patterns with different types of contraceptive device fitted during elective cesarean delivery. Int J Gynaecol Obstet. 2012 Jan;116(1):31–4. X-5, X-9, X-10. [PubMed: 22036512]

456.

Elstein M. IUCD liability. Br J Obstet Gynaecol. 1982 Sep;89(Suppl 4):11–9. X-1, X-3, X-5. [PubMed: 7150526]

457.

Eltabbakh GH, Piver MS, Hempling RE, et al. Estrogen replacement therapy following oophorectomy in women with a family history of ovarian cancer. Gynecol Oncol. 1997 Jul;66(1):103–7. X-4, X-5, X-9. [PubMed: 9234929]

458.

Emde C, Cilluffo T, Bauerfeind P, et al. Effect of a slow-release formula of trimoprostil on intragastric acidity in healthy volunteers. Aliment Pharmacol Ther. 1988 Apr;2(2):135–41. X-3, X-4, X-5. [PubMed: 2979239]

459.

Emsley R, Oosthuizen P, Koen L, et al. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther. 2008 Dec;30(12):2378–86. X-5, X-9. [PubMed: 19167596]

460.

Endrikat J, Cronin M, Gerlinger C, et al. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel. Contraception. 2001 Sep;64(3):201–7. X-5. [PubMed: 11704101]

461.

Endrikat J, Cronin M, Gerlinger C, et al. Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 microg ethinyl estradiol and 75 microg gestodene. Contraception. 2001 Aug;64(2):99–105. X-5. [PubMed: 11704086]

462.

Endrikat J, Dusterberg B, Ruebig A, et al. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception. 1999 Nov;60(5):269–74. X-5. [PubMed: 10717778]

463.

Endrikat J, Hite R, Bannemerschult R, et al. Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 mug ethinylestradiol/100 mug levonorgestrel and 20 mug ethinylestradiol/500 mug norethisterone. Contraception. 2001;64(1):3–10. X-9. [PubMed: 11535206]

464.

Endrikat J, Lange E, Kunz M, et al. A one-year randomized double-blind, multicentre study to evaluate the effects of an oestrogen-reduced, continuous combined hormone replacement therapy preparation containing 1 mg oestradiol valerate and 2 mg dienogest on metabolism in postmenopausal women. European Journal of Contraception and Reproductive Health Care. 2007;12(3):229–39. X-4, X-7. [PubMed: 17763261]

465.

Endrikat J, Muller U, Dusterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception. 1997 Mar;55(3):131–7. X-6, X-9. [PubMed: 9115000]

466.

Endrikat J, Muller U, Dusterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 mug ethinylestradiol/75 mug gestodene and 30 mug ethinylestradiol/75 mug gestodene, with respect to efficacy, cycle control, and tolerance. Contraception. 1997;55(3):131–7. X-9. [PubMed: 9115000]

467.

Endrikat JS, Milchev NP, Kapamadzija A, et al. Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada. Contraception. 2009 Jun;79(6):428–32. X-4, X-5. [PubMed: 19442777]

468.

Engman M, Granberg S, Williams AR, et al. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod. 2009 Aug;24(8):1870–9. X-5, X-6, X-9. [PubMed: 19389793]

469.

Epstein E. Management of postmenopausal bleeding in Sweden: a need for increased use of hydrosonography and hysteroscopy. Acta Obstet Gynecol Scand. 2004 Jan;83(1):89–95. X-4, X-5, X-7. [PubMed: 14678091]

470.

Epstein E, Valentin L. Rebleeding and endometrial growth in women with postmenopausal bleeding and endometrial thickness < 5 mm managed by dilatation and curettage or ultrasound follow-up: a randomized controlled study. Ultrasound Obstet Gynecol. 2001 Nov;18(5):499–504. X-5, X-7. [PubMed: 11844172]

471.

Erel CT, Senturk LM, Oral E, et al. Adrenal androgenic response to 2-hour ACTH stimulation test in women with PCOS. Gynecol Endocrinol. 1998 Aug;12(4):223–9. X-4, X-5, X-9. [PubMed: 9798131]

472.

Erel CT, Senturk LM, Oral E, et al. Results of the ACTH stimulation test in hirsute women. J Reprod Med. 1999 Mar;44(3):247–52. X-3, X-4, X-5. [PubMed: 10202742]

473.

Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol. 1999 May;180(5):1072–9. X-5, X-7. [PubMed: 10329858]

474.

Erkkola R, Mattila L, Powles T, et al. Bone mineral density and lipid changes during 5 years of follow-up in a study of prevention of breast cancer with toremifene in healthy, high-risk pre- and post-menopausal women. Breast Cancer Research and Treatment. 2005;93(3):277–87. X-5. [PubMed: 16172794]

475.

Eschenbach DA. Earth, motherhood, and the intrauterine device. Fertil Steril. 1992 Jun;57(6):1177–9. X-1, X-3, X-9, X-10. [PubMed: 1601138]

476.

Esteve JL, Varela L, Velazco A, et al. Early abortion with 800 micrograms of misoprostol by the vaginal route. Contraception. 1999 Apr;59(4):219–25. X-4, X-5, X-9. [PubMed: 10457865]

477.

Ettinger B, Kenemans P, Johnson SR, et al. Endometrial effects of tibolone in elderly, osteoporotic women. Obstet Gynecol. 2008 Sep;112(3):653–9. X-5, X-7, X-9. [PubMed: 18757665]

478.

Evans KD. A cost utility analysis of sonohysterography compared with hysteroscopic evaluation for dysfunctional uterine bleeding. Journal of Diagnostic Medical Sonography. 2000;16(2):68–72. X-3, X-4, X-8.

479.

Ezechi OC, Jogo A, Gab-Okafor C, et al. Effect of HIV-1 infection and increasing immunosuppression on menstrual function. J Obstet Gynaecol Res. 2010 Oct;36(5):1053–8. X-4, X-5. [PubMed: 21058440]

480.

Facchinetti F, De Pietri R, Giunchi M, et al. Use of meclofenamic acid in gynecology and obstetrics: effects on postsurgical stress. Clin J Pain. 1991;7 Suppl 1:S60–3. X-5. [PubMed: 1810523]

481.

Facchinetti F, Neri I, Fava M, et al. Menstrual-related mood changes in patients with oligomenorrhea. Gynecol Obstet Invest. 1994;38(2):122–6. X-3, X-4, X-5. [PubMed: 7959339]

482.

Fairburn CG, Jones R, Peveler RC, et al. Psychotherapy and bulimia nervosa. Longer-term effects of interpersonal psychotherapy, behavior therapy, and cognitive behavior therapy. Arch Gen Psychiatry. 1993 Jun;50(6):419–28. X-5. [PubMed: 8498876]

483.

Falaschi P, Martocchia A, Proietti A, et al. High incidence of hyperandrogenism-related clinical signs in patients with multiple sclerosis. Neuro Endocrinol Lett. 2001 Aug;22(4):248–50. X-4, X-5, X-6, X-9. [PubMed: 11524631]

484.

Falcone T, Desjardins C, Bourque J, et al. Dysfunctional uterine bleeding in adolescents. J Reprod Med. 1994 Oct;39(10):761–4. X-3. [PubMed: 7837120]

485.

Fallahian M, Ilkhani M. Menstrual disorders in nongenital tuberculosis. Infect Dis Obstet Gynecol. 2006;2006:18452. X-4, X-5, X-9. [PMC free article: PMC1581462] [PubMed: 17093348]

486.

Fanta M, Hill M, Belacek J, et al. Comparison of corticoid substitution versus combined oral contraception administration in the treatment of non-classic adrenal hyperplasia: a prospective study. Gynecol Endocrinol. 2009 Jun;25(6):398–402. X-4, X-5, X-9. [PubMed: 19903032]

487.

Farhi J, Orvieto R, Homburg R. Administration of clomiphene citrate in patients with polycystic ovary syndrome, without inducing withdrawal bleeding, achieves comparable treatment characteristics and outcome. Fertil Steril. 2010 Apr;93(6):2077–9. X-3, X-5. [PubMed: 19732872]

488.

Farkas M, Szigethy A, Sas M. Clinicopharmacological examination of Anteovin. Ther Hung. 1987;35(1):14–8. X-3, X-9, X-10. [PubMed: 3438859]

489.

Farquhar CM. The levonorgestrel intrauterine system: a simple and effective alternative for the management of menorrhagia? Med J Aust. 2002 Oct 21;177(8):444–5. X-8. [PubMed: 12381255]

490.

Farquhar CM, Prentice A, Barlow DH, et al. Effective treatment of subfertility: introducing the Cochrane Menstrual Disorders and Subfertility Group. Hum Reprod. 1999 Jul;14(7):1678–83. X-1, X-4, X-5, X-9. [PubMed: 10402367]

491.

Farr G, Amatya R. Contraceptive efficacy of the Copper T380A and the Multiload Cu250 IUD in three developing countries. Adv Contracept. 1994 Jun;10(2):137–49. X-9. [PubMed: 7942261]

492.

Farr G, Amatya R. Contraceptive efficacy of the Copper T 380A and Copper T 200 intrauterine devices: results from a comparative clinical trial in six developing countries. Contraception. 1994 Mar;49(3):231–43. X-9. [PubMed: 8200217]

493.

Farr G, Amatya R, Acosta M, et al. Clinical performance of the TCu 380A and Lippes Loop IUDs in three developing countries. Contraception. 1995 Jul;52(1):17–22. X-3, X-5, X-9. [PubMed: 8521710]

494.

Farr G, Amatya R, Betancourt JD, et al. Clinical performance of the TCu 380A and TCu 220C IUDs in four developing country family planning clinics. Contraception. 1994 Nov;50(5):417–29. X-9. [PubMed: 7859451]

495.

Farr G, Amatya R, Doh A, et al. An evaluation of the copper-T 380A IUD's safety and efficacy at three African centers. Contraception. 1996 May;53(5):293–8. X-4, X-5, X-9. [PubMed: 8724619]

496.

Farr G, Rivera R, Amatya R. Non-physician insertion of IUDs: clinical outcomes among TCu380A insertions in three developing-country clinics. Adv Contracept. 1998 Mar;14(1):45–57. X-3, X-5, X-9. [PubMed: 9587008]

497.

Faundes A, Alvarez F, Brache V, et al. Endometrial thickness and oestradiol concentration in women with bleeding complaints during use of Norplant implants. Hum Reprod. 1998 Jan;13(1):188–91. X-4, X-5, X-9. [PubMed: 9512255]

498.

Fedele L, Bianchi S, Baglioni A, et al. Intranasal buserelin versus surgery in the treatment of uterine leiomyomata: long-term follow-up. Eur J Obstet Gynecol Reprod Biol. 1991 Jan 4;38(1):53–7. X-6, X-8. [PubMed: 1899079]

499.

Fedele L, Bianchi S, Raffaelli R, et al. A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas. European Journal of Obstetrics Gynecology and Reproductive Biology. 2000;88(1):91–4. X-6, X-7. [PubMed: 10659924]

500.

Feely M, Gibson J. Intermittent clobazam for catamenial epilepsy: tolerance avoided. J Neurol Neurosurg Psychiatry. 1984 Dec;47(12):1279–82. X-3, X-5. [PMC free article: PMC1028134] [PubMed: 6392481]

501.

Fender GR, Prentice A, Gorst T, et al. Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia menorrhagia education study. BMJ. 1999 May 8;318(7193):1246–50. X-5, X-10, OTHER. [PMC free article: PMC27863] [PubMed: 10231255]

502.

Feng C, Sun CC, Wang TT, et al. Decreased expression of endometrial vessel AQP1 and endometrial epithelium AQP2 related to anovulatory uterine bleeding in premenopausal women. Menopause. 2008 Jul-Aug;15(4 Pt 1):648–54. X-4, X-5. [PubMed: 18463544]

503.

Ferenczy A, Gelfand MM, van de Weijer PH, et al. Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17 beta-estradiol combined with sequential 5-20 mg dydrogesterone. Climacteric. 2002 Mar;5(1):26–35. X-5, X-7. [PubMed: 11974556]

504.

Fernandez H, Capella S, Audibert F. Uterine thermal balloon therapy under local anaesthesia for the treatment of menorrhagia: a pilot study. Hum Reprod. 1997 Nov;12(11):2511–4. X-4, X-5, X-8, X-9. [PubMed: 9436696]

505.

Fernandez H, Lucas C, Hedon B, et al. One year comparison between two add-back therapies in pateints treated with a GmRH agonist for symptomatic endometriosis: A randomized double-blind trial. Human Reproduction. 2004;19(6):1465–71. X-4, X-5, X-10. [PubMed: 15105403]

506.

Fernandez H, Sefrioui O, Virelizier C, et al. Hysteroscopic resection of submucosal myomas in patients with infertility. Hum Reprod. 2001 Jul;16(7):1489–92. X-4, X-5, X-6, X-9. [PubMed: 11425835]

507.

Fernandez-Mentoli ME, Diez-Gibert O, Samaniego JM, et al. Total and unbound cytosolic estrogen and progesterone receptors in myometrium and fibroid after gonadotropin-releasing hormone agonist treatment. Fertility and Sterility. 1995;63(3):522–7. X-4, X-6. [PubMed: 7851581]

508.

Ferrari CI, Abs R, Bevan JS, et al. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf). 1997 Apr;46(4):409–13. X-4, X-5, X-9. [PubMed: 9196602]

509.

Ferrero S, Camerini G, Seracchioli R, et al. Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. Human Reproduction. 2010;24(12):3033–41. X-3, X-5, X-6. [PubMed: 19726448]

510.

Ferrero S, Venturini PL, Gillott DJ, et al. Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: A randomized controlled trial. Reproductive Biology and Endocrinology. 2011;9(88) X-5, X-10. [PMC free article: PMC3141645] [PubMed: 21693037]

511.

Ferry S, Hannaford P, Warskyj M, et al. Carpal tunnel syndrome: a nested case-control study of risk factors in women. Am J Epidemiol. 2000 Mar 15;151(6):566–74. X-4, X-5, X-9. [PubMed: 10733038]

512.

Fine PM. Ulipristal acetate: A new emergency contraceptive that is safe and more effective than levonorgestrel. Women's Health. 2011;7(1):9–17. X-1, X-5, X-9. [PubMed: 21175385]

513.

Fleischmann R, Vencovsky J, Van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: The FAST4WARD study. Annals of the Rheumatic Diseases. 2009;68(6):805–11. X-5. [PMC free article: PMC2674555] [PubMed: 19015206]

514.

Fleming R, Haxton MJ, Hamilton MP, et al. Successful treatment of infertile women with oligomenorrhoea using a combination of an LHRH agonist and exogenous gonadotrophins. Br J Obstet Gynaecol. 1985 Apr;92(4):369–73. X-3, X-4, X-5. [PubMed: 3921050]

515.

Florio P, Gubbini G, Marra E, et al. A retrospective case-control study comparing hysteroscopic resection versus hormonal modulation in treating menstrual disorders due to isthmocele. Gynecol Endocrinol. 2011 Jun;27(6):434–8. X-4, X-5, X-8. [PubMed: 21204608]

516.

Focan C, Beauduin M, Majois F, et al. High-dose oral medroxyprogesterone acetate or tamoxifen as adjuvant hormone therapy for node-negative early-stage breast cancer: Randomized trial with 7-year update. Clinical Breast Cancer. 2004;5(2):136–41. X-5. [PubMed: 15245618]

517.

Foden-Shroff J, Redman CW, Tucker H, et al. Do routine antibiotics after loop diathermy excision reduce morbidity? Br J Obstet Gynaecol. 1998 Sep;105(9):1022–5. X-5, X-8, X-9. [PubMed: 9763056]

518.

Fogelholm M, Hiilloskorpi H. Weight and diet concerns in Finnish female and male athletes. Med Sci Sports Exerc. 1999 Feb;31(2):229–35. X-4, X-5, X-9. [PubMed: 10063811]

519.

Foidart JM, Sulak PJ, Schellschmidt I, et al. The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days. Contraception. 2006 Jan;73(1):34–40. X-4, X-5. [PubMed: 16371292]

520.

Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care. 2000 Jun;5(2):124–34. X-4, X-5. [PubMed: 10943575]

521.

Fontaine D, Lazorthes Y, Mertens P, et al. Safety and efficacy of deep brain stimulation in refractory cluster headache: A randomized placebo-controlled double-blind trial followed by a 1-year open extension. Journal of Headache and Pain. 2010;11(1):23–31. X-5. [PMC free article: PMC3452182] [PubMed: 19936616]

522.

Foster PA. The reproductive health of women with von Willebrand Disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1995 Aug;74(2):784–90. X-3, X-6. [PubMed: 8585022]

523.

Fouda UM, Yossef D, Gaafar HM. Uterine artery blood flow in patients with copper intrauterine device-induced abnormal uterine bleeding. Middle East Fertility Society Journal. 2010;15(3):168–73. X-3, X-4, X-5.

524.

Frajndlich R, von Eye Corleta H, Frantz N. Color Doppler sonographic study of the uterine artery in patients using intrauterine contraceptive devices. J Ultrasound Med. 2000 Aug;19(8):577–9. X-4, X-5, X-9. [PubMed: 10944044]

525.

Franke HR, Snaaijer FF, Houben PW, et al. Treatment of dysfunctional uterine bleeding in the perimenopause: the effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment--a randomized, placebo-controlled, double-blind trial. Gynecol Endocrinol. 2006 Dec;22(12):692–7. X-5. [PubMed: 17162712]

526.

Franke HR, Snaaijer FF, Houben PWH, et al. Treatment of dysfunctional uterine bleeding in the perimenopause: The effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment - A randomized, placebo-controlled, double-blind trial. Gynecological Endocrinology. 2006;22(12):692–7. X-5. [PubMed: 17162712]

527.

Franssen AM, Kauer FM, Rolland R, et al. The effect of LHRH agonist therapy in the treatment of endometriosis (Dutch experience). Prog Clin Biol Res. 1986;225:201–10. X-11. [PubMed: 3097666]

528.

Fraser DI, Padwick ML, Whitehead MI, et al. The effects of the addition of nomegestrol acetate to post-menopausal oestrogen therapy. Maturitas. 1989 Mar;11(1):21–34. X-7. [PubMed: 2725335]

529.

Fraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust N Z J Obstet Gynaecol. 1990 Nov;30(4):353–6. X-3. [PubMed: 2150587]

530.

Fraser IS, Healy DL, Torode H, et al. Depot goserelin and danazol pre-treatment before rollerball endometrial ablation for menorrhagia. Obstet Gynecol. 1996 Apr;87(4):544–50. X-5, X-8, X-9. [PubMed: 8602306]

531.

Fraser IS, McCarron G, Markham R, et al. Long-term treatment of menorrhagia with mefenamic acid. Obstet Gynecol. 1983 Jan;61(1):109–12. X-3. [PubMed: 6337354]

532.

Fraser IS, Weisberg E, Minehan E, et al. A detailed analysis of menstrual blood loss in women using Norplant and Nestorone progestogen-only contraceptive implants or vaginal rings. Contraception. 2000 Apr;61(4):241–51. X-4, X-5, X-6. [PubMed: 10899479]

533.

Frederick JL, Chenette PE, Paulson RJ, et al. Random urinary pregnanediol glucuronide measurements in pregnancy: lack of utility for evaluation of first-trimester vaginal bleeding. Hum Reprod. 1990 May;5(4):468–70. X-3, X-4, X-5. [PubMed: 2362010]

534.

French JI, McGregor JA, Draper D, et al. Gestational bleeding, bacterial vaginosis, and common reproductive tract infections: risk for preterm birth and benefit of treatment. Obstet Gynecol. 1999 May;93(5 Pt 1):715–24. X-4, X-5, X-9. [PubMed: 10912974]

535.

French L. What strategy is most likely to result in the least missed ectopic pregnancies, while also considering the likelihood of interruption of intrauterine pregnancy and cost? Evidence-Based Practice. 2001;4(7):10–1. commentary on Gracia CR, Barnhart KT. Diagnosing ectopic pregnancy: decision analysis comparing six strategies. OBSTET GYNECOL 2001;97:464-70. insert 2p. X-1, X-3, X-5.

536.

Friberg B, Persson BR, Willen R, et al. Endometrial destruction by hyperthermia--a possible treatment of menorrhagia. An experimental study. Acta Obstet Gynecol Scand. 1996 Apr;75(4):330–5. X-4, X-5, X-8. [PubMed: 8638450]

537.

Friedman AJ, Daly M, Juneau-Norcross M, et al. Long-term medical therapy for leiomyomata uteri: A prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin ‘add-back’ for 2 years. Human Reproduction. 1994;9(9):1618–25. X-6. [PubMed: 7836510]

538.

Friedman AJ, Hoffman DI, Comite F, et al. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. Obstet Gynecol. 1991 May;77(5):720–5. X-5, X-6. [PubMed: 1901638]

539.

Fruzzetti F, De Lorenzo D, Ricci C, et al. Clinical and endocrine effects of flutamide in hyperandrogenic women. Fertil Steril. 1993 Nov;60(5):806–13. X-5. [PubMed: 8224265]

540.

Fukui H, Toyoshima K, Komaki R. Psychological and neuroendocrinological effects of odor of saffron (Crocus sativus). Phytomedicine. 2011 Jun 15;18(8-9):726–30. X-4, X-5. [PubMed: 21242071]

541.

Fulghesu AM, Angioni S, Frau E, et al. Ultrasound in polycystic ovary syndrome - The measuring of ovarian stroma and relationship with circulating androgens: Results of a multicentric study. Human Reproduction. 2007;22(9):2501–8. X-3, X-4, X-5. [PubMed: 17635847]

542.

Funder JW. Eplerenone: Hypertension, heart failure and the importance of mineralocorticoid receptor blockade. Future Cardiology. 2006;2(5):535–41. X-1, X-3, X-5. [PubMed: 19804189]

543.

Funk S, Miller MM, Mishell DR Jr., et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception. 2005 May;71(5):319–26. X-4, X-5. [PubMed: 15854630]

544.

Furst DE, Manorama MV, Mary M, et al. Double-blind, randomized, controlled, pilot study comparing classic ayurvedic medicine, methotrexate, and their combination in rheumatoid arthritis. Journal of Clinical Rheumatology. 2011;17(4):185–92. X-5. [PubMed: 21617554]

545.

Furtado RNV, Oliveira LM, Natour J. Polyarticular corticosteroid injection versus systemic administration in treatment of rheumatoid arthritis patients: A randomized controlled study. Journal of Rheumatology. 2005;32(9):1691–8. X-5. [PubMed: 16142862]

546.

Gaete X, Vivanco M, Eyzaguirre FC, et al. Menstrual cycle irregularities and their relationship with HbA1c and insulin dose in adolescents with type 1 diabetes mellitus. Fertil Steril. 2010 Oct;94(5):1822–6. X-4, X-5, X-6, X-9. [PubMed: 19796762]

547.

Galley P, Thiollet M. A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility. Int Angiol. 1993 Mar;12(1):69–72. X-5, X-6. [PubMed: 8376915]

548.

Gallo MF, Nanda K, Grimes DA, et al. 20 g versus >20 g estrogen combined oral contraceptives for contraception. Cochrane Database of Systematic Reviews. 2008;(4) X-9. [PubMed: 18843653]

549.

Gama CRB, Gama GF, Lasmar RB, et al. Clinical assessment of ethinylestradiol and cyproterone acetate in menstrual irregularities of hyper-androgenic origin. Revista Brasileira de Medicina. 2010;67(9):319–25. X-5.

550.

Gambacciani M, Cappagli B, Piaggesi L, et al. Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists. Calcif Tissue Int. 1997;61 Suppl 1:S15–8. X-4, X-5. [PubMed: 9263611]

551.

Gangale MF, Miele L, Lanzone A, et al. Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol (Oxf). 2011 Oct;75(4):520–7. X-3, X-4. [PubMed: 21569072]

552.

Gao J, Sun HZ, Song GY, et al. Clinical investigation of a low-dose levonorgestrel-releasing vaginal ring. Fertil Steril. 1986 Oct;46(4):626–30. X-3, X-9. [PubMed: 3093283]

553.

Gao J, Wang SL, Wu SC, et al. Comparison of the clinical performance, contraceptive efficacy and acceptability of levonorgestrel-releasing IUD and Norplant-2 implants in China. Contraception. 1990 May;41(5):485–94. X-9. [PubMed: 2112079]

554.

Garceau RJ, Wajszczuk CJ, Kaunitz AM. Bleeding patterns of women using Lunelle monthly contraceptive injections (medroxyprogesterone acetate and estradiol cypionate injectable suspension) compared with those of women using Ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol triphasic) or other oral contraceptives. Contraception. 2000 Dec;62(6):289–95. X-4, X-5, X-6. [PubMed: 11239615]

555.

Garcia-Giralt E, Ayme Y, Carton M, et al. Second and third line hormonotherapy in advanced post-menopausal breast cancer: A multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Breast Cancer Research and Treatment. 1992;24(2):139–45. X-7. [PubMed: 8443401]

556.

Gardner FJ, Konje JC, Abrams KR, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet. 2000 Nov 18;356(9243):1711–7. X-5, X-7. [PubMed: 11095258]

557.

Garry R. Endometrial laser ablation. Baillieres Clin Obstet Gynaecol. 1995 Jun;9(2):317–28. X-3, X-8. [PubMed: 7554615]

558.

Gaspard UJ, Deville JL, Dubois M. Clinical experience with a triphasic oral contraceptive (‘Trinordiol’) in young women. Curr Med Res Opin. 1983;8(6):395–404. X-3, X-9. [PubMed: 6406157]

559.

Gebauer G, Hafner A, Siebzehnrubl E, et al. Role of hysteroscopy in detection and extraction of endometrial polyps: results of a prospective study. Am J Obstet Gynecol. 2001 Jan;184(2):59–63. X-4, X-5, X-6, X-7, X-8. [PubMed: 11174480]

560.

Gelfand MM, Ferenczy A. A prospective 1-year study of estrogen and progestin in postmenopausal women: effects on the endometrium. Obstet Gynecol. 1989 Sep;74(3 Pt 1):398–402. X-3, X-7. [PubMed: 2548135]

561.

Geller SE, Harlow SD, Bernstein SJ. Differences in menstrual bleeding characteristics, functional status, and attitudes toward menstruation in three groups of women. Journal of Women's Health & Gender-Based Medicine. 1999;8(4):533–40. X-3, X-4, X-5. [PubMed: 10839708]

562.

Gemzell-Danielsson K, Inki P, Boubli L, et al. Bleeding pattern and safety of consecutive use of the levonorgestrel-releasing intrauterine system (LNG-IUS)--a multicentre prospective study. Hum Reprod. 2010 Feb;25(2):354–9. X-4, X-5. [PubMed: 19955104]

563.

Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertility and Sterility. 2012 March;97(3):616–22.e3. X-9, X-10. [PubMed: 22222193]

564.

Gemzell-Danielsson K, van Heusden AM, Killick SR, et al. Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen. Hum Reprod. 2002 Oct;17(10):2588–93. X-4, X-5, X-6, X-9. [PubMed: 12351534]

565.

Genazzani AD, Lanzoni C, Ricchieri F, et al. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecol Endocrinol. 2007 Mar;23(3):146–52. X-4, X-5, X-9. [PubMed: 17454168]

566.

Geng SS, Li HZ, Wu XK, et al. Effect of Wujijing Oral Liquid on menstrual disturbance of women. J Ethnopharmacol. 2010 Apr 21;128(3):649–53. X-6, X-10. [PubMed: 20051257]

567.

Geraghty P. Beyond birth control. The health benefits of hormonal contraception. Adv Nurse Pract. 2009 Feb;17(2):47–8. 50, 2. X-1, X-3, X-5, X-10. [PubMed: 19999425]

568.

Gerber B, Krause A, Reimer T, et al. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology. Clin Cancer Res. 2006 Feb 15;12(4):1245–50. X-5, X-7, X-9. [PubMed: 16489080]

569.

Gerli S, Gholami H, Manna C, et al. Use of ethinyl estradiol to reverse the antiestrogenic effects of clomiphene citrate in patients undergoing intrauterine insemination: a comparative, randomized study. Fertil Steril. 2000 Jan;73(1):85–9. X-5, X-9. [PubMed: 10632418]

570.

Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci. 2003 Nov-Dec;7(6):151–9. X-4, X-5, X-9. [PubMed: 15206484]

571.

Gerli S, Papaleo E, Ferrari A, et al. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007 Sep-Oct;11(5):347–54. X-4, X-5. [PubMed: 18074942]

572.

Geyman JP, Oliver LM, Sullivan SD. Expectant, medical, or surgical treatment of spontaneous abortion in first trimester of pregnancy? A pooled quantitative literature evaluation. J Am Board Fam Pract. 1999 Jan-Feb;12(1):55–64. X-1, X-4, X-5, X-8, X-9. [PubMed: 10050644]

573.

Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis. 1982 Aug;170(8):463–7. X-3, X-5, X-6. [PubMed: 6124580]

574.

Ghatak SB, Panchal SJ. Ulipristal acetate- a novel oral emergency contraceptive: Hype or hope? International Journal of Pharmaceutical Sciences Review and Research. 2010;4(3):152–5. X-1, X-3, X-5, X-9.

575.

Ghazizadeh S, Bakhtiari F, Rahmanpour H, et al. A randomized clinical trial to compare levonorgestrel-releasing intrauterine system (Mirena) vs trans- ervical endometrial resection for treatment of menorrhagia. International Journal of Women's Health. 2011;3(1):207–11. X-8. [PMC free article: PMC3150205] [PubMed: 21845065]

576.

Gheorghiade M, Khan S, Blair JEA, et al. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. American Heart Journal. 2009;158(3):437–43. X-5. [PubMed: 19699868]

577.

Ghosh AK, Konar JR. The relative value of two concentrations of hypertonic saline for midtrimester abortion. Int J Gynaecol Obstet. 1980 Jan-Feb;17(4):368–71. X-5. [PubMed: 6102059]

578.

Giacovazzo M, Gallo MF, Guidi V, et al. Nimesulide in the treatment of menstrual migraine. Drugs. 1993;46 Suppl 1:140–1. X-5. [PubMed: 7506154]

579.

Gibson JH, Mitchell A, Reeve J, et al. Treatment of reduced bone mineral density in athletic amenorrhea: a pilot study. Osteoporos Int. 1999;10(4):284–9. X-4, X-5, X-9. [PubMed: 10692976]

580.

Gilbert WM, Moore TR, Resnik R, et al. Angiographic embolization in the management of hemorrhagic complications of pregnancy. Am J Obstet Gynecol. 1992 Feb;166(2):493–7. X-3, X-5, X-8. [PubMed: 1536217]

581.

Ginsburg J, Prelevic G, Butler D, et al. Clinical experience with tibolone (Livial) over 8 years. Maturitas. 1995 Jan;21(1):71–6. X-3, X-7. [PubMed: 7731388]

582.

Glasier A, Thong KJ, Dewar M, et al. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. New England Journal of Medicine. 1992;327(15):1041–4. X-5, X-9. [PubMed: 1522839]

583.

Glasier AF, Wang H, Davie JE, et al. Administration of an antiprogesterone up-regulates estrogen receptors in the endometrium of women using Norplant: a pilot study. Fertil Steril. 2002 Feb;77(2):366–72. X-4, X-5, X-6. [PubMed: 11821099]

584.

Glueck CJ, Phillips H, Cameron D, et al. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril. 2001 Jan;75(1):46–52. X-4, X-5, X-6, X-9. [PubMed: 11163815]

585.

Gnoth C, Frank-Herrmann P, Schmoll A, et al. Cycle characteristics after discontinuation of oral contraceptives. Gynecol Endocrinol. 2002 Aug;16(4):307–17. X-4, X-5, X-9. [PubMed: 12396560]

586.

Godfrey EM, Wu S, Dong J, et al. Gestrinone compared with mifepristone for emergency contraception: A randomized controlled trial. Obstetrics and Gynecology. 2010;115(4):740–4. X-5. [PubMed: 20308833]

587.

Gol M, Akan P, Dogan E, et al. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas. 2006;53(3):252–9. X-7. [PubMed: 15990257]

588.

Goldberg AB, Cardenas LH, Hubbard AE, et al. Postabortion depot medroxyprogesterone acetate continuation rates: a randomized trial of cyclic estradiol. Contraception. 2002 Oct;66(4):215–20. X-5, X-9. [PubMed: 12413614]

589.

Goldenberg M, Cohen SB, Etchin A, et al. A randomized prospective comparative study of general versus epidural anesthesia for transcervical hysteroscopic endometrial resection. Am J Obstet Gynecol. 2001 Feb;184(3):273–6. X-4, X-5, X-8, X-9. [PubMed: 11228472]

590.

Goldenberg M, Zolti M, Bider D, et al. The effect of intracervical vasopressin on the systemic absorption of glycine during hysteroscopic endometrial ablation. Obstet Gynecol. 1996 Jun;87(6):1025–9. X-4, X-5, X-8, X-9. [PubMed: 8649684]

591.

Goldrath MH. Uterine tamponade for the control of acute uterine bleeding. Am J Obstet Gynecol. 1983 Dec 15;147(8):869–72. X-3, X-5. [PubMed: 6650623]

592.

Goldrath MH. Use of danazol in hysteroscopic surgery for menorrhagia. J Reprod Med. 1990 Jan;35(1 Suppl):91–6. X-3, X-8. [PubMed: 2136915]

593.

Goldrath MH. Evaluation of HydroThermAblator and rollerball endometrial ablation for menorrhagia 3 Years after treatment. J Am Assoc Gynecol Laparosc. 2003 Nov;10(4):505–11. X-5, X-8. [PubMed: 14738639]

594.

Goldstein SR, Bhattoa HP, Neven P, et al. Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass. Menopause. 2012 Jan;19(1):41–7. X-5, X-7. [PubMed: 21993078]

595.

Gompel A, Bergeron C, Jondet M, et al. Endometrial safety and tolerability of AERODIOL(R) (intranasal estradiol) for 1 year. Maturitas. 2000 Oct 31;36(3):209–15. X-4, X-5, X-7. [PubMed: 11063903]

596.

Gong C, Song E, Jia W, et al. A double-blind randomized controlled trial of toremifen therapy for mastalgia. Archives of Surgery. 2006;141(1):43–7. X-5. [PubMed: 16415410]

597.

Gong Y, Zha Q, Li L, et al. Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: A double-blinded and randomized study. Journal of Ethnopharmacology. 2012 Jun 01;141(2):592–8. X-5. [PubMed: 21911045]

598.

Gonzalez-Barcena D, Alvarez RB, Ochoa EP, et al. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod. 1997 Sep;12(9):2028–35. X-4, X-5, X-6. [PubMed: 9363724]

599.

Gorgen H, Api M, Akca A, et al. Use of the Levonorgestrel-IUS in the treatment of menorrhagia: assessment of quality of life in Turkish users. Arch Gynecol Obstet. 2009 Jun;279(6):835–40. X-4. [PubMed: 19018547]

600.

Gorins A, Perret F, Tournant B, et al. A French double-blind crossover study (danazol versus placebo) in the treatment of severe fibrocystic breast disease. Eur J Gynaecol Oncol. 1984;5(2):85–9. X-5. [PubMed: 6373293]

601.

Grady D, Applegate W, Bush T, et al. Heart and estrogen/progestin replacement study (HERS): Design, methods, and baseline characteristics. Controlled Clinical Trials. 1998;19(4):314–35. X-7. [PubMed: 9683309]

602.

Grady D, Sawaya GF, Johnson KC, et al. MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause. 2009 May-Jun;16(3):458–65. X-5, X-7, X-9. [PubMed: 19182698]

603.

Graser T, Koytchev R, Muller A, et al. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest for continuous combined hormone replacement therapy in postmenopausal women. Climacteric. 2000 Jun;3(2):109–18. X-5, X-7. [PubMed: 11910651]

604.

Graser T, Muller A, Mellinger U, et al. Continuous-combined treatment of the menopause with combinations of oestradiol valerate and dienogest - A dose-ranging study. Maturitas. 2000;35(3):253–61. X-7. [PubMed: 10936742]

605.

Graser T, Romer T, Wiedey KD, et al. Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints. Climacteric. 2001 Dec;4(4):332–42. X-4, X-5, X-7. [PubMed: 11770190]

606.

Graser T, Rossner P, Schubert K, et al. A comparative study of two levonorgestrel-containing hormone replacement therapy regimens of efficacy and tolerability variables. Maturitas. 1997 Dec 15;28(2):169–79. X-5, X-7. [PubMed: 9522325]

607.

Gray RH, Parker RA, Diethelm P. Vaginal bleeding disturbances associated with the discontinuation of long-acting injectable contraceptives. From the World Health Organization Special Programme for Research, Development, and Research Training in Human Reproduction; Task Force on Long-acting Systemic Agents for the Regulation of Fertility. Br J Obstet Gynaecol. 1981 Mar;88(3):317–21. X-9. [PubMed: 7008825]

608.

Gray RH, Parker RA, Diethelm P. Vaginal bleeding disturbances associated with the discontinuation of long-acting injectable contraceptives. British Journal of Obstetrics and Gynaecology. 1981;88(3):317–21. X-6, X-9. [PubMed: 7008825]

609.

Greenblatt RB. Dwarfs, standing on the shoulders of giants, see further. Prog Clin Biol Res. 1982;112 Pt A:1–11. X-1, X-3, X-5, X-10. [PubMed: 7163294]

610.

Greenspan SL, Resnick NM, Parker RA. The effect of hormone replacement on physical performance in community-dwelling elderly women. American Journal of Medicine. 2005;118(11):1232–9. X-7. [PubMed: 16271907]

611.

Greenwood LH, Glickman MG, Schwartz PE, et al. Obstetric and nonmalignant gynecologic bleeding: treatment with angiographic embolization. Radiology. 1987 Jul;164(1):155–9. X-3, X-5, X-8. [PubMed: 3495816]

612.

Grimbizis G, Tsalikis T, Tzioufa V, et al. Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study. Hum Reprod. 1999 Feb;14(2):479–84. X-3, X-6. [PubMed: 10099998]

613.

Grimes DA, Mishell DR Jr., Shoupe D, et al. Early abortion with a single dose of the antiprogestin RU-486. Am J Obstet Gynecol. 1988 Jun;158(6 Pt 1):1307–12. X-3, X-5. [PubMed: 2454578]

614.

Grodnitskaya EE, Grigoryan OR, Klinyshkova EV, et al. Effect on carbohydrate metabolism and analysis of acceptability (menstrual cycle control) of extended regimens of the vaginally inserted hormone-releasing system ‘NuvaRing’ as compared with the standard 21/7 regime in reproductive-age women with type 1 diabetes mellitus. Gynecological Endocrinology. 2010;26(9):663–8. X-5. [PubMed: 20334583]

615.

Grubb GS, Welch JD, Cole L, et al. A comparative evaluation of the safety and contraceptive effectiveness of 65 mg and 100 mg of 90-day norethindrone (NET) injectable microspheres: a multicenter study. Fertil Steril. 1989 May;51(5):803–10. X-9. [PubMed: 2523322]

616.

Gruber DM, Huber JC, Melis GB, et al. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20mug and drospirenone 3mg with a 21-day regimen of ethinylestradiol 20mug and desogestrel 150mug. Treatments in Endocrinology. 2006;5(2):115–21. X-9. [PubMed: 16542051]

617.

Gu SJ, Du MK, Zhang LD, et al. A 5-year evaluation of NORPLANT contraceptive implants in China. Obstet Gynecol. 1994 May;83(5 Pt 1):673–8. X-3, X-9. [PubMed: 8164924]

618.

Guazzelli CA, Barreiros FA, Barbosa R, et al. Extended regimens of the vaginal contraceptive ring: cycle control. Contraception. 2009 Nov;80(5):430–5. X-4, X-5, X-9. [PubMed: 19835716]

619.

Gudmundsson JA, Nillius SJ, Bergquist C. Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six months' clinical results. Fertil Steril. 1986 May;45(5):617–23. X-3, X-9. [PubMed: 2938984]

620.

Guest J, Chien P, Thomson M, et al. Randomised controlled trial comparing efficacy of same day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36- to 48-hour protocol. BJOG. 2005 Oct;112(10):1457. X-5, X-9. [PubMed: 16167962]

621.

Guichard JP, Sauron R, Jones AB. Comparison of the pharmacokinetics of 17 beta-estradiol after a single 4-day application of Oesclim 50, Oesclim 100, and Vivelle 0.05 (Menorest 50) transdermal delivery systems. J Clin Pharmacol. 1999 Aug;39(8):811–6. X-5, X-7. [PubMed: 10434233]

622.

Guida M, Di Spiezio Sardo A, Bramante S, et al. Effects of two types of hormonal contraception - Oral versus intravaginal - On the sexual life of women and their partners. Human Reproduction. 2005;20(4):1100–6. X-5, X-9. [PubMed: 15608030]

623.

Guida M, Pellicano M, Zullo F, et al. Outpatient operative hysteroscopy with bipolar electrode: A prospective multicentre randomized study between local anaesthesia and conscious sedation. Human Reproduction. 2003;18(4):840–3. X-8. [PubMed: 12660281]

624.

Guidotti M, Mauri M, Barrila C, et al. Frovatriptan vs. transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine. J Headache Pain. 2007 Oct;8(5):283–8. X-4, X-5, X-9. [PMC free article: PMC3476156] [PubMed: 17955167]

625.

Guilleminault C, Stoohs R, Kim YD, et al. Upper airway sleep-disordered breathing in women. Ann Intern Med. 1995 Apr 1;122(7):493–501. X-3, X-5. [PubMed: 7872583]

626.

Gull B, Carlsson S, Karlsson B, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding: is it always necessary to perform an endometrial biopsy? Am J Obstet Gynecol. 2000 Mar;182(3):509–15. X-4, X-5, X-7. [PubMed: 10739500]

627.

Gultekin M, Diribas K, Buru E, et al. Role of a non-hormonal oral anti-fibrinolytic hemostatic agent (tranexamic acid) for management of patients with dysfunctional uterine bleeding. Clin Exp Obstet Gynecol. 2009;36(3):163–5. X-4. [PubMed: 19860359]

628.

Gunson MJ, Arnett GW, Formby B, et al. Oral contraceptive pill use and abnormal menstrual cycles in women with severe condylar resorption: a case for low serum 17beta-estradiol as a major factor in progressive condylar resorption. Am J Orthod Dentofacial Orthop. 2009 Dec;136(6):772–9. X-4, X-5, X-9. [PubMed: 19962599]

629.

Gupta AN, Dhaliwal LK, Gulati K. Clinical performance with contraceptive vaginal rings containing levonorgestrel. Indian J Med Res. 1986 Sep;84:321–5. X-3, X-9, X-10. [PubMed: 3102365]

630.

Gupta B, Mittal S, Misra R, et al. Levonorgestrel-releasing intrauterine system vs. transcervical endometrial resection for dysfunctional uterine bleeding. Int J Gynaecol Obstet. 2006 Dec;95(3):261–6. X-8. [PubMed: 16999960]

631.

Gupta P, Singh S, Goyal V, et al. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache. 2007;47(3):402–12. X-5. [PubMed: 17371357]

632.

Gurates B, Parmaksiz C, Kilic G, et al. Treatment of symptomatic uterine leiomyoma with letrozole. Reprod Biomed Online. 2008 Oct;17(4):569–74. X-4, X-5, X-6. [PubMed: 18854113]

633.

Gusberg SB. An approach to the control of carcinoma of the endometrium. CA Cancer J Clin. 1980 Jan-Feb;30(1):16–22. X-5. [PubMed: 6766346]

634.

Guzick DS, Wing R, Smith D, et al. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertility and Sterility. 1994;61(4):598–604. X-3, X-5, X-10. [PubMed: 8150098]

635.

Hakimian S, Cheng-Hakimian A, Anderson GD, et al. Rufinamide: A new anti-epileptic medication. Expert Opinion on Pharmacotherapy. 2007;8(12):1931–40. X-1, X-3, X-5. [PubMed: 17696794]

636.

Halbe HW, de Melo NR, Bahamondes L, et al. Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene. Eur J Contracept Reprod Health Care. 1998 Sep;3(3):113–20. X-9. [PubMed: 9853201]

637.

Hald K, Klow NE, Qvigstad E, et al. Laparoscopic occlusion compared with embolization of uterine vessels: a randomized controlled trial. Obstet Gynecol. 2007 Jan;109(1):20–7. X-5, X-6, X-8. [PubMed: 17197583]

638.

Hald K, Klow NE, Qvigstad E, et al. Treatment of uterine myomas with transvaginal uterine artery occlusion: possibilities and limitations. J Minim Invasive Gynecol. 2008 Sep-Oct;15(5):631–5. X-4, X-5, X-6, X-8, X-9. [PubMed: 18722975]

639.

Hall P, Bahamondes L, Diaz J, et al. Introductory study of the once-a-month, injectable contraceptive Cyclofem in Brazil, Chile, Colombia, and Peru. Contraception. 1997 Dec;56(6):353–9. X-4, X-5, X-9. [PubMed: 9494768]

640.

Halmesmaki K, Hurskainen R, Teperi J, et al. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on sexual functioning among women with menorrhagia: a 5-year randomised controlled trial. BJOG. 2007 May;114(5):563–8. X-8. [PubMed: 17439564]

641.

Halmesmaki K, Hurskainen R, Tiitinen A, et al. A randomized controlled trial of hysterectomy or levonorgestrel-releasing intrauterine system in the treatment of menorrhagia-effect on FSH levels and menopausal symptoms. Hum Reprod. 2004 Feb;19(2):378–82. X-5, X-8, X-9. [PubMed: 14747185]

642.

Halmesmaki K, Hurskainen R, Tiitinen A, et al. A randomized controlled trial hysterectomy of levenorgestrel-releasing intrauterine system in the treatment of menorrhagia - Effect of FSH levels and menopausal symptoms. Human Reproduction. 2004;19(2):378–82. X-8. [PubMed: 14747185]

643.

Halmesmaki KH, Hurskainen RA, Cacciatore B, et al. Effect of hysterectomy or LNG-IUS on serum inhibin B levels and ovarian blood flow. Maturitas. 2007 Jul 20;57(3):279–85. X-4, X-5, X-8. [PubMed: 17329045]

644.

Halmesmaki KH, Paavonen JA, Tuppurainen MT, et al. Randomized controlled trial of the effect of hysterectomy or LNG-IUS use on bone mineral density: A five-year follow-up. Therapy. 2006;3(4):509–15. X-8.

645.

Hamilton RA, Grant AM, Henry OA, et al. The management of bleeding in early pregnancy. Ir Med J. 1991 Mar;84(1):18–9. X-3, X-5. [PubMed: 2045259]

646.

Hammar M, Christau S, Nathorst-Boos J, et al. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol. 1998 Aug;105(8):904–11. X-5, X-7. [PubMed: 9746385]

647.

Hammar ML, van de Weijer P, Franke HR, et al. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. BJOG. 2007 Dec;114(12):1522–9. X-5, X-7. [PubMed: 17995496]

648.

Hammerstein J, Daume E, Simon A, et al. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol. Contraception. 1993 Mar;47(3):263–81. X-4. [PubMed: 8462317]

649.

Hamou JE. Microhysteroscopy. Clin Obstet Gynecol. 1983 Jun;26(2):285–301. X-4, X-5, X-8. [PubMed: 6406117]

650.

Hampton NR, Rees MC, Lowe DG, et al. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod. 2005 Sep;20(9):2653–60. X-4, X-5, X-9. [PubMed: 15905289]

651.

Hampton RM, Fisher AC, Pagano S, et al. Scheduled and unscheduled bleeding patterns with two combined hormonal contraceptives: application of new recommendations for standardization. Fertil Steril. 2009 Aug;92(2):434–40. X-4, X-5, X-9. [PubMed: 18930189]

652.

Hampton RM, Short M, Bieber E, et al. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. Contraception. 2001;63(6):289–95. X-9. [PubMed: 11672549]

653.

Hampton RM, Zhang HF, Barnowski C, et al. Bleeding patterns with monophasic and triphasic low-dose ethinyl estradiol combined oral contraceptives. Contraception. 2008 Jun;77(6):415–9. X-4, X-5, X-9. [PubMed: 18477490]

654.

Hanggi W, Bersinger N, Altermatt HJ, et al. Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRT users. Maturitas. 1997 Jun;27(2):133–43. X-5, X-7, X-8, X-9. [PubMed: 9255748]

655.

Haoula ZJ, Walker KF, Powell MC. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol. 2011 Nov;159(1):176–9. X-3, X-6. [PubMed: 21741152]

656.

Hapangama DK, Critchley HO, Henderson TA, et al. Mifepristone-induced vaginal bleeding is associated with increased immunostaining for cyclooxygenase-2 and decrease in prostaglandin dehydrogenase in luteal phase endometrium. J Clin Endocrinol Metab. 2002 Nov;87(11):5229–34. X-4, X-5, X-6, X-9. [PubMed: 12414896]

657.

Haq G, Tayyab S. Control of postpartum and post abortal haemorrhage with uterine packing. J Pak Med Assoc. 2005 Sep;55(9):369–71. X-4, X-5, X-9. [PubMed: 16302468]

658.

Harada T, Momoeda M, Terakawa N, et al. Evaluation of a low-dose oral contraceptive pill for primary dysmenorrhea: A placebo-controlled, double-blind, randomized trial. Fertility and Sterility. 2011;95(6):1928–31. X-5. [PubMed: 21420678]

659.

Harden CL, Herzog AG, Nikolov BG, et al. Hormone replacement therapy in women with epilepsy: A randomized, double-blind, placebo-controlled study. Epilepsia. 2006;47(9):1447–51. X-5, X-7. [PubMed: 16981859]

660.

Harding CM, Vail C, Brown R. Effect of oral contraceptives and some psychological factors on the menstrual experience. J Biosoc Sci. 1985 Jul;17(3):291–304. X-3, X-5, X-10. [PubMed: 4040913]

661.

Harel Z, Biro F, Kollar L, et al. Supplementation with vitamin C and/or vitamin B(6) in the prevention of Depo-Provera side effects in adolescents. J Pediatr Adolesc Gynecol. 2002 Jun;15(3):153–8. X-5, X-6, X-9. [PubMed: 12106752]

662.

Harper C, Winikoff B, Ellertson C, et al. Blood loss with mifepristone--misoprostol abortion: measures from a trial in China, Cuba and India. Int J Gynaecol Obstet. 1998 Oct;63(1):39–49. X-4, X-5, X-9. [PubMed: 9849710]

663.

Harrison RF, Barry-Kinsella C. Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: A prospective, randomized, placebo-controlled study. Fertility and Sterility. 2000;74(1):24–30. X-10. [PubMed: 10899492]

664.

Hasham F, Garry R, Kokri MS, et al. Fluid absorption during laser ablation of the endometrium in the treatment of menorrhagia. Br J Anaesth. 1992 Feb;68(2):151–4. X-8. [PubMed: 1540456]

665.

Hashemi F, Pasyar N, Dehbashi S. Relationship of chemotherapeutic agents with menstrual disorders in nursing staff. Journal of Nursing & Midwifery. 2009;19(64):38. X-11.

666.

Hassan WA, Darwish AM. Impact of pulmonary tuberculosis on menstrual pattern and fertility. Clin Respir J. 2010 Jul;4(3):157–61. X-4, X-5, X-9. [PubMed: 20565494]

667.

Hassanin IM, Shahin AY, Abdel-Hafeez AT, et al. Bilateral uterine artery ligation via minilaparotomy for heavy menstrual bleeding. Int J Gynaecol Obstet. 2008 Dec;103(3):222–6. X-4, X-5, X-8. [PubMed: 18805523]

668.

Haugan T, Skjeldestad FE, Halvorsen LE, et al. A randomized trial on the clinical performance of Nova T380 and Gyne T380 Slimline copper IUDs. Contraception. 2007 Mar;75(3):171–6. X-4, X-5. [PubMed: 17303485]

669.

Hawe JA, Phillips AG, Chien PF, et al. Cavaterm thermal balloon ablation for the treatment of menorrhagia. Br J Obstet Gynaecol. 1999 Nov;106(11):1143–8. X-4, X-5, X-8. [PubMed: 10549958]

670.

Hayes JL, Achilles SL, Creinin MD, et al. Outcomes of medical abortion through 63 days in women with twin gestations. Contraception. 2011 Nov;84(5):505–7. X-3, X-5. [PMC free article: PMC3979718] [PubMed: 22018125]

671.

Haynes PJ, Flint AP, Hodgson H, et al. Studies in menorrhagia: (a) mefenamic acid, (b) endometrial prostaglandin concentrations. Int J Gynaecol Obstet. 1980 May-Jun;17(6):567–72. X-3. [PubMed: 6106574]

672.

Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003 May 8;348(19):1839–54. X-7. [PubMed: 12642637]

673.

He CH, Shi YE, Xu JQ, et al. A multicenter clinical study on two types of levonorgestrel tablets administered for postcoital contraception. Int J Gynaecol Obstet. 1991 Sep;36(1):43–8. X-5, X-9. [PubMed: 1683301]

674.

He Y, Lu A, Zha Y, et al. Correlations between symptoms as assessed in traditional Chinese medicine (TCM) and ACR20 efficacy response: A comparison study in 396 patients with rheumatoid arthritis treated with TCM or Western medicine. Journal of Clinical Rheumatology. 2007;13(6):317–21. X-5. [PubMed: 18176139]

675.

Heber KR. Medroxyprogesterone acetate as an injectable contraceptive. Aust Fam Physician. 1988 Mar;17(3):199–201. 4. X-3, X-5, X-9, X-10. [PubMed: 2965570]

676.

Hee P, Pagel JD. Primary carcinoma of the fallopian tube. Eur J Obstet Gynecol Reprod Biol. 1987 Jun;25(2):131–8. X-3, X-5. [PubMed: 3609428]

677.

Hehenkamp WJ, Volkers NA, Broekmans FJ, et al. Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. Hum Reprod. 2007 Jul;22(7):1996–2005. X-5, X-6, X-8. [PubMed: 17582145]

678.

Heikinheimo O, Inki P, Kunz M, et al. Predictors of bleeding and user satisfaction during consecutive use of the levonorgestrel-releasing intrauterine system. Hum Reprod. 2010 Jun;25(6):1423–7. X-4, X-5. [PubMed: 20378611]

679.

Heikinheimo O, Inki P, Kunz M, et al. Double-blind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine system. Contraception. 2010;81(6):481–6. X-5. [PubMed: 20472114]

680.

Heikinheimo O, Vani S, Carpen O, et al. Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study. Hum Reprod. 2007 Sep;22(9):2515–22. X-4, X-5, X-9. [PubMed: 17636280]

681.

Heikkila M. Puerperal insertion of a copper-releasing and a levonorgestrel-releasing intrauterine contraceptive device. Contraception. 1982 Jun;25(6):561–72. X-3, X-4, X-9. [PubMed: 6811195]

682.

Heikkinen J, Vaheri R, Timonen U. Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: Results from a seven-year randomised comparison of low and standard doses. Journal of the British Menopause Society. 2004;10(3):95–102. X-7. [PubMed: 15494100]

683.

Heikkinen J, Vaheri R, Timonen U. A 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: Update of safety and quality-of-life findings. Journal of the British Menopause Society. 2006;12(3):115–25. X-5, X-7. [PubMed: 16953985]

684.

Heikkinen JE, Vaheri RT, Ahomaki SM, et al. Optimizing continuous-combined hormone replacement therapy for postmenopausal women: A comparison of six different treatment regimens. American Journal of Obstetrics and Gynecology. 2000;182(3):560–7. X-7. [PubMed: 10739508]

685.

Heisterberg L, Sonne-Holm S, Andersen JT, et al. Risk factors in first-trimester abortion. Acta Obstet Gynecol Scand. 1982;61(4):357–60. X-3, X-4, X-5. [PubMed: 7148411]

686.

Helge EW, Kanstrup IL. Bone density in female elite gymnasts: impact of muscle strength and sex hormones. Med Sci Sports Exerc. 2002 Jan;34(1):174–80. X-4, X-5, X-9. [PubMed: 11782664]

687.

Heliovaara-Peippo S, Halmesmaki K, Hurskainen R, et al. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on lower abdominal pain and back pain among women treated for menorrhagia: a five-year randomized controlled trial. Acta Obstet Gynecol Scand. 2009;88(12):1389–96. X-5, X-8. [PubMed: 19878089]

688.

Heliovaara-Peippo S, Halmesmaki K, Hurskainen R, et al. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on lower urinary tract symptoms: a 10-year follow-up study of a randomised trial. BJOG. 2010 Apr;117(5):602–9. X-5, X-8. [PubMed: 20156209]

689.

Heliovaara-Peippo S, Oksjoki R, Halmesmaki K, et al. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on cardiovascular disease risk factors in menorrhagia patients: A 10-year follow-up of a randomised trial. Maturitas. 2011;69(4):354–8. X-8. [PubMed: 21684096]

690.

Hellberg D, Nilsson S. Pilot study to evaluate a new regimen to treat climacteric complaints with cyclic combined oestradiol valerate/medroxyprogesterone acetate. Maturitas. 1987 Apr;9(1):103–7. X-3, X-7. [PubMed: 2955203]

691.

Hellgren M, Conard J, Norris L, et al. Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone. Maturitas. 2009 Mar 20;62(3):287–93. X-4, X-5, X-7, X-9. [PubMed: 19268506]

692.

Hemmerling A, Harrison W, Schroeder A, et al. Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis. Sex Transm Dis. 2009 Sep;36(9):564–9. X-4, X-5, X-9. [PMC free article: PMC2758081] [PubMed: 19543144]

693.

Hergenroeder AC, Smith EO, Shypailo R, et al. Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months. Am J Obstet Gynecol. 1997 May;176(5):1017–25. X-5, X-9. [PubMed: 9166162]

694.

Herzog AG. Continuous bromocriptine therapy in menstrual migraine. Neurology. 1997 Jan;48(1):101–2. X-4, X-5, X-9. [PubMed: 9008502]

695.

Herzog AG, Coleman AE, Jacobs AR, et al. Interictal EEG discharges, reproductive hormones, and menstrual disorders in epilepsy. Ann Neurol. 2003 Nov;54(5):625–37. X-4, X-5, X-9. [PubMed: 14595652]

696.

Hickey M, Carati C, Manconi F, et al. The measurement of endometrial perfusion in norplant users: a pilot study. Hum Reprod. 2000 May;15(5):1086–91. X-4, X-5, X-6, X-9. [PubMed: 10783358]

697.

Hickey M, Dwarte D, Fraser IS. Precise measurements of intrauterine vascular structures at hysteroscopy in menorrhagia and during Norplant use. Hum Reprod. 1998 Nov;13(11):3190–6. X-3, X-4. [PubMed: 9853879]

698.

Hickey M, Dwarte D, Fraser IS. Superficial endometrial vascular fragility in Norplant users and in women with ovulatory dysfunctional uterine bleeding. Hum Reprod. 2000 Jul;15(7):1509–14. X-4, X-5. [PubMed: 10875858]

699.

Hickey M, Fraser I, Dwarte D, et al. Endometrial vasculature in Norplant users: preliminary results from a hysteroscopic study. Hum Reprod. 1996 Oct;11 Suppl 2:35–44. X-4, X-5, X-6. [PubMed: 8982744]

700.

Hickey M, Higham J, Sullivan M, et al. Endometrial bleeding in hormone replacement therapy users: preliminary findings regarding the role of matrix metalloproteinase 9 (MMP-9) and tissue inhibitors of MMPs. Fertil Steril. 2001 Feb;75(2):288–96. X-4, X-5, X-7, X-9. [PubMed: 11172829]

701.

Hickey M, Pillai G, Higham JM, et al. Changes in endometrial blood vessels in the endometrium of women with hormone replacement therapy-related irregular bleeding. Hum Reprod. 2003 May;18(5):1100–6. X-4, X-5, X-6. [PubMed: 12721191]

702.

Hidalgo M, Bahamondes L, Perrotti M, et al. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception. 2002 Feb;65(2):129–32. X-4, X-5, X-6. [PubMed: 11927115]

703.

Hidalgo MM, Lisondo C, Juliato CT, et al. Ovarian cysts in users of Implanon and Jadelle subdermal contraceptive implants. Contraception. 2006 May;73(5):532–6. X-4, X-5, X-9. [PubMed: 16627041]

704.

Higham JM, Shaw RW. A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. Am J Obstet Gynecol. 1993 Nov;169(5):1134–9. X-5. [PubMed: 8238173]

705.

Hill GA, Wheeler JM. Incidence of breakthrough bleeding during oral contraceptive therapy. J Reprod Med. 1991 Apr;36(4 Suppl):334–9. X-3, X-4, X-5, X-9. [PubMed: 2046082]

706.

Hillard PJ. The patient's reaction to side effects of oral contraceptives. Am J Obstet Gynecol. 1989 Nov;161(5):1412–5. X-3, X-9. [PubMed: 2589465]

707.

Hingorani V, Jalnawala SF, Kochhar M. Task force on hormonal contraception. Phase II randomized comparative clinical trial of Norplant(R) (six capsules) with Norplant(R)-2 (two covered rods) subdermal implants for long-term contraception: Report of a 24-month study. Contraception. 1986;33(3):233–44. X-9. [PubMed: 3087694]

708.

Hingorani V, Jalnawala SF, Kochhar M, et al. Phase II randomized comparative clinical trial of Norplant (six capsules) with Norplant-2 (two covered rods) subdermal implants for long-term contraception: report of a 24-month study. National Programme of Research in Human Reproduction. Contraception. 1986 Mar;33(3):233–44. X-9. [PubMed: 3087694]

709.

Hirakawa M, Tajima T, Yoshimitsu K, et al. Uterine artery embolization along with the administration of methotrexate for cervical ectopic pregnancy: technical and clinical outcomes. AJR Am J Roentgenol. 2009 Jun;192(6):1601–7. X-4, X-5, X-9. [PubMed: 19457824]

710.

Hirvonen E, Allonen H, Anttila M, et al. Oral contraceptive containing natural estradiol for premenopausal women. Maturitas. 1995 Jan;21(1):27–32. X-3, X-9. [PubMed: 7731379]

711.

Hirvonen E, Cacciatore B, Wahlstrom T, et al. Effects of transdermal oestrogen therapy in postmenopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch. Br J Obstet Gynaecol. 1997 Nov;104 Suppl 16:26–31. X-5, X-7. [PubMed: 9389780]

712.

Hirvonen E, Crona N, Wahlstrom T, et al. Effect of an estradiol gel with monthly or quarterly progestogen on menopausal symptoms and bleeding. Climacteric. 2000 Dec;3(4):262–70. X-4, X-5, X-7. [PubMed: 11910586]

713.

Hirvonen E, Lamberg-Allardt C, Lankinen KS, et al. Transdermal oestradiol gel in the treatment of the climacterium: a comparison with oral therapy. Br J Obstet Gynaecol. 1997 Nov;104 Suppl 16:19–25. X-5, X-7, X-9. [PubMed: 9389779]

714.

Hirvonen E, Salmi T, Puolakka J, et al. Can progestin be limited to every third month only in postmenopausal women taking estrogen? Maturitas. 1995 Jan;21(1):39–44. X-3, X-7. [PubMed: 7731382]

715.

Horn SD, Prather S, Jones CA. A cohort analysis of pre-menopausal women with dysfunctional uterine bleeding. HMO Pract. 1996 Jun;10(2):59–64. X-4, X-5, X-8. [PubMed: 10158542]

716.

Horwitz RI, Feinstein AR. The problem of “protopathic bias” in case-control studies. Am J Med. 1980 Feb;68(2):255–8. X-3, X-5. [PubMed: 7355896]

717.

Hourihan HM, Sheppard BL, Bonnar J. A morphometric study of the effect of oral norethisterone or levonorgestrel on endometrial blood vessels. Contraception. 1986 Dec;34(6):603–12. X-3, X-4. [PubMed: 3103980]

718.

Hovik P, Sundsbak HP, Gaasemyr M, et al. Comparison of continuous and sequential oestrogen-progestogen treatment in women with climacteric symptoms. Maturitas. 1989 Mar;11(1):75–82. X-4, X-5, X-7, X-10. [PubMed: 2498620]

719.

Hreinsson J, Rosenlund B, Friden B, et al. Recombinant LH is equally effective as recombinant hCG in promoting oocyte maturation in a clinical in-vitro maturation programme: A randomized study. Human Reproduction. 2003;18(10):2131–6. X-5. [PubMed: 14507834]

720.

Huang KE, Bonfiglio TA, Muechler EK. Transient hyperprolactinemia in infertile women with luteal phase deficiency. Obstet Gynecol. 1991 Oct;78(4):651–5. X-3, X-4, X-5. [PubMed: 1923170]

721.

Hubacher D, Reyes V, Lillo S, et al. Preventing copper intrauterine device removals due to side effects among first-time users: Randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction. 2006;21(6):1467–72. X-5. [PubMed: 16484309]

722.

Huber J, Palacios S, Berglund L, et al. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. BJOG. 2002 Aug;109(8):886–93. X-5, X-7. [PubMed: 12197367]

723.

Huber MG, Wildschut HI, Boer K, et al. Umbilical vein administration of oxytocin for the management of retained placenta: is it effective? Am J Obstet Gynecol. 1991 May;164(5 Pt 1):1216–9. X-5. [PubMed: 1709781]

724.

Hudita D, Posea C, Ceausu I, et al. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women. Eur Rev Med Pharmacol Sci. 2003 Sep-Oct;7(5):117–25. X-5, X-7. [PubMed: 15214586]

725.

Huggins GR. IUD use and unexplained vaginal bleeding. Obstet Gynecol. 1981 Oct;58(4):409–16. X-3, X-5, X-6. [PubMed: 7279336]

726.

Hui-Qin L, Zhuan-Chong F, Yu-Bao W, et al. Performance of the frameless IUD (Flexigard prototype inserter) and the TCu380A after six years as part of a WHO multicenter randomized comparative clinical trial in parous women. Adv Contracept. 1999;15(3):201–9. X-4, X-5. [PubMed: 11019951]

727.

Humpl T, Reyes JT, Holtby H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: Twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation. 2005;111(24):3274–80. X-3, X-5. [PubMed: 15956137]

728.

Hurskaienen R, Teperi J, Rissanen P. A levonorgestrel releasing intrauterine system was more cost effective than was hysterectomy for menorrhagia. Evidence Based Medicine. 2001;6(4) X-8.

729.

Hurskainen R, Salmi A, Paavonen J, et al. Expression of sex steroid receptors and Ki-67 in the endometria of menorrhagic women: effects of intrauterine levonorgestrel. Mol Hum Reprod. 2000 Nov;6(11):1013–8. X-4, X-5. [PubMed: 11044464]

730.

Hurskainen R, Teperi J, Aalto AM, et al. Levonorgestrel-releasing intrauterine system or hysterectomy in the treatment of essential menorrhagia: predictors of outcome. Acta Obstet Gynecol Scand. 2004 Apr;83(4):401–3. X-8. [PubMed: 15005790]

731.

Hurskainen R, Teperi J, Rissanen P, et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet. 2001 Jan 27;357(9252):273–7. X-5, X-8. [PubMed: 11214131]

732.

Hurskainen R, Teperi J, Rissanen P, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA. 2004 Mar 24;291(12):1456–63. X-8. [PubMed: 15039412]

733.

Hussein M. Transvaginal Doppler sonography for evaluation of irregular uterine bleeding with DMPA. Arch Gynecol Obstet. 2011 Jun;283(6):1325–8. X-4, X-5, X-9. [PubMed: 20582427]

734.

Hutspardol S, Sirachainan N, Soisamrong A, et al. Hemostatic defects in Thai adolescents with menorrhagia. J Med Assoc Thai. 2010 Apr;93(4):436–42. X-4, X-5, X-6. [PubMed: 20462086]

735.

Ibanez L, Hall JE, Potau N, et al. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin- releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: Evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. Journal of Clinical Endocrinology and Metabolism. 1996;81(11):4103–7. X-3, X-4. [PubMed: 8923867]

736.

Ibanez L, Lopez-Bermejo A, Diaz M, et al. Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. J Clin Endocrinol Metab. 2011 Aug;96(8):E1262–7. X-5, X-10. [PubMed: 21632811]

737.

Ibanez L, Ong K, Ferrer A, et al. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. J Clin Endocrinol Metab. 2003 Jun;88(6):2600–6. X-4, X-5, X-9. [PubMed: 12788862]

738.

Ibanez L, Potau N, Marcos MV, et al. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab. 2000 Sep;85(9):3251–5. X-4, X-5, X-9. [PubMed: 10999817]

739.

Ibanez L, Potau N, Marcos MV, et al. Corticotropin-releasing hormone: A potent androgen secretagogue in girls with hyperandrogenism after precocious pubarche. Journal of Clinical Endocrinology and Metabolism. 2000;84(12):4602–6. X-4, X-5. [PubMed: 10599726]

740.

Ibanez L, Valls C, de Zegher F. Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: Normalizing effects on CRP, TNF-alpha and the neutrophil/lymphocyte ratio. Human Reproduction. 2006;21(2):451–6. X-4, X-5, X-10. [PubMed: 16239318]

741.

Ibanez L, Valls C, Potau N, et al. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab. 2000 Oct;85(10):3526–30. X-4, X-5, X-9. [PubMed: 11061495]

742.

Ikomi A, Gupta N. Randomised controlled trial exists of levonorgestrel intrauterine system for menorrhagia. BMJ. 1998 Oct 31;317(7167):1250. X-1, X-3. [PMC free article: PMC1114173] [PubMed: 9794876]

743.

Imani B, Eijkemans MJ, te Velde ER, et al. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 1998 Jul;83(7):2361–5. X-3, X-5. [PubMed: 9661609]

744.

Imani B, Eijkemans MJ, te Velde ER, et al. Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 1999 May;84(5):1617–22. X-4, X-5, X-6, X-9. [PubMed: 10323389]

745.

Inki P, Hurskainen R, Palo P, et al. Comparison of ovarian cyst formation in women using the levonorgestrel-releasing intrauterine system vs. hysterectomy. Ultrasound Obstet Gynecol. 2002 Oct;20(4):381–5. X-4, X-5, X-8, X-9. [PubMed: 12383322]

746.

Irahara M, Uemura H, Yasui T, et al. Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis. Gynecol Obstet Invest. 2001;52(4):217–22. X-5, X-6, X-9. [PubMed: 11729332]

747.

Ismail SI, Pugh DH, Gower-Thomas K, et al. A pilot evaluation of saline sonohysterography for postmenopausal bleeding with thickened endometrium. J Obstet Gynaecol. 2009 Feb;29(2):132–4. X-4, X-5, X-7. [PubMed: 19274548]

748.

Isojarvi JI, Laatikainen TJ, Pakarinen AJ, et al. Menstrual disorders in women with epilepsy receiving carbamazepine. Epilepsia. 1995 Jul;36(7):676–81. X-3, X-4, X-5. [PubMed: 7555984]

749.

Isojarvi JI, Tauboll E, Pakarinen AJ, et al. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med. 2001 Sep;111(4):290–6. X-4, X-5, X-6, X-9. [PubMed: 11566460]

750.

Istre O, Johnstad B, Skajaa K, et al. Effects of indomethacin on postoperative pain and nausea after transcervical endometrial resection. Gynaecological Endoscopy. 1994;3(4):225–8. X-5, X-8.

751.

Istre O, Skajaa K, Schjoensby AP, et al. Changes in serum electrolytes after transcervical resection of endometrium and submucous fibroids with use of glycine 1.5% for uterine irrigation. Obstet Gynecol. 1992 Aug;80(2):218–22. X-3, X-8. [PubMed: 1635735]

752.

Istre O, Trolle B. Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. Fertil Steril. 2001 Aug;76(2):304–9. X-5, X-8. [PubMed: 11476777]

753.

Itoi H, Minakami H, Iwasaki R, et al. Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen on serum lipid profile in early menopausal women. Maturitas. 2000 Oct 31;36(3):217–22. X-4, X-5, X-7. [PubMed: 11063904]

754.

Jabiry-Zieniewicz Z, Kaminski P, Bobrowska K, et al. Menstrual function in female liver transplant recipients of reproductive age. Transplant Proc. 2009 Jun;41(5):1735–9. X-4, X-5, X-6, X-9. [PubMed: 19545718]

755.

Jack SA, Cooper KG, Seymour J, et al. A randomised controlled trial of microwave endometrial ablation without endometrial preparation in the outpatient setting: patient acceptability, treatment outcome and costs. BJOG. 2005 Aug;112(8):1109–16. X-8. [PubMed: 16045526]

756.

Jain A, Katewa SS, Chaudhary BL, et al. Folk herbal medicines used in birth control and sexual diseases by tribals of southern Rajasthan, India. J Ethnopharmacol. 2004 Jan;90(1):171–7. X-4, X-5, X-9. [PubMed: 14698527]

757.

Jain J, Jakimiuk AJ, Bode FR, et al. Contraceptive efficacy and safety of DMPA-SC. Contraception. 2004 Oct;70(4):269–75. X-4, X-5. [PubMed: 15451329]

758.

Jain JK, Meckstroth KR, Mishell DR Jr. Early pregnancy termination with intravaginally administered sodium chloride solution-moistened misoprostol tablets: historical comparison with mifepristone and oral misoprostol. Am J Obstet Gynecol. 1999 Dec;181(6):1386–91. X-4, X-5, X-9. [PubMed: 10601917]

759.

Jain JK, Nicosia AF, Nucatola DL, et al. Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate. Steroids. 2003 Nov;68(10-13):1115–9. X-4, X-5, X-6. [PubMed: 14668006]

760.

Jakubowicz DL, Godard E, Dewhurst J. The treatment of premenstrual tension with mefenamic acid: analysis of prostaglandin concentrations. Br J Obstet Gynaecol. 1984 Jan;91(1):78–84. X-3, X-4, X-5, X-10. [PubMed: 6362715]

761.

Janssen CA. Menorrhagia and 3-keto-desogestrel-copper medicated intrauterine device. Eur J Obstet Gynecol Reprod Biol. 1999 Aug;85(2):135–6. X-1, X-3. [PubMed: 10610326]

762.

Janssen CA, Scholten PC, Heintz AP. The effect of low-dose 3-keto-desogestrel added to a copper-releasing intrauterine contraceptive device on menstrual blood loss: a double-blind, dose-finding, placebo-controlled study. Am J Obstet Gynecol. 2000 Mar;182(3):575–81. X-5, X-9, X-10. [PubMed: 10739510]

763.

Janssen OE, Mehlmauer N, Hahn S, et al. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol. 2004 Mar;150(3):363–9. X-4, X-5, X-6, X-9. [PubMed: 15012623]

764.

Jarrell A, Olsen ME. Patient satisfaction with thermal balloon endometrial ablation. A retrospective review. J Reprod Med. 2003 Aug;48(8):635–6. X-4, X-5, X-8. [PubMed: 12971146]

765.

Jarvela I, Tekay A, Santala M, et al. Thermal balloon endometrial ablation therapy induces a rise in uterine blood flow impedance: a randomized prospective color Doppler study. Ultrasound Obstet Gynecol. 2001 Jan;17(1):65–70. X-5, X-8. [PubMed: 11244659]

766.

Jarvela I, Tekay A, Santala M, et al. Ultrasonographic features following thermal balloon endometrial ablation therapy. Gynecologic and Obstetric Investigation. 2002;54(1):11–6. X-3, X-4, X-8. [PubMed: 12297711]

767.

Jenkinson C, Peto V, Coulter A. Measuring change over time: a comparison of results from a global single item of health status and the multi-dimensional SF-36 health status survey questionnaire in patients presenting with menorrhagia. Qual Life Res. 1994 Oct;3(5):317–21. X-3. [PubMed: 7841965]

768.

Jenkinson C, Peto V, Coulter A. Making sense of ambiguity: evaluation of internal reliability and face validity of the SF 36 questionnaire in women presenting with menorrhagia. Quality in Health Care. 1996;5(1):9–12. X-3, X-4, X-5. [PMC free article: PMC1055348] [PubMed: 10157276]

769.

Jensen JT. Noncontraceptive applications of the levonorgestrel intrauterine system. Curr Womens Health Rep. 2002 Dec;2(6):417–22. X-1, X-4, X-5, X-9. [PubMed: 12429074]

770.

Jensen JT, Nelson AL, Costales AC. Subject and clinician experience with the levonorgestrel-releasing intrauterine system. Contraception. 2008 Jan;77(1):22–9. X-4, X-5. [PubMed: 18082662]

771.

Jensen LC, Obel EB, Lindhard A, et al. Frequency of curettage in middle-aged women treated with sequential preparations versus untreated women. Maturitas. 1992 Aug;15(1):61–9. X-3, X-5, X-8. [PubMed: 1326709]

772.

Jimenez MF, Vetori D, Fagundes PA, et al. Subendometrial microvascularization and uterine artery blood flow in IUD-induced side effects (levonorgestrel intrauterine system and copper intrauterine device). Contraception. 2008 Oct;78(4):324–7. X-4, X-5, X-9. [PubMed: 18847582]

773.

Jin Z, Huang G. Prevention and treatment of vaginal bleeding after drug-induced abortion by Yaoliuan capsule and its effects on menses recovery. J Huazhong Univ Sci Technolog Med Sci. 2005;25(3):346–7. 67. X-5, X-9. [PubMed: 16201292]

774.

Jirapinyo M, Theppisai U, Manonai J, et al. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naive Thai women. Acta Obstet Gynecol Scand. 2003 Sep;82(9):857–66. X-5, X-7. [PubMed: 12911449]

775.

Joffe H, Cohen LS, Suppes T, et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry. 2006 Jun 1;59(11):1078–86. X-4, X-5, X-9. [PubMed: 16448626]

776.

Joffre F, Tubiana JM, Pelage JP. FEMIC (Fibromes Embolises aux MICrospheres calibrees): uterine fibroid embolization using tris-acryl microspheres. A French multicenter study. Cardiovasc Intervent Radiol. 2004 Nov-Dec;27(6):600–6. X-4, X-5, X-8. [PubMed: 15578135]

777.

Johannisson E, Landgren BM, Diczfalusy E. Endometrial morphology and peripheral steroid levels in women with and without intermenstrual bleeding during contraception with the 300 mug norethisterone (NET) minipill. Contraception. 1982;25(1):13–30. X-3, X-4, X-6. [PubMed: 7060371]

778.

Johnson JV, Davidson M, Archer D, et al. Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy. Menopause. 2002 Jan-Feb;9(1):16–22. X-5, X-7. [PubMed: 11791082]

779.

Johnson JV, Grubb GS, Constantine GD. Endometrial histology following 1 year of a continuous daily regimen of levonorgestrel 90 micro g/ethinyl estradiol 20 micro g. Contraception. 2007 Jan;75(1):23–6. X-4, X-5. [PubMed: 17161119]

780.

Johnson JV, Grubb GS, Constantine GD. Endometrial histology following 1 year of a continuous daily regimen of levonorgestrel 90 mug/ethinyl estradiol 20 mug. Contraception. 2007;75(1):23–6. X-3, X-4. [PubMed: 17161119]

781.

Johnson N, Priestnall M, Marsay T, et al. A randomised trial evaluating pain and bleeding after a first trimester miscarriage treated surgically or medically. Eur J Obstet Gynecol Reprod Biol. 1997 Apr;72(2):213–5. X-5, X-9. [PubMed: 9134405]

782.

Jones KP, Ravnikar VA, Schiff I. Results of human menopausal gonadotropin therapy at the Boston Hospital for Women (1979-1981). Int J Fertil. 1987 Mar-Apr;32(2):131–4. X-3, X-5. [PubMed: 2883138]

783.

Joshi UM, Joshi JV, Donde UM, et al. Phase I comparative clinical trial with subdermal implants--bioabsorbable levonorgestrel or norethisterone pellet fused with cholesterol. Contraception. 1985 Jan;31(1):71–82. X-3, X-5, X-9. [PubMed: 3921309]

784.

Jovanovic R, Barone CM, Van Natta FC, et al. Preventing infection related to insertion of an intrauterine device. J Reprod Med. 1988 Apr;33(4):347–52. X-3, X-5, X-9. [PubMed: 3367334]

785.

Julian S, Naftalin NJ, Clark M, et al. An integrated care pathway for menorrhagia across the primary-secondary interface: patients' experience, clinical outcomes, and service utilisation. Qual Saf Health Care. 2007 Apr;16(2):110–5. X-4, X-5, X-9. [PMC free article: PMC2653147] [PubMed: 17403756]

786.

Junge W, El-Samalouti V, Gerlinger C, et al. Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: Open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate. European Journal of Obstetrics Gynecology and Reproductive Biology. 2009;147(2):195–200. X-7. [PubMed: 19879683]

787.

Jung-Hoffmann C, Kuhl H. Intra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleedings. Contraception. 1990 Oct;42(4):423–38. X-3, X-5, X-6. [PubMed: 2147887]

788.

Junquera F, Feu F, Papo M, et al. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology. 2001;121(5):1073–9. X-5. [PubMed: 11677198]

789.

Kadir RA, Lee CA, Sabin CA, et al. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. Haemophilia. 2002 Nov;8(6):787–93. X-5, X-6, X-9. [PubMed: 12410648]

790.

Kaewrudee S, Taneepanichskul S, Jaisamraun U, et al. The effect of mefenamic acid on controlling irregular uterine bleeding secondary to Norplant use. Contraception. 1999 Jul;60(1):25–30. X-4, X-5, X-6. [PubMed: 10549449]

791.

Kalmuss D, Davidson AR, Cushman LF, et al. Determinants of early implant discontinuation among low-income women. Fam Plann Perspect. 1996 Nov-Dec;28(6):256–60. X-4, X-5, X-9. [PubMed: 8959415]

792.

Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008;57(7):893–902. X-5. [PMC free article: PMC2564831] [PubMed: 18272546]

793.

Kaneshiro B, Edelman A, Carlson N, et al. Treatment of unscheduled bleeding in continuous oral contraceptive users with doxycycline: a randomized controlled trial. Obstet Gynecol. 2010 Jun;115(6):1141–9. X-5, X-6. [PubMed: 20502283]

794.

Kaneshiro B, Edelman A, Carlson NE, et al. A randomized controlled trial of subantimicrobial-dose doxycycline to prevent unscheduled bleeding with continuous oral contraceptive pill use. Contraception. 2012 April;85(4):351–8. X-6. [PMC free article: PMC5045031] [PubMed: 22067758]

795.

Kanetsky PA, Mandelblatt J, Richart R, et al. Risk factors for cervical cancer in a black elderly population: preliminary findings. Ethn Dis. 1992 Fall;2(4):337–42. X-3, X-5. [PubMed: 1337003]

796.

Kang JL, Wang DY, Wang XX, et al. Up-regulation of apoptosis by gonadotrophin-releasing hormone agonist in cultures of endometrial cells from women with symptomatic myomas. Hum Reprod. 2010 Sep;25(9):2270–5. X-4, X-5. [PubMed: 20634188]

797.

Kapp KS, Poschauko J, Tauss J, et al. Analysis of the prognostic impact of tumor embolization before definitive radiotherapy for cervical carcinoma. Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1399–404. X-4, X-5, X-9. [PubMed: 16029799]

798.

Karkanis SG, Caloia D, Salenieks ME, et al. Randomized controlled trial of rectal misoprostol versus oxytocin in third stage management. J Obstet Gynaecol Can. 2002 Feb;24(2):149–54. X-5, X-9. [PubMed: 12196880]

799.

Kashanian M, Shahpourian F, Zare O. A comparison between monophasic levonorgestrel-ethinyl estradiol 150/30 and triphasic levonorgestrel-ethinyl estradiol 50-75-125/30-40-30 contraceptive pills for side effects and patient satisfaction: a study in Iran. Eur J Obstet Gynecol Reprod Biol. 2010 May;150(1):47–51. X-5. [PubMed: 20185226]

800.

Kaunitz AM. Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial. Contraception. 2000 May;61(5):295–302. X-5. [PubMed: 10906499]

801.

Kaunitz AM, Burkman RT, Fisher AC, et al. Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial. Obstet Gynecol. 2009 Dec;114(6):1205–12. X-4, X-5. [PubMed: 19935020]

802.

Kaunitz AM, Darney PD, Ross D, et al. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception. 2009 Jul;80(1):7–17. X-5. [PubMed: 19501210]

803.

Kaunitz AM, Garceau RJ, Cromie MA. Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lunelle Study Group. Contraception. 1999 Oct;60(4):179–87. X-4, X-5. [PubMed: 10640164]

804.

Kauppila A, Heikkinen J, Viinikka L. Dynamic evaluation of prolactin secretion by successive TRH and metoclopramide stimulations. Acta Endocrinol (Copenh). 1986 Jan;111(1):10–6. X-3, X-4, X-5. [PubMed: 3080846]

805.

Kaya A, Aydin N, Topsever P, et al. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother. 2004 Dec;58(10):582–7. X-5, X-9. [PubMed: 15589067]

806.

Kayikcioglu F, Gunes M, Ozdegirmenci O, et al. Effects of levonorgestrel-releasing intrauterine system on glucose and lipid metabolism: a 1-year follow-up study. Contraception. 2006 May;73(5):528–31. X-4, X-5, X-6, X-9. [PubMed: 16627040]

807.

Kazerooni T, Zolghadri J. The comparison of bleeding patterns with high-dose and low-dose hormone replacement therapy in postmenopausal women. Gynecol Endocrinol. 2004 Aug;19(2):64–8. X-4, X-5, X-7. [PubMed: 15624267]

808.

Kazi A, Holck SE, Diethelm P. Phase IV study of the injection Norigest in Pakistan. Contraception. 1985 Oct;32(4):395–403. X-3, X-9. [PubMed: 3907968]

809.

Keder LM, Rulin MC, Gruss J. Compliance with depot medroxyprogesterone acetate: a randomized, controlled trial of intensive reminders. Am J Obstet Gynecol. 1998 Sep;179(3 Pt 1):583–5. X-5, X-6, X-9. [PubMed: 9757955]

810.

Kekkonen R, Lahteenmaki P, Luukkainen T, et al. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception. Fertil Steril. 1993 Oct;60(4):610–5. X-3, X-4, X-5. [PubMed: 8405512]

811.

Kelekci KH, Kelekci S, Yengel I, et al. Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: Randomized comparison of three regimens. Journal of Dermatological Treatment. 2012 June;23(3):177–83. X-5. [PubMed: 21254871]

812.

Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. The Lancet Oncology. 2009;10(2):135–46. X-5, X-7, X-10. [PubMed: 19167925]

813.

Khan SA, Ul Amin Z, Fouzia, et al. A comparative trial of copper T 380 and Cu 375 IUCD. J Ayub Med Coll Abbottabad. 2010 Jul-Sep;22(3):185–7. X-3, X-9. [PubMed: 22338452]

814.

Khanna A, Biswas AK, Dubey B, et al. Fibrinolytic activity in bleeding associated with intrauterine contraceptive devices. Indian J Med Res. 1992 Jun;96:147–9. X-3, X-4. [PubMed: 1512035]

815.

Khaund A, Moss JG, McMillan N, et al. Evaluation of the effect of uterine artery embolisation on menstrual blood loss and uterine volume. BJOG. 2004 Jul;111(7):700–5. X-4, X-5, X-6, X-8. [PubMed: 15198761]

816.

Kilic S, Yilmaz N, Zulfikaroglu E, et al. Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecological Endocrinology. 2011;27(9):622–9. X-4, X-5, X-6, X-10. [PubMed: 21105835]

817.

Kilic S, Yuksel B, Doganay M, et al. The effect of levonorgestrel-releasing intrauterine device on menorrhagia in women taking anticoagulant medication after cardiac valve replacement. Contraception. 2009 Aug;80(2):152–7. X-5, X-6. [PubMed: 19631790]

818.

Kilonzo MM, Sambrook AM, Cook JA, et al. A cost-utility analysis of microwave endometrial ablation versus thermal balloon endometrial ablation. Value Health. 2010 Aug;13(5):528–34. X-4, X-5, X-8. [PubMed: 20712602]

819.

Kim CY, Chung S, Lee JN, et al. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. International Clinical Psychopharmacology. 2009;24(4):181–8. X-5. [PubMed: 19451828]

820.

Kim KS, Pae CU, Chae JH, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry. 2002 May;63(5):408–13. X-4, X-5, X-9. [PubMed: 12019665]

821.

Kim MD, Kim YM, Kim HC, et al. Uterine artery embolization for symptomatic adenomyosis: a new technical development of the 1-2-3 protocol and predictive factors of MR imaging affecting outcomes. J Vasc Interv Radiol. 2011 Apr;22(4):497–502. X-4, X-5, X-8. [PubMed: 21377897]

822.

Kim MD, Lee HS, Lee MH, et al. Long-term results of symptomatic fibroids treated with uterine artery embolization: in conjunction with MR evaluation. Eur J Radiol. 2010 Feb;73(2):339–44. X-4, X-5, X-6, X-8. [PubMed: 19084365]

823.

Kim SW, Shin IS, Kim JM, et al. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: A randomized, open-label, controlled trial. Progress in Neuro Psychopharmacology and Biological Psychiatry. 2007;31(7):1504–9. X-5. [PubMed: 17692448]

824.

Kim YH, Chung HH, Kang SB, et al. Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: a phase IV, open-label, prospective, randomized study. Acta Haematol. 2009;121(1):37–41. X-4, X-5, X-9. [PubMed: 19332985]

825.

Kinon BJ, Gilmore JA, Liu H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003 Apr;28 Suppl 2:55–68. X-4, X-5, X-9. [PubMed: 12650681]

826.

Kircher C, Smith KP. Acarbose for polycystic ovary syndrome. Ann Pharmacother. 2008 Jun;42(6):847–51. X-1, X-4, X-5, X-9. [PubMed: 18460589]

827.

Kirkman RJ, Pedersen JH, Fioretti P, et al. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age. Contraception. 1994 Jan;49(1):33–46. X-6, X-9. [PubMed: 8137624]

828.

Kirss F, Lang K, Tuimala R. Feminine life-course of Estonian women born in 1937-47: a questionnaire survey. Acta Obstet Gynecol Scand. 2006;85(2):224–8. X-4, X-5, X-9. [PubMed: 16532919]

829.

Kirtava A, Crudder S, Dilley A, et al. Trends in clinical management of women with von Willebrand disease: a survey of 75 women enrolled in haemophilia treatment centres in the United States. Haemophilia. 2004 Mar;10(2):158–61. X-4, X-5, X-6, X-9. [PubMed: 14962204]

830.

Kitawaki J, Kusuki I, Yamanaka K, et al. Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain. European Journal of Obstetrics Gynecology and Reproductive Biology. 2011;157(2):212–6. X-3, X-6. [PubMed: 21474232]

831.

Kittelsen N, Istre O. A randomized study comparing levonorgestrel intrauterine system (LNG IUS) and transcervical resection of the endometrium (TCRE) in the treatment of menorrhagia: Preliminary results. Gynaecological Endoscopy. 1998;7(2):61–5. X-8.

832.

Kjotrod SB, von During V, Carlsen SM. Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction. 2004;19(6):1315–22. X-4, X-5, X-10. [PubMed: 15117902]

833.

Klipping C, Duijkers I, Fortier MP, et al. Long-term tolerability of ethinylestradiol 20 mug/drospirenone 3 mg in a flexible extended regimen: Results from a randomised, controlled, multicentrestudy. Journal of Family Planning and Reproductive Health Care. 2012 April;38(2):84–93. X-9. [PMC free article: PMC3353878] [PubMed: 22454004]

834.

Klipping C, Duijkers I, Fortier MP, et al. Contraceptive efficacy and tolerability of ethinylestradiol 20 mug/drospirenone 3 mg in a flexible extended regimen: An open-label, multicentre, randomised, controlled study. Journal of Family Planning and Reproductive Health Care. 2012 April;38(2):73–83. X-9. [PMC free article: PMC3353880] [PubMed: 22454003]

835.

Koetsawang S, Charoenvisal C, Banharnsupawat L, et al. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women. Contraception. 1995 Apr;51(4):225–9. X-9. [PubMed: 7796587]

836.

Koh SC, Singh K. The effect of levonorgestrel-releasing intrauterine system use on menstrual blood loss and the hemostatic, fibrinolytic/inhibitor systems in women with menorrhagia. J Thromb Haemost. 2007 Jan;5(1):133–8. X-4, X-5, X-6. [PubMed: 17010149]

837.

Kohnen G, Campbell S, Irvine GA, et al. Endothelin receptor expression in human decidua. Mol Hum Reprod. 1998 Feb;4(2):185–93. X-4, X-5, X-9. [PubMed: 9542978]

838.

Koike K, Yamamoto Y, Suzuki N, et al. Efficacy of porcine placental extracts with hormone therapy for postmenopausal women with knee pain. Climacteric. 2012 February;15(1):30–5. X-7. [PubMed: 22066827]

839.

Koltun W, Lucky AW, Thiboutot D, et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception. 2008;77(4):249–56. X-5. [PubMed: 18342647]

840.

Komulainen MH, Kroger H, Tuppurainen MT, et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; A 5 year randomized trial. Maturitas. 1998;31(1):45–54. X-7. [PubMed: 10091204]

841.

Kong GW, Yim SF, Cheung TH, et al. Cryotherapy as the treatment modality of postcoital bleeding: a randomised clinical trial of efficacy and safety. Aust N Z J Obstet Gynaecol. 2009 Oct;49(5):517–24. X-5, X-9. [PubMed: 19780737]

842.

Koninckx PR, Spielmann D. A comparative 2-year study of the effects of sequential regimens of 1 mg 17beta-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women. Gynecological Endocrinology. 2005;21(2):82–9. X-7. [PubMed: 16294460]

843.

Korytkowski MT, Mokan M, Horwitz MJ, et al. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1995 Nov;80(11):3327–34. X-3, X-4. [PubMed: 7593446]

844.

Kotsa K, Yavropoulou MP, Anastasiou O, et al. Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome. Fertil Steril. 2009 Sep;92(3):1053–8. X-4, X-5, X-9. [PubMed: 18930208]

845.

Kouides PA, Byams VR, Philipp CS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol. 2009 Apr;145(2):212–20. X-6. [PubMed: 19236375]

846.

Kozman E, Collins P, Howard A, et al. The effect of an intrauterine application of two percent lignocaine gel on pain perception during Vabra endometrial sampling: a randomised double-blind, placebo-controlled trial. BJOG. 2001 Jan;108(1):87–90. X-5, X-9. [PubMed: 11213009]

847.

Krassas GE, Pontikides N, Kaltsas T, et al. Disturbances of menstruation in hypothyroidism. Clin Endocrinol (Oxf). 1999 May;50(5):655–9. X-4, X-5, X-6. [PubMed: 10468932]

848.

Krettek JE, Arkin SI, Chaisilwattana P, et al. Chlamydia trachomatis in patients who used oral contraceptives and had intermenstrual spotting. Obstet Gynecol. 1993 May;81(5 ( Pt 1)):728–31. X-3, X-4, X-5. [PubMed: 8469461]

849.

Krikun G, Critchley H, Schatz F, et al. Abnormal uterine bleeding during progestin-only contraception may result from free radical-induced alterations in angiopoietin expression. Am J Pathol. 2002 Sep;161(3):979–86. X-4, X-5, X-9. [PMC free article: PMC1867248] [PubMed: 12213726]

850.

Kriplani A, Agarwal N. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome. J Reprod Med. 2004 May;49(5):361–7. X-4, X-5, X-9. [PubMed: 15214709]

851.

Kriplani A, Manchanda R, Monga D, et al. Depot medroxy progesterone acetate: a poor preparatory agent for endometrial resection. Gynecol Obstet Invest. 2001;52(3):180–3. X-4, X-5, X-8. [PubMed: 11598360]

852.

Kriplani A, Manchanda R, Nath J, et al. A randomized trial of danazol pretreatment prior to endometrial resection. Eur J Obstet Gynecol Reprod Biol. 2002 Jun 10;103(1):68–71. X-5, X-8. [PubMed: 12039468]

853.

Kriplani A, Periyasamy AJ, Agarwal N, et al. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception. 2010;82(2):139–46. X-4, X-5, X-10. [PubMed: 20654754]

854.

Kriplani A, Singh BM, Lal S, et al. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia. Int J Gynaecol Obstet. 2007 Jun;97(3):190–4. X-4. [PubMed: 17382331]

855.

Kritz-Silverstein D, Wingard DL, Garland FC. The association of behavior and lifestyle factors with menstrual symptoms. Journal of Women's Health & Gender-Based Medicine. 1999;8(9):1185–93. X-3, X-4, X-5. [PubMed: 10595332]

856.

Kroencke TJ, Scheurig C, Poellinger A, et al. Uterine artery embolization for leiomyomas: percentage of infarction predicts clinical outcome. Radiology. 2010 Jun;255(3):834–41. X-4, X-5, X-6, X-8. [PubMed: 20392986]

857.

Kubba AA. The benefits of oral contraceptives. J R Soc Health. 1985 Apr;105(2):73–4. X-11. [PubMed: 3921718]

858.

Kucuk M, Okman TK. Intrauterine instillation of trichloroacetic acid is effective for the treatment of dysfunctional uterine bleeding. Fertil Steril. 2005 Jan;83(1):189–94. X-4. [PubMed: 15652906]

859.

Kucukozkan T, Kadioglu BG, Uygur D, et al. Chemical ablation of endometrium with trichloroacetic acid. Int J Gynaecol Obstet. 2004 Jan;84(1):41–6. X-5, X-8. [PubMed: 14698828]

860.

Kuhl H, Gahn G, Romberg C. A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters: I. Effects upon sexual hormone levels. Contraception. 1985;31(6):583–93. X-4, X-6, X-9. [PubMed: 2931247]

861.

Kulkarni S, Wynter HH, Desai P. Hysteroscopic assessment of abnormal uterine bleeding in users of the intrauterine contraceptive device. West Indian Med J. 1993 Sep;42(3):124–5. X-3, X-4, X-5. [PubMed: 8273322]

862.

Kuppermann M, Varner RE, Summitt RL Jr., et al. Effect of hysterectomy vs medical treatment on health-related quality of life and sexual functioning: the medicine or surgery (Ms) randomized trial. JAMA. 2004 Mar 24;291(12):1447–55. X-8. [PubMed: 15039411]

863.

Kurtoglu M, Koksoy C, Hasan E, et al. Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial. J Vasc Surg. 2010 Nov;52(5):1262–70. X-4, X-5, X-9. [PubMed: 20732787]

864.

Kwak HM, Chi I, Gardner SD, et al. Menstrual pattern changes in laparoscopic sterilization patients whose last pregnancy was terminated by therapeutic abortion. A two-year follow-up study. J Reprod Med. 1980 Aug;25(2):67–71. X-3, X-5, X-8. [PubMed: 7411527]

865.

Kwiecien M, Edelman A, Nichols MD, et al. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: A randomized trial. Contraception. 2003;67(1):9–13. X-9. [PubMed: 12521651]

866.

Kyriakis KP, Kontochristopoulos GJ, Panteleos DN. Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol. 2000 Mar;39(3):218–22. X-4, X-5, X-6, X-9. [PubMed: 10759967]

867.

Ladson G, Dodson WC, Sweet SD, et al. The effects of metformin with lifestyle therapy in polycystic ovary syndrome: A randomized double-blind study. Fertility and Sterility. 2011;95(3):1059–66. X-5, X-10. [PMC free article: PMC3073705] [PubMed: 21193187]

868.

LaGuardia KD, Fisher AC, Bainbridge JD, et al. Suppression of estrogen-withdrawal headache with extended transdermal contraception. Fertility and Sterility. 2005;83(6):1875–7. X-5, X-9. [PubMed: 15950671]

869.

LaGuardia KD, Shangold G, Fisher A, et al. Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradiol. Contraception. 2003 Jun;67(6):431–7. X-5. [PubMed: 12814811]

870.

Lakha F, Ho PC, Van der Spuy ZM, et al. A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum Reprod. 2007 Sep;22(9):2428–36. X-5. [PubMed: 17609247]

871.

Lal S, Kriplani A, Kulshrestha V, et al. Efficacy of mifepristone in reducing intermenstrual vaginal bleeding in users of the levonorgestrel intrauterine system. Int J Gynaecol Obstet. 2010 May;109(2):128–30. X-4. [PubMed: 20223454]

872.

Landgren BM, Aedo AR, Johannisson E, et al. Studies on a vaginal ring releasing levonorgestrel at an initial rate of 27 micrograms/24 h when used alone or in combination with transdermal systems releasing estradiol. Contraception. 1994 Jul;50(1):87–100. X-3, X-6, X-9. [PubMed: 7924325]

873.

Landgren BM, Aedo AR, Johannisson E, et al. Studies on a vaginal ring releasing levonorgestrel at an initial rate of 27 mug/24h when used alone or in combination with transdermal systems releasing estradiol. Contraception. 1994;50(1):87–100. X-3, X-4, X-5, X-9. [PubMed: 7924325]

874.

Landgren BM, Johannisson E, Masironi B, et al. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate. Contraception. 1982 Dec;26(6):567–85. X-3, X-4. [PubMed: 6820337]

875.

Landgren MB, Bennink HJ, Helmond FA, et al. Dose-response analysis of effects of tibolone on climacteric symptoms. BJOG. 2002 Oct;109(10):1109–14. X-5, X-7. [PubMed: 12387462]

876.

Lang EK, Myers L. Outcome of superselective uterine artery embolization of fibroids. Journal of Women's Imaging. 2004;6(1):23. X-3, X-8.

877.

Langer RD, Landgren BM, Rymer J, et al. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study. Am J Obstet Gynecol. 2006 Nov;195(5):1320–7. X-5, X-7. [PubMed: 16875644]

878.

Laoag-Fernandez JB, Maruo T, Pakarinen P, et al. Effects of levonorgestrel-releasing intra-uterine system on the expression of vascular endothelial growth factor and adrenomedullin in the endometrium in adenomyosis. Hum Reprod. 2003 Apr;18(4):694–9. X-4, X-5, X-9. [PubMed: 12660258]

879.

Lappohn RE, van de Wiel HB, Brownell J. The effect of two dopaminergic drugs on menstrual function and psychological state in hyperprolactinemia. Fertil Steril. 1992 Aug;58(2):321–7. X-5, X-6. [PubMed: 1353028]

880.

Larsson PG, Bergman B, Forsum U, et al. Treatment of bacterial vaginosis in women with vaginal bleeding complications or discharge and harboring. Mobiluncus Gynecol Obstet Invest. 1990;29(4):296–300. X-5, X-6. [PubMed: 2361638]

881.

Laufe LE, Sokal DC, Cole LP, et al. Phase I prehysterectomy studies of the transcervical administration of quinacrine pellets. Contraception. 1996 Sep;54(3):181–6. X-4, X-5, X-8, X-9. [PubMed: 8899260]

882.

Laurikka-Routti M, Haukkamaa M, Lahteenmaki P. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435. Fertil Steril. 1992 Oct;58(4):680–4. X-3, X-4, X-5, X-9. [PubMed: 1426309]

883.

Lawrie TA, Hofmeyr GJ, De Jager M, et al. A double-blind randomised placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. Br J Obstet Gynaecol. 1998 Oct;105(10):1082–90. X-5, X-6, X-9. [PubMed: 9800931]

884.

Lazovic G, Radivojevic U, Milicevic S, et al. The most frequent hormone dysfunctions in juvenile bleeding. Int J Fertil Womens Med. 2007 Jan-Feb;52(1):35–40. X-4, X-5. [PubMed: 17987886]

885.

Lazzarin N, Vaquero E, Exacoustos C, et al. Low-dose aspirin and omega-3 fatty acids improve uterine artery blood flow velocity in women with recurrent miscarriage due to impaired uterine perfusion. Fertility and Sterility. 2009;92(1):296–300. X-4, X-5. [PubMed: 18692841]

886.

Learman LA, Summitt RL Jr., Varner RE, et al. Hysterectomy versus expanded medical treatment for abnormal uterine bleeding: clinical outcomes in the medicine or surgery trial. Obstet Gynecol. 2004 May;103(5 Pt 1):824–33. X-8. [PubMed: 15121552]

887.

Lebwohl M, Ortonne JP, Andres P, et al. Calcitriol ointment 3 microg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis. Cutis. 2009 Apr;83(4):205–12. X-4, X-5, X-9. [PubMed: 19445311]

888.

Lefebvre Y, Proulx L, Elie R, et al. The effects of RU-38486 on cervical ripening. Clinical studies. Am J Obstet Gynecol. 1990 Jan;162(1):61–5. X-3, X-5. [PubMed: 2301519]

889.

Legro RS. Polycystic ovary syndrome: Current and future treatment paradigms. American Journal of Obstetrics and Gynecology. 1998;179(6 II):S101–S8. X-1, X-3, X-5. [PubMed: 9855616]

890.

Legro RS, Muhleman DR, Comings DE, et al. A dopamine D3 receptor genotype is associated with hyperandrogenic chronic anovulation and resistant to ovulation induction with clomiphene citrate in female Hispanics. Fertil Steril. 1995 Apr;63(4):779–84. X-3, X-4, X-5. [PubMed: 7890062]

891.

Legro RS, Myers ER, Barnhart HX, et al. The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. Fertil Steril. 2006 Oct;86(4):914–33. X-5, X-9. [PubMed: 16963034]

892.

Legro RS, Urbanek M, Kunselman AR, et al. Self-selected women with polycystic ovary syndrome are reproductively and metabolically abnormal and undertreated. Fertil Steril. 2002 Jul;78(1):51–7. X-4, X-5, X-9. [PubMed: 12095490]

893.

Lei ZW, Wu SC, Garceau RJ, et al. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception. Contraception. 1996 Jun;53(6):357–61. X-4, X-5. [PubMed: 8773423]

894.

Leissinger C, Becton D, Cornell C Jr., et al. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia. 2001 May;7(3):258–66. X-4, X-5, X-6. [PubMed: 11380629]

895.

Lelaidier C, Baton-Saint-Mleux C, Fernandez H, et al. Mifepristone (RU 486) induces embryo expulsion in first trimester non-developing pregnancies: a prospective randomized trial. Hum Reprod. 1993 Mar;8(3):492–5. X-5. [PubMed: 8473474]

896.

Lemay A, Faure N. Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: a pilot study. J Clin Endocrinol Metab. 1994 Dec;79(6):1716–22. X-3. [PubMed: 7989480]

897.

Leminen H, Heliovaara-Peippo S, Halmesmaki K, et al. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on premenstrual symptoms in women treated for menorrhagia: secondary analysis of a randomized controlled trial. Acta Obstet Gynecol Scand. 2012 Mar;91(3):318–25. X-8. [PubMed: 22168810]

898.

Lete I, del Carme Cuesta M, Marin JM, et al. Acceptability of the levonorgestrel intrauterine system in the long-term treatment of heavy menstrual bleeding: how many women choose to use a second device? Eur J Obstet Gynecol Reprod Biol. 2011 Jan;154(1):67–70. X-4. [PubMed: 20728261]

899.

Lete I, Obispo C, Izaguirre F, et al. The levonorgestrel intrauterine system (Mirena) for treatment of idiopathic menorrhagia. Assessment of quality of life and satisfaction. Eur J Contracept Reprod Health Care. 2008 Sep;13(3):231–7. X-4. [PubMed: 18609346]

900.

Lethaby A, Hickey M, Garry R, et al. Endometrial resection / ablation techniques for heavy menstrual bleeding. Cochrane Database of Systematic Reviews. 2009;(4) X-8. [PubMed: 19821278]

901.

Lethaby A, Shepperd S, Farquhar C, et al. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. Cochrane Database of Systematic Reviews. 1999;(2) X-8. [PubMed: 10796528]

902.

Leyden J, Shalita A, Hordinsky M, et al. Efficacy of a low-dose oral contraceptive containing 20 mug of ethinyl estradiol and 100 mug of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial. Journal of the American Academy of Dermatology. 2002;47(3):399–409. X-5, X-9. [PubMed: 12196750]

903.

Lhomme C, Brault P, Bourhis JH, et al. Prevention of menstruation with leuprorelin (GnRH agonist) in women undergoing myelosuppressive chemotherapy or radiochemotherapy for hematological malignancies: a pilot study. Leuk Lymphoma. 2001 Sep-Oct;42(5):1033–41. X-4, X-5, X-6, X-9. [PubMed: 11697620]

904.

Li A, Felix JC, Yang W, et al. Effect of mifepristone on endometrial matrix metalloproteinase expression and leukocyte abundance in new medroxyprogesterone acetate users. Contraception. 2007 Jul;76(1):57–65. X-4, X-5, X-9. [PubMed: 17586139]

905.

Li L, Zhou Z, Huang L. Abnormal expression of MMP-9 and imbalance of MMP-9/TIMP-1 is associated with prolonged uterine bleeding after a medical abortion with mifepristone and misoprostol. Acta Obstet Gynecol Scand. 2009;88(6):673–9. X-4, X-5, X-9. [PubMed: 19353331]

906.

Li X, Liu R, Zhang W, et al. Up-regulation of Fas/FasL activation contribute to the apoptosis enhancement of RU486 by Gong-Qing Decoction, a traditional Chinese prescription. Journal of Ethnopharmacology. 2011;134(2):386–92. X-5. [PubMed: 21195151]

907.

Lian F, Liu HP, Wang YX, et al. Expressions of VEGF and Ki-67 in eutopic endometrium of patients with endometriosis and effect of Quyu Jiedu Recipe on VEGF expression. Chin J Integr Med. 2007 Jun;13(2):109–14. X-4, X-5. [PubMed: 17609908]

908.

Liao EY, Luo XH, Deng XG, et al. The effect of low dose nylestriol-levonorgestrel replacement therapy on bone mineral density in women with postmenopausal osteoporosis. Endocrine Research. 2003;29(2):217–26. X-7. [PubMed: 12856809]

909.

Lim AK, Agarwal R, Seckl MJ, et al. Embolization of bleeding residual uterine vascular malformations in patients with treated gestational trophoblastic tumors. Radiology. 2002 Mar;222(3):640–4. X-4, X-5, X-6, X-8, X-9. [PubMed: 11867779]

910.

Lim LS, McCarthy TG, Yong YM, et al. Postabortion insertion of MLCu 250 and MLCu 375--a comparative trial. Contraception. 1985 May;31(5):471–7. X-9. [PubMed: 4028724]

911.

Limpaphayom KK, Bunyavejchevin S. Clinical effects of 17 beta-estradiol and norethisterone acetate in postmenopausal Thai women. J Med Assoc Thai. 2000 Apr;83(4):407–16. X-5, X-7. [PubMed: 10808701]

912.

Lin CH, Kuo CC, Chou LS, et al. A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia. Journal of Clinical Psychopharmacology. 2010;30(5):518–25. X-5. [PubMed: 20814315]

913.

Lin H. Comparison between microwave endometrial ablation and total hysterectomy. Chin Med J (Engl). 2006 Jul 20;119(14):1195–7. X-4, X-5, X-8. [PubMed: 16863612]

914.

Lin KC. Relationship between pituitary reserve and efficacy of bromocriptine in women with euprolactinemic ovulatory dysfunction. Gaoxiong Yi Xue Ke Xue Za Zhi. 1994 May;10(5):222–8. X-3, X-4, X-5. [PubMed: 8040924]

915.

Lin SQ, Sun LZ, Lin JF, et al. Estradiol 1mg and drospirenone 2mg as hormone replacement therapy in postmenopausal Chinese women. Climacteric. 2011;14(4):472–81. X-7. [PubMed: 21469973]

916.

Lin X, Gao ES, Li D, et al. Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstet Gynecol Scand. 2007;86(9):1126–9. X-5, X-6, X-9. [PubMed: 17712656]

917.

Lin YH, Hwang JL, Huang LW, et al. Use of sublingual buprenorphine for pain relief in office hysteroscopy. J Minim Invasive Gynecol. 2005 Jul-Aug;12(4):347–50. X-5, X-9. [PubMed: 16036196]

918.

Lindenfeld EA, Langer RD. Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial. Obstetrics and Gynecology. 2002;100(5):853–63. X-7. [PubMed: 12423841]

919.

Lindgren R, Risberg B, Hammar M, et al. Endometrial effects of transdermal estradiol/norethisterone acetate. Maturitas. 1992 Aug;15(1):71–8. X-3, X-7. [PubMed: 1528133]

920.

Lindholm A, Bixo M, Bjorn I, et al. Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Fertil Steril. 2008 May;89(5):1221–8. X-5, X-9. [PubMed: 17603048]

921.

Lindner HR, Zor U, Kohen F, et al. Significance of prostaglandins in the regulation of cyclic events in the ovary and uterus. Adv Prostaglandin Thromboxane Res. 1980;8:1371–90. X-3, X-4. [PubMed: 7376986]

922.

Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thromboembolic complications. Thromb Haemost. 1993 Aug 2;70(2):238–40. X-3, X-5. [PubMed: 8236125]

923.

Lisi F, Rinaldi L, Fishel S, et al. Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertil Steril. 2005 Feb;83(2):309–15. X-5, X-9. [PubMed: 15705367]

924.

Lissak A, Fruchter O, Mashiach S, et al. Immediate versus delayed treatment of perimenopausal bleeding due to benign causes by balloon thermal ablation. J Am Assoc Gynecol Laparosc. 1999 May;6(2):145–50. X-3, X-5, X-8. [PubMed: 10226122]

925.

Liu X. TCM treatment for severe climacteric dysfunctional uterine bleeding--a report of 43 cases. J Tradit Chin Med. 2007 Mar;27(1):46–8. X-3. [PubMed: 17393627]

926.

Lockwood CJ, Kumar P, Krikun G, et al. Effects of thrombin, hypoxia, and steroids on interleukin-8 expression in decidualized human endometrial stromal cells: implications for long-term progestin-only contraceptive-induced bleeding. J Clin Endocrinol Metab. 2004 Mar;89(3):1467–75. X-4, X-5, X-9. [PubMed: 15001649]

927.

Lockwood CJ, Nemerson Y, Krikun G, et al. Steroid-modulated stromal cell tissue factor expression: a model for the regulation of endometrial hemostasis and menstruation. J Clin Endocrinol Metab. 1993 Oct;77(4):1014–9. X-3, X-4. [PubMed: 8408448]

928.

Lockwood CJ, Runic R, Wan L, et al. The role of tissue factor in regulating endometrial haemostasis: implications for progestin-only contraception. Hum Reprod. 2000 Aug;15 Suppl 3:144–51. X-4, X-5. [PubMed: 11041230]

929.

Loffer FD, Grainger D. Five-year follow-up of patients participating in a randomized trial of uterine balloon therapy versus rollerball ablation for treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 2002 Nov;9(4):429–35. X-4, X-5, X-8. [PubMed: 12386351]

930.

Lofgren E, Tapanainen JS, Koivunen R, et al. Effects of carbamazepine and oxcarbazepine on the reproductive endocrine function in women with epilepsy. Epilepsia. 2006 Sep;47(9):1441–6. X-4, X-5, X-9. [PubMed: 16981858]

931.

Loh FH, Chen LH, Yu SL, et al. The efficacy of two dosages of a continuous combined hormone replacement regimen. Maturitas. 2002 Feb 26;41(2):123–31. X-5, X-7. [PubMed: 11836043]

932.

Lok IH, Chan M, Tam WH, et al. Patient-controlled sedation for outpatient thermal balloon endometrial ablation. J Am Assoc Gynecol Laparosc. 2002 Nov;9(4):436–41. X-4, X-5, X-8, X-9. [PubMed: 12386352]

933.

Lok IH, Leung PL, Ng PS, et al. Life-table analysis of the success of thermal balloon endometrial ablation in the treatment of menorrhagia. Fertil Steril. 2003 Nov;80(5):1255–9. X-4, X-5, X-8. [PubMed: 14607584]

934.

Lokugamage AU, Paine M, Bassaw-Balroop K, et al. Active management of the third stage at caesarean section: a randomised controlled trial of misoprostol versus syntocinon. Aust N Z J Obstet Gynaecol. 2001 Nov;41(4):411–4. X-5, X-9. [PubMed: 11787915]

935.

London RS, Sundaram GS, Murphy L, et al. The effect of alpha-tocopherol on premenstrual symptomatology: a double-blind study. J Am Coll Nutr. 1983;2(2):115–22. X-5. [PubMed: 6350402]

936.

Longo MF, Cohen DR, Hood K, et al. Involving patients in primary care consultations: assessing preferences using discrete choice experiments. Br J Gen Pract. 2006 Jan;56(522):35–42. X-3, X-4, X-5, X-9. [PMC free article: PMC1821413] [PubMed: 16438813]

937.

Lopez G, Rodriguez A, Rengifo J, et al. Two-year prospective study in Colombia of Norplant implants. Obstet Gynecol. 1986 Aug;68(2):204–8. X-3, X-9. [PubMed: 3090492]

938.

Loprinzi CL, Levitt R, Barton D, et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. Journal of Clinical Oncology. 2007;24(9):1409–14. X-5. [PubMed: 16505409]

939.

Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Journal of Clinical Oncology. 1993;11(4):762–7. X-5. [PubMed: 8478668]

940.

Loucopoulos A, Ferin M. The treatment of luteal phase defects with pulsatile infusion of gonadotropin-releasing hormone. Fertil Steril. 1987 Dec;48(6):933–6. X-3, X-5. [PubMed: 3119374]

941.

Lu W, Li Q, Li J, et al. Polysaccharide from Patrinia heterophylla Bunge inhibits HeLa cell proliferation through induction of apoptosis and cell cycle arrest. Laboratory Medicine. 2009;40(3):161–6. X-3, X-4.

942.

Lubbert H, Nauert C. Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern. Maturitas. 1997 Dec 15;28(2):117–25. X-5, X-7. [PubMed: 9522319]

943.

Ludicke F, Gaspard UJ, Demeyer F, et al. Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism. Contraception. 2002 Dec;66(6):411–5. X-4, X-5, X-9. [PubMed: 12499033]

944.

Luisi M, Franchi F, Bianchi S, et al. Radio-immunoassay of salivary progesterone for monitoring ovarian function in female infertility. Ann Biol Clin (Paris). 1987;45(4):449–52. X-3, X-4, X-5. [PubMed: 3674548]

945.

Luisi S, Razzi S, Lazzeri L, et al. Efficacy of vaginal danazol treatment in women with menorrhagia during fertile age. Fertil Steril. 2009 Oct;92(4):1351–4. X-4. [PubMed: 18930222]

946.

Lukes AS, Muse K, Richter HE, et al. Estimating a meaningful reduction in menstrual blood loss for women with heavy menstrual bleeding. Curr Med Res Opin. 2010 Nov;26(11):2673–8. X-3, X-4. [PubMed: 20942615]

947.

Lundvall F, Nielsen NC. The hemostatic effect of tranexamic acid in conisatio colli uteri. Acta Obstet Gynecol Scand. 1984;63(1):81–4. X-5, X-8. [PubMed: 6372362]

948.

Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, et al. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. Diabetes Care. 2007 Sep;30(9):2309–13. X-4, X-5, X-9. [PubMed: 17536071]

949.

Luukkainen T, Allonen H, Haukkamaa M, et al. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study. Contraception. 1987 Aug;36(2):169–79. X-3, X-9. [PubMed: 3123132]

950.

Luukkainen T, Allonen H, Nielsen NC, et al. Five years' experience of intrauterine contraception with the Nova-T and the Copper-T-200. Am J Obstet Gynecol. 1983 Dec 15;147(8):885–92. X-9. [PubMed: 6650625]

951.

Luukkainen T, Heikinheimo O, Haukkamaa M, et al. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486. Fertil Steril. 1988 Jun;49(6):961–3. X-3, X-4, X-5. [PubMed: 3371492]

952.

Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intrauterine systems. Semin Reprod Med. 2001 Dec;19(4):355–63. X-1, X-3, X-5. [PubMed: 11727177]

953.

Lydeking-Olsen E, Beck-Jensen JE, Setchell KDR, et al. Soymilk or progesterone for prevention of bone loss: A 2 year randomized, placebo-controlled trial. European Journal of Nutrition. 2004;43(4):246–57. X-7. [PubMed: 15309425]

954.

M, Vardhanabhuti VV, Pearson SA. Education and Service Delivery: The use of transvaginal ultrasound evaluation premicrowave endometrial ablation. Ultrasound. 2011;19(1):36–8. X-8.

955.

Ma W, Bai W, Lin C, et al. Effects of Sanyinjiao (SP6) with electroacupuncture on labour pain in women during labour. Complement Ther Med. 2011 Jan;19 Suppl 1:S13–8. X-5, X-9. [PubMed: 21195290]

956.

MacGregor EA, Brandes JL, Silberstein S, et al. Safety and tolerability of short-term preventive frovatriptan: a combined analysis. Headache. 2009 Oct;49(9):1298–314. X-5, X-9. [PubMed: 19788471]

957.

MacGregor EA, Frith A, Ellis J, et al. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology. 2006 Dec 26;67(12):2159–63. X-5, X-9. [PubMed: 17190936]

958.

MacGregor EA, Victor TW, Hu X, et al. Characteristics of menstrual vs nonmenstrual migraine: a post hoc, within-woman analysis of the usual-care phase of a nonrandomized menstrual migraine clinical trial. Headache. 2010 Apr;50(4):528–38. X-4, X-5, X-9. [PubMed: 20236340]

959.

Machado RB, de Melo NR, Maia H Jr. Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized study. Contraception. 2010 Mar;81(3):215–22. X-5. [PubMed: 20159177]

960.

Madden T, Proehl S, Allsworth JE, et al. Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: A randomized controlled trial. American Journal of Obstetrics and Gynecology. 2012 February;206(2):129.e1–e8. X-5, X-9, X-10. [PMC free article: PMC3268863] [PubMed: 22055339]

961.

Mady MA, Kossoff EH, McGregor AL, et al. The ketogenic diet: adolescents can do it, too. Epilepsia. 2003 Jun;44(6):847–51. X-4, X-5, X-9. [PubMed: 12790900]

962.

Magalhaes J, Aldrighi JM, de Lima GR. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception. 2007 Mar;75(3):193–8. X-4, X-5, X-6, X-9. [PubMed: 17303488]

963.

Magill PJ, Beaumont G, Gringras M, et al. Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. British Journal of General Practice. 1995;45(400):589–93. X-5, X-6. [PMC free article: PMC1239433] [PubMed: 8554838]

964.

Magos A, Brincat M, Zilkha KJ, et al. Serum dopamine beta-hydroxylase activity in menstrual migraine. J Neurol Neurosurg Psychiatry. 1985 Apr;48(4):328–31. X-3, X-4, X-5. [PMC free article: PMC1028296] [PubMed: 4039748]

965.

Maia H Jr., Maltez A, Coelho G, et al. Insertion of mirena after endometrial resection in patients with adenomyosis. J Am Assoc Gynecol Laparosc. 2003 Nov;10(4):512–6. X-4, X-5, X-6, X-8. [PubMed: 14738640]

966.

Maia H Jr., Pimentel K, Casoy J, et al. Aromatase expression in the eutopic endometrium of myomatous uteri: the influence of the menstrual cycle and oral contraceptive use. Gynecol Endocrinol. 2007 Jun;23(6):320–4. X-4, X-5, X-6, X-9. [PubMed: 17616855]

967.

Mainini G, Scaffa C, Rotondi M, et al. Local estrogen replacement therapy in postmenopausal atrophic vaginitis: efficacy and safety of low dose 17beta-estradiol vaginal tablets. Clin Exp Obstet Gynecol. 2005;32(2):111–3. X-5, X-7. [PubMed: 16108394]

968.

Makarainen L, Ylikorkala O. Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen. Br J Obstet Gynaecol. 1986 Sep;93(9):974–8. X-5, X-6. [PubMed: 3533137]

969.

Makarainen L, Ylikorkala O. Ibuprofen prevents IUCD-induced increases in menstrual blood loss. Br J Obstet Gynaecol. 1986 Mar;93(3):285–8. X-5, X-6. [PubMed: 3516203]

970.

Makhubele JC. Indigenous knowledge in the context of sexual and reproductive health and rights amongst the Tsonga/ Shangaan speaking people in a rural community of Limpopo Province: A social work perspective. International Journal of Health Promotion & Education. 2011;49(4):161–8. X-3, X-5, X-7.

971.

Maloney JM, Dietze P Jr, Watson D, et al. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 mug ethinylestradiol in the treatment of acne vulgaris: Lesion counts, investigator ratings and subject self-assessment. Journal of Drugs in Dermatology. 2009;8(9):837–44. X-5. [PubMed: 19746676]

972.

Maloney JM, Dietze P, Watson D, et al. Treatment of acne using A 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: A randomized controlled trial. Obstetrics and Gynecology. 2008;112(4):773–81. X-5. [PubMed: 18827119]

973.

Mannix LK, Loder E, Nett R, et al. Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia. 2007 May;27(5):414–21. X-5, X-9. [PubMed: 17448179]

974.

Mansour D, Verhoeven C, Sommer W, et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17beta-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care. 2011 Dec;16(6):430–43. X-9. [PMC free article: PMC3233274] [PubMed: 21995590]

975.

Marbaix E, Vekemans M, Galant C, et al. Circulating sex hormones and endometrial stromelysin-1 (matrix metalloproteinase-3) at the start of bleeding episodes in levonorgestrel-implant users. Hum Reprod. 2000 Aug;15 Suppl 3:120–34. X-4, X-5. [PubMed: 11041228]

976.

Marchant-Haycox S, Liu D, Nicholas N, et al. Patients' expectations of outcome of hysterectomy and alternative treatments for menstrual problems. J Behav Med. 1998 Jun;21(3):283–97. X-4, X-5, X-8, X-9. [PubMed: 9642573]

977.

Marchbanks PA, Coulam CB, Annegers JF. An association between clomiphene citrate and ectopic pregnancy: a preliminary report. Fertil Steril. 1985 Aug;44(2):268–70. X-3, X-5, X-9. [PubMed: 4018282]

978.

Marchini M, Dorta M, Bombelli F, et al. Effects of clomiphene citrate on cervical mucus: analysis of some influencing factors. Int J Fertil. 1989 Mar-Apr;34(2):154–9. X-3, X-4, X-5. [PubMed: 2565319]

979.

Marcus DA, Bernstein CD, Sullivan EA, et al. A prospective comparison between ICHD-II and probability menstrual migraine diagnostic criteria. Headache. 2010 Apr;50(4):539–50. X-4, X-5, X-9. [PubMed: 20236338]

980.

Marcus DA, Bernstein CD, Sullivan EA, et al. Perimenstrual eletriptan prevents menstrual migraine: an open-label study. Headache. 2010 Apr;50(4):551–62. X-4, X-5, X-9. [PubMed: 20236337]

981.

Marsh F, Kremer C, Duffy S. Delivering an effective outpatient service in gynaecology. A randomised controlled trial analysing the cost of outpatient versus daycase hysteroscopy. BJOG. 2004 Mar;111(3):243–8. X-5, X-8. [PubMed: 14961886]

982.

Marsh F, Thewlis J, Duffy S. Thermachoice endometrial ablation in the outpatient setting, without local anesthesia or intravenous sedation: a prospective cohort study. Fertil Steril. 2005 Mar;83(3):715–20. X-4, X-5, X-8. [PubMed: 15749503]

983.

Marsh F, Thewlis J, Duffy S. Randomized controlled trial comparing Thermachoice III* in the outpatient versus daycase setting. Fertil Steril. 2007 Mar;87(3):642–50. X-5, X-8. [PubMed: 17109859]

984.

Marsh MM, Butt AR, Riley SC, et al. Immunolocalization of endothelin and neutral endopeptidase in the endometrium of users of subdermally implanted levonorgestrel (Norplant). Hum Reprod. 1995 Oct;10(10):2584–9. X-3, X-4, X-9. [PubMed: 8567775]

985.

Marslew U, Overgaard K, Riis BJ, et al. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Obstet Gynecol. 1992 Feb;79(2):202–10. X-7. [PubMed: 1309944]

986.

Martin CW, Brown AH, Baird DT. A pilot study of the effect of methotrexate or combined oral contraceptive on bleeding patterns after induction of abortion with mifepristone and a prostaglandin pessary. Contraception. 1998 Aug;58(2):99–103. X-5, X-9. [PubMed: 9773264]

987.

Martin V, Cady R, Mauskop A, et al. Efficacy of rizatriptan for menstrual migraine in an early intervention model: a prospective subgroup analysis of the rizatriptan TAME (Treat A Migraine Early) studies. Headache. 2008 Feb;48(2):226–35. X-4, X-5, X-9. [PubMed: 18005144]

988.

Martinez GH, Castaneda A, Correa JE. Vaginal bleeding patterns in users of Perlutal, a once-a-month injectable contraceptive consisting of 10 mg estradiol enanthate combined with 150 mg dihydroxyprogesterone acetophenide. A trial of 5462 woman-months. Contraception. 1998 Jul;58(1):21–7. X-3, X-5, X-6. [PubMed: 9743892]

989.

Masahashi T, Wu MC, Ohsawa M, et al. Spironolactone therapy for hyperandrogenic anovulatory women--clinical and endocrinological study. Nihon Sanka Fujinka Gakkai Zasshi. 1986 Jan;38(1):95–101. X-3, X-5. [PubMed: 3950464]

990.

Massai MR, Diaz S, Quinteros E, et al. Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women. Contraception. 2001 Dec;64(6):369–76. X-4, X-5. [PubMed: 11834236]

991.

Massai MR, Pavez M, Fuentealba B, et al. Effect of intermittent treatment with mifepristone on bleeding patterns in Norplant implant users. Contraception. 2004 Jul;70(1):47–54. X-5, X-6. [PubMed: 15208052]

992.

Matsumoto Y, Yamabe S, Sugishima T, et al. Perception of oral contraceptives among women of reproductive age in Japan: a comparison with the USA and France. J Obstet Gynaecol Res. 2011 Jul;37(7):887–92. X-3, X-5. [PubMed: 21450030]

993.

Mattsson LA. Safety and tolerability of pulsed estrogen therapy: Key factors for an improved compliance. Climacteric. 2002;5(SUPPL. 2):40–5. X-1, X-5. [PubMed: 12482110]

994.

Mattsson LA, Bohnet HG, Gredmark T, et al. Continuous, combined hormone replacement: Randomized comparison of transdermal and oral preparations. Obstetrics and Gynecology. 1999;94(1):61–5. X-7. [PubMed: 10389719]

995.

Mattsson LA, Skouby S, Mattila L, et al. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women. Menopause International. 2007;13(3):124–31. X-7. [PubMed: 17785038]

996.

Mattsson LA, Skouby SO, Heikkinen J, et al. A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional-dose regimen. Climacteric. 2004 Mar;7(1):59–69. X-5, X-7. [PubMed: 15259284]

997.

Matuszkiewicz-Rowinska J, Skorzewska K, Radowicki S, et al. Endometrial morphology and pituitary-gonadal axis dysfunction in women of reproductive age undergoing chronic haemodialysis--a multicentre study. Nephrol Dial Transplant. 2004 Aug;19(8):2074–7. X-4, X-5, X-9. [PubMed: 15173376]

998.

Mavrelos D, Ben-Nagi J, Davies A, et al. The value of pre-operative treatment with GnRH analogues in women with submucous fibroids: a double-blind, placebo-controlled randomized trial. Hum Reprod. 2010 Sep;25(9):2264–9. X-5, X-6, X-8. [PubMed: 20663795]

999.

Mayagoitia SB, Hernandez-Morales C, Macias AM, et al. Luteinizing hormone releasing hormone agonist for postpartum contraception. Adv Contracept. 1996 Mar;12(1):27–41. X-5, X-9. [PubMed: 8739514]

1000.

Mazaro-Costa R, Andersen ML, Hachul H, et al. Medicinal plants as alternative treatments for female sexual dysfunction: Utopian vision or possible treatment in climacteric women? Journal of Sexual Medicine. 2010;7(11):3695–714. X-1, X-3, X-5. [PubMed: 20722793]

1001.

McArthur JW, Turnbull BA, Pehrson J, et al. Nalmefene enhances LH secretion in a proportion of oligoamenorrheic athletes. Acta Endocrinol (Copenh). 1993 Apr;128(4):325–33. X-3, X-4, X-5. [PubMed: 8498150]

1002.

McBride D, Hardoon S, Walters K, et al. Explaining variation in referral from primary to secondary care: cohort study. BMJ. 2010;341:c6267. X-4, X-5, X-7, X-9. [PMC free article: PMC2995017] [PubMed: 21118873]

1003.

McCowan KA, Edelstein S. Are female ultra-endurance triathletes getting a sufficient daily carbohydrate intake? Topics in Clinical Nutrition. 2006;21(2):139–44. X-3, X-5.

1004.

McEwan J. Hormonal contraceptive methods. Practitioner. 1985 May;229(1403):415–23. X-9. [PubMed: 4011568]

1005.

McGavigan CJ, Dockery P, Metaxa-Mariatou V, et al. Hormonally mediated disturbance of angiogenesis in the human endometrium after exposure to intrauterine levonorgestrel. Hum Reprod. 2003 Jan;18(1):77–84. X-4, X-5, X-6. [PubMed: 12525444]

1006.

McIvor J, Cameron EW. Pregnancy after uterine artery embolization to control haemorrhage from gestational trophoblastic tumour. Br J Radiol. 1996 Jul;69(823):624–9. X-4, X-5, X-9. [PubMed: 8696698]

1007.

McKenzie J, Fisher BM, Jaap AJ, et al. Effects of HRT on liver enzyme levels in women with type 2 diabetes: A randomized placebo-controlled trial. Clinical Endocrinology. 2006;65(1):40–4. X-4, X-5. [PubMed: 16817817]

1008.

McLean JA, Barr SI. Cognitive dietary restraint is associated with eating behaviors, lifestyle practices, personality characteristics and menstrual irregularity in college women. Appetite. 2003 Apr;40(2):185–92. X-4, X-5, X-9. [PubMed: 12781168]

1009.

McLintock C, McCowan LM, North RA. Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin. BJOG. 2009 Nov;116(12):1585–92. X-4, X-5, X-9. [PubMed: 19681850]

1010.

Meirik O, Rowe PJ, Peregoudov A, et al. The frameless copper IUD (GyneFix) and the TCu380A IUD: results of an 8-year multicenter randomized comparative trial. Contraception. 2009 Aug;80(2):133–41. X-5. [PubMed: 19631788]

1011.

Menyhart K. Therapeutic usefulness of anteovin. Ther Hung. 1989;37(3):168–71. X-3. [PubMed: 2588200]

1012.

Mercorio F, De Simone R, Di Carlo C, et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Hum Reprod. 2003 Nov;18(11):2319–22. X-4, X-5, X-6. [PubMed: 14585881]

1013.

Mercorio F, De Simone R, Landi P, et al. Oral dexketoprofen for pain treatment during diagnostic hysteroscopy in postmenopausal women. Maturitas. 2002;43(4):277–81. X-7. [PubMed: 12468136]

1014.

Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: A phase I, multicentre, double-blind randomised study. Annals of the Rheumatic Diseases. 2011;70(11):1905–13. X-5. [PubMed: 21798883]

1015.

Messina ML, Bozzini N, Halbe HW, et al. Uterine artery embolization for the treatment of uterine leiomyomata. Int J Gynaecol Obstet. 2002 Oct;79(1):11–6. X-4, X-5, X-6, X-8. [PubMed: 12399085]

1016.

Meuwissen JHJM, Beijers-De Bie L, Vihtamaki T, et al. A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone. Gynecological Endocrinology. 2001;15(5):349–58. X-7. [PubMed: 11727357]

1017.

Meyer BH, Muller RO, De la Rey N, et al. The effects of buserelin microparticles on ovarian function in healthy women. South African Medical Journal. 1995;85(8):766–7. X-4, X-9. [PubMed: 8553146]

1018.

Meyer WR, Walsh BW, Grainger DA, et al. Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstet Gynecol. 1998 Jul;92(1):98–103. X-5, X-8. [PubMed: 9649102]

1019.

Michielutte R, Diseker RA, Corbett WT, et al. Characteristics of women with cervical intraepithelial dysplasia. Prog Clin Biol Res. 1983;130:203–15. X-5. [PubMed: 6622455]

1020.

Micks E, Jensen JT. Estradiol valerate and dienogest: a novel four-phasic oral contraceptive pill effective for pregnancy prevention and treatment of heavy menstrual bleeding. Womens Health (Lond Engl). 2011 Sep;7(5):513–24. X-1, X-3, X-5. [PubMed: 21879819]

1021.

Miech RP. Pathopharmacology of excessive hemorrhage in mifepristone abortions. Ann Pharmacother. 2007 Dec;41(12):2002–7. X-1, X-4, X-5, X-9. [PubMed: 17956963]

1022.

Mieszczak J, Lowe ES, Plourde P, et al. The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome. J Clin Endocrinol Metab. 2008 Jul;93(7):2751–4. X-4, X-5, X-9. [PubMed: 18397987]

1023.

Migoya E, Larson P, Bergman A, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not affect the pharmacokinetics of ethinyl estradiol or norethindrone in healthy female subjects. Journal of Clinical Pharmacology. 2011;51(9):1319–25. X-4, X-5, X-9. [PubMed: 21209231]

1024.

Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol. 2003 Apr;101(4):653–61. X-4, X-5, X-9. [PubMed: 12681866]

1025.

Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: Randomized controlled trial. Obstetrics and Gynecology. 2001;98(5):771–8. X-6, X-9. [PubMed: 11704167]

1026.

Miller L, Verhoeven CH, Hout J. Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet Gynecol. 2005 Sep;106(3):473–82. X-9, X-10. [PubMed: 16135576]

1027.

Miller S, Fathalla MM, Ojengbede OA, et al. Obstetric hemorrhage and shock management: using the low technology Non-pneumatic Anti-Shock Garment in Nigerian and Egyptian tertiary care facilities. BMC Pregnancy Childbirth. 2010;10:64. X-4, X-5, X-9. [PMC free article: PMC2966449] [PubMed: 20955600]

1028.

Milsom I, Andersson K, Andersch B, et al. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol. 1991 Mar;164(3):879–83. X-3. [PubMed: 1900665]

1029.

Milsom I, Lete I, Bjertnaes A, et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 mug ethinyl estradiol and 3 mg drospirenone. Human Reproduction. 2006;21(9):2304–11. X-6, X-9. [PubMed: 16763008]

1030.

Mints M, Luksha L, Kublickiene K. Altered responsiveness of small uterine arteries in women with idiopathic menorrhagia. Am J Obstet Gynecol. 2008 Dec;199(6):646 e1–5. X-4, X-5. [PubMed: 18667186]

1031.

Mishell DR Jr., Shoupe D, Moyer DL, et al. Postmenopausal hormone replacement with a combination estrogen-progestin regimen for five days per week. J Reprod Med. 1991 May;36(5):351–5. X-3, X-7. [PubMed: 2061882]

1032.

Mitchell ES, Woods NF, Bryant J. Understanding the menopausal transition: bleeding patterns during the menopausal transition; 34th Annual Communicating Nursing Research Conference/15th Annual WIN Assembly, “Health Care Challenges Beyond 2001: Mapping the Journey for Research and Practice,”; Communicating Nursing Research; April 19-21, 2001; Seattle, Washington. 2001. p. 203. X-1, X-3, X-5.

1033.

Mizrak A, Ugur GM, Erdaloglu P, et al. Intra-uterine bupivacaine and levobupivacaine. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2010;50(1):65–9. X-4, X-5, X-8. [PubMed: 20219000]

1034.

Mizunuma H, Okano H, Soda M, et al. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study. Maturitas. 1997 May;27(1):69–76. X-4, X-5, X-7, X-9. [PubMed: 9158080]

1035.

Mlcochova H, Horejsi J, Martinek J, et al. Treatment of autoimunne ovarian damage in adolescent girls. Neuro Endocrinol Lett. 2005 Apr;26(2):131–5. X-4, X-5, X-9. [PubMed: 15855884]

1036.

Mohamed AMM, El-Sherbiny WSM, Mostafa WAI. Combined contraceptive ring versus combined oral contraceptive (30-mug ethinylestradiol and 3-mg drospirenone). International Journal of Gynecology and Obstetrics. 2011;114(2):145–8. X-9. [PubMed: 21669426]

1037.

Mohan PC, Tan BS, Kwek BH, et al. Uterine artery embolisation for symptomatic fibroids in a tertiary hospital in Singapore. Ann Acad Med Singapore. 2005 Jan;34(1):78–83. X-4, X-5, X-6, X-8, X-9. [PubMed: 15726223]

1038.

Molina RC, Sandoval JZ, Montero AV, et al. Comparative performance of a combined injectable contraceptive (50 mg norethisterone enanthate plus 5mg estradiol valerate) and a combined oral contraceptive (0.15 mg levonorgestrel plus 0.03 mg ethinyl estradiol) in adolescents. J Pediatr Adolesc Gynecol. 2009 Feb;22(1):25–31. X-4, X-5, X-9. [PubMed: 19232299]

1039.

Momoeda M, Harada T, Terakawa N, et al. Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res. 2009 Dec;35(6):1069–76. X-4, X-5, X-6, X-9. [PubMed: 20025633]

1040.

Monteiro I, Bahamondes L, Diaz J, et al. Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study(1). Contraception. 2002 May;65(5):325–8. X-4. [PubMed: 12057782]

1041.

Moodley J, Cohen M, Devraj K, et al. Vaginal absorption of low-dose tranexamic acid from impregnated tampons. S Afr Med J. 1992 Feb 1;81(3):150–2. X-3, X-5, X-6, X-10. [PubMed: 1734554]

1042.

Moore C, Carol W, Graser T, et al. Influence of dienogest on ovulation in young fertile women. Clinical Drug Investigation. 1999;18(4):271–8. X-4, X-5, X-9.

1043.

Moore KA, Callahan TS, Maison-Blanche P, et al. Thorough cardiac QTc interval conductance assessment of a novel oral tranexamic acid treatment for heavy menstrual bleeding. Expert Opin Pharmacother. 2010 Oct;11(14):2281–90. X-4, X-5, X-9. [PubMed: 20698724]

1044.

Moore KA, Morin I, Marenco T, et al. Pharmacokinetic studies in women of 2 novel oral formulations of tranexamic acid therapy for heavy menstrual bleeding. American Journal of Therapeutics. 2012 May;19(3):190–8. X-4. [PubMed: 21248612]

1045.

Moore N, Charlesworth A, Van Ganse E, et al. Risk factors for adverse events in analgesic drug users: Results from the PAIN study. Pharmacoepidemiology and Drug Safety. 2003;12(7):601–10. X-5. [PubMed: 14558184]

1046.

Moraes-de-Souza H, Kerbauy J, Yamamoto M, et al. Depressed cell-mediated immunity in iron-deficiency anemia due to chronic loss of blood. Braz J Med Biol Res. 1984;17(2):143–50. X-3, X-4, X-5. [PubMed: 6518338]

1047.

Moreau C, Trussell J, Gilbert F, et al. Oral contraceptive tolerance: does the type of pill matter? Obstet Gynecol. 2007 Jun;109(6):1277–85. X-4, X-5, X-9. [PubMed: 17540798]

1048.

Moreno J, Rowan AJ. A comparative study of Norinyl 1/35 versus Brevicon in Panama City, Panama. Contraception. 1987 Dec;36(6):615–25. X-9. [PubMed: 3446438]

1049.

Moro M, Maraschini C, Toja P, et al. Comparison between a slow-release oral preparation of bromocriptine and regular bromocriptine in patients with hyperprolactinemia: a double blind, double dummy study. Horm Res. 1991;35(3-4):137–41. X-3, X-5. [PubMed: 1806467]

1050.

Morris EP, Rymer J, Robinson J, et al. Efficacy of tibolone as “add-back therapy” in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids. Fertil Steril. 2008 Feb;89(2):421–8. X-5, X-6, X-9. [PubMed: 17572410]

1051.

Morris JL, Meyer C, Fathalla MMF, et al. Treating uterine atony with the nonpneumatic anti-shock garment in Egypt. African Journal of Midwifery & Women's Health. 2011 Jan-Mar;5(1):37–42. 2011. X-3, X-5, X-6, X-10.

1052.

Mossa B, Imperato F, Marziani R, et al. Hormonal replacement therapy and evaluation of intrauterine pathology in postmenopausal women: a ten-year study. Eur J Gynaecol Oncol. 2003;24(6):507–12. X-4, X-5, X-7. [PubMed: 14658591]

1053.

Mourali M, Fkih C, Essoussi-Chikhaoui J, et al. Gestational trophoblastic disease in Tunisia. Tunis Med. 2008 Jul;86(7):665–9. X-4, X-5, X-9. [PubMed: 19472728]

1054.

Movafegh A, Eslamian L, Dorabadi A. Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery. Int J Gynaecol Obstet. 2011 Dec;115(3):224–6. X-5. [PubMed: 21872857]

1055.

Muasher SJ, Kruithoff C, Simonetti S, et al. Controlled preparation of the endometrium with exogenous steroids for the transfer of frozen-thawed pre-embryos in patients with anovulatory or irregular cycles. Hum Reprod. 1991 Mar;6(3):443–5. X-3, X-5. [PubMed: 1955555]

1056.

Mukherjee GG, Gajaraj AJ, Mathias J, et al. Treatment of abnormal uterine bleeding with micronized flavonoids. Int J Gynaecol Obstet. 2005 May;89(2):156–7. X-3. [PubMed: 15847886]

1057.

Mulders AG, Eijkemans MJ, Imani B, et al. Prediction of chances for success or complications in gonadotrophin ovulation induction in normogonadotrophic anovulatory infertility. Reprod Biomed Online. 2003 Sep;7(2):170–8. X-4, X-5, X-9. [PubMed: 14567885]

1058.

Mulligan K, Zackin R, Clark RA, et al. Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss: A randomized, double-blind, placebo-controlled, multicenter trial. Archives of Internal Medicine. 2005;165(5):578–85. X-5. [PubMed: 15767536]

1059.

Muneyyirci-Delale O, Richard-Davis G, Morris T, et al. Goserelin Acetate 10.8 mg Plus Iron Versus Iron Monotherapy Prior to Surgery in Premenopausal Women with Iron-Deficiency Anemia Due to Uterine Leiomyomas: Results from a Phase III, Randomized, Multicenter, Double-Blind, Controlled Trial. Clinical Therapeutics. 2007;29(8):1682–91. X-6, X-8. [PubMed: 17919549]

1060.

Muneyyirci-Delale O, Weisberg GW. Do heavier women benefit from a higher dose of leuprolide acetate for suppression of serum estradiol? Int J Fertil Womens Med. 2000 Nov-Dec;45(6):368–71. X-4, X-5, X-6. [PubMed: 11140546]

1061.

Munro MG, Mainor N, Basu R, et al. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. Obstet Gynecol. 2006 Oct;108(4):924–9. X-5, X-9. [PubMed: 17012455]

1062.

Murphy PA, Kern SE, Stanczyk FZ, et al. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception. 2005 Jun;71(6):402–8. X-4, X-5, X-9. [PubMed: 15914127]

1063.

Murray SC, Muse KN. Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist and “add-back” therapy. Fertil Steril. 1997 Feb;67(2):390–3. X-3, X-5. [PubMed: 9022620]

1064.

Muse K, Lukes AS, Gersten J, et al. Long-term evaluation of safety and health-related quality of life in women with heavy menstrual bleeding treated with oral tranexamic acid. Womens Health (Lond Engl). 2011 Nov;7(6):699–707. X-3. [PubMed: 21867401]

1065.

Muzii L, Boni T, Bellati F, et al. GnRH analogue treatment before hysteroscopic resection of submucous myomas: a prospective, randomized, multicenter study. Fertil Steril. 2010 Sep;94(4):1496–9. X-5, X-6, X-8, X-9. [PubMed: 19541299]

1066.

Muzii L, Maneschi F, Marana R, et al. Oral Estroprogestins after Laparoscopic Surgery to Excise Endometriomas: Continuous or Cyclic Administration? Results of a Multicenter Randomized Study. Journal of Minimally Invasive Gynecology. 2011;18(2):173–8. X-5, X-6, X-8. [PubMed: 21262590]

1067.

Mwamburi DM, Gerrior J, Wilson IB, et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: Similar results in 2 months. Clinical Infectious Diseases. 2004;38(6):895–902. X-5. [PubMed: 14999637]

1068.

Myburgh KH, Watkin VA, Noakes TD. Are risk factors for menstrual dysfunction cumulative? Physician & Sportsmedicine. 1992;20(4):114. X-3, X-4, X-5, X-10. [PubMed: 27424644]

1069.

Nabavi SM, Koupai SA, Nejati MR, et al. Menstrual irregularities and related plasma hormone levels in multiple sclerosis patients treated with beta interferone. Acta Med Iran. 2010 Jan-Feb;48(1):36–41. X-4, X-5, X-6, X-9. [PubMed: 21137667]

1070.

Nagele F, Lockwood G, Magos AL. Randomised placebo controlled trial of mefenamic acid for premedication at outpatient hysteroscopy: a pilot study. Br J Obstet Gynaecol. 1997 Jul;104(7):842–4. X-4, X-5, X-8, X-9. [PubMed: 9236652]

1071.

Nagele F, O'Connor H, Baskett TF, et al. Hysteroscopy in women with abnormal uterine bleeding on hormone replacement therapy: a comparison with postmenopausal bleeding. Fertil Steril. 1996 Jun;65(6):1145–50. X-4, X-5, X-7, X-8, X-9. [PubMed: 8641488]

1072.

Nahidi F, Jalalinia S. Comparing the complications of 2 copper intrauterine devices: T380A and Cu-Safe 300. East Mediterr Health J. 2008 Jan-Feb;14(1):95–102. X-4, X-5, X-9. [PubMed: 18557456]

1073.

Nakagawa K, Takahashi Y, Ito M, et al. Intraovarian arterial blood flow resistance in oligomenorrheal infertile women. J Assist Reprod Genet. 2006 Mar;23(3):105–10. X-4, X-5, X-9. [PMC free article: PMC3455036] [PubMed: 16758342]

1074.

Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe). Contraception. 2007 Jan;75(1):16–22. X-4, X-5. [PubMed: 17161118]

1075.

Nakajima ST, Brumsted JR, Riddick DH, et al. Absence of progestational activity of oral spironolactone. Fertil Steril. 1989 Jul;52(1):155–8. X-3, X-4, X-5, X-6. [PubMed: 2744183]

1076.

Nand SL, Webster MA, Baber R, et al. Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy. The Ogen/Provera Study Group. Obstet Gynecol. 1998 May;91(5 Pt 1):678–84. X-5, X-7. [PubMed: 9572210]

1077.

Nand SL, Webster MA, Wren BG. Continuous combined piperazine oestrone sulphate and medroxyprogesterone acetate hormone replacement therapy--a study of bleeding pattern, endometrial response, serum lipid and bone density changes. Aust N Z J Obstet Gynaecol. 1995 Feb;35(1):92–6. X-7. [PubMed: 7772012]

1078.

Nappi C, Farace MJ, Leone F, et al. Effect of a combination of ethinylestradiol and desogestrel in adolescents with oligomenorrhea and ovarian hyperandrogenism. Eur J Obstet Gynecol Reprod Biol. 1987 Jul;25(3):209–19. X-3, X-5. [PubMed: 2956138]

1079.

Nappi RE, Sances G, Sommacal A, et al. Different effects of tibolone and low-dose EPT in the management of postmenopausal women with primary headaches. Menopause. 2006;13(5):818–25. X-5, X-7. [PubMed: 16894336]

1080.

Narbone MC, Ruello C, Oliva A, et al. Hormonal disregulation and catamenial epilepsy. Funct Neurol. 1990 Jan-Mar;5(1):49–53. X-3, X-4, X-5. [PubMed: 2119330]

1081.

Nassaralla CL, Stanford JB, Daly KD, et al. Characteristics of the menstrual cycle after discontinuation of oral contraceptives. J Womens Health (Larchmt). 2011 Feb;20(2):169–77. X-4, X-5, X-9. [PMC free article: PMC7643763] [PubMed: 21219248]

1082.

Nathirojanakun P, Taneepanichskul S, Sappakitkumjorn N. Efficacy of a selective COX-2 inhibitor for controlling irregular uterine bleeding in DMPA users. Contraception. 2006 Jun;73(6):584–7. X-5, X-6. [PubMed: 16730488]

1083.

Navarro PA, Kaddouz D, de Ziegler D, et al. Vaginal administration of allopregnanolone to postmenopausal women undergoing estrogen replacement therapy: preliminary results. Maturitas. 2003 Oct 20;46(2):147–52. X-4, X-5, X-7. [PubMed: 14559386]

1084.

Nazar H, Usmanghani K. Clinical evaluation to assess the safety and efficacy of coded herbal medicine “Dysmo-off” versus allopathic medicine “Diclofenac Sodium” for the treatment of primary dysmenorrhea. Journal of Herbal Pharmacotherapy. 2006;6(1):21–39. X-5, X-10. [PubMed: 17135158]

1085.

Need JA, Forbes KL, Milazzo L, et al. Danazol in the treatment of menorrhagia: the effect of a 1 month induction dose (200 mg) and 2 month's maintenance therapy (200 mg, 100 mg, 50 mg or placebo). Aust N Z J Obstet Gynaecol. 1992 Nov;32(4):346–52. X-5. [PubMed: 1290434]

1086.

Nel A, Smythe S, Young K, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. Journal of Acquired Immune Deficiency Syndromes. 2009;51(4):416–23. X-4, X-5. [PubMed: 19623693]

1087.

Nelskyla K, Korttila K, Yli-Hankala A. Comparison of sevoflurane-nitrous oxide and propofol-alfentanil-nitrous oxide anaesthesia for minor gynaecological surgery. British Journal of Anaesthesia. 1999;83(4):576–9. X-5, X-8. [PubMed: 10673872]

1088.

Nelson AL. Levonorgestrel intrauterine system: a first-line medical treatment for heavy menstrual bleeding. Womens Health (Lond Engl). 2010 May;6(3):347–56. X-1, X-3, X-5, X-10. [PubMed: 20426599]

1089.

Nett R, Mannix LK, Mueller L, et al. Rizatriptan efficacy in ICHD-II pure menstrual migraine and menstrually related migraine. Headache. 2008 Sep;48(8):1194–201. X-5, X-9. [PubMed: 18422606]

1090.

Neuwirth RS, Duran AA, Singer A, et al. The endometrial ablator: a new instrument. Obstet Gynecol. 1994 May;83(5 Pt 1):792–6. X-3, X-8. [PubMed: 8164945]

1091.

Neven P, Lunde T, Benedetti-Panici P, et al. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate. BJOG. 2003 Feb;110(2):157–67. X-5, X-7, X-9. [PubMed: 12618160]

1092.

Neveu N, Granger L, St-Michel P, et al. Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome. Fertil Steril. 2007 Jan;87(1):113–20. X-4, X-5, X-9. [PubMed: 17081535]

1093.

Newman CB, Hurley AM, Kleinberg DL. Effect of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine. Clin Endocrinol (Oxf). 1989 Oct;31(4):391–400. X-3, X-5. [PubMed: 2576397]

1094.

Newman LC, Lipton RB, Lay CL, et al. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology. 1998 Jul;51(1):307–9. X-4, X-5, X-9. [PubMed: 9674831]

1095.

Newton KM, Reed SD, LaCroix AZ, et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: A randomized trial. Annals of Internal Medicine. 2006;145(12):869–79. X-5. [PubMed: 17179056]

1096.

Nezhat C, Karpas AE, Greenblatt RB, et al. Estradiol implants for conception control. Am J Obstet Gynecol. 1980 Dec 15;138(8):1151–6. X-3, X-9. [PubMed: 7446623]

1097.

Ngai SW, Chan YM, Tang OS, et al. Vaginal misoprostol as medical treatment for first trimester spontaneous miscarriage. Hum Reprod. 2001 Jul;16(7):1493–6. X-5, X-9. [PubMed: 11425836]

1098.

Ngai SW, Fan S, Li S, et al. A randomized trial to compare 24 h versus 12 h double dose regimen of levonorgestrel for emergency contraception. Human Reproduction. 2005;20(1):307–11. X-5. [PubMed: 15567882]

1099.

Ngai SW, Yeung KC, Lao T, et al. Oral misoprostol versus mifepristone for cervical dilatation before vacuum aspiration in first trimester nulliparous pregnancy: a double blind prospective randomised study. Br J Obstet Gynaecol. 1996 Nov;103(11):1120–3. X-5, X-9. [PubMed: 8917000]

1100.

Nguyen TN, Blum J, Durocher J, et al. A randomized controlled study comparing 600 versus 1,200 microg oral misoprostol for medical management of incomplete abortion. Contraception. 2005 Dec;72(6):438–42. X-5, X-9. [PubMed: 16307967]

1101.

Nicholas SL, Rulin MC. Acute vaginal bleeding in women undergoing liver transplantation. Am J Obstet Gynecol. 1994 Mar;170(3):733–6. X-3, X-5, X-6. [PubMed: 8141191]

1102.

Nielsen J, Emborg C, Gydesen S, et al. Augmenting clozapine with sertindole: A double-blind, randomized, placebo-controlled study. Journal of Clinical Psychopharmacology. 2012 April;32(2):173–8. X-5. [PubMed: 22367659]

1103.

Nielsen TF, Ravn P, Bagger YZ, et al. Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study. Osteoporosis International. 2004;15(2):168–74. X-7. [PubMed: 14647880]

1104.

Nijland EA, Nathorst-Boos J, Palacios S, et al. Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction. Climacteric. 2009 Apr;12(2):114–21. X-5, X-7, X-9. [PubMed: 19177255]

1105.

Nilsen JF, Bassoe CF. Contraception in general practice analyzed by a computerized medical record. Scand J Prim Health Care. 1987 Nov;5(4):217–20. X-3, X-5. [PubMed: 3423491]

1106.

Nilsson CG, Allonen H, Diaz J, et al. Two years' experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine device: a randomized comparative performance study. Fertil Steril. 1983 Feb;39(2):187–92. X-9. [PubMed: 6401636]

1107.

Nilsson CG, Holma P. Menstrual blood loss with contraceptive subdermal levonorgestrel implants. Fertil Steril. 1981 Mar;35(3):304–6. X-3, X-5, X-9. [PubMed: 6781939]

1108.

Nilsson CG, Luukkainen T, Diaz J, et al. Intrauterine contraception with levonorgestrel: A comparative randomised clinical performance study. Lancet. 1981;1(8220):577–80. X-9. [PubMed: 6110819]

1109.

Nixon RM, Duffy SW, Fender GR. Imputation of a true endpoint from a surrogate: application to a cluster randomized controlled trial with partial information on the true endpoint. BMC Med Res Methodol. 2003 Sep 24;3:17. X-3, X-5, X-10. [PMC free article: PMC270060] [PubMed: 14507420]

1110.

Nixon RM, Duffy SW, Fender GR, et al. Randomization at the level of primary care practice: use of pre-intervention data and random effects models. Stat Med. 2001 Jun 30;20(12):1727–38. X-3, X-5, X-10. [PubMed: 11406837]

1111.

Nixon RM, Thompson SG. Baseline adjustments for binary data in repeated cross-sectional cluster randomized trials. Statistics in Medicine. 2003;22(17):2673–92. X-1, X-3, X-5, X-10. [PubMed: 12939779]

1112.

Noerpramana NP. Blood-lipid fractions: the side-effects and continuation of Norplant use. Adv Contracept. 1997 Mar;13(1):13–37. X-4, X-5, X-6, X-9. [PubMed: 9181182]

1113.

Norris RV. Progesterone for premenstrual tension. J Reprod Med. 1983 Aug;28(8):509–16. X-1, X-3, X-5. [PubMed: 6355465]

1114.

Notelovitz M. Contraceptive efficacy and safety of a monophasic oral contraceptive containing 150 micrograms desogestrel and 30 micrograms ethinyl estradiol: United States clinical experience using a “Sunday start” approach. Fertil Steril. 1995 Aug;64(2):261–6. X-3, X-9. [PubMed: 7615100]

1115.

Nutley T, Dunson TR. Treatment of bleeding problems associated with progestin-only contraceptives: survey results. Adv Contracept. 1997 Dec;13(4):419–28. X-4, X-5, X-6. [PubMed: 9404551]

1116.

NyboeAndersen A, Balen A, Platteau P, et al. Predicting the FSH threshold dose in women with WHO Group II anovulatory infertility failing to ovulate or conceive on clomiphene citrate. Hum Reprod. 2008 Jun;23(6):1424–30. X-4, X-5, X-9. [PMC free article: PMC2387217] [PubMed: 18372254]

1117.

Nygren KG, Rybo G. Prostaglandins and menorrhagia. Acta Obstet Gynecol Scand Suppl. 1983;113:101–3. X-1, X-3, X-5. [PubMed: 6344539]

1118.

Oddsson K, Leifels-Fischer B, Wiel-Masson D, et al. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. Hum Reprod. 2005 Feb;20(2):557–62. X-5. [PubMed: 15539438]

1119.

Oddsson K, Leifels-Fischer B, Wiel-Masson D, et al. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 mug ethinylestradiol and 150 mug levonorgestrel: A randomized trial. Human Reproduction. 2005;20(2):557–62. X-6, X-9. [PubMed: 15539438]

1120.

Odmark IS, Bixo M, Englund D, et al. Endometrial safety and bleeding pattern during a five-year treatment with long-cycle hormone therapy. Menopause. 2005 Nov-Dec;12(6):699–707. X-4, X-5, X-7. [PubMed: 16278613]

1121.

O'Donovan C, Kusumakar V, Graves GR, et al. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry. 2002 Apr;63(4):322–30. X-4, X-5, X-6, X-9. [PubMed: 12000206]

1122.

Oguz S, Sargin A, Kelekci S, et al. The role of hormone replacement therapy in endometrial polyp formation. Maturitas. 2005;50(3):231–6. X-5. [PubMed: 15734604]

1123.

Ojule JD, Oriji VK, Okongwu C. A five year review of the complications of progestogen only injectable contraceptive at the University of Port-Harcourt Teaching Hospital. Niger J Med. 2010 Jan-Mar;19(1):87–95. X-4, X-5, X-6, X-9. [PubMed: 20232762]

1124.

Okon MA, Lee S, Laird SM, et al. A prospective randomized controlled study comparing the morphological and biochemical responses of the endometrium to two different forms of ‘period-free’ hormone replacement therapy. Human Reproduction. 1998;13(8):2261–5. X-7. [PubMed: 9756307]

1125.

Okon MA, Lee S, Laird SM, et al. A prospective randomized controlled study comparing two doses of gestodene in cyclic combined HRT preparations on endometrial physiology. Hum Reprod. 2001 Jun;16(6):1244–50. X-5, X-7. [PubMed: 11387299]

1126.

Oksa S, Luukkaala T, Maenpaa J. Toremifene for premenstrual mastalgia: a randomised, placebo-controlled crossover study. BJOG. 2006 Jun;113(6):713–8. X-5, X-9. [PubMed: 16709215]

1127.

Oksa S, Parkkola R, Luukkaala T, et al. Breast magnetic resonance imaging findings in women treated with toremifene for premenstrual mastalgia. Acta Radiol. 2009 Nov;50(9):984–9. X-4, X-5, X-9. [PubMed: 19863407]

1128.

Oliveira-Ribeiro M, Petta CA, De Angelo Andrade LA, et al. Endometrial histology, microvascular density and caliber, and matrix metalloproteinase-3 in users of the Nestorone-releasing contraceptive implant with and without endometrial breakthrough bleeding. Contraception. 2006 Jun;73(6):634–40. X-4, X-5, X-6, X-9. [PubMed: 16730498]

1129.

Olsson SE. Contraception with subdermal implants releasing levonorgestrel. A clinical and pharmacological study. Acta Obstet Gynecol Scand Suppl. 1987;142:1–45. X-9. [PubMed: 3116821]

1130.

Omodei U, Ferrazzi E, Ramazzotto F, et al. Endometrial evaluation with transvaginal ultrasound during hormone therapy: a prospective multicenter study. Fertil Steril. 2004 Jun;81(6):1632–7. X-4, X-5, X-7, X-9. [PubMed: 15193487]

1131.

Orrego JJ, Chandler WF, Barkan AL. Pergolide as primary therapy for macroprolactinomas. Pituitary. 2000 Dec;3(4):251–6. X-4, X-5, X-6, X-9. [PubMed: 11788013]

1132.

Otero-Flores JB, Guerrero-Carreno FJ, Vazquez-Estrada LA. A comparative randomized study of three different IUDs in nulliparous Mexican women. Contraception. 2003 Apr;67(4):273–6. X-4, X-5. [PubMed: 12684147]

1133.

Otolorin EO, Falase EA, Ladipo OA. A comparative study of three oral contraceptives in Ibadan: Norinyl 1/35, Lo-Ovral and Noriday 1/50. Afr J Med Med Sci. 1990 Mar;19(1):15–22. X-9. [PubMed: 2109515]

1134.

Overton C, Hargreaves J, Maresh M. A national survey of the complications of endometrial destruction for menstrual disorders: the MISTLETOE study. Minimally Invasive Surgical Techniques--Laser, EndoThermal or Endorescetion. Br J Obstet Gynaecol. 1997 Dec;104(12):1351–9. X-4, X-5, X-8. [PubMed: 9422012]

1135.

Ovesen P, Moller J, Moller N, et al. Growth hormone secretory capacity and serum insulin-like growth factor I levels in primary infertile, anovulatory women with regular menses. Fertil Steril. 1992 Jan;57(1):97–101. X-3, X-4. [PubMed: 1730338]

1136.

Oyelola OO, Okonofua FE, Adediran TO. Menstrual bleeding pattern and iron status in women fitted with copper and non-medicated intrauterine contraceptive devices. East Afr Med J. 1994 Apr;71(4):268–70. X-3, X-5, X-9. [PubMed: 8062778]

1137.

Ozdegirmenci O, Kayikcioglu F, Akgul MA, et al. Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis. Fertil Steril. 2011 Feb;95(2):497–502. X-5, X-6, X-8. [PubMed: 21074150]

1138.

Paffenbarger RS Jr., Kampert JB, Chang HG. Characteristics that predict risk of breast cancer before and after the menopause. Am J Epidemiol. 1980 Aug;112(2):258–68. X-3, X-5. [PubMed: 7416152]

1139.

Pafumi C, Ciotta L, Farina M, et al. Uterine bleeding pattern during low dosage Noretisterone acetate and 17-b-Estradiol treatment in postmenopausal patients. Minerva Ginecol. 2002 Dec;54(6):513–8. X-4, X-5, X-6, X-7. [PubMed: 12432336]

1140.

Pakarinen P, Luukkainen T. Five years' experience with a small intracervical/intrauterine levonorgestrel-releasing device. Contraception. 2005 Nov;72(5):342–5. X-4, X-5. [PubMed: 16246659]

1141.

Pakarinen P, Luukkainen T, Elomaa K, et al. A 12-month comparative clinical investigation of a levonorgestrel- releasing intracervical device situated in the uterine cavity or cervical canal. Contraception. 1996;54(3):187–92. X-9. [PubMed: 8899261]

1142.

Pakarinen P, Toivonen J, Luukkainen T. Randomized comparison of levonorgestrel- and copper-releasing intrauterine systems immediately after abortion, with 5 years' follow-up. Contraception. 2003 Jul;68(1):31–4. X-5, X-6. [PubMed: 12878284]

1143.

Pakarinen PI, Suvisaari J, Luukkainen T, et al. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles. Fertil Steril. 1997 Jul;68(1):59–64. X-5. [PubMed: 9207585]

1144.

Pal MN, Pal I. Menstrual behaviour with steroid implant. J Indian Med Assoc. 1981 Jul 1;77(1):16–7. X-3, X-5, X-9, X-10. [PubMed: 7328324]

1145.

Palacios S, Pornel B, Vazquez F, et al. Long-term endometrial and breast safety of a specific, standardized soy extract. Climacteric. 2010 Aug;13(4):368–75. X-4, X-5, X-7. [PubMed: 20380569]

1146.

Palomba S, Orio F Jr., Falbo A, et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 Jul;90(7):4068–74. X-5, X-10. [PubMed: 15840746]

1147.

Palomba S, Orio F Jr., Falbo A, et al. Metformin administration and laparoscopic ovarian drilling improve ovarian response to clomiphene citrate (CC) in oligo-anovulatory CC-resistant women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2005 Dec;63(6):631–5. X-4, X-5, X-9. [PubMed: 16343096]

1148.

Palomba S, Orio F Jr, Nardo LG, et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: A prospective parallel randomized double-blind placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism. 2004;89(10):4801–9. X-5, X-8. [PubMed: 15472166]

1149.

Palomba S, Orio F Jr, Russo T, et al. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas. Human Reproduction. 2004;19(6):1308–14. X-3, X-6. [PubMed: 15117890]

1150.

Palomba S, Orio F Jr, Russo T, et al. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporosis International. 2005;16(8):943–52. X-7. [PubMed: 15739035]

1151.

Palomba S, Russo T, Orio F Jr., et al. Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. Hum Reprod. 2002 Dec;17(12):3213–9. X-5, X-6. [PubMed: 12456626]

1152.

Palomba S, Sena T, Morelli M, et al. Effect of different doses of progestin on uterine leiomyomas in postmenopausal women. Eur J Obstet Gynecol Reprod Biol. 2002 May 10;102(2):199–201. X-4, X-5, X-7. [PubMed: 11950491]

1153.

Palomba S, Sena T, Noia R, et al. Transdermal hormone replacement therapy in postmenopausal women with uterine leiomyomas. Obstet Gynecol. 2001 Dec;98(6):1053–8. X-5, X-6, X-7. [PubMed: 11755553]

1154.

Palombo-Kinne E, Schellschmidt I, Schumacher U, et al. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate. Contraception. 2009;79(4):282–9. X-5. [PubMed: 19272497]

1155.

Pan JF, Yu YL, Wang LJ, et al. The morphologic changes of endometrial spiral arterioles in IUD-induced menorrhagia. Adv Contracept. 1994 Sep;10(3):213–22. X-3, X-4. [PubMed: 7863847]

1156.

Panay N, Pritsch M, Alt J. Cyclical dydrogesterone in secondary amenorrhea: results of a double-blind, placebo-controlled, randomized study. Gynecol Endocrinol. 2007 Nov;23(11):611–8. X-5, X-9. [PubMed: 17891596]

1157.

Panjari M, Bell RJ, Jane F, et al. The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas. 2009 Jul 20;63(3):240–5. X-5, X-7. [PubMed: 19410392]

1158.

Parazzini F, Bortolotti A, Chiantera V, et al. Goserelin acetate to avoid hysterectomy in pre-menopausal women with fibroids requiring surgery. Eur J Obstet Gynecol Reprod Biol. 1999 Nov;87(1):31–3. X-5, X-6, X-8. [PubMed: 10579613]

1159.

Parazzini F, La Vecchia C, Negri E, et al. Lifelong menstrual pattern and risk of breast cancer. Oncology. 1993 Jul-Aug;50(4):222–5. X-3, X-4, X-5. [PubMed: 8497374]

1160.

Park H, Yoon BS, Seong SJ, et al. Can misoprostol reduce blood loss in laparoscopy-assisted vaginal hysterectomy? Aust N Z J Obstet Gynaecol. 2011 Jun;51(3):248–51. X-4, X-5, X-6, X-8. [PubMed: 21631445]

1161.

Parker RA, McDaniel EB. The use of quinesterol for the control of vaginal bleeding irregularities caused by DMPA. Contraception. 1980 Jul;22(1):1–7. X-6. [PubMed: 7418403]

1162.

Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertility and Sterility. 2007;87(4):725–36. X-1, X-3, X-5. [PubMed: 17430732]

1163.

Parmigiani L, Furtado RNV, Lopes RV, et al. Joint lavage associated with triamcinolone hexacetonide injection in knee osteoarthritis: A randomized double-blind controlled study. Clinical Rheumatology. 2010;29(11):1311–5. X-5. [PubMed: 20623311]

1164.

Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 2000 Feb;61(2):105–11. X-4, X-5. [PubMed: 10802275]

1165.

Paschopoulos M, Lavasidis LG, Vrekoussis T, et al. Greek experience in the use of Thermachoice for treating heavy menstrual bleeding: prospective study. Ann N Y Acad Sci. 2006 Dec;1092:460–5. X-3, X-5, X-8. [PubMed: 17308173]

1166.

Pasquale SA, Brandeis V, Cruz RI, et al. Norplant contraceptive implants: rods versus capsules. Contraception. 1987 Sep;36(3):305–16. X-3, X-9. [PubMed: 3119287]

1167.

Pasquale SA, Foldesy RG, Levine JP, et al. Peripheral progesterone (P) levels and endometrial response to various dosages of vaginally administered P in estrogen-primed women. Fertil Steril. 1997 Nov;68(5):810–5. X-4, X-5, X-7, X-9. [PubMed: 9389807]

1168.

Pasquale SA, Knuppel RA, Owens AG, et al. Irregular bleeding, body mass index and coital frequency in Norplant contraceptive users. Contraception. 1994 Aug;50(2):109–16. X-3, X-6, X-9. [PubMed: 7956210]

1169.

Pauleta JR, Clode N, Graca LM. Expectant management of incomplete abortion in the first trimester. Int J Gynaecol Obstet. 2009 Jul;106(1):35–8. X-4, X-5, X-9. [PubMed: 19329115]

1170.

Pazos F, Escobar-Morreale HF, Balsa J, et al. Prospective randomized study comparing the long-acting gonadotropin- releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism. Fertility and Sterility. 1999;71(1):122–8. X-5. [PubMed: 9935128]

1171.

Pearlstein TB, Bachmann GA, Zacur HA, et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005;72(6):414–21. X-5. [PubMed: 16307962]

1172.

Peillon F, Vincens M, Cesselin F, et al. Exaggerated prolactin response of thyrotropin-releasing hormone in women with anovulatory cycles: possible role of endogenous estrogens and effect of bromocriptine. Fertil Steril. 1982 Apr;37(4):530–5. X-3, X-4, X-5. [PubMed: 6802681]

1173.

Pelissier C, Maroni M, Yaneva H, et al. Chlormadinone acetate versus micronized progesterone in the sequential combined hormone replacement therapy of the menopause. Maturitas. 2001 Oct 31;40(1):85–94. X-5, X-7. [PubMed: 11684377]

1174.

Peres MF, Zukerman E, da Cunha Tanuri F, et al. Melatonin, 3 mg, is effective for migraine prevention. Neurology. 2004 Aug 24;63(4):757. X-5, X-9. [PubMed: 15326268]

1175.

Perino A, Castelli A, Cucinella G, et al. A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertil Steril. 2004 Sep;82(3):731–4. X-5, X-8. [PubMed: 15374722]

1176.

Perino A, Chianchiano N, Petronio M, et al. Role of leuprolide acetate depot in hysteroscopic surgery: a controlled study. Fertil Steril. 1993 Mar;59(3):507–10. X-3, X-8. [PubMed: 8458448]

1177.

Perlitz Y, Rahav D, Ben-Ami M. Endometrial ablation using hysteroscopic instillation of hot saline solution into the uterus. Eur J Obstet Gynecol Reprod Biol. 2001 Nov;99(1):90–2. X-4, X-5, X-8. [PubMed: 11604192]

1178.

Petta CA, Amatya R, Farr G. Clinical evaluation of the TCu 380A IUD at six Latin American centers. Contraception. 1994 Jul;50(1):17–25. X-3, X-9. [PubMed: 7924319]

1179.

Pezeshki K, Feldman J, Stein DE, et al. Bleeding and spontaneous abortion after therapy for infertility. Fertil Steril. 2000 Sep;74(3):504–8. X-4, X-5, X-6, X-9. [PubMed: 10973646]

1180.

Pfeifer S, Patrizio P. The female athlete: Some gynecologic considerations. Sports Medicine and Arthroscopy Review. 2002;10(1):2–9. X-1, X-3, X-5.

1181.

Pfrunder A, Schiesser M, Gerber S, et al. Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol. 2003 Dec;56(6):683–90. X-4, X-5, X-6. [PMC free article: PMC1884294] [PubMed: 14616430]

1182.

Phaliwong P, Taneepanichskul S. The effect of mefenamic acid on controlling irregular uterine bleeding second to Implanon use. J Med Assoc Thai. 2004 Oct;87 Suppl 3:S64–8. X-5, X-6. [PubMed: 21213495]

1183.

Phemister DA, Laurent S, Harrison FN Jr. Use of Norplant contraceptive implants in the immediate postpartum period: safety and tolerance. Am J Obstet Gynecol. 1995 Jan;172(1 Pt 1):175–9. X-5, X-9. [PubMed: 7847530]

1184.

Phittayawechwiwat W, Thanantaseth C, Ayudhya NI, et al. Oral etoricoxib for pain relief during fractional curettage: a randomized controlled trial. J Med Assoc Thai. 2007 Jun;90(6):1053–7. X-5, X-9. [PubMed: 17624196]

1185.

Phittayawechwiwat W, Thanantaseth C, Ayudhya NIN, et al. Oral etoricoxib for pain relief during fractional curettage: A ramdomized controlled trial. Journal of the Medical Association of Thailand. 2007;90(6):1053–7. X-5, X-8. [PubMed: 17624196]

1186.

Phupong V, Sophonsritsuk A, Taneepanichskul S. The effect of tranexamic acid for treatment of irregular uterine bleeding secondary to Norplant use. Contraception. 2006 Mar;73(3):253–6. X-5, X-6, X-9. [PubMed: 16472565]

1187.

Piaggio G, Pinol AP. Use of the equivalence approach in reproductive health clinical trials. Statistics in medicine. 2001;20(23):3571–7. X-1, X-3, X-5. [PubMed: 11746338]

1188.

Pickar JH, Bottiglioni F, Archer DF. Amenorrhea frequency with continuous combined hormone replacement therapy: a retrospective analysis. Menopause Study Group. Climacteric. 1998 Jun;1(2):130–6. X-4, X-5, X-7. [PubMed: 11913408]

1189.

Pillai M, O'Brien K, Hill E. The levonorgestrel intrauterine system (Mirena) for the treatment of menstrual problems in adolescents with medical disorders, or physical or learning disabilities. BJOG. 2010 Jan;117(2):216–21. X-4. [PubMed: 19874296]

1190.

Pinto AB, Binder EF, Kohrt WM, et al. Effects of trimonthly progestin administration on the endometrium in elderly postmenopausal women who receive hormone replacement therapy: a pilot study. Am J Obstet Gynecol. 2003 Jul;189(1):11–5. X-4, X-5, X-7. [PubMed: 12861131]

1191.

Pirke KM, Fichter MM, Chlond C, et al. Disturbances of the menstrual cycle in bulimia nervosa. Clin Endocrinol (Oxf). 1987 Aug;27(2):245–51. X-3, X-4, X-5. [PubMed: 3665132]

1192.

Pirke KM, Schweiger U, Broocks A, et al. Luteinizing hormone and follicle stimulating hormone secretion patterns in female athletes with and without menstrual disturbances. Clin Endocrinol (Oxf). 1990 Sep;33(3):345–53. X-3, X-4. [PubMed: 2123757]

1193.

Pirke KM, Schweiger U, Strowitzki T, et al. Dieting causes menstrual irregularities in normal weight young women through impairment of episodic luteinizing hormone secretion. Fertil Steril. 1989 Feb;51(2):263–8. X-3, X-4, X-5. [PubMed: 2912772]

1194.

Pisco JM, Bilhim T, Duarte M, et al. Management of uterine artery embolization for fibroids as an outpatient procedure. J Vasc Interv Radiol. 2009 Jun;20(6):730–5. X-4, X-5, X-6, X-8, X-9. [PubMed: 19339205]

1195.

Piya-Anant M, Koetsawang S, Patrasupapong N, et al. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea. Contraception. 1998 Jan;57(1):23–8. X-4, X-5, X-6, X-9. [PubMed: 9554247]

1196.

Place VA, Powers M, Darley PE, et al. A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms. Am J Obstet Gynecol. 1985 Aug 15;152(8):1092–9. X-7. [PubMed: 2992278]

1197.

Plewig G, Cunliffe WJ, Binder N, et al. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial. Contraception. 2009;80(1):25–33. X-5. [PubMed: 19501212]

1198.

Plotkin D, Miller S, Nakajima S, et al. Lowering low density lipoprotein cholesterol with simvastatin, a hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, does not affect luteal function in premenopausal women. Journal of Clinical Endocrinology and Metabolism. 2002;87(7):3155–61. X-4, X-5. [PubMed: 12107216]

1199.

Poindexter A, Reape KZ, Hait H. Efficacy and safety of a 28-day oral contraceptive with 7 days of low-dose estrogen in place of placebo. Contraception. 2008 Aug;78(2):113–9. X-4, X-5. [PubMed: 18672111]

1200.

Poindexter AN, Burkman R, Fisher AC, et al. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO. Int J Fertil Womens Med. 2003 Jul-Aug;48(4):163–72. X-4, X-5. [PubMed: 13677549]

1201.

Polednak AP, Janerich DT. Maternal factors in congenital limb-reduction defects. Teratology. 1985 Aug;32(1):41–50. X-3, X-5. [PubMed: 4035591]

1202.

Pornel B, Spielmann D. A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17beta-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a two-year period. Gynecol Endocrinol. 2005 Aug;21(2):74–81. X-5, X-7. [PubMed: 16294458]

1203.

Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. Journal of the National Cancer Institute. 2007;99(4):283–90. X-5. [PubMed: 17312305]

1204.

Prasad RN, Choolani M, Roy A, et al. Blood loss in termination of early pregnancy with mifepristone and gemeprost. Aust N Z J Obstet Gynaecol. 1995 Aug;35(3):329–31. X-3, X-5. [PubMed: 8546658]

1205.

Preuss HG, Bagchi D, Bagchi M, et al. Effects of a natural extract of (-)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX plus niacin-bound chromium and Gymnema sylvestre extract on weight loss. Diabetes. Obesity and Metabolism. 2004;6(3):171–80. X-5. [PubMed: 15056124]

1206.

Prezelj J, Kocijancic A, Andolsek L. Dexamethasone and spironolactone in the treatment of non-tumorous hyperandrogenism. Gynecol Endocrinol. 1989 Dec;3(4):281–8. X-3, X-4, X-5, X-6. [PubMed: 2516705]

1207.

Price TM, Dupuis RE, Carr BR, et al. Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis. Am J Obstet Gynecol. 1993 May;168(5):1400–6. X-3, X-4. [PubMed: 8498419]

1208.

Prince MI, Mitchison HC, Ashley D, et al. Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: Results of a multicentre, randomized, placebo-controlled, cross-over trial. Alimentary Pharmacology and Therapeutics. 2003;17(1):137–43. X-5. [PubMed: 12492743]

1209.

Prior J, Burdge D, Maan E, et al. Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int. 2007 Oct;18(10):1345–53. X-4, X-5, X-9. [PubMed: 17665239]

1210.

Prior JC, Vigna YM, Barr SI, et al. Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances. Am J Med. 1994 Jun;96(6):521–30. X-5, X-10. [PubMed: 8017450]

1211.

Prior MV, Phipps JH, Roberts T, et al. Treatment of menorrhagia by radiofrequency heating. Int J Hyperthermia. 1991 Mar-Apr;7(2):213–20. X-3, X-8. [PubMed: 1880453]

1212.

Pritts EA, Ryan IP, Mueller MD, et al. Angiogenic effects of norplant contraception on endometrial histology and uterine bleeding. J Clin Endocrinol Metab. 2005 Apr;90(4):2142–7. X-4, X-5. [PubMed: 15623808]

1213.

Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: Double-blind comparison in newly diagnosed epilepsy. Acta Neurologica Scandinavica. 2003;107(3):165–75. X-9. [PubMed: 12614309]

1214.

Privrel T, Daubenfeld O. Clinical experience in Switzerland with the new monophasic oral contraceptive Minulet (75 mcg gestodene, 30 mcg ethinyl oestradiol). Br J Clin Pract. 1988 Jul;42(7):292–8. X-3, X-9, X-10. [PubMed: 3075505]

1215.

Procter-Gray E, Cobb KL, Crawford SL, et al. Effect of oral contraceptives on weight and body composition in young female runners. Med Sci Sports Exerc. 2008 Jul;40(7):1205–12. X-5, X-9. [PubMed: 18580398]

1216.

Prollius A, de Vries C, Loggenberg E, et al. Uterine artery embolisation for symptomatic fibroids: the effect of the large uterus on outcome. BJOG. 2004 Mar;111(3):239–42. X-4, X-5, X-6, X-8. [PubMed: 14961885]

1217.

Pron G, Bennett J, Common A, et al. The Ontario Uterine Fibroid Embolization Trial. Part 2. Uterine fibroid reduction and symptom relief after uterine artery embolization for fibroids. Fertil Steril. 2003 Jan;79(1):120–7. X-4, X-5, X-6, X-8. [PubMed: 12524074]

1218.

Pron G, Cohen M, Soucie J, et al. The Ontario Uterine Fibroid Embolization Trial. Part 1. Baseline patient characteristics, fibroid burden, and impact on life. Fertil Steril. 2003 Jan;79(1):112–9. X-4, X-5, X-6, X-8. [PubMed: 12524073]

1219.

Protheroe J, Bower P, Chew-Graham C. The use of mixed methodology in evaluating complex interventions: identifying patient factors that moderate the effects of a decision aid. Fam Pract. 2007 Dec;24(6):594–600. X-5. [PubMed: 18039724]

1220.

Pulkkinen MO. Uterine activity and blood flow in response to sulprostone during midtrimester pregnancy termination. Arch Gynecol. 1981;231(1):57–9. X-5. [PubMed: 7332359]

1221.

Pulkkinen MO, Dusterberg B, Hasan H, et al. Norethisterone acetate and ethinylestradiol in early human pregnancy. Teratology. 1984 Apr;29(2):241–9. X-5, X-6. [PubMed: 6429876]

1222.

Pulle C, Sturlese E. Clinical trial comparing the activity and efficacy of ibuprofen isobutanolammonium vs Benzydamine hydrochloride, applied as vaginal irrigations, in patients with vaginitis. Clin Exp Obstet Gynecol. 2002;29(3):173–9. X-4, X-5, X-6, X-9. [PubMed: 12519036]

1223.

Purohit R, Sharma J. Cervical clamping following ultrasound-guided uterocervical packing to control postpartum uterine hemorrhage. Int J Gynaecol Obstet. 2010 May;109(2):160–1. X-5, X-8, X-9. [PubMed: 20176354]

1224.

Qi A, Yi T, Liu X, et al. Clinical observations on treatment of lupus nephritis with kidney-nourishing and toxin-removing method - A report of 60 cases. Journal of Traditional Chinese Medicine. 2006;26(4):269–74. X-5, X-6.

1225.

Qian HL, Wang HF, Yang ML. The expression of angiopoietin-1 and -2 in the endometrium of women with abnormal bleeding induced by an intra-uterine device. J Int Med Res. 2010 Jan-Feb;38(1):100–10. X-4, X-5, X-6. [PubMed: 20233519]

1226.

Quenby S, Farquharson RG. Human chorionic gonadotropin supplementation in recurring pregnancy loss: a controlled trial. Fertil Steril. 1994 Oct;62(4):708–10. X-5. [PubMed: 7646609]

1227.

Quereux C, Pornel B, Bergeron C, et al. Continuous combined hormone replacement therapy with 1 mg 17beta-oestradiol and 5 mg dydrogesterone (Femoston-conti): endometrial safety and bleeding profile. Maturitas. 2006 Feb 20;53(3):299–305. X-4, X-5, X-7. [PubMed: 16043317]

1228.

Querido L, Ketting E, Haspels AA. IUD insertion following induced abortion. Contraception. 1985 Jun;31(6):603–10. X-3, X-5, X-9. [PubMed: 3899506]

1229.

Quigg M, Smithson SD, Fowler KM, et al. Laterality and location influence catamenial seizure expression in women with partial epilepsy. Neurology. 2009 Jul 21;73(3):223–7. X-4, X-5, X-9. [PMC free article: PMC2715574] [PubMed: 19620611]

1230.

Qureshi NS, Edi-Osagie EC, Ogbo V, et al. First trimester threatened miscarriage treatment with human chorionic gonadotrophins: a randomised controlled trial. BJOG. 2005 Nov;112(11):1536–41. X-5, X-9. [PubMed: 16225575]

1231.

Rabe T, Mueck AO, Deuringer FU, et al. Spacing-out of progestin--efficacy, tolerability and compliance of two regimens for hormonal replacement in the late postmenopause. Gynecol Endocrinol. 1997 Dec;11(6):383–92. X-5, X-7, X-9. [PubMed: 9476087]

1232.

Rabe T, Runnebaum B, Kohlmeier M, et al. Clinical and metabolic effects of gestodene and levonorgestrel. International journal of fertility. 1987;32:29–44. X-9. [PubMed: 2906345]

1233.

Rachmiel M, Kives S, Atenafu E, et al. Primary amenorrhea as a manifestation of polycystic ovarian syndrome in adolescents: a unique subgroup? Arch Pediatr Adolesc Med. 2008 Jun;162(6):521–5. X-4, X-5, X-9. [PubMed: 18524741]

1234.

Radowicki S, Kunicki M. Prostate specific antigen in women with menstrual disturbances and fibrocystic mastopathy. J Endocrinol Invest. 2009 Nov;32(10):821–4. X-4, X-5, X-9. [PubMed: 19602918]

1235.

Radulovic N, Norstrom A, Ekerhovd E. Outpatient cervical ripening before first-trimester surgical abortion: a comparison between misoprostol and isosorbide mononitrate. Acta Obstet Gynecol Scand. 2007;86(3):344–8. X-5, X-9. [PubMed: 17364311]

1236.

Radwanska E, Headley SK, Dmowski P. Evaluation of ovarian function after tubal sterilization. J Reprod Med. 1982 Jul;27(7):376–84. X-3, X-4, X-5. [PubMed: 6811740]

1237.

Raffone E, Rizzo P, Benedetto V. Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol. 2010 Apr;26(4):275–80. X-5, X-9. [PubMed: 20222840]

1238.

Rafie S, Choy KA. Procedures to improve prescribing and dispensing of oral contraceptives at an academic medical center. Am J Health Syst Pharm. 2012 Feb 1;69(3):249–52. X-3, X-5. [PubMed: 22261948]

1239.

Ragni MV, Jankowitz RC, Jaworski K, et al. Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia. Thromb Haemost. 2011 Oct;106(4):641–5. X-3. [PMC free article: PMC3947632] [PubMed: 21833452]

1240.

Ragueneau-Majlessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia. 2002;43(7):697–702. X-4, X-9. [PubMed: 12102671]

1241.

Rai VS, Gillmer MD, Gray W. Is endometrial pre-treatment of value in improving the outcome of transcervical resection of the endometrium? Hum Reprod. 2000 Sep;15(9):1989–92. X-4, X-5, X-9. [PubMed: 10967001]

1242.

Raja A, Hashmi SN, Sultana N, et al. Presentation of polycystic ovary syndrome and its management with clomiphene alone and in combination with metformin. J Ayub Med Coll Abbottabad. 2005 Apr-Jun;17(2):50–3. X-4, X-5, X-9. [PubMed: 16092652]

1243.

Ramos R, Apelo R, Osteria T, et al. A comparative analysis of three different dose combinations of oral contraceptives. Contraception. 1989 Feb;39(2):165–77. X-9. [PubMed: 2495891]

1244.

Rasgon NL, Altshuler LL, Gudeman D, et al. Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. J Clin Psychiatry. 2000 Mar;61(3):173–8. X-4, X-5, X-6, X-9. [PubMed: 10817101]

1245.

Rasgon NL, Reynolds MF, Elman S, et al. Longitudinal evaluation of reproductive function in women treated for bipolar disorder. J Affect Disord. 2005 Dec;89(1-3):217–25. X-4, X-5, X-9. [PubMed: 16171873]

1246.

Rashidi B, Haghollahi F, Shariat M, et al. The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study. Taiwan J Obstet Gynecol. 2009 Jun;48(2):142–7. X-4, X-5, X-9. [PubMed: 19574176]

1247.

Rasuli P, Hammond I, Al-Mutairi B, et al. Spherical versus conventional polyvinyl alcohol particles for uterine artery embolization. J Vasc Interv Radiol. 2008 Jan;19(1):42–6. X-5, X-8, X-9. [PubMed: 18192466]

1248.

Rath W, Meyer D, Hildebrandt J, et al. Comparative study of various intracervically administered PG gel preparations for termination of first trimester pregnancies. Contraception. 1983 Sep;28(3):209–22. X-5. [PubMed: 6357631]

1249.

Rattanachaiyanont M, Angsuwathana S, Techatrisak K, et al. Clinical and pathological responses of progestin therapy for non-atypical endometrial hyperplasia: a prospective study. J Obstet Gynaecol Res. 2005 Apr;31(2):98–106. X-4. [PubMed: 15771634]

1250.

Rattanachaiyanont M, Leerasiri P, Indhavivadhana S. Effectiveness of intrauterine anesthesia for pain relief during fractional curettage. Obstet Gynecol. 2005 Sep;106(3):533–9. X-5, X-9. [PubMed: 16135583]

1251.

Raudaskoski T, Tapanainen J, Tomas E, et al. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG. 2002 Feb;109(2):136–44. X-5, X-7. [PubMed: 11888095]

1252.

Raudaskoski TH, Lahti EI, Kauppila AJ, et al. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol. 1995 Jan;172(1 Pt 1):114–9. X-7. [PubMed: 7847516]

1253.

Rauramo I, Elo I, Istre O. Long-term treatment of menorrhagia with levonorgestrel intrauterine system versus endometrial resection. Obstet Gynecol. 2004 Dec;104(6):1314–21. X-8. [PubMed: 15572496]

1254.

Raynaud JP, Levrier M, Calaf J, et al. Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch 40 and Estrapatch 60) with a twice week system. J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):309–18. X-5, X-7. [PubMed: 15860275]

1255.

Razavi MK, Hwang G, Jahed A, et al. Abdominal myomectomy versus uterine fibroid embolization in the treatment of symptomatic uterine leiomyomas. AJR Am J Roentgenol. 2003 Jun;180(6):1571–5. X-4, X-5, X-6, X-8. [PubMed: 12760922]

1256.

Razzi S, Luisi S, Ferretti C, et al. Use of a progestogen only preparation containing desogestrel in the treatment of recurrent pelvic pain after conservative surgery for endometriosis. Eur J Obstet Gynecol Reprod Biol. 2007 Dec;135(2):188–90. X-5, X-9. [PubMed: 16963174]

1257.

Rebar RW, Trabal J, Mortola J. Low-dose esterified estrogens (0.3 mg/day): long-term and short-term effects on menopausal symptoms and quality of life in postmenopausal women. Climacteric. 2000 Sep;3(3):176–82. X-5, X-7. [PubMed: 11910619]

1258.

Recio R, Hernandez-Morales C, Perez-Rodriguez RM, et al. Effects of low steroid doses administered in the mid and late follicular phase on the LH surge, ovarian steroids and follicular maturation in eumenorrheic women. Adv Contracept. 1997 Mar;13(1):39–46. X-3, X-4. [PubMed: 9181183]

1259.

Rees MC, Kuhl H, Engelstein M, et al. Endometrial safety and tolerability of triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate therapy regimen. Climacteric. 2004 Mar;7(1):23–32. X-5, X-7. [PubMed: 15259280]

1260.

Reid RL, Fortier MP, Smith L, et al. Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada. Contraception. 2010 Dec;82(6):497–502. X-4, X-5, X-9. [PubMed: 21074011]

1261.

Reig E. Tramadol in musculoskeletal pin - A survey. Clinical Rheumatology. 2002;21(1 SUPPL):S9–S12. X-1, X-3, X-5. [PubMed: 11954901]

1262.

Reinders DM, Baldwin SA, Bert JL. Endometrial thermal balloon ablation using a high temperature, pulsed system: a mathematical model. J Biomech Eng. 2003 Dec;125(6):841–51. X-4, X-5, X-8, X-9. [PubMed: 14986409]

1263.

Reinprayoon D, Gilmore C, Farr G, et al. Twelve-month comparative multicenter study of the TCu 380A and ML 250 intrauterine devices in Bangkok, Thailand. Contraception. 1998 Oct;58(4):201–6. X-3, X-9. [PubMed: 9865999]

1264.

Reisman H, Martin D, Gast MJ. A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 mug levonorgestrel with 20 mug ethinyl estradiol or triphasic norethindrone with ethinyl estradiol. American Journal of Obstetrics and Gynecology. 1999;181(5 II):S45–S52. X-6, X-9. [PubMed: 10561675]

1265.

Rekers H. Multicenter trial of a monophasic oral contraceptive containing ethinyl estradiol and desogestrel. Acta Obstet Gynecol Scand. 1988;67(2):171–4. X-3, X-9. [PubMed: 2972160]

1266.

Reslova T, Tosner J, Resl M, et al. Endometrial polyps. A clinical study of 245 cases. Arch Gynecol Obstet. 1999;262(3-4):133–9. X-4, X-5, X-6, X-7. [PubMed: 10326632]

1267.

Rice C, Killick S, Hickling D, et al. Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses. Hum Reprod. 1996 Apr;11(4):737–40. X-9. [PubMed: 8671319]

1268.

Rich AD, Manyonda IT, Patel R, et al. A comparison of the efficacy of danazol, norethisterone, cyproterone acetate and medroxyprogesterone acetate in endometrial thinning prior to ablation: A pilot study. Gynaecological Endoscopy. 1995;4(1):59–61. X-3, X-5, X-6.

1269.

Richter HE, Learman LA, Lin F, et al. Medroxyprogesterone acetate treatment of abnormal uterine bleeding: factors predicting satisfaction. Am J Obstet Gynecol. 2003 Jul;189(1):37–42. X-3. [PubMed: 12861135]

1270.

Richtig E, Soyer HP, Posch M, et al. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European cooperative adjuvant melanoma treatment study group. Journal of Clinical Oncology. 2007;23(34):8655–63. X-5. [PubMed: 16260701]

1271.

Rickenlund A, Thoren M, Nybacka A, et al. Effects of oral contraceptives on diurnal profiles of insulin, insulin-like growth factor binding protein-1, growth hormone and cortisol in endurance athletes with menstrual disturbance. Hum Reprod. 2010 Jan;25(1):85–93. X-4, X-5. [PMC free article: PMC2794666] [PubMed: 19840988]

1272.

Rigaud AS, Andre G, Vellas B, et al. No additional benefit of HRT on response to rivastigmine in menopausal women with AD. Neurology. 2003;60(1):148–50. X-3, X-5, X-7. [PubMed: 12525745]

1273.

Rivera R, Chen-Mok M, McMullen S. Analysis of client characteristics that may affect early discontinuation of the TCu-380A IUD. Contraception. 1999 Sep;60(3):155–60. X-4, X-5, X-6, X-9. [PubMed: 10640159]

1274.

Rizk DE. Subdermal levonorgestrel implants. Three years' experience in Cairo, Egypt. J Reprod Med. 1995 Sep;40(9):638–44. X-3, X-9. [PubMed: 8576880]

1275.

Roberts TE, Tsourapas A, Middleton LJ, et al. Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine system (Mirena) for treatment of heavy menstrual bleeding: cost effectiveness analysis. BMJ: British Medical Journal (Overseas & Retired Doctors Edition). 2011;342(7805):1012. X-1, X-3, X-5, X-8. [PMC free article: PMC3082380] [PubMed: 21521730]

1276.

Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost. 1996 Nov;76(5):692–6. X-4, X-5, X-6, X-9. [PubMed: 8950775]

1277.

Rogers PA. Endometrial vasculature in Norplant users. Hum Reprod. 1996 Oct;11 Suppl 2:45–50. X-4, X-5, X-6. [PubMed: 8982745]

1278.

Rogers PA, Lederman F, Plunkett D, et al. Bcl-2, Fas and caspase 3 expression in endometrium from levonorgestrel implant users with and without breakthrough bleeding. Hum Reprod. 2000 Aug;15 Suppl 3:152–61. X-4, X-5. [PubMed: 11041231]

1279.

Rogers PA, Martinez F, Girling JE, et al. Influence of different hormonal regimens on endometrial microvascular density and VEGF expression in women suffering from breakthrough bleeding. Hum Reprod. 2005 Dec;20(12):3341–7. X-4, X-5, X-6, X-9. [PubMed: 16085661]

1280.

Rogers PA, Plunkett D, Affandi B. Perivascular smooth muscle alpha-actin is reduced in the endometrium of women with progestin-only contraceptive breakthrough bleeding. Hum Reprod. 2000 Aug;15 Suppl 3:78–84. X-4, X-5. [PubMed: 11041224]

1281.

Rogerson L, Duffy S, Crocombe W, et al. Management of menorrhagia--SMART study (Satisfaction with Mirena and Ablation: a Randomised Trial). BJOG. 2000 Oct;107(10):1325–6. X1, X-3, X-5, X-6, X-8. [PubMed: 11028596]

1282.

Rogerson L, Hawe J, Duffy S. Modern approaches to management of menorrhagia. Hospital medicine. 1998;61(2):90–2. X-1, X-3, X-5, X-10. [PubMed: 10748784]

1283.

Rojanasakul A, Sirimongkolkasem R, Piromsawasdi S, et al. Effects of combined ethinylestradiol and desogestrel on hormone profiles and sex hormone binding globulin in women with polycystic ovarian disease. Contraception. 1987 Dec;36(6):633–40. X-3. [PubMed: 2965636]

1284.

Rolnick SJ, Flores SK, Fowler SE, et al. Conducting randomized, controlled trials. Experience with the dysfunctional uterine bleeding intervention trial. J Reprod Med. 2001 Jan;46(1):1–5. discussion -6. X-8. [PubMed: 11209624]

1285.

Romer T. Prospective comparison study of levonorgestrel IUD versus Roller-Ball endometrial ablation in the management of refractory recurrent hypermenorrhea. Eur J Obstet Gynecol Reprod Biol. 2000 May;90(1):27–9. X-5, X-8. [PubMed: 10767506]

1286.

Romer T, Muller J. A simple method of coagulating endometrium in patients with therapy-resistant, recurring hypermenorrhea. J Am Assoc Gynecol Laparosc. 1999 Aug;6(3):265–8. X-4, X-5, X-8. [PubMed: 10459024]

1287.

Romer T, Schwesinger G. Hormonal inhibition of endometrium for transcervical endometrial ablation--a prospective study with a 2-year follow-up. Eur J Obstet Gynecol Reprod Biol. 1997 Aug;74(2):201–3. X-4, X-5, X-8, X-9. [PubMed: 9306119]

1288.

Ronkin S, Northington R, Baracat E, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstetrics and Gynecology. 2005;105(6):1397–404. X-7. [PubMed: 15932835]

1289.

Ronnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand. 1999 Sep;78(8):716–21. X-4, X-5, X-6. [PubMed: 10468065]

1290.

Ronnerdag M, Odlind V. Late bleeding problems with the levonorgestrel-releasing intrauterine system: evaluation of the endometrial cavity. Contraception. 2007 Apr;75(4):268–70. X-4, X-5, X-9. [PubMed: 17362704]

1291.

Rorarius MG, Suominen P, Baer GA, et al. Diclofenac and ketoprofen for pain treatment after elective caesarean section. Br J Anaesth. 1993 Mar;70(3):293–7. X-5. [PubMed: 8471372]

1292.

Rosen DM, Peek MJ. Do women with placenta praevia without antepartum haemorrhage require hospitalization? Aust N Z J Obstet Gynaecol. 1994 May;34(2):130–4. X-3, X-5. [PubMed: 7980298]

1293.

Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception. 1999 Dec;60(6):321–9. X-5. [PubMed: 10715366]

1294.

Rosenberg MJ, Waugh MS, Higgins JE. The effect of desogestrel, gestodene, and other factors on spotting and bleeding. Contraception. 1996 Feb;53(2):85–90. X-9. [PubMed: 8838484]

1295.

Rosenberg MJ, Waugh MS, Stevens CM. Smoking and cycle control among oral contraceptive users. Am J Obstet Gynecol. 1996 Feb;174(2):628–32. X-3, X-5, X-9. [PubMed: 8623797]

1296.

Rosencrantz MA, Coffler MS, Haggan A, et al. Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2011 Apr;96(4):1106–13. X-4, X-5, X-9. [PMC free article: PMC3070255] [PubMed: 21270326]

1297.

Rosetta L, Harrison GA, Read GF. Ovarian impairments of female recreational distance runners during a season of training. Ann Hum Biol. 1998 Jul-Aug;25(4):345–57. X-4, X-5, X-9. [PubMed: 9667360]

1298.

Ross AH, Boyd ME, Colgan TJ, et al. Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: effects on bleeding patterns and endometrial histology. Obstet Gynecol. 1993 Nov;82(5):773–9. X-5, X-6, X-7. [PubMed: 8414325]

1299.

Ross D, Cooper AJ, Pryse-Davies J, et al. Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women. Am J Obstet Gynecol. 1997 Oct;177(4):937–41. X-5, X-7. [PubMed: 9369848]

1300.

Roux C, Pelissier C, Fechtenbaum J, et al. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporos Int. 2002 Mar;13(3):241–8. X-5, X-7. [PubMed: 11991445]

1301.

Roy S, Mishell DR Jr., Robertson DN, et al. Long-term reversible contraception with levonorgestrel-releasing Silastic rods. Am J Obstet Gynecol. 1984 Apr 1;148(7):1006–13. X-4, X-5, X-9. [PubMed: 6424474]

1302.

Roy S, Shaw ST Jr. Role of prostaglandins in IUD-associated uterine bleeding--effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstet Gynecol. 1981 Jul;58(1):101–6. X-5, X-6. [PubMed: 7243136]

1303.

Rozenberg S, Caubel P, Lim PC. Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms. Int J Gynaecol Obstet. 2001 Mar;72(3):235–43. X-4, X-5, X-7. [PubMed: 11226444]

1304.

Rozenberg S, Ylikorkala O, Arrenbrecht S. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids. Int J Fertil Womens Med. 1997;42 Suppl 2:376–87. X-4, X-5, X-7. [PubMed: 9397385]

1305.

Rubinacci A, Peruzzi E, Modena AB, et al. Effect of low-dose transdermal E<sub>2</sub</NETA on the reduction of postmenopausal bone loss in women. Menopause. 2003;10(3):241–9. X-7. [PubMed: 12792297]

1306.

Rubinacci A, Peruzzi E, Modena AB, et al. Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women. Menopause. 2003 May/June;10(3):241–9. X-7. [PubMed: 12792297]

1307.

Rulin MC, Turner JH, Dunworth R, et al. Post-tubal sterilization syndrome--a misnomer. Am J Obstet Gynecol. 1985 Jan 1;151(1):13–9. X-3, X-5, X-6. [PubMed: 3966496]

1308.

Ruminjo JK, Sekadde-Kigondu CB, Karanja JG, et al. Comparative acceptability of combined and progestin-only injectable contraceptives in Kenya. Contraception. 2005 Aug;72(2):138–45. X-5. [PubMed: 16022854]

1309.

Runic R, Schatz F, Krey L, et al. Alterations in endometrial stromal cell tissue factor protein and messenger ribonucleic acid expression in patients experiencing abnormal uterine bleeding while using Norplant-2 contraception. J Clin Endocrinol Metab. 1997 Jun;82(6):1983–8. X-4, X-5, X-6. [PubMed: 9177417]

1310.

Runic R, Schatz F, Wan L, et al. Effects of norplant on endometrial tissue factor expression and blood vessel structure. J Clin Endocrinol Metab. 2000 Oct;85(10):3853–9. X-4, X-5, X-6, X-9. [PubMed: 11061549]

1311.

Rutanen E, Hurskainen R, Finne P, et al. Induction of endometrial plasminogen activator-inhibitor 1: a possible mechanism contributing to the effect of intrauterine levonorgestrel in the treatment of menorrhagia. Fertil Steril. 2000 May;73(5):1020–4. X-4, X-5, X-8. [PubMed: 10785231]

1312.

Ruuskanen A, Hippelainen M, Sipola P, et al. Uterine artery embolisation versus hysterectomy for leiomyomas: primary and 2-year follow-up results of a randomised prospective clinical trial. Eur Radiol. 2010 Oct;20(10):2524–32. X-5, X-8. [PubMed: 20526776]

1313.

Rybo G, Nilsson S, Sikstrom B, et al. Naproxen in menorrhagia. Lancet. 1981 Mar 14;1(8220 Pt 1):608–9. X-1, X-3. [PubMed: 6110836]

1314.

Saarikoski S, Yliskoski M, Penttila I. Sequential use of norethisterone and natural progesterone in pre-menopausal bleeding disorders. Maturitas. 1990 Jun;12(2):89–97. X-4, X-6. [PubMed: 2255266]

1315.

Saav I, Aronsson A, Marions L, et al. Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: A randomized controlled trial. Human Reproduction. 2007;22(10):2647–52. X-5. [PubMed: 17652452]

1316.

Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception. 2006 Sep;74(3):220–3. X-5, X-9. [PubMed: 16904415]

1317.

Sabatini R, Orsini G, Cagiano R, et al. Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents. Contraception. 2007;76(5):342–7. X-3, X-5, X-9. [PubMed: 17963857]

1318.

Sadan O, Frohlich EP, Driscoll JA, et al. Is it safe to prescribe hormonal contraception and replacement therapy to patients with premalignant and malignant uterine cervices? Gynecol Oncol. 1989 Aug;34(2):159–63. X-3, X-4, X-5. [PubMed: 2753422]

1319.

Sadan O, Ginath S, Sofer D, et al. The role of tamoxifen in the treatment of symptomatic uterine leiomyomata -- a pilot study. Eur J Obstet Gynecol Reprod Biol. 2001 Jun;96(2):183–6. X-5, X-6. [PubMed: 11384804]

1320.

Sahota J, Barnes PMF, Mansfield E, et al. Initial UK experience of the levonorgestrel-releasing contraceptive intravaginal ring. Advances in Contraception. 1999;15(4):313–24. X-3, X-9. [PubMed: 11145373]

1321.

Sahota P, Prabhakar S, Kharbanda PS, et al. Seizure type, antiepileptic drugs, and reproductive endocrine dysfunction in Indian women with epilepsy: a cross-sectional study. Epilepsia. 2008 Dec;49(12):2069–77. X-4, X-5, X-9. [PubMed: 18503558]

1322.

Said S, Omar K, Koetsawang S. A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: I. Contraceptive efficacy and side effects. Contraception. 1986;34(3):223–35. X-9. [PubMed: 2947777]

1323.

Said S, Omar K, Koetsawang S, et al. A multicentered phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: II The comparison of bleeding patterns. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction. Contraception. 1987 Jun;35(6):591–610. X-6, X-9. [PubMed: 2959448]

1324.

Said S, Sadek W, Kholeif A, et al. A multicentred phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection. II. The comparison of bleeding patterns. Contraception. 1989;40(5):531–51. X-5. [PubMed: 2692962]

1325.

Said S, Sadek W, Rocca M, et al. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation. Hum Reprod. 1996 Oct;11 Suppl 2:1–13. X-4, X-5, X-6. [PubMed: 8982739]

1326.

Sakamoto S, Yoshino H, Shirahata Y, et al. Pharmacotherapeutic effects of kuei-chih-fu-ling-wan (keishi-bukuryo-gan) on human uterine myomas. Am J Chin Med. 1992;20(3-4):313–7. X-3, X-6. [PubMed: 1471615]

1327.

Saleh WA, Burkman RT, Zacur HA, et al. A randomized trial of three oral contraceptives: comparison of bleeding patterns by contraceptive types and steroid levels. Am J Obstet Gynecol. 1993 Jun;168(6 Pt 1):1740–5. discussion 5-7. X-4, X-6, X-9, X-10. [PubMed: 8317516]

1328.

Salem HT, Salah M, Aly MY, et al. Acceptability of injectable contraceptives in Assiut, Egypt. Contraception. 1988 Dec;38(6):697–710. X-6, X-9, X-10. [PubMed: 2975583]

1329.

Salim R, Lee C, Davies A, et al. A comparative study of three-dimensional saline infusion sonohysterography and diagnostic hysteroscopy for the classification of submucous fibroids. Hum Reprod. 2005 Jan;20(1):253–7. X-4, X-5, X-6. [PubMed: 15498782]

1330.

Samsioe G, Boschitsch E, Concin H, et al. Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: A randomized open-label study. Climacteric. 2006;9(5):368–79. X-7. [PubMed: 17080587]

1331.

Samsioe G, Dvorak V, Genazzani AR, et al. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women. Maturitas. 2007;57(2):171–81. X-7. [PubMed: 17317046]

1332.

Samsioe G, Hruska J. Optimal tolerability of ultra-low-dose continuous combined 17beta-estradiol and norethisterone acetate: laboratory and safety results. Climacteric. 2010 Feb;13(1):34–44. X-4, X-5, X-7. [PubMed: 20001563]

1333.

Sanada M, Higashi Y, Nakagawa K, et al. A comparison of low-dose and standard-dose oral estrogen on forearm endothelial function in early postmenopausal women. J Clin Endocrinol Metab. 2003 Mar;88(3):1303–9. X-4, X-5, X-7. [PubMed: 12629123]

1334.

Sandstrom O, Brooks L, Schantz A, et al. Interruption of early pregnancy with mifepristone in combination with gemeprost. Acta Obstet Gynecol Scand. 1999 Oct;78(9):806–9. X-5, X-8, X-9. [PubMed: 10535346]

1335.

Sang GW, Shao QX, Ge RS, et al. A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given by intramuscular injection to Chinese women. II. The comparison of bleeding patterns. Contraception. 1995 Mar;51(3):185–92. X-6, X-9. [PubMed: 7621686]

1336.

Sang GW, Shao QX, Ge RS, et al. A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given monthly by intramuscular injection to Chinese women. I. Contraceptive efficacy and sid effects. Contraception. 1995 Mar;51(3):167–83. X-9. [PubMed: 7621685]

1337.

Sang GW, Weng LJ, Shao QX, et al. Termination of early pregnancy by two regimens of mifepristone with misoprostol and mifepristone with PG05--a multicentre randomized clinical trial in China. Contraception. 1994 Dec;50(6):501–10. X-5. [PubMed: 7705093]

1338.

Santagostino E, Mancuso ME, Morfini M, et al. Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy. Haematologica. 2006 May;91(5):634–9. X-4, X-5, X-9. [PubMed: 16670069]

1339.

Sapire KE. A study of bleeding patterns with two injectable contraceptives given postpartum and the effect of two non-hormonal treatments. Adv Contracept. 1991 Dec;7(4):379–87. X-3, X-5, X-10. [PubMed: 1837974]

1340.

Saracoglu OF, Aksel S, Yeoman RR, et al. Endometrial estradiol and progesterone receptors in patients with luteal phase defects and endometriosis. Fertil Steril. 1985 Jun;43(6):851–5. X-3, X-4. [PubMed: 3996629]

1341.

Sathanandan M, Macnamee MC, Rainsbury P, et al. Replacement of frozen-thawed embryos in artificial and natural cycles: a prospective semi-randomized study. Hum Reprod. 1991 May;6(5):685–7. X-5. [PubMed: 1939549]

1342.

Saure A, Hirvonen E, Milsom I, et al. A randomized, double-blind, multicentre study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms. Maturitas. 1996 May;24(1-2):111–8. X-5, X-7, X-9. [PubMed: 8794442]

1343.

Saure A, Planellas J, Poulsen HK, et al. A double-blind, randomized, comparative study evaluating clinical effects of two sequential estradiol-progestogen combinations containing either desogestrel or medroxyprogesterone acetate in climacteric women. Maturitas. 2000 Feb 15;34(2):133–42. X-5, X-6, X-7. [PubMed: 10714908]

1344.

Savabi-Esfahany M, Fadaei S, Yousefy A. Use of combined oral contraceptives: retrospective study in Isfahan, Islamic Republic of Iran. East Mediterr Health J. 2006 May-Jul;12(3-4):417–22. X-4, X-5, X-9. [PubMed: 17037711]

1345.

Sayed GH, Zakherah MS, El-Nashar SA, et al. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int J Gynaecol Obstet. 2011 Feb;112(2):126–30. X-5, X-6. [PubMed: 21092958]

1346.

Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute. 2007;99(16):1232–9. X-1, X-3, X-5. [PubMed: 17686822]

1347.

Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception. 2002 Oct;66(4):247–50. X-5, X-9. [PubMed: 12413620]

1348.

Schaison G. Emergency contragestion. Contraception. 1987;36(Suppl):7–11. X-6. [PubMed: 2445524]

1349.

Schaison G, George M, Lestrat N, et al. Effects of the antiprogesterone steroid RU 486 during midluteal phase in normal women. J Clin Endocrinol Metab. 1985 Sep;61(3):484–9. X-3, X-5, X-9. [PubMed: 2991322]

1350.

Schatz F, Kuczynski E, Kloosterboer HJ, et al. Tibolone and its metabolites enhance tissue factor and PAI-1 expression in human endometrial stromal cells: Evidence of progestogenic effects. Steroids. 2005 Nov;70(12):840–5. X-4, X-5, X-7. [PubMed: 16011840]

1351.

Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril. 2006 Feb;85(2):314–25. X-5, X-9. [PubMed: 16595206]

1352.

Schmidt-Gollwitzer M, Hardt W, Schmidt-Gollwitzer K, et al. Influence of the LH-RH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control? Contraception. 1981 Feb;23(2):187–95. X-3, X-5. [PubMed: 6786826]

1353.

Schnabel P, Merki-Feld GS, Malvy A, et al. Bioequivalence and X-ray visibility of a radiopaque etonogestrel implant versus a non-radiopaque implant: A 3-year, randomized, double-blind study. Clinical Drug Investigation. 2012;32(6):413–22. X-4, X-5, X-9. [PubMed: 22540269]

1354.

Schorn MN. The effect of guided imagery on the third stage of labor: a pilot study. J Altern Complement Med. 2009 Aug;15(8):863–70. X-4, X-5, X-9. [PubMed: 19678776]

1355.

Schroeder B, Hertweck SP, Sanfilippo JS, et al. Correlation between glycemic control and menstruation in diabetic adolescents. J Reprod Med. 2000 Jan;45(1):1–5. X-4, X-5, X-6, X-9. [PubMed: 10664939]

1356.

Schulman S, Kinnman N, Lindmarker P, et al. A randomized study of alpha-interferon plus ribavirin for 6 months or 12 months for the treatment of chronic hepatitis C in patients with bleeding disorders. Haemophilia. 2002;8(2):129–35. X-5, X-6. [PubMed: 11952848]

1357.

Schulz KD, Schmidt-Rhode P, Weymar P, et al. The influence of a polychemotherapeutic regimen on the female endocrine control mechanisms in mammary carcinoma patients. Recent Results Cancer Res. 1980;71:162–8. X-5. [PubMed: 7367730]

1358.

Schwartz JI, Agrawal NGB, Hartford AH, et al. The effect of etoricoxib on the pharmacodynamics and pharmacokinetics of warfarin. Journal of Clinical Pharmacology. 2007;47(5):620–7. X-4, X-5. [PubMed: 17442687]

1359.

Schwartz JI, Liu F, Wang YH, et al. Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women. American Journal of Therapeutics. 2009;16(6):487–95. X-4. [PubMed: 19940609]

1360.

Schweiger U, Laessle R, Pfister H, et al. Diet-induced menstrual irregularities: effects of age and weight loss. Fertil Steril. 1987 Nov;48(5):746–51. X-3, X-4, X-5. [PubMed: 3117591]

1361.

Scialli AR, Jestila KJ. Sustained benefits of leuprolide acetate with or without subsequent medroxyprogesterone acetate in the nonsurgical management of leiomyomata uteri. Fertil Steril. 1995 Aug;64(2):313–20. X-5, X-6. [PubMed: 7615109]

1362.

Sculpher MJ, Dwyer N, Browning J, et al. A survey of women's preferences regarding alternative surgical treatments for menorrhagia. Health Expectations. 1998;1(2):96–105. X-3, X-5, X-8. [PMC free article: PMC5139895] [PubMed: 11281864]

1363.

Segal SJ, Alvarez-Sanchez F, Brache V, et al. Norplant implants: the mechanism of contraceptive action. Fertil Steril. 1991 Aug;56(2):273–7. X-3, X-4, X-5, X-9. [PubMed: 1906407]

1364.

Seibold JR, Korn JH, Simms R, et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000 Jun 6;132(11):871–9. X-5, X-6, X-9. [PubMed: 10836913]

1365.

Sekhavat L, Tabatabaii A, Dalili M, et al. Efficacy of tranexamic acid in reducing blood loss after cesarean section. J Matern Fetal Neonatal Med. 2009 Jan;22(1):72–5. X-5, X-9. [PubMed: 19165682]

1366.

Sena-Martins M, Roteli-Martins CM, Tadini V, et al. Uterine artery embolization for the treatment of symptomatic myomas in Brazilian women. Sao Paulo Med J. 2003 Sep 1;121(5):185–90. X-4, X-5, X-6, X-8. [PubMed: 14666289]

1367.

Sendag F, Terek MC, Karadadas N. Sequential combined transdermal and oral postmenopausal hormone replacement therapies: effects on bleeding patterns and endometrial histology. Arch Gynecol Obstet. 2001 Nov;265(4):209–13. X-5, X-7. [PubMed: 11789748]

1368.

Senthong AJ, Taneepanichskul S. The effect of tranexamic acid for treatment irregular uterine bleeding secondary to DMPA use. J Med Assoc Thai. 2009 Apr;92(4):461–5. X-6. [PubMed: 19374294]

1369.

Serden SP, Brooks PG. Treatment of abnormal uterine bleeding with the gynecologic resectoscope. J Reprod Med. 1991 Oct;36(10):697–9. X-3, X-8. [PubMed: 1835500]

1370.

Serfaty D, Vree ML. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene. Eur J Contracept Reprod Health Care. 1998 Dec;3(4):179–89. X-6, X-9. [PubMed: 10036600]

1371.

Serra GB, Panetta V, Colosimo M, et al. Efficacy of leuprorelin acetate depot in symptomatic fibromatous uteri: the Italian Multicentre Trial. Clin Ther. 1992;14 Suppl A:57–73. X-3, X-6. [PubMed: 1606594]

1372.

Serup J, Bostofte E, Larsen S, et al. Effectivity and acceptability of oral contraceptives containing natural and artificial estrogens in combination with a gestagen. A controlled double-blind investigation. Acta Obstet Gynecol Scand. 1981;60(2):203–6. X-6, X-9. [PubMed: 7018165]

1373.

Shaaban MM, Segal S, Salem HT, et al. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels. Fertil Steril. 1993 May;59(5):998–1002. X-3, X-4, X-5, X-9. [PubMed: 8486202]

1374.

Shaamash AH, Zakhari MM. Increased serum levels of nitric oxide metabolites among users of levonorgestrel-releasing implants [corrected] a possible role in progestin-induced bleeding. Hum Reprod. 2005 Jan;20(1):302–6. X-4, X-5, X-9. [PubMed: 15471931]

1375.

Shabanova SS, Ananieva LP, Alekberova ZS, et al. Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2008 May-Jun;26(3):436–41. X-4, X-5, X-9. [PubMed: 18578965]

1376.

Shade AR. Gynecologic and obstetric problems of the female dancer. Clin Sports Med. 1983 Nov;2(3):515–23. X-1, X-3, X-5. [PubMed: 6686087]

1377.

Shamonki MI, Ziegler WF, Badger GJ, et al. Prediction of endometrial ablation success according to perioperative findings. Am J Obstet Gynecol. 2000 May;182(5):1005–7. X-4, X-5, X-8. [PubMed: 10819809]

1378.

Shangold MM, Tomai TP, Cook JD, et al. Factors associated with withdrawal bleeding after administration of oral micronized progesterone in women with secondary amenorrhea. Fertil Steril. 1991 Dec;56(6):1040–7. X-4, X-5, X-6, X-10. [PubMed: 1743319]

1379.

Shannon C, Wiebe E, Jacot F, et al. Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial. BJOG. 2006 Jun;113(6):621–8. X-5, X-9. [PubMed: 16709204]

1380.

Shapley M, Jordan K, Croft PR. Why women consult with increased vaginal bleeding: a case-control study. Br J Gen Pract. 2002 Feb;52(475):108–13. X-4, X-5, X-9. [PMC free article: PMC1314217] [PubMed: 11885820]

1381.

Shapley M, Jordan K, Croft PR. Increased vaginal bleeding: the reasons women give for consulting primary care. J Obstet Gynaecol. 2003 Jan;23(1):48–50. X-4, X-5, X-9. [PubMed: 12623484]

1382.

Shapley M, Jordan K, Croft PR. An investigation in primary care of the relationship between consultation behaviour, increased vaginal bleeding and mental disorder. J Obstet Gynaecol. 2004 Sep;24(6):684–6. X-4, X-5, X-9. [PubMed: 16147612]

1383.

Sharma D, Dahiya K, Dora A, et al. Effect of rosiglitazone in spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Journal of Gynecologic Surgery. 2006;22(4):151–6. X-5.

1384.

Sharma JB, Aruna J, Kumar P, et al. Comparison of efficacy of oral drotaverine plus mefenamic acid with paracervical block and with intravenous sedation for pain relief during hysteroscopy and endometrial biopsy. Indian J Med Sci. 2009 Jun;63(6):244–52. X-5, X-8, X-9. [PubMed: 19602758]

1385.

Shaw RW, Fraser HM. Use of a superactive luteinizing hormone releasing hormone (LHRH) agonist in the treatment of menorrhagia. Br J Obstet Gynaecol. 1984 Sep;91(9):913–6. X-3. [PubMed: 6433966]

1386.

Shaw RW, Symonds IM, Tamizian O, et al. Randomised comparative trial of thermal balloon ablation and levonorgestrel intrauterine system in patients with idiopathic menorrhagia. Aust N Z J Obstet Gynaecol. 2007 Aug;47(4):335–40. X-8. [PubMed: 17627692]

1387.

Shaw ST Jr., Macaulay LK, Sun NC, et al. Changes of plasminogen activator in human uterine tissue induced by intrauterine contraceptive devices. Contraception. 1983 Feb;27(2):131–40. X-9. [PubMed: 6682747]

1388.

Shawki O, Peters A, Abraham-Hebert S. Hysteroscopic endometrial destruction, optimum method for preoperative endometrial preparation: a prospective, randomized, multicenter evaluation. JSLS. 2002 Jan-Mar;6(1):23–7. X-5, X-8. [PMC free article: PMC3043405] [PubMed: 12002292]

1389.

Shearman RP. Oral contraceptives. Aust Fam Physician. 1984 Sep;13(9):685–91. X-1, X-3, X-5, X-10. [PubMed: 6508652]

1390.

Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol. 1981 Sep;68(3):181–7. X-3, X-5. [PubMed: 6790595]

1391.

Sheikh-El-Arab Elsedeek M, Elmaghraby HAH. Predictors and characteristics of letrozole induced ovulation in comparison with clomiphene induced ovulation in anovulatory PCOS women. Middle East Fertility Society Journal. 2011;16(2):125–30. X-5.

1392.

Sheppard BL, Bonnar J. The response of endometrial blood vessels to intrauterine contraceptive devices: an electron microscopic study. Br J Obstet Gynaecol. 1980 Feb;87(2):143–54. X-3, X-4. [PubMed: 7362802]

1393.

Sheth A, Jain U, Sharma S. A randomized, double-blind study of two combined and two progestogen-only oral contraceptives. Contraception. 1982;25(3):243–52. X-9. [PubMed: 6804162]

1394.

Shobeiri SF, Sharei S, Heidari A, et al. Portulaca oleracea L. in the treatment of patients with abnormal uterine bleeding: a pilot clinical trial. Phytother Res. 2009 Oct;23(10):1411–4. X-4. [PubMed: 19274703]

1395.

Shobokshi A, Shaarawy M. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. J Soc Gynecol Investig. 2003 Feb;10(2):99–104. X-4, X-5, X-9. [PubMed: 12593999]

1396.

Shokry M, Shahin AY, Fathalla MM, et al. Oral misoprostol reduces vaginal bleeding following surgical evacuation for first trimester spontaneous abortion. Int J Gynaecol Obstet. 2009 Nov;107(2):117–20. X-5, X-9. [PubMed: 19616778]

1397.

Shoupe D. Multicenter randomized comparative trial of two low-dose triphasic combined oral contraceptives containing desogestrel or norethindrone. Obstet Gynecol. 1994 May;83(5 Pt 1):679–85. X-9. [PubMed: 8164925]

1398.

Shoupe D, Mishell DR Jr., Brenner PF, et al. Pregnancy termination with a high and medium dosage regimen of RU 486. Contraception. 1986 May;33(5):455–61. X-5. [PubMed: 3757511]

1399.

Showstack J, Lin F, Learman LA, et al. Randomized trial of medical treatment versus hysterectomy for abnormal uterine bleeding: resource use in the Medicine or Surgery (Ms) trial. Am J Obstet Gynecol. 2006 Feb;194(2):332–8. X-8. [PubMed: 16458625]

1400.

Shravage J, Mekhala D, Bellad MB, et al. Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding: A double-blind randomized controlled trial. Journal of SAFOG. 2011 January-April;3(1):21–4. X-5.

1401.

Shy KK, McTiernan AM, Daling JR, et al. Oral contraceptive use and the occurrence of pituitary prolactinoma. JAMA. 1983 Apr 22-29;249(16):2204–7. X-3, X-5. [PubMed: 6834618]

1402.

Sibai BM, Caritis SN, Thom E, et al. Low-dose aspirin in nulliparous women: safety of continuous epidural block and correlation between bleeding time and maternal-neonatal bleeding complications. National Institute of Child Health and Human Developmental Maternal-Fetal Medicine Network. Am J Obstet Gynecol. 1995 May;172(5):1553–7. X-5. [PubMed: 7755070]

1403.

Siboni SM, Spreafico M, Calo L, et al. Gynaecological and obstetrical problems in women with different bleeding disorders. Haemophilia. 2009 Nov;15(6):1291–9. X-4, X-5, X-9. [PubMed: 19664014]

1404.

Sica S, Salutari P, Di Mario A, et al. Treatment and prophylaxis of hypermenorrhea with leuprorelin in premenopausal women affected by acute leukemia at diagnosis. Am J Hematol. 1996 Mar;51(3):248–9. X-1, X-3, X-5, X-10. [PubMed: 8619413]

1405.

Sidhu MS, Kent DR. Effects of prostaglandin E2 analogue suppository on blood loss in suction abortion. Obstet Gynecol. 1984 Jul;64(1):128–30. X-5. [PubMed: 6738937]

1406.

Siegberg R, Nilsson CG, Stenman UH, et al. Sex hormone profiles in oligomenorrheic adolescent girls and the effect of oral contraceptives. Fertil Steril. 1984 Jun;41(6):888–93. X-3, X-4. [PubMed: 6233177]

1407.

Siegberg R, Nilsson CG, Stenman UH, et al. The effect of oral contraceptives on hormone profiles of oligomenorrheic adolescent cycles. Contraception. 1987 Jan;35(1):29–40. X-3, X-5. [PubMed: 3568657]

1408.

Siegberg R, Ylostalo P, Laatikainen T, et al. Endocrine and clinical effects of spironolactone in female hyperandrogenism. Arch Gynecol. 1987;240(2):67–73. X-6. [PubMed: 3566358]

1409.

Siegler AM. Therapeutic hysteroscopy. Acta Eur Fertil. 1986 Nov-Dec;17(6):467–71. X-1, X-3, X-5. [PubMed: 3630558]

1410.

Siegler AM, Kontopoulos VG. Lysis of intrauterine adhesions under hysteroscopic control. A report of 25 operations. J Reprod Med. 1981 Jul;26(7):372–4. X-3, X-5, X-8. [PubMed: 7277346]

1411.

Sihvo S, Ollila E, Hemminki E. Perceptions and satisfaction among Norplant users in Finland. Acta Obstet Gynecol Scand. 1995 Jul;74(6):441–5. X-3, X-9. [PubMed: 7604687]

1412.

Silberstein SD, Berner T, Tobin J, et al. Scheduled short-term prevention with frovatriptan for migraine occurring exclusively in association with menstruation. Headache. 2009 Oct;49(9):1283–97. X-4, X-5, X-9. [PubMed: 19751371]

1413.

Silberstein SD, Massiou H, Le Jeunne C, et al. Rizatriptan in the treatment of menstrual migraine. Obstet Gynecol. 2000 Aug;96(2):237–42. X-4, X-5, X-9. [PubMed: 10908770]

1414.

Simbar M, Tehrani FR, Hashemi Z, et al. A comparative study of Cyclofem and depot medroxyprogesterone acetate (DMPA) effects on endometrial vasculature. Journal of Family Planning and Reproductive Health Care. 2007;33(4):271–6. X-4, X-5, X-9. [PubMed: 17925114]

1415.

Simon JA, Liu JH, Speroff L, et al. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. Am J Obstet Gynecol. 2003 Jan;188(1):92–9. X-5, X-7. [PubMed: 12548201]

1416.

Simon JA, Symons JP. Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: A direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens. Menopause. 2001;8(5):321–7. X-7. [PubMed: 11528357]

1417.

Simsek T, Karakus C, Trak B. Impact of different hormone replacement therapy regimens on the size of myoma uteri in postmenopausal period: tibolone versus transdermal hormonal replacement system. Maturitas. 2002 Jul 25;42(3):243–6. X-4, X-5, X-7. [PubMed: 12161049]

1418.

Singer A, Almanza R, Gutierrez A, et al. Preliminary clinical experience with a thermal balloon endometrial ablation method to treat menorrhagia. Obstet Gynecol. 1994 May;83(5 Pt 1):732–4. X-3, X-8. [PubMed: 8164933]

1419.

Singh M, Saxena BB, Raghubanshi RS, et al. Biodegradable norethindrone (NET:cholesterol) contraceptive implants: phase II-A: a clinical study in women. Contraception. 1997 Jan;55(1):23–33. X-3, X-9. [PubMed: 9013058]

1420.

Singh M, Saxena BB, Singh R, et al. Contraceptive efficacy of norethindrone encapsulated in injectable biodegradable poly-dl-lactide-co-glycolide microspheres (NET-90): phase III clinical study. Adv Contracept. 1997 Mar;13(1):1–11. X-4, X-5. [PubMed: 9181181]

1421.

Singh N, Ghosh B, Naha M, et al. Vaginal misoprostol for cervical priming prior to diagnostic hysteroscopy - Efficacy, safety and patient satisfaction: A randomized controlled trial. Archives of Gynecology and Obstetrics. 2009;279(1):37–40. X-4, X-5. [PubMed: 18449549]

1422.

Siskin GP, Shlansky-Goldberg RD, Goodwin SC, et al. A prospective multicenter comparative study between myomectomy and uterine artery embolization with polyvinyl alcohol microspheres: long-term clinical outcomes in patients with symptomatic uterine fibroids. J Vasc Interv Radiol. 2006 Aug;17(8):1287–95. X-4, X-5, X-6, X-8. [PubMed: 16923975]

1423.

Siskin GP, Stainken BF, Dowling K, et al. Outpatient uterine artery embolization for symptomatic uterine fibroids: experience in 49 patients. J Vasc Interv Radiol. 2000 Mar;11(3):305–11. X-4, X-5, X-6. [PubMed: 10735424]

1424.

Sivin I, Alvarez F, Mishell DR Jr., et al. Contraception with two levonorgestrel rod implants. A 5-year study in the United States and Dominican Republic. Contraception. 1998 Nov;58(5):275–82. X-4, X-5, X-6. [PubMed: 9883382]

1425.

Sivin I, Campodonico I, Kiriwat O, et al. The performance of levonorgestrel rod and Norplant contraceptive implants: A 5 year randomized study. Human Reproduction. 1999;13(12):3371–8. X-9. [PubMed: 9886517]

1426.

Sivin I, Croxatto H, Bahamondes L, et al. Two-year performance of a Nestorone-releasing contraceptive implant: a three-center study of 300 women. Contraception. 2004 Feb;69(2):137–44. X-4, X-5. [PubMed: 14759619]

1427.

Sivin I, Diaz S, Croxatto HB, et al. Contraceptives for lactating women: a comparative trial of a progesterone- releasing vaginal ring and the copper T 380A IUD. Contraception. 1997 Apr;55(4):225–32. X-4, X-5. [PubMed: 9179454]

1428.

Sivin I, Mishell DR Jr., Victor A, et al. A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings. III-Menstrual patterns. An international comparative trial. Contraception. 1981 Oct;24(4):377–92. X-6, X-9. [PubMed: 6797783]

1429.

Sivin I, Robertson DN, Stern J, et al. Norplant: reversible implant contraception. Stud Fam Plann. 1980 Jul-Aug;11(7-8):227–35. X-1, X-3, X-9, X-10. [PubMed: 6996230]

1430.

Sivin I, Sanchez FA, Diaz S, et al. Three-year experience with NORPLANT subdermal contraception. Fertil Steril. 1983 Jun;39(6):799–808. X-3, X-9. [PubMed: 6406273]

1431.

Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 mug/d and the copper TCu 380Ag intrauterine contraceptive devices: A multicenter study. Fertility and Sterility. 1994;61(1):70–7. X-9. [PubMed: 8293847]

1432.

Sivin I, Stern J, Coutinho E, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. Contraception. 1991 Nov;44(5):473–80. X-9. [PubMed: 1797462]

1433.

Sivin I, Stern J, Diaz J, et al. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices. Contraception. 1987 Mar;35(3):245–55. X-9. [PubMed: 3111785]

1434.

Sivin I, Tatum HJ. Four years of experience with the TCu 380A intrauterine contraceptive device. Fertil Steril. 1981 Aug;36(2):159–63. X-3, X-9. [PubMed: 7262334]

1435.

Sivin I, Viegas O, Campodonico I, et al. Clinical performance of a new two-rod levonorgestrel contraceptive implant: a three-year randomized study with Norplant implants as controls. Contraception. 1997 Feb;55(2):73–80. X-4, X-5. [PubMed: 9071515]

1436.

Skibola CF. The effect of Fucus vesiculosus, an edible brown seaweed, upon menstrual cycle length and hormonal status in three pre-menopausal women: a case report. BMC Complement Altern Med. 2004 Aug 4;4:10. X-4. [PMC free article: PMC514561] [PubMed: 15294021]

1437.

Small DS, Wrishko RE, Ernest ICS, et al. Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: An open-label, single-sequence, clinical trial. Drugs and Aging. 2009;26(9):781–90. X-3, X-5. [PubMed: 19728751]

1438.

Smith SK, Abel MH, Kelly RW, et al. Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. Br J Obstet Gynaecol. 1981 Apr;88(4):434–42. X-3, X-4. [PubMed: 7225303]

1439.

Smits MG, van der Meer YG, Pfeil JP, et al. Perimenstrual migraine: effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test. Headache. 1994 Feb;34(2):103–6. X-5. [PubMed: 8163364]

1440.

Snead DB, Weltman A, Weltman JY, et al. Reproductive hormones and bone mineral density in women runners. J Appl Physiol. 1992 Jun;72(6):2149–56. X-3, X-4. [PubMed: 1385803]

1441.

Socolov D, Blidaru I, Tamba B, et al. Levonorgestrel releasing-intrauterine system for the treatment of menorrhagia and/or frequent irregular uterine bleeding associated with uterine leiomyoma. Eur J Contracept Reprod Health Care. 2011 Dec;16(6):480–7. X-3, X-6. [PubMed: 21942657]

1442.

Sojo-Aranda I, Alonso-Uriarte R, Gonzalez-Diddi M, et al. The biological expression of natural progesterone. J Steroid Biochem. 1988 Aug;31(2):219–22. X-3, X-5. [PubMed: 3404991]

1443.

Sone M, Arai Y, Shimizu T, et al. Phase I/II multiinstitutional study of uterine artery embolization with gelatin sponge for symptomatic uterine leiomyomata: Japan Interventional Radiology in Oncology Study Group study. J Vasc Interv Radiol. 2010 Nov;21(11):1665–71. X-4, X-5, X-8. [PubMed: 20884240]

1444.

Sotnikova LS, Abramova EV, Shevtsova NM, et al. Clinical study of the efficiency of Poetam in the treatment of the anemic syndrome in pubertal uterine hemorrhages. Bull Exp Biol Med. 2006 Jul;142(1):61–5. X-3, X-4, X-5. [PubMed: 17369904]

1445.

Sotnikova LS, Shevtsova NM, Sherstoboev EY, et al. Complex application of preparation containing ultralow doses of antibodies for the treatment of anemia caused by pubertal uterine bleedings. Bull Exp Biol Med. 2009 Sep;148(3):505–7. X-3. [PubMed: 20396724]

1446.

Sotnikova LS, Zhdanov VV, Udut VV, et al. Influence of poetam preparation on the state of autonomic nervous system in patients with severe anemia caused by dysfunctional uterine bleedings. Bull Exp Biol Med. 2009 Sep;148(3):508–10. X-3, X-5, X-10. [PubMed: 20396725]

1447.

Soysal M, Soysal S, Ozer S. A randomized controlled trial of levonorgestrel releasing IUD and thermal balloon ablation in the treatment of menorrhagia. Zentralbl Gynakol. 2002 Apr;124(4):213–9. X-5, X-8. [PubMed: 12080483]

1448.

Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. Gynecol Obstet Invest. 2005;59(1):29–35. X-4, X-5, X-6. [PubMed: 15377823]

1449.

Speroff L, Haney AF, Gilbert RD, et al. Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms. Menopause. 2006;13(3):442–50. X-7. [PubMed: 16735941]

1450.

Spies JB, Benenati JF, Worthington-Kirsch RL, et al. Initial experience with use of tris-acryl gelatin microspheres for uterine artery embolization for leiomyomata. J Vasc Interv Radiol. 2001 Sep;12(9):1059–63. X-4, X-5, X-6, X-8. [PubMed: 11535768]

1451.

Spies JB, Cooper JM, Worthington-Kirsch R, et al. Outcome of uterine embolization and hysterectomy for leiomyomas: results of a multicenter study. Am J Obstet Gynecol. 2004 Jul;191(1):22–31. X-4, X-5, X-6, X-8. [PubMed: 15295340]

1452.

Spies JB, Cornell C, Worthington-Kirsch R, et al. Long-term outcome from uterine fibroid embolization with tris-acryl gelatin microspheres: results of a multicenter study. J Vasc Interv Radiol. 2007 Feb;18(2):203–7. X-4, X-5, X-8, X-9. [PubMed: 17327552]

1453.

Spitz IM, Bardin CW, Benton L, et al. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med. 1998 Apr 30;338(18):1241–7. X-4, X-5, X-6, X-9. [PubMed: 9562577]

1454.

Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception. 1996;54(2):71–7. X-9. [PubMed: 8842582]

1455.

Sporrong T, Hellgren M, Samsioe G, et al. Comparison of four continuously administered progestogen plus oestradiol combinations for climacteric complaints. Br J Obstet Gynaecol. 1988 Oct;95(10):1042–8. X-5, X-7. [PubMed: 3056498]

1456.

Sporrong T, Rybo G, Mattsson LA, et al. An objective and subjective assessment of uterine blood loss in postmenopausal women on hormone replacement therapy. Br J Obstet Gynaecol. 1992 May;99(5):399–401. X-7. [PubMed: 1535788]

1457.

Sporrong T, Samsioe G, Larsen S, et al. A novel statistical approach to analysis of bleeding patterns during continuous hormone replacement therapy. Maturitas. 1989 Sep;11(3):209–15. X-7. [PubMed: 2593864]

1458.

Stadberg E, Mattsson LA, Uvebrant M. 17 beta-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy. Maturitas. 1996 Feb;23(1):31–9. X-7. [PubMed: 8861084]

1459.

Stadtmauer L, Harrison DD, Boyd J, et al. Pilot study evaluating a progesterone vaginal ring for luteal-phase replacement in donor oocyte recipients. Fertility and Sterility. 2009;92(5):1600–5. X-5. [PubMed: 18990373]

1460.

Stamets K, Taylor DS, Kunselman A, et al. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertility and Sterility. 2004 March;81(3):630–7. X-5, X-10. [PubMed: 15037413]

1461.

Stanback J, Grimes D. Can intrauterine device removals for bleeding or pain be predicted at a one-month follow-up visit?: A multivariate analysis. Contraception. 1998;58(6):357–60. X-3, X-5, X-6. [PubMed: 10095972]

1462.

Stein RC, Rawson NSB, Gazet JC, et al. Gestrinone in mastalgia: A randomized double blind placebo controlled trial. Breast. 1994;3(2):90–3. X-5.

1463.

Steiner AZ, Xiang M, Mack WJ, et al. Unopposed estradiol therapy in postmenopausal women: results from two randomized trials. Obstet Gynecol. 2007 Mar;109(3):581–7. X-5, X-7. [PubMed: 17329508]

1464.

Stener-Victorin E, Jedel E, Janson PO, et al. Low-frequency electroacupuncture and physical exercise decrease high muscle sympathetic nerve activity in polycystic ovary syndrome. Am J Physiol Regul Integr Comp Physiol. 2009 Aug;297(2):R387–95. X-4, X-5. [PubMed: 19494176]

1465.

Stener-Victorin E, Waldenstrom U, Tagnfors U, et al. Effects of electro-acupuncture on anovulation in women with polycystic ovary syndrome. Acta Obstetricia et Gynecologica Scandinavica. 2000;79(3):180–8. X-3, X-5. [PubMed: 10716298]

1466.

Stephanie R, Labied S, Blacher S, et al. Endometrial vessel maturation in women exposed to levonorgestrel-releasing intrauterine system for a short or prolonged period of time. Hum Reprod. 2007 Dec;22(12):3084–91. X-4, X-5. [PubMed: 17921480]

1467.

Stephen LJ, Kwan P, Shapiro D, et al. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia. 2001 Aug;42(8):1002–6. X-4, X-5, X-6, X-9. [PubMed: 11554885]

1468.

Stephenson K, Neuenschwander PF, Kurdowska AK, et al. Transdermal progesterone: Effects on menopausal symptoms and on thrombotic, anticoagulant, and inflammatory factors in postmenopausal women. International Journal of Pharmaceutical Compounding. 2008;12(4):295–304. X-7. [PubMed: 23969765]

1469.

Stevenson JC, Durand G, Kahler E, et al. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17beta-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: Results from a double-blind, controlled study. Maturitas. 2010;67(3):227–32. X-7. [PubMed: 20688442]

1470.

Stewart FH, Kaunitz AM, LaGuardia KD, et al. Extended use of transdermal norelgestromin/ethinyl estradiol: A randomized trial. Obstetrics and Gynecology. 2005;105(6):1389–96. X-5, X-6, X-9. [PubMed: 15932834]

1471.

Stovall TG, Muneyyirci-Delale O, Summitt RL Jr, et al. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: A randomized controlled trial. Obstetrics and Gynecology. 1995;86(1):65–71. X-6. [PubMed: 7784025]

1472.

Stovall TG, Muneyyirci-Delale O, Summitt RL Jr., et al. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Leuprolide Acetate Study Group. Obstet Gynecol. 1995 Jul;86(1):65–71. X-6, X-8. [PubMed: 7784025]

1473.

Strokosch GR, Friedman AJ, Wu SC, et al. Effects of an Oral Contraceptive (Norgestimate/Ethinyl Estradiol) on Bone Mineral Density in Adolescent Females with Anorexia Nervosa: A Double-Blind, Placebo-Controlled Study. Journal of Adolescent Health. 2006;39(6):819–27. X-5. [PubMed: 17116511]

1474.

Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of Antipsychotics for Metabolic Problems (CAMP). American Journal of Psychiatry. 2011;168(9):947–56. X-5. [PMC free article: PMC3773729] [PubMed: 21768610]

1475.

Strowitzki T, Kirsch B, Elliesen J. Efficacy of ethinylestradiol 20 mug/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: An open-label, multicentre, randomised, controlled study. Journal of Family Planning and Reproductive Health Care. 2012 April;38(2):94–101. X-5. [PMC free article: PMC3353877] [PubMed: 22454006]

1476.

Sturdee DW, Archer DF, Rakov V, et al. Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women. Climacteric. 2008 Feb;11(1):63–73. X-5, X-7. [PubMed: 18202966]

1477.

Sturdee DW, Barlow DH, Ulrich LG, et al. Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestagen replacement therapy? UK Continuous Combined HRT Study Investigators. Lancet. 1994 Oct 8;344(8928):979–82. X-3, X-7. [PubMed: 7934429]

1478.

Sturdee DW, Rantala ML, Colau JC, et al. The acceptability of a small intrauterine progestogen-releasing system for continuous combined hormone therapy in early postmenopausal women. Climacteric. 2004 Dec;7(4):404–11. X-4, X-5, X-7, X-9. [PubMed: 15799612]

1479.

Sturdee DW, Van de Weijer P, Von Holst T. Endometrial safety of a transdermal sequential estradiol-levonorgestrel combination. Climacteric. 2002;5(2):170–7. X-7. [PubMed: 12051113]

1480.

Sturgess AD, Evans DT, Mackay IR, et al. Effects of the oestrogen antagonist tamoxifen on disease indices in systemic lupus erythematosus. J Clin Lab Immunol. 1984 Jan;13(1):11–4. X-5. [PubMed: 6371236]

1481.

Subakir SB, Abdul Madjid O, Sabariah S, et al. Oxidative stress, vitamin E and progestin breakthrough bleeding. Hum Reprod. 2000 Aug;15 Suppl 3:18–23. X-4, X-5. [PubMed: 11041217]

1482.

Subakir SB, Hadisaputra W, Handoyo AE, et al. Endometrial angiogenic response in Norplant users. Hum Reprod. 1996 Oct;11 Suppl 2:51–5. X-3, X-4, X-6. [PubMed: 8982746]

1483.

Subakir SB, Setiadi E, Affandi B, et al. Benefits of vitamin E supplementation to Norplant users--in vitro and in vivo studies. Toxicology. 2000 Aug 7;148(2-3):173–8. X-4, X-5, X-6. [PubMed: 10962136]

1484.

Subtil D, Goeusse P, Puech F, et al. Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: The Essai Regional Aspirine Mere-Enfant study (Part 1). BJOG: An International Journal of Obstetrics and Gynaecology. 2003;110(5):475–84. X-5. [PubMed: 12742332]

1485.

Suhonen SP, Allonen HO, Lahteenmaki P. Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 1):562–7. X-7. [PubMed: 7856686]

1486.

Suhonen SP, Holmstrom T, Allonen HO, et al. Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy. Fertil Steril. 1995 Feb;63(2):336–42. X-7. [PubMed: 7843440]

1487.

Sulak PJ, Caubel P, Lane R. Efficacy and safety of a constant-estrogen, pulsed-progestin regimen in hormone replacement therapy. Int J Fertil Womens Med. 1999 Nov-Dec;44(6):286–96. X-5, X-7. [PubMed: 10617250]

1488.

Sulak PJ, Kuehl TJ, Coffee A, et al. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. American Journal of Obstetrics and Gynecology. 2006;195(4):935–41. X-3, X-6. [PubMed: 16647684]

1489.

Sulak PJ, Smith V, Coffee A, et al. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial. Obstet Gynecol. 2008 Sep;112(3):563–71. X-5, X-7. [PubMed: 18757653]

1490.

Sundarrajan C, Liao WX, Roy AC, et al. Association between estrogen receptor-beta gene polymorphisms and ovulatory dysfunctions in patients with menstrual disorders. J Clin Endocrinol Metab. 2001 Jan;86(1):135–9. X-4, X-5, X-9. [PubMed: 11231990]

1491.

Sundstrom A, Seaman H, Kieler H, et al. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. BJOG. 2009 Jan;116(1):91–7. X-4. [PubMed: 19016686]

1492.

Suri V, Aggarwal N, Kaur R, et al. Safety of intrauterine contraceptive device (copper T 200 B) in women with cardiac disease. Contraception. 2008 Oct;78(4):315–8. X-4, X-5, X-9. [PubMed: 18847580]

1493.

Suthipongse W, Taneepanichskul S. An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 mug ethinylestradiol and 150 mug levonogestrel/30 mug ethinylestradiol in Thai women. Contraception. 2004;69(1):23–6. X-9. [PubMed: 14720615]

1494.

Suzuki N, Uebaba K, Kohama T, et al. French maritime pine bark extract significantly lowers the requirement for analgesic medication in dysmenorrhea: A multicenter, randomized, double-blind, placebo-controlled study. Journal of Reproductive Medicine for the Obstetrician and Gynecologist. 2008;53(5):338–46. X-3, X-5. [PubMed: 18567279]

1495.

Swahn ML, Kovacs L, Cekan SZ, et al. Termination of early pregnancy with ZK 98,734: pharmacokinetic behaviour and clinical effect. Hum Reprod. 1994 Jan;9(1):57–63. X-3, X-5. [PubMed: 8195352]

1496.

Swenson I, Khan AR, Jahan FA. A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh. Contraception. 1980 Mar;21(3):207–15. X-6, X-9. [PubMed: 6446442]

1497.

Symons J, Kempfert N, Speroff L. Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. The FemHRT Study Investigators. Obstet Gynecol. 2000 Sep;96(3):366–72. X-5, X-7. [PubMed: 10960627]

1498.

Symons J, Kempfert N, Speroff L. Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. Mechanisms of Development. 2000;96(2):366–72. X-7. [PubMed: 10960627]

1499.

Tagore S, Yim CF, Kwek K. Dengue haemorrhagic fever complicated by eclampsia in pregnancy. Singapore Med J. 2007 Oct;48(10):e281–3. X-1, X-4, X-5, X-9. [PubMed: 17909667]

1500.

Tahara M, Shimizu T, Shimoura H. Preliminary report of treatment with oral contraceptive pills for intermenstrual vaginal bleeding secondary to a cesarean section scar. Fertil Steril. 2006 Aug;86(2):477–9. X-4, X-5, X-9. [PubMed: 16769058]

1501.

Tai BC, Peregoudov A, Machin D. A competing risk approach to the analysis of trials of alternative intra-uterine devices (IUDs) for fertility regulation. Statistics in Medicine. 2001;20(23):3589–600. X-9. [PubMed: 11746339]

1502.

Takahashi K, Karino K, Kanasaki H, et al. Altered kinetics of pituitary response to gonadotropin-releasing hormone in women with variant luteinizing hormone: correlation with ovulatory disorders. Horm Res. 2004;61(1):27–32. X-4, X-5, X-9. [PubMed: 14646399]

1503.

Takeuchi H, Kobori H, Kikuchi I, et al. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis. J Obstet Gynaecol Res. 2000 Oct;26(5):325–31. X-4, X-5, X-6. [PubMed: 11147718]

1504.

Takeuchi S, Futamura N, Takubo S, et al. Polycystic ovary syndrome treated with laparoscopic ovarian drilling with a harmonic scalpel: A prospective, randomized study. Journal of Reproductive Medicine for the Obstetrician and Gynecologist. 2002;47(10):816–20. X-8. [PubMed: 12418063]

1505.

Taler SJ, Coulam CB, Annegers JF, et al. Case-control study of galactorrhea and its relationship to the use of oral contraceptives. Obstet Gynecol. 1985 May;65(5):665–8. X-3, X-5. [PubMed: 4039047]

1506.

Tam WH, Yuen PM, Shan Ng DP, et al. Health status function after treatment with thermal balloon endometrial ablation and levonorgestrel intrauterine system for idiopathic menorrhagia: a randomized study. Gynecol Obstet Invest. 2006;62(2):84–8. X-8. [PubMed: 16612101]

1507.

Tan D, Haines CJ, Limpaphayom KK, et al. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia menopause (PAM) study. Maturitas. 2005;52(1):35–51. X-7. [PubMed: 16211697]

1508.

Taneepanichskul S, Kriengsinyot R, Jaisamrarn U. A comparison of cycle control, efficacy, and side effects among healthy Thai women between two low-dose oral contraceptives containing 20 microg ethinylestradio1/75 microg gestodene (Meliane) and 30 microg ethinylestradio1/75 microg gestodene (Gynera). Contraception. 2002 Dec;66(6):407–9. X-5. [PubMed: 12499032]

1509.

Taneepanichskul S, Reinprayoon D, Phaosavadi S. DMPA use above the age of 35 in Thai women. Contraception. 2000 Apr;61(4):281–2. X-4, X-5, X-6. [PubMed: 10899485]

1510.

Taner C, Inal M, Basogul O, et al. Comparison of the clinical efficacy and safety of flutamide versus flutamide plus an oral contraceptive in the treatment of hirsutism. Gynecol Obstet Invest. 2002;54(2):105–8. X-5, X-9. [PubMed: 12566753]

1511.

Tang GW, Lo SS. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: efficacy versus acceptability. Contraception. 1995 Apr;51(4):231–5. X-3. [PubMed: 7796588]

1512.

Tang OS, Gao PP, Cheng L, et al. A randomized double-blind placebo-controlled study to assess the effect of oral contraceptive pills on the outcome of medical abortion with mifepristone and misoprostol. Hum Reprod. 1999 Mar;14(3):722–5. X-5, X-9. [PubMed: 10221703]

1513.

Tang OS, Lee SW, Ho PC. A prospective randomized study on the measured blood loss in medical termination of early pregnancy by three different misoprostol regimens after pretreatment with mifepristone. Hum Reprod. 2002 Nov;17(11):2865–8. X-5, X-9. [PubMed: 12407040]

1514.

Tang OS, Xu J, Cheng L, et al. The effect of contraceptive pills on the measured blood loss in medical termination of pregnancy by mifepristone and misoprostol: a randomized placebo controlled trial. Hum Reprod. 2002 Jan;17(1):99–102. X-5, X-9. [PubMed: 11756369]

1515.

Tang T, Glanville J, Hayden CJ, et al. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Human Reproduction. 2006;21(1):80–9. X-5. [PubMed: 16199429]

1516.

Tantbirojn P, Taneepanichskul S. Clinical comparative study of oral contraceptives containing 30 microg ethinylestradiol/150 microg levonorgestrel, and 35 microg ethinylestradiol/250 microg norgestimate in Thai women. Contraception. 2002 Dec;66(6):401–5. X-5. [PubMed: 12499031]

1517.

Tantiwattanakul P, Taneepanichskul S. Effect of mefenamic acid on controlling irregular uterine bleeding in DMPA users. Contraception. 2004 Oct;70(4):277–9. X-5, X-6. [PubMed: 15451330]

1518.

Taskin O, Buhur A, Birincioglu M, et al. Endometrial Na+, K+-ATPase pump function and vasopressin levels during hysteroscopic surgery in patients pretreated with GnRH agonist. J Am Assoc Gynecol Laparosc. 1998 May;5(2):119–24. X-4, X-5, X-8. [PubMed: 9564057]

1519.

Taskin O, Yalcinoglu A, Kucuk S, et al. The degree of fluid absorption during hysteroscopic surgery in patients pretreated with goserelin. J Am Assoc Gynecol Laparosc. 1996 Aug;3(4):555–9. X-5, X-8, X-9. [PubMed: 9050688]

1520.

Tatum HJ, Beltran RS, Ramos R, et al. Immediate postplacental insertion of GYNE-T 380 and GYNE-T 380 postpartum intrauterine contraceptive devices: randomized study. Am J Obstet Gynecol. 1996 Nov;175(5):1231–5. X-5. [PubMed: 8942493]

1521.

Teal SB, Dempsey-Fanning A, Westhoff C. Predictors of acceptability of medication abortion. Contraception. 2007 Mar;75(3):224–9. X-5, X-9. [PubMed: 17303494]

1522.

Tehrani FR, Rashidi H, Azizi F. The prevalence of idiopathic hirsutism and polycystic ovary syndrome in the Tehran Lipid and Glucose Study. Reprod Biol Endocrinol. 2011;9:144. X-3, X-4. [PMC free article: PMC3214199] [PubMed: 22044512]

1523.

Tehrani FR, Simbar M, Tohidi M, et al. The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reproductive Biology and Endocrinology. 2011;9(39) X-3, X-4. [PMC free article: PMC3070632] [PubMed: 21435276]

1524.

Teichmann A, Apter D, Emerich J, et al. Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial. Contraception. 2009 Dec;80(6):504–11. X-4, X-5. [PubMed: 19913143]

1525.

Terakawa N, Inoue M, Shimizu I, et al. Preliminary report on the use of danazol in the treatment of endometrial adenomatous hyperplasia. Cancer. 1988 Dec 15;62(12):2618–21. X-3, X-9. [PubMed: 3191463]

1526.

Thomas AG, Klihr-Beall S, Siqueira L, et al. Concentration of depot medroxyprogesterone acetate and pain scores in adolescents: A randomized clinical trial. Contraception. 2005;72(2):126–9. X-5, X-6, X-9. [PubMed: 16022852]

1527.

Thomas EJ. Add-back therapy for long-term use in dysfunctional uterine bleeding and uterine fibroids. Br J Obstet Gynaecol. 1996 Oct;103 Suppl 14:18–21. X-3, X-6. [PubMed: 8916983]

1528.

Thomas EJ, Okuda KJ, Thomas NM. The combination of a depot gonadotrophin releasing hormone agonist and cyclical hormone replacement therapy for dysfunctional uterine bleeding. Br J Obstet Gynaecol. 1991 Nov;98(11):1155–9. X-3. [PubMed: 1836959]

1529.

Thomson RL, Buckley JD, Moran LJ, et al. The effect of weight loss on anti-Mullerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Hum Reprod. 2009 Aug;24(8):1976–81. X-4, X-5, X-9. [PubMed: 19380385]

1530.

Thongrong P, Jarruwale P, Panichkul P. Effectiveness of paracervical block versus intravenous morphine during uterine curettage: a randomized controlled trial. J Med Assoc Thai. 2011 Apr;94(4):403–7. X-5, X-8. [PubMed: 21591523]

1531.

Thonneau P, Poirel H, Fougeyrollas B, et al. A comparative analysis of fall in haemoglobin following abortions conducted by mifepristone (600 mg) and vacuum aspiration. Hum Reprod. 1995 Jun;10(6):1512–5. X-3, X-5. [PubMed: 7593526]

1532.

Thorburn J, Berntsson C, Philipson M, et al. Background factors of ectopic pregnancy. I. Frequency distribution in a case-control study. Eur J Obstet Gynecol Reprod Biol. 1986 Dec;23(5-6):321–31. X-3, X-4, X-5. [PubMed: 3803684]

1533.

Tice JA, Ettinger B, Ensrud K, et al. Phytoestrogen Supplements for the Treatment of Hot Flashes: The Isoflavone Clover Extract (ICE) Study: A Randomized Controlled Trial. Journal of the American Medical Association. 2003;290(2):207–14. X-5, X-7. [PubMed: 12851275]

1534.

Tolley E, Loza S, Kafafi L, et al. The impact of menstrual side effects on contraceptive discontinuation: findings from a longitudinal study in Cairo, Egypt. International Family Planning Perspectives. 2005;31(1):15–23. X-3, X-4, X-5. [PubMed: 15888405]

1535.

Toppozada M, El-Attar A, El-Ayyat MA, et al. Management of uterine bleeding by PGs or their synthesis inhibitors. Adv Prostaglandin Thromboxane Res. 1980;8:1459–63. X-5, X-10. [PubMed: 6769315]

1536.

Towers CV, Pircon RA, Heppard M. Is tocolysis safe in the management of third-trimester bleeding? Am J Obstet Gynecol. 1999 Jun;180(6 Pt 1):1572–8. X-4, X-5, X-9. [PubMed: 10368505]

1537.

Trambert JJ, Einstein MH, Banks E, et al. Uterine artery embolization in the management of vaginal bleeding from cervical pregnancy: a case series. J Reprod Med. 2005 Nov;50(11):844–50. X-4, X-5, X-8, X-9. [PubMed: 16419633]

1538.

Tredway DR, Buraglio M, Hemsey G, et al. A phase I study of the pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose anastrozole in healthy, premenopausal female volunteers. Fertil Steril. 2004 Dec;82(6):1587–93. X-4, X-5, X-9. [PubMed: 15589864]

1539.

Trivedi P, Rocha I, Padhye A. Is routine preoperative preparation necessary for hysteroscopic endometrial resection? Gynaecological Endoscopy. 1999;8(5):287–91. X-8.

1540.

Tsikouras P, Liberis V, Galazios G, et al. Uterine sarcoma: a report of 57 cases over a 16-year period analysis. Eur J Gynaecol Oncol. 2008;29(2):129–34. X-4, X-5, X-9. [PubMed: 18459545]

1541.

Tuchman M, Hee A, Emeribe U, et al. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs. 2006;20(12):1019–26. X-5, X-9. [PubMed: 17140280]

1542.

Tuchman MM, Hee A, Emeribe U, et al. Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. CNS Drugs. 2008;22(10):877–86. X-5, X-9. [PubMed: 18788838]

1543.

Tuppurainen M, Harma K, Komulainen M, et al. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: A 5-year follow-up. Maturitas. 2010;66(4):423–30. X-7. [PubMed: 20547017]

1544.

Tur-Kaspa I, Gal M, Hartman M, et al. A prospective evaluation of uterine abnormalities by saline infusion sonohysterography in 1,009 women with infertility or abnormal uterine bleeding. Fertil Steril. 2006 Dec;86(6):1731–5. X-4, X-5, X-9. [PubMed: 17007850]

1545.

Turnbull AC, Rees MC. Gestrinone in the treatment of menorrhagia. Br J Obstet Gynaecol. 1990 Aug;97(8):713–5. X-3. [PubMed: 2205289]

1546.

Turner JA, Mancl L, Huggins KH, et al. Targeting temporomandibular disorder pain treatment to hormonal fluctuations: A randomized clinical trial. Pain. 2011;152(9):2074–84. X-5. [PMC free article: PMC3157596] [PubMed: 21680092]

1547.

Ulmann A, Dubois C, Philibert D. Fertility control with RU 486. Horm Res. 1987;28(2-4):274–8. X-1, X-3, X-5. [PubMed: 3331378]

1548.

Ulmann A, Silvestre L. RU486: the French experience. Hum Reprod. 1994 Jun;9 Suppl 1:126–30. X-3, X-5. [PubMed: 7962459]

1549.

Ulmann A, Teutsch G, Philibert D. RU 486. Sci Am. 1990 Jun;262(6):42–8. X-11. [PubMed: 2343294]

1550.

Ulstein M, Svendsen E, Steier A, et al. Clinical experience with a triphasic oral contraceptive. Acta Obstet Gynecol Scand. 1984;63(3):233–6. X-3, X-9. [PubMed: 6428157]

1551.

Umbarje K. Thermal Balloon Endometrial Ablation (TBEA): an audit of pain management. Journal of One-Day Surgery. 2009;19(3):78–80. X-8.

1552.

Unfer V, Casini ML, Costabile L, et al. High dose of phytoestrogens can reverse the antiestrogenic effects of clomiphene citrate on the endometrium in patients undergoing intrauterine insemination: a randomized trial. J Soc Gynecol Investig. 2004 Jul;11(5):323–8. X-5, X-9. [PubMed: 15219887]

1553.

Ushiroyama T, Araki R, Sakuma K, et al. Efficacy of the kampo medicine Xiong-Gui-Jiao-Ai-Tang, a traditional herbal medicine, in the treatment of threatened abortion in early pregnancy. American Journal of Chinese Medicine. 2006;34(5):731–40. X-5. [PubMed: 17080540]

1554.

Ushiroyama T, Ikeda A, Higashio S, et al. Unkei-to for correcting luteal phase defects. J Reprod Med. 2003 Sep;48(9):729–34. X-4, X-5, X-9. [PubMed: 14562640]

1555.

Ushiroyama T, Ikeda A, Sakai M, et al. Effects of unkei-to, an herbal medicine, on endocrine function and ovulation in women with high basal levels of luteinizing hormone secretion. J Reprod Med. 2001 May;46(5):451–6. X-4, X-5, X-10. [PubMed: 11396371]

1556.

Utian WH, Burry KA, Archer DF, et al. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group. Am J Obstet Gynecol. 1999 Jul;181(1):71–9. X-5, X-7, X-9. [PubMed: 10411798]

1557.

Utian WH, Gass MLS, Pickar JH. Body mass index does not influence response to treatment, nor does body weight change with lower doses of conjugated estrogens and medroxyprogesterone acetate in early postmenopausal women. Menopause. 2004;11(3):306–14. X-7. [PubMed: 15167310]

1558.

Uygur D, Yesildaglar N, Erkaya S. Effect on sexual life - A comparison between tibolone and continuous combined conjugated equine estrogens and medroxyprogesterone acetate. Gynecological Endocrinology. 2005;20(4):209–12. X-7. [PubMed: 16019363]

1559.

Vairojanavong K, Limchitti D, Sasivimolkul V. Clinical trial of the efficacy of mefenamic acid in relief of menorrhagia and/or dysmenorrhoea. J Med Assoc Thai. 1983 Feb;66(2):99–105. X-3, X-5. [PubMed: 6343540]

1560.

van de Weijer PH, Barentsen R, de Vries M, et al. Relationship of estradiol levels to breakthrough bleeding during continuous combined hormone replacement therapy. Obstet Gynecol. 1999 Apr;93(4):551–7. X-5, X-6, X-7. [PubMed: 10214832]

1561.

van de Weijer PH, Barentsen R, Kenemans P. Women's expectations and acceptance of cyclic induced HRT bleeds. Maturitas. 1998 Nov 16;30(3):257–63. X-3, X-5, X-6. [PubMed: 9881325]

1562.

van de Weijer PH, Scholten PC, van der Mooren MJ, et al. Bleeding patterns and endometrial histology during administration of low-dose estradiol sequentially combined with dydrogesterone. Climacteric. 1999 Jun;2(2):101–9. X-5, X-7. [PubMed: 11910662]

1563.

van de Weijer PH, Sturdee DW, von Holst T. Estradiol and levonorgestrel: effects on bleeding pattern when administered in a sequential combined regimen with a new transdermal patch. Climacteric. 2002 Mar;5(1):36–44. X-5, X-7. [PubMed: 11974558]

1564.

van den Berg I, Liem YS, Wesseldijk F, et al. Complex regional pain syndrome type 1 may be associated with menstrual cycle disorders: a case-control study. Complement Ther Med. 2009 Oct-Dec;17(5-6):262–8. X-4, X-5, X-9. [PubMed: 19942105]

1565.

Van Den Heuvel MW, Van Bragt AJM, Alnabawy AKM, et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: The vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72(3):168–74. X-4, X-9. [PubMed: 16102549]

1566.

van der Straten A, Napierala S, Cheng H, et al. A randomized controlled safety trial of the diaphragm and cellulose sulfate microbicide gel in sexually active women in Zimbabwe. Contraception. 2007;76(5):389–99. X-5, X-9. [PubMed: 17963865]

1567.

van Dessel HJ, Schoot BC, Schipper I, et al. Circulating immunoreactive and bioactive follicle stimulating hormone concentrations in anovulatory infertile women and during gonadotrophin induction of ovulation using a decremental dose regimen. Hum Reprod. 1996 Mar;11(3):478–85. X-3, X-4, X-5. [PubMed: 8671250]

1568.

Van Doorn HC, Timmermans A, Opmeer BC, et al. What is the recurrence rate of postmenopausal bleeding in women who have a thin endometrium during a first episode of postmenopausal bleeding? Acta Obstet Gynecol Scand. 2008;87(1):89–93. X-4, X-5, X-7. [PubMed: 18158632]

1569.

van Eijkeren MA, Christiaens GC, Geuze JJ, et al. Morphology of menstrual hemostasis in essential menorrhagia. Lab Invest. 1991 Feb;64(2):284–94. X-3, X-4. [PubMed: 1997737]

1570.

van Kets H, Vrijens M, Van Trappen Y, et al. The frameless GyneFix intrauterine implant: a major improvement in efficacy, expulsion and tolerance. Adv Contracept. 1995 Jun;11(2):131–42. X-3, X-9. [PubMed: 7491854]

1571.

Van Kets HE, Van der Pas H, Delbarge W, et al. A randomized comparative study of the TCu380A and Cu-Safe 300 IUDs. Adv Contracept. 1995 Jun;11(2):123–9. X-9. [PubMed: 7491853]

1572.

van Santbrink EJ, Hohmann FP, Eijkemans MJ, et al. Does metformin modify ovarian responsiveness during exogenous FSH ovulation induction in normogonadotrophic anovulation? A placebo-controlled double-blind assessment. Eur J Endocrinol. 2005 Apr;152(4):611–7. X-5, X-9. [PubMed: 15817918]

1573.

Van Wyck DB, Mangione A, Morrison J, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009 Dec;49(12):2719–28. X-5. [PubMed: 19682342]

1574.

Vance ML, Cragun JR, Reimnitz C, et al. CV 205-502 treatment of hyperprolactinemia. J Clin Endocrinol Metab. 1989 Feb;68(2):336–9. X-4, X-5. [PubMed: 2521863]

1575.

Vandever MA, Kuehl TJ, Sulak PJ, et al. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens. Contraception. 2008;77(3):162–70. X-4, X-5, X-9. [PubMed: 18279685]

1576.

Varner RE, Ireland CC, Summitt RL Jr., et al. Medicine or Surgery (Ms): a randomized clinical trial comparing hysterectomy and medical treatment in premenopausal women with abnormal uterine bleeding. Control Clin Trials. 2004 Feb;25(1):104–18. X-8. [PubMed: 14980755]

1577.

Vega RR, Barraza-Vazquez A, Vega MG, et al. GnRH agonist for postpartum contraception: biochemical, hormonal and endometrial effects. Adv Contracept. 1996 Mar;12(1):15–25. X-4, X-5, X-9. [PubMed: 8739513]

1578.

Veldhuis HM, Vos AG, Lagro-Janssen AL. Complications of the intrauterine device in nulliparous and parous women. Eur J Gen Pract. 2004 Sep;10(3):82–7. X-4, X-5, X-9. [PubMed: 15534571]

1579.

Venkatachalam S, Bagratee JS, Moodley J. Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study. J Obstet Gynaecol. 2004 Oct;24(7):798–800. X-4, X-5, X-6, X-9. [PubMed: 15763792]

1580.

Vercellin P, Perin A, Consonn R, et al. Does preoperative treatment with a gonadotropin-releasing hormone agonist improve the outcome of endometrial resection? J Am Assoc Gynecol Laparosc. 1998 Nov;5(4):357–60. X-4, X-5, X-8. [PubMed: 9782138]

1581.

Vercellini P, Barbara G, Somigliana E, et al. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril. 2010 May 1;93(7):2150–61. X-4, X-5, X-9. [PubMed: 19328469]

1582.

Vercellini P, Bocciolone L, Colombo A, et al. Gonadotropin releasing hormone agonist treatment before hysterectomy for menorrhagia and uterine leiomyomas. Acta Obstet Gynecol Scand. 1993 Jul;72(5):369–73. X-3, X-6, X-8. [PubMed: 8392268]

1583.

Vercellini P, Colombo A, Mauro F, et al. Paracervical anesthesia for outpatient hysteroscopy. Fertility and Sterility. 1994;62(5):1083–5. X-5, X-8. [PubMed: 7646610]

1584.

Vercellini P, De Giorgi O, Oldani S, et al. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. American Journal of Obstetrics and Gynecology. 1996;175(2):396–401. X-5, X-10. [PubMed: 8765259]

1585.

Vercellini P, Perino A, Consonni R, et al. Treatment with a gonadotrophin releasing hormone agonist before endometrial resection: a multicentre, randomised controlled trial. Br J Obstet Gynaecol. 1996 Jun;103(6):562–8. X-5, X-8, X-9. [PubMed: 8645650]

1586.

Vercellini P, Sacerdote P, Trespidi L, et al. Veralipride for hot flushes induced by a gonadotropin-releasing hormone agonist: a controlled study. Fertil Steril. 1994 Nov;62(5):938–42. X-5, X-6. [PubMed: 7926138]

1587.

Vercellini P, Soma M, Moro GL. Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: A multicenter, randomized, double-blind study. Fertility and Sterility. 1996;66(6):911–9. X-4, X-5, X-10. [PubMed: 8941054]

1588.

Vercellini P, Vendola N, Colombo A, et al. Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment. Gynecol Obstet Invest. 1992;34(2):102–4. X-3, X-5, X-6. [PubMed: 1398260]

1589.

Vetr M, Sobek A. Low dose spironolactone in the treatment of female hyperandrogenemia and hirsutism. Acta Univ Palacki Olomuc Fac Med. 1993;135:55–7. X-3, X-5. [PubMed: 7976677]

1590.

Vickers MR, Martin J, Meade TW, et al. The Women's International Study of Long-duration Oestrogen after Menopause (WISDOM): A randomised controlled trial. BMC Women's Health. 2007;7(2) X-7. [PMC free article: PMC1828722] [PubMed: 17324282]

1591.

Vidal-Puig AJ, Munoz-Torres M, Jodar-Gimeno E, et al. Ketoconazole therapy: hormonal and clinical effects in non-tumoral hyperandrogenism. Eur J Endocrinol. 1994 Apr;130(4):333–8. X-3, X-5. [PubMed: 8162160]

1592.

Vigano GL, Mannucci PM, Lattuada A, et al. Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia. Am J Hematol. 1989 May;31(1):32–5. X-3, X-6. [PubMed: 2705441]

1593.

Vilos GA, Fortin CA, Sanders B, et al. Clinical trial of the uterine thermal balloon for treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 1997 Nov;4(5):559–65. X-4, X-5, X-8. [PubMed: 9348362]

1594.

Vilos GA, Vilos EC, Pendley L. Endometrial ablation with a thermal balloon for the treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 1996 May;3(3):383–7. X-4, X-5, X-8. [PubMed: 9050660]

1595.

Vimala N, Mittal S, Kumar S, et al. A randomized comparison of sublingual and vaginal misoprostol for cervical priming before suction termination of first-trimester pregnancy. Contraception. 2004 Aug;70(2):117–20. X-5, X-9. [PubMed: 15288215]

1596.

Vincent AJ, Malakooti N, Zhang J, et al. Endometrial breakdown in women using Norplant is associated with migratory cells expressing matrix metalloproteinase-9 (gelatinase B). Hum Reprod. 1999 Mar;14(3):807–15. X-3, X-4. [PubMed: 10221718]

1597.

Vincent AJ, Zhang J, Ostor A, et al. Matrix metalloproteinase-1 and -3 and mast cells are present in the endometrium of women using progestin-only contraceptives. Hum Reprod. 2000 Jan;15(1):123–30. X-4, X-5. [PubMed: 10611200]

1598.

Vincent AJ, Zhang J, Ostor A, et al. Decreased tissue inhibitor of metalloproteinase in the endometrium of women using depot medroxyprogesterone acetate: a role for altered endometrial matrix metalloproteinase/tissue inhibitor of metalloproteinase balance in the pathogenesis of abnormal uterine bleeding? Hum Reprod. 2002 May;17(5):1189–98. X-4, X-5. [PubMed: 11980737]

1599.

Vincenti E, Tambuscio B, Marchesoni D, et al. Use of intramyometrial injection of prostaglandin F 2 alpha in the management of intractable hemorrhage due to uterine atony. Clin Exp Obstet Gynecol. 1982;9(1):26–30. X-3, X-5. [PubMed: 6959742]

1600.

Viniker DA. Late luteal phase dydrogesterone in combination with clomiphene or tamoxifen in the treatment of infertility associated with irregular and infrequent menstruation: enhancing patient compliance. Hum Reprod. 1996 Jul;11(7):1435–7. X-3, X-5. [PubMed: 8671482]

1601.

Volkers NA, Hehenkamp WJ, Birnie E, et al. Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids: 2 years' outcome from the randomized EMMY trial. Am J Obstet Gynecol. 2007 Jun;196(6):519 e1–11. X-5, X-6, X-8, X-9. [PubMed: 17547877]

1602.

von Holst T, Lang E, Winkler U, et al. Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone. Maturitas. 2002 Dec 10;43(4):265–75. X-5, X-6, X-7. [PubMed: 12468135]

1603.

von Kesseru E, Aydinlik S, Etchepareborda JJ. Multicentred, phase III clinical trial of norethisterone enanthate 50 mg plus estradiol valerate 5 mg as a monthly injectable contraceptive; final three-year report. Contraception. 1994 Oct;50(4):329–37. X-3, X-9. [PubMed: 7813221]

1604.

von Kesseru E, Aydinlik S, Etchepareborda JJ, et al. A multicentred, two-year, phase III clinical trial of norethisterone enanthate 50 mg plus estradiol valerate 5 mg as a monthly injectable contraceptive. Contraception. 1991 Dec;44(6):589–98. X-3, X-9. [PubMed: 1773616]

1605.

von Kesseru E, Etchepareborda JJ, Wikinski R, et al. Premenopause contraception with monthly injectable Mesigyna with special emphasis on serum lipid and bone density patterns. Contraception. 2000 May;61(5):317–22. X-4, X-5, X-6. [PubMed: 10906502]

1606.

Von Seggern RL, Mannix LK, Adelman JU. Rofecoxib in the Prevention of Perimenstrual Migraine: An Open-Label Pilot Trial. Headache. 2004;44(2):160–5. X-5. [PubMed: 14756855]

1607.

Vorsanger GJ, Xiang J, Gana TJ, et al. Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain. Journal of Opioid Management. 2008;4(2):87–97. X-5. [PubMed: 18557165]

1608.

Vuorma S, Rissanen P, Aalto AM, et al. Impact of patient information booklet on treatment decision - A randomized trial among women with heavy menstruation. Health Expectations. 2003;6(4):290–7. X-5. [PMC free article: PMC5060205] [PubMed: 15040791]

1609.

Vuorma S, Rissanen P, Aalto AM, et al. Factors predicting choice of treatment for menorrhagia in gynaecology outpatient clinics. Soc Sci Med. 2003 Apr;56(8):1653–60. X-4. [PubMed: 12639582]

1610.

Wahab M, Al-Azzawi F. Trimegestone: Expanding therapeutic choices for the treatment of the menopause. Expert Opinion on Investigational Drugs. 2001;10(9):1737–44. X-1, X-3, X-5. [PubMed: 11772282]

1611.

Wahab M, Thompson J, Al-Azzawi F. The distribution of endometrial leukocytes and their proliferation markers in trimegestone-treated postmenopausal women compared to the endometrium of the natural cycle: A dose-ranging study. Human Reproduction. 1999;14(5):1201–6. X-3, X-4, X-7. [PubMed: 10325261]

1612.

Wahab M, Thompson J, Al-Azzawi F. The effect of submucous fibroids on the dose-dependent modulation of uterine bleeding by trimegestone in postmenopausal women treated with hormone replacement therapy. BJOG. 2000 Mar;107(3):329–34. X-5, X-7. [PubMed: 10740328]

1613.

Wahab M, Thompson J, Whitehead M, et al. The effect of a change in the dose of trimegestone on the pattern of bleeding in estrogen-treated post-menopausal women: 6 month extension of a dose-ranging study. Hum Reprod. 2002 May;17(5):1386–90. X-4, X-5, X-7. [PubMed: 11980769]

1614.

Walberg JL, Johnston CS. Menstrual function and eating behavior in female recreational weight lifters and competitive body builders. Med Sci Sports Exerc. 1991 Jan;23(1):30–6. X-3, X-4, X-5. [PubMed: 1997810]

1615.

Walberg-Rankin J, Edmonds CE, Gwazdauskas FC. Diet and weight changes of female bodybuilders before and after competition. Int J Sport Nutr. 1993 Mar;3(1):87–102. X-3, X-5. [PubMed: 8499941]

1616.

Wang F, Shen X, Guo X, et al. Analgesic effectiveness of flurbiprofen axetil after uterine curettage on abortion: A randomized controlled trial. Acute Pain. 2009;11(2):43–50. X-5.

1617.

Wang HS, Wang TH, Soong YK. Low dose flutamide in the treatment of acne vulgaris in women with or without oligomenorrhea or amenorrhea. Changgeng Yi Xue Za Zhi. 1999 Sep;22(3):423–32. X-4, X-5, X-6, X-9. [PubMed: 10584414]

1618.

Wang HS, Wang TH, Soong YK. Cyclic changes in serum levels of insulin-like growth factor binding protein-1 in women treated with clomiphene citrate and tamoxifen. Gynecol Endocrinol. 2000 Aug;14(4):236–44. X-4, X-5. [PubMed: 11075292]

1619.

Wang HS, Wang TH, Soong YK. Elevation of insulin-like growth factor-binding protein-1 mRNA expression following hormone replacement therapy. Hum Reprod. 2000 Jan;15(1):50–4. X-4, X-5, X-7. [PubMed: 10611187]

1620.

Wang IY, Russell P, Fraser IS. Endometrial morphometry in users of intrauterine contraceptive devices and women with ovulatory dysfunctional uterine bleeding: a comparison with normal endometrium. Contraception. 1995 Apr;51(4):243–8. X-3, X-4. [PubMed: 7796590]

1621.

Wang J, Zhang G, Shi H, et al. Dextran uterine artery embolization to treat fibroids. Chin Med J (Engl). 2002 Aug;115(8):1132–6. X-4, X-5, X-6, X-8. [PubMed: 12215276]

1622.

Wang MC, Hsu MC, Chien LW, et al. Effects of auricular acupressure on menstrual symptoms and nitric oxide for women with primary dysmenorrhea. Journal of Alternative and Complementary Medicine. 2009;15(3):235–42. X-5. [PubMed: 19292653]

1623.

Wang Y, Xu B, Dai S, et al. An efficient conservative treatment modality for cervical pregnancy: angiographic uterine artery embolization followed by immediate curettage. Am J Obstet Gynecol. 2011 Jan;204(1):31 e1–7. X-4, X-5, X-9. [PubMed: 20889136]

1624.

Warming L, Ravn P, Spielman D, et al. Trimegestone in a low-dose, continuous-combined hormone therapy regimen prevents bone loss in osteopenic postmenopausal women. Menopause. 2004 May-Jun;11(3):337–42. X-5, X-7. [PubMed: 15167314]

1625.

Warner P. Preferences regarding treatments for period problems: relationship to menstrual and demographic factors. J Psychosom Obstet Gynaecol. 1994 Jun;15(2):93–110. X-3, X-5. [PubMed: 7921011]

1626.

Warner P, Critchley HO, Lumsden MA, et al. Referral for menstrual problems: cross sectional survey of symptoms, reasons for referral, and management. BMJ. 2001 Jul 7;323(7303):24–8. X-4, X-5, X-9. [PMC free article: PMC34329] [PubMed: 11440940]

1627.

Warner P, Guttinger A, Glasier AF, et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Hum Reprod. 2010 Feb;25(2):345–53. X-4, X-5, X-9. [PMC free article: PMC2806180] [PubMed: 19897857]

1628.

Warren MP, Brooks-Gunn J, Fox RP, et al. Persistent osteopenia in ballet dancers with amenorrhea and delayed menarche despite hormone therapy: A longitudinal study. Fertility and Sterility. 2003;80(2):398–404. X-5. [PubMed: 12909505]

1629.

Warren MP, Perlroth NE. The effects of intense exercise on the female reproductive system. Journal of Endocrinology. 2001;170(1):3–11. X-1, X-3, X-5. [PubMed: 11431132]

1630.

Wartenberg KE, Mayer SA. Reducing the risk of ICH enlargement. Journal of the Neurological Sciences. 2007;261(1-2):99–107. X-5. [PubMed: 17631908]

1631.

Wasnich RD, Bagger YZ, Hosking DJ, et al. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause. 2004;11(6 I):622–30. X-7. [PubMed: 15545790]

1632.

Watson P, Besch N, Bowes WA Jr. Management of acute and subacute puerperal inversion of the uterus. Obstet Gynecol. 1980 Jan;55(1):12–6. X-3, X-5, X-6. [PubMed: 7352052]

1633.

Webb A, Shochet T, Bigrigg A, et al. Effect of hormonal emergency contraception on bleeding patterns. Contraception. 2004 Feb;69(2):133–5. X-4, X-5, X-9. [PubMed: 14759618]

1634.

Weeks AD, Duffy SR, Walker JJ. Uterine ultrasonographic changes with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol. 1999 Jan;180(1 Pt 1):8–13. X-4, X-5, X-8, X-9. [PubMed: 9914569]

1635.

Weeks AD, Duffy SR, Walker JJ. A double-blind randomised trial of leuprorelin acetate prior to hysterectomy for dysfunctional uterine bleeding. BJOG. 2000 Mar;107(3):323–8. X-5, X-8. [PubMed: 10740327]

1636.

Wegienka G, Baird DD. Potential bias due to excluding oral contraceptive users when estimating menstrual cycle characteristics. Am J Epidemiol. 2003 Nov 15;158(10):947–50. X-4, X-5, X-9. [PubMed: 14607802]

1637.

Wehr E, Pieber TR, Obermayer-Pietsch B. Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in polycystic ovary syndrome women: a pilot study. J Endocrinol Invest. 2011 Nov;34(10):757–63. X-3, X-5. [PubMed: 21613813]

1638.

Weingrill CO, Mussio W, Moraes CR, et al. Long-acting oral bromocriptine (Parlodel SRO) in the treatment of hyperprolactinemia. Fertil Steril. 1992 Feb;57(2):331–5. X-5, X-6. [PubMed: 1735484]

1639.

Weinstein MC. Estrogen use in postmenopausal women--costs, risks, and benefits. N Engl J Med. 1980 Aug 7;303(6):308–16. X-1, X-3, X-7. [PubMed: 6770270]

1640.

Weisberg E, Brache V, Alvarez F, et al. Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone progestogen/ethinyl estradiol contraceptive vaginal ring used on a bleeding-signaled regimen. Contraception. 2005 Jul;72(1):46–52. X-5, X-6, X-9, X-10. [PubMed: 15964292]

1641.

Weisberg E, Croxatto HB, Findlay JK, et al. A randomized study of the effect of mifepristone alone or in conjunction with ethinyl estradiol on ovarian function in women using the etonogestrel-releasing subdermal implant, Implanon(R). Contraception. 2011 Dec;84(6):600–8. X-4. [PubMed: 22078189]

1642.

Weisberg E, Fraser IS, Lacarra M, et al. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring. Contraception. 1999;59(5):311–8. X-3, X-9. [PubMed: 10494485]

1643.

Weisberg E, Fraser IS, Mishell DR Jr, et al. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol. Contraception. 1999;59(5):305–10. X-3, X-9. [PubMed: 10494484]

1644.

Weisberg E, Hickey M, Palmer D, et al. A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. Hum Reprod. 2006 Jan;21(1):295–302. X-5, X-6, X-9. [PubMed: 16284061]

1645.

Weisberg E, Hickey M, Palmer D, et al. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. Hum Reprod. 2009 Aug;24(8):1852–61. X-5, X-6. [PMC free article: PMC2710284] [PubMed: 19369294]

1646.

Weisberg M, Goldrath MH, Berman J, et al. Hysteroscopic endometrial ablation using free heated saline for the treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 2000 Aug;7(3):311–6. X-4, X-5, X-8. [PubMed: 10924623]

1647.

Weise HC, Fiedler K, Kato K. Buserelin suppression of endogenous gonadotropin secretion in infertile women with ovarian feedback disorders given human menopausal/human chorionic gonadotropin treatment. Fertil Steril. 1988 Mar;49(3):399–403. X-3, X-5, X-10. [PubMed: 3125067]

1648.

Welt CK, Chan JL, Bullen J, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med. 2004 Sep 2;351(10):987–97. X-4, X-5, X-9. [PubMed: 15342807]

1649.

Wen J, Li Y, Wang L, et al. Comparative cost-effectiveness of three intrauterine devices: A multi-center randomized trial. Journal of Evidence Based Medicine. 2010;3(2):76–82. X-5, X-9. [PubMed: 21349048]

1650.

Weng LJ, Xu D, Zheng HZ, et al. Clinical experience with triphasic oral contraceptive (Triquilar) in 527 women in China. Contraception. 1991 Mar;43(3):263–71. X-3, X-9. [PubMed: 2036797]

1651.

Westhoff C, Kaunitz AM, Korver T, et al. Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17beta-estradiol: A randomized controlled trial. Obstetrics and Gynecology. 2012 May;119(5):989–99. X-9. [PubMed: 22525910]

1652.

Westhoff C, Osborne LM, Schafer JE, et al. Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive. Obstetrics and Gynecology. 2005;106(1):89–96. X-6, X-9. [PubMed: 15994622]

1653.

Westphal LM, Polan ML, Trant AS. Double-blind, placebo-controlled study of FertilityBlend: A nutritional supplement for improving fertility in women. Clinical and Experimental Obstetrics and Gynecology. 2006;33(4):205–8. X-5. [PubMed: 17211965]

1654.

White WB, Hanes V, Chauhan V, et al. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension. 2006;48(2):246–53. X-7. [PubMed: 16801478]

1655.

Wiegratz I, Stahlberg S, Manthey T, et al. Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy. Contraception. 2011;84(2):133–43. X-9. [PubMed: 21757054]

1656.

Wigington S. Depo-Provera: an injectable contraceptive. Nurs Times. 1981 Oct 14-20;77(42):1794–8. X-1, X-3, X-5, X-10. [PubMed: 6458020]

1657.

Wijesinghe PS, Padumadasa GS, Palihawadana TS, et al. A trial of expectant management in incomplete miscarriage. Ceylon Med J. 2011 Mar;56(1):10–3. X-5, X-9. [PubMed: 21542427]

1658.

Wiklund I, Karlberg J, Mattsson LA. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol. 1993 Mar;168(3 Pt 1):824–30. X-7. [PubMed: 8456888]

1659.

Wilansky DL, Greisman B. Early hypothyroidism in patients with menorrhagia. Am J Obstet Gynecol. 1989 Mar;160(3):673–7. X-3, X-4, X-6. [PubMed: 2929691]

1660.

Wildemeersch D, Batar I, Affandi B, et al. The ‘frameless’ intrauterine system for long-term, reversible contraception: A review of 15 years of clinical experience. Journal of Obstetrics and Gynaecology Research. 2003;29(3):164–73. X-1, X-3, X-5, X-9. [PubMed: 12841701]

1661.

Wildemeersch D, Dhont M, Temmerman M, et al. GyneFix-LNG: preliminary clinical experience with a copper and levonorgestrel-releasing intrauterine system. Eur J Contracept Reprod Health Care. 1999 Mar;4(1):15–9. X-4. [PubMed: 10367191]

1662.

Wildemeersch D, Schacht E. Treatment of menorrhagia with a novel ‘frameless’ intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Contracept Reprod Health Care. 2001 Jun;6(2):93–101. X-3. [PubMed: 11518454]

1663.

Wildemeersch D, Schacht E, Wildemeersch P. Contraception and treatment in the perimenopause with a novel “frameless” intrauterine levonorgestrel-releasing drug delivery system: an extended pilot study. Contraception. 2002 Aug;66(2):93–9. X-4, X-5, X-9. [PubMed: 12204781]

1664.

Wildemeersch D, Schacht E, Wildemeersch P. Performance and acceptability of intrauterine release of levonorgestrel with a miniature delivery system for hormonal substitution therapy, contraception and treatment in peri and postmenopausal women. Maturitas. 2003 Mar 28;44(3):237–45. X-4. [PubMed: 12648887]

1665.

Wildemeersch D, van der Pas H, Thiery M, et al. The Copper-Fix (Cu-Fix): a new concept in IUD technology. Adv Contracept. 1988 Sep;4(3):197–205. X-1, X-3, X-9. [PubMed: 3071109]

1666.

Wilkens J, Chwalisz K, Han C, et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab. 2008 Dec;93(12):4664–71. X-4, X-5, X-6. [PubMed: 18765509]

1667.

Williams DB, Voigt BJ, Fu YS, et al. Assessment of less than monthly progestin therapy in postmenopausal women given estrogen replacement. Obstet Gynecol. 1994 Nov;84(5):787–93. X-7. [PubMed: 7936513]

1668.

Williams NI, Reed JL, Leidy HJ, et al. Estrogen and progesterone exposure is reduced in response to energy deficiency in women aged 25-40 years. Hum Reprod. 2010 Sep;25(9):2328–39. X-3, X-5, X-10. [PMC free article: PMC2922999] [PubMed: 20605898]

1669.

Wimberly YH, Cotton S, Wanchick AM, et al. Attitudes and experiences with levonorgestrel 100 microg/ethinyl estradiol 20 microg among women during a 3-month trial. Contraception. 2002 Jun;65(6):403–6. X-4, X-5, X-9. [PubMed: 12127637]

1670.

Wing DA, Paul RH, Millar LK. Management of the symptomatic placenta previa: a randomized, controlled trial of inpatient versus outpatient expectant management. Am J Obstet Gynecol. 1996 Oct;175(4 Pt 1):806–11. X-4, X-5, X-9. [PubMed: 8885726]

1671.

Winkler UH. The effect of tranexamic acid on the quality of life of women with heavy menstrual bleeding. Eur J Obstet Gynecol Reprod Biol. 2001 Dec 1;99(2):238–43. X-4. [PubMed: 11788179]

1672.

Winkler UH, Ferguson H, Mulders JAPA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 mug ethinylestradiol. Contraception. 2004;69(6):469–76. X-6, X-9. [PubMed: 15157791]

1673.

Witjaksono J, Lau TM, Affandi B, et al. Oestrogen treatment for increased bleeding in Norplant users: preliminary results. Hum Reprod. 1996 Oct;11 Suppl 2:109–14. X-5, X-6. [PubMed: 8982752]

1674.

Wolfe BMJ, Koval JJ, Nisker JA. Impact on postmenopausal symptoms of adding continuous C-21 versus C-19 progestin to estrogen. Maturitas. 1999;33(2):153–61. X-7. [PubMed: 10597880]

1675.

Wollter-Svensson LO, Stadberg E, Andersson K, et al. Intrauterine administration of levonorgestrel 5 and 10 microg/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year. Acta Obstet Gynecol Scand. 1997 May;76(5):449–54. X-5, X-10. [PubMed: 9197448]

1676.

Wollter-Svensson LO, Stadberg E, Andersson K, et al. Intrauterine administration of levonorgestrel 5 and 10 mug/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year. Acta Obstetricia et. Gynecologica Scandinavica. 1997;76(5):449–54. X-4, X-5. [PubMed: 9197448]

1677.

Wong AYK, Tang L. An open and randomized study comparing the efficacy of standard danazol and modified triptorelin regimens for postoperative disease management of moderate to severe endometriosis. Fertility and Sterility. 2004;81(6):1522–7. X-5, X-8. [PubMed: 15193471]

1678.

Wong RC, Bell RJ, Thunuguntla K, et al. Implanon users are less likely to be satisfied with their contraception after 6 months than IUD users. Contraception. 2009 Nov;80(5):452–6. X-4, X-5, X-9. [PubMed: 19835719]

1679.

Wonodirekso S, Affandi B, Siregar B, et al. Endometrial epithelial integrity and subepithelial reticular fibre expression in progestin contraceptive acceptors. Hum Reprod. 2000 Aug;15 Suppl 3:189–96. X-4, X-5. [PubMed: 11041235]

1680.

Wood SL, Brain PH. Medical management of missed abortion: a randomized clinical trial. Obstet Gynecol. 2002 Apr;99(4):563–6. X-5, X-9. [PubMed: 12039111]

1681.

Woolley JA, Seleem S, Hills FA, et al. Raised circulating levels of interleukin-6 in women with an intrauterine contraceptive device. Gynecol Obstet Invest. 1996;42(4):241–3. X-3, X-4, X-5. [PubMed: 8979095]

1682.

Worthington-Kirsch RL, Popky GL, Hutchins FL Jr. Uterine arterial embolization for the management of leiomyomas: quality-of-life assessment and clinical response. Radiology. 1998 Sep;208(3):625–9. X-4, X-5, X-6, X-8. [PubMed: 9722838]

1683.

Wren BG, McFarland K, Edwards L, et al. Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women. Climacteric. 2000 Sep;3(3):155–60. X-4, X-5, X-7. [PubMed: 11910616]

1684.

Wright VC, Schieve LA, Reynolds MA, et al. Assisted reproductive technology surveillance -- United States, 2001. MMWR: Morbidity & Mortality Weekly Report. 2004;53(SS-1):1–20. X-3, X-5. [PubMed: 15123982]

1685.

Wu S, Godfrey EM, Wojdyla D, et al. Copper T380A intrauterine device for emergency contraception: a prospective, multicentre, cohort clinical trial. BJOG. 2010 Sep;117(10):1205–10. X-4, X-5. [PubMed: 20618314]

1686.

Wu YJJ, Luo SF, Yang SH, et al. Vascular response of Raynaud's phenomenon to nifedipine or herbal medication (Duhuo-Tisheng Tang with Danggui-Sini Tang): A preliminary study. Chang Gung Medical Journal. 2008;31(5):492–502. X-3, X-5. [PubMed: 19097597]

1687.

Xiao B, Wu SC, Chong J, et al. Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril. 2003 Apr;79(4):963–9. X-4. [PubMed: 12749438]

1688.

Xiao B, Zeng T, Wu S, et al. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use. Contraception. 1995 Jun;51(6):359–65. X-3, X-4. [PubMed: 7554977]

1689.

Xiao BL, Zhang XL, Feng DD. Pharmacokinetic and pharmacodynamic studies of vaginal rings releasing low-dose levonorgestrel. Contraception. 1985 Nov;32(5):455–71. X-3, X-9. [PubMed: 3936678]

1690.

Xing S, Wu Y, Liu J, et al. A comparison of two different dosages of conjugated equine estrogen in continuous combined hormone replacement therapy with progestin. Chin Med J (Engl). 2003 Apr;116(4):584–7. X-5, X-7. [PubMed: 12875727]

1691.

Yamashita Y, Harada M, Yamamoto H, et al. Transcatheter arterial embolization of obstetric and gynaecological bleeding: efficacy and clinical outcome. Br J Radiol. 1994 Jun;67(798):530–4. X-3, X-6, X-8. [PubMed: 8032805]

1692.

Yang LC, Lan Y, Hu J, et al. Relatively high bone mineral density in Chinese adolescent dancers despite lower energy intake and menstrual disorder. Biomed Environ Sci. 2010 Apr;23(2):130–6. X-4, X-5, X-9. [PubMed: 20514988]

1693.

Yang TS, Liang WH, Chang SP, et al. Effects of period-free hormone replacement therapy in postmenopausal women in Taiwan. Chinese Medical Journal. 2002;65(1):23–8. X-7. [PubMed: 11939671]

1694.

Yang TS, Tsan SH, Chen CR, et al. Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women. Chinese Medical Journal. 1999;62(5):308–15. X-7. [PubMed: 10389286]

1695.

Yanushpolsky E, Hurwitz S, Greenberg L, et al. Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone--impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertil Steril. 2011 Feb;95(2):617–20. X-5, X-6, X-9. [PubMed: 20537624]

1696.

Yarkoni S, Anteby SO. Treatment of IUD related menorrhagia by indomethacin. Clin Exp Obstet Gynecol. 1984;11(4):120–2. X-5, X-6. [PubMed: 6437699]

1697.

Yasui T, Uemura H, Tezuka M, et al. Biological effects of hormone replacement therapy in relation to serum estradiol levels. Horm Res. 2001;56(1-2):38–44. X-5, X-7. [PubMed: 11815726]

1698.

Yeh LLL, Liu JY, Lin KS, et al. A randomised placebo-controlled trial of a traditional Chinese herbal formula in the treatment of primary dysmenorrhoea. PLoS One. 2007;2(8) X-5. [PMC free article: PMC1940310] [PubMed: 17710126]

1699.

Yeshaya A, Orvieto R, Kauschansky A, et al. A delayed starting schedule of oral contraception: the effect on the incidence of breakthrough bleeding and compliance in women. Eur J Contracept Reprod Health Care. 1996 Sep;1(3):263–5. X-4, X-5, X-6. [PubMed: 9678125]

1700.

Yildirim G, Tugrul S, Uslu H, et al. Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding. Arch Gynecol Obstet. 2006 Feb;273(5):268–73. X-5, X-7. [PubMed: 16315025]

1701.

Yildizhan B, Yildizhan R, Ozkesici B, et al. Transvaginal ultrasonography and saline infusion sonohysterography for the detection of intra-uterine lesions in pre- and post-menopausal women with abnormal uterine bleeding. J Int Med Res. 2008 Nov-Dec;36(6):1205–13. X-4, X-5. [PubMed: 19094428]

1702.

Yin M, Zhu P, Luo H, et al. The presence of mast cells in the human endometrium pre- and post-insertion of intrauterine devices. Contraception. 1993 Sep;48(3):245–54. X-3, X-4. [PubMed: 8222654]

1703.

Yingna S, Yang X, Xiuyu Y, et al. Clinical characteristics and treatment of gestational trophoblastic tumor with vaginal metastasis. Gynecol Oncol. 2002 Mar;84(3):416–9. X-4, X-5, X-6, X-9. [PubMed: 11855880]

1704.

Ylanen K, Laatikainen T, Lahteenmaki P, et al. Subdermal progestin implant (Nestorone) in the treatment of endometriosis: clinical response to various doses. Acta Obstet Gynecol Scand. 2003 Feb;82(2):167–72. X-4, X-5, X-8. [PubMed: 12648180]

1705.

Ylikorkala O, Pekonen F. Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia. Obstet Gynecol. 1986 Jul;68(1):10–2. X-3, X-5, X-6. [PubMed: 3523328]

1706.

Ylikorkala O, Tiitinen A, Hulkko S, et al. Decrease in symptoms, blood loss and uterine size with nafarelin acetate before abdominal hysterectomy: a placebo-controlled, double-blind study. Hum Reprod. 1995 Jun;10(6):1470–4. X-3, X-8. [PubMed: 7593517]

1707.

Ylikorkala O, Viinikka L. Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. Br J Obstet Gynaecol. 1983 Jan;90(1):78–83. X-5, X-6. [PubMed: 6336951]

1708.

Ylikorkala O, Wahlstrom T, Caubel P, et al. Intermittent progestin administration as part of hormone replacement therapy: long-term comparison between estradiol 1 mg combined with intermittent norgestimate and estradiol 2 mg combined with constant norethisterone acetate. Acta Obstet Gynecol Scand. 2002 Jul;81(7):654–60. X-5, X-7. [PubMed: 12190841]

1709.

Yong EL, Glasier A, Hillier H, et al. Effect of cyclofenil on hormonal dynamics, follicular development and cervical mucus in normal and oligomenorrhoeic women. Hum Reprod. 1992 Jan;7(1):39–43. X-4, X-5. [PubMed: 1551955]

1710.

Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005 Sep;106(3):492–501. X-5, X-9. [PubMed: 16135578]

1711.

Youssef G, Maguid AA, El-Inany H. Progesterone supplementation in clomiphene citrate treated anovulatory patients with menstrual irregularities: A randomized controlled trial. Middle East Fertility Society Journal. 2000;5(3):209–12. X-5.

1712.

Yuan HN, Wang CY, Sze CW, et al. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. J Clin Psychopharmacol. 2008 Jun;28(3):264–370. X-5, X-9. [PubMed: 18480682]

1713.

Zachariae H, Abrams B, Bleehen SS, et al. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability. Dermatology. 1998;196(2):231–6. X-5, X-9. [PubMed: 9568413]

1714.

Zafar S. Role of metformin in correcting hyperinsulinemia, menstrual irregularity and anovulation in polycystic ovary syndrome. J Ayub Med Coll Abbottabad. 2005 Oct-Dec;17(4):54–6. X-4, X-5, X-9. [PubMed: 16599037]

1715.

Zaidi J, Jacobs H, Campbell S, et al. Blood flow changes in the ovarian and uterine arteries in women with polycystic ovary syndrome who respond to clomiphene citrate: correlation with serum hormone concentrations. Ultrasound Obstet Gynecol. 1998 Sep;12(3):188–96. X-3, X-4. [PubMed: 9793191]

1716.

Zalel Y, Shulman A, Lidor A, et al. The local progestational effect of the levonorgestrel-releasing intrauterine system: a sonographic and Doppler flow study. Hum Reprod. 2002 Nov;17(11):2878–80. X-4, X-5, X-6. [PubMed: 12407042]

1717.

Zapico A, Grassa A, Martinez E, et al. Endometrial resection and preoperative LH-RH agonists: a prospective 5-year trial. Eur J Obstet Gynecol Reprod Biol. 2005 Mar 1;119(1):114–8. X-4, X-5, X-6, X-8, X-9. [PubMed: 15734095]

1718.

Zervou S, Klentzeris LD, Old RW. Nitric oxide synthase expression and steroid regulation in the uterus of women with menorrhagia. Mol Hum Reprod. 1999 Nov;5(11):1048–54. X-4, X-5. [PubMed: 10541567]

1719.

Zhang HJ. 76 cases of hypomenorrhea treated by acupuncture to regulate the menstrual cycle. J Tradit Chin Med. 2009 Sep;29(3):177–8. X-3, X-5, X-10. [PubMed: 19894379]

1720.

Zhao G, Li M, Zhu P, et al. A preliminary morphometric study on the endometrium from patients treated with indomethacin-releasing copper intrauterine device. Hum Reprod. 1997 Jul;12(7):1563–6. X-4, X-5, X-6. [PubMed: 9262297]

1721.

Zhao S, Choksuchat C, Zhao Y, et al. Effects of doxycycline on serum and endometrial levels of MMP-2, MMP-9 and TIMP-1 in women using a levonorgestrel-releasing subcutaneous implant. Contraception. 2009 Jun;79(6):469–78. X-4, X-5, X-9. [PubMed: 19442784]

1722.

Zheng SR, Zheng HM, Qian SZ, et al. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception. 1999 Jul;60(1):1–8. X-5, X-6. [PubMed: 10549446]

1723.

Zheng SR, Zheng HM, Qian SZ, et al. A long-term study of the efficacy and acceptability of a single-rod hormonal contraceptive implant (Implanon) in healthy women in China. Eur J Contracept Reprod Health Care. 1999 Jun;4(2):85–93. X-4, X-5. [PubMed: 10427483]

1724.

Zheng XL, Lo LL. Studies on IUD-induced menorrhagia and increased synthesis of prostacyclin in endometrium. J Tongji Med Univ. 1988;8(4):232–4. X-3, X-4, X-5, X-6. [PubMed: 3150468]

1725.

Zhou L, Xiao B. Emergency contraception with Multiload Cu-375 SL IUD: a multicenter clinical trial. Contraception. 2001 Aug;64(2):107–12. X-4, X-5, X-9. [PubMed: 11704087]

1726.

Zhu PD, Luo HZ, Xu RH, et al. The effect of intrauterine devices, the stainless steel ring, the copper T220, and releasing levonorgestrel, on the bleeding profile and the morphological structure of the human endometrium--a comparative study of three IUDs. A morphometric study of 96 cases. Contraception. 1989 Oct;40(4):425–38. X-3, X-4. [PubMed: 2510968]

1727.

Zhuang Y, Huang L. Uterine artery embolization compared with methotrexate for the management of pregnancy implanted within a cesarean scar. Am J Obstet Gynecol. 2009 Aug;201(2):152 e1–3. X-5, X-9. [PubMed: 19527897]

1728.

Ziaei S, Rajaei L, Faghihzadeh S, et al. Comparative study and evaluation of side effects of low-dose contraceptive pills administered by the oral and vaginal route. Contraception. 2002 May;65(5):329–31. X-4, X-5. [PubMed: 12057783]

1729.

Zulian E, Sartorato P, Benedini S, et al. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest. 2005 Jan;28(1):49–53. X-4, X-5, X-9. [PubMed: 15816371]

1730.

Zupi E, Luciano AA, Marconi D, et al. The use of topical anesthesia in diagnostic hysteroscopy and endometrial biopsy. J Am Assoc Gynecol Laparosc. 1994 May;1(3):249–52. X-4, X-8. [PubMed: 9050495]

1731.

Zupi E, Marconi D, Sbracia M, et al. Add-back therapy in the treatment of endometriosis-associated pain. Fertility and Sterility. 2004;82(5):1303–8. X-5, X-6, X-10. [PubMed: 15533351]

1732.

Zupi E, Sbracia M, Marconi D, et al. TNFalpha expression in hyperplastic endometrium. Am J Reprod Immunol. 2000 Sep;44(3):153–9. X-4, X-5. [PubMed: 11028902]

1733.

Zwart JJ, Yazdani ST, Harvey MS, et al. Underreporting of major obstetric haemorrhage in the Netherlands. Transfus Med. 2010 Apr;20(2):118–22. X-4, X-5, X-9. [PubMed: 19708894]

1734.

Lukes AS, Freeman EW, Van Drie D, et al. Safety of tranexamic acid in women with heavy menstrual bleeding: an open-label extension study. Womens Health (Lond Engl). 2011 Sep;7(5):591–8. X-3. [PubMed: 21879827]